

Gut

*Journal of the British Society of Gastroenterology which
is a registered charity*

Editor: R N Allan

Technical Editor: Jackie Foulds

Review Editor: Ian Forgacs

Editorial Assistant: Michelle Dimler

EDITORIAL BOARD

M J P Arthur

T G Cooke

D Rampton

R G Newcombe
(Statistical adviser)

D C C Bartolo

C A Hart

P J Shorvon

I S Benjamin

C J Hawkey

D Swallow

Editor
British Medical Journal

P Bland

S G Hubscher

D G Thompson

J Calam

J Neuberger

B J R Whittle

D C A Candy

H O'Connor

R Chapman

P Quirke

INTERNATIONAL ADVISORY BOARD

B S Anand (USA)

D Y Graham (USA)

R Modigliani (France)

C Arvanitakis (Greece)

J Hansky (Australia)

T Muto (Japan)

G P van Berge Henegouwen
(Netherlands)

J Heathcote (Canada)

G Paumgartner (Germany)

G Bianchi-Porro (Italy)

R H Hunt (Canada)

E W Pomare (New Zealand)

A L Blum (Switzerland)

J R Jass (New Zealand)

D Rachmilewitz (Israel)

M van Blankenstein

S-J Jiang (China)

J Rask-Madsen (Denmark)

(Netherlands)

S J Konturek (Poland)

E Rene (France)

J P Delmont (France)

S K Lam (Hong Kong)

A Torsoli (Italy)

J Dent (Australia)

M M Levine (USA)

J-R Malagelada (Spain)

students may not necessarily be attached to the gastroenterology unit during their training, they may not see that many patients with gastrointestinal disease and, for them, I would have thought that this atlas would be fun as well as being informative.

My favourite picture is that of *Triatoma magistrus* – no problem seeing why this particular beast might cause havoc to the myenteric plexus. Having last seen, but never forgotten, the pus of an amoebic abscess (anchovy sauce on fish fingers every other Friday) at my prep school, circa 1966, I thought the hue inside the saucebowl (Fig 11.62) was a touch too red rather than pink-grey. While on the subject of Escoffier's contribution to our specialty, I was sorry to see that redcurrant jelly did not make it into any of the photographs of stools.

The first edition was a very good picture book, as those who have slide sets from the original will know. This revision is a timely update, which is beautifully produced with the single exception that the similarity in style between pagination of text and numbering of figures is seriously confusing throughout.

IAN FORGACS

NOTES

Cross-Sectional Imaging

A seminar designed for the radiologist in clinical practice will be held at El Conquistador Resort, Puerto Rico on 30 January-4 February 1995. Further information from Janice Ford, Hospital of the

University of Pennsylvania, 3400 Spruce Street, 1 Silverstein Building, Philadelphia, PA 19104, USA. Tel: 215 662 6904; fax: 215 349 5925.

Magnetic Resonance Imaging

A course designed to provide a state of the art summary of both neuroradiological and body applications of MR imaging will be held at Hapuna Prince Resort, The Big Island of Hawaii on 13-18 February 1995. Further information from: Janice Ford, Hospital of the University of Pennsylvania, 3400 Spruce Street, 1 Silverstein Building, Philadelphia, PA 19104, USA. Tel: 215 662 6904; fax: 215 349 5925.

Gall stone disease and its treatment – with live demonstrations

This congress will be held at Academic Medical Center, University of Amsterdam, The Netherlands on 12-13 January 1995. Further information from: Mrs Helma Stockmann, European Postgraduate Gastro-Surgical School, G-4-109.3, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Tel: 31 20 5663926; fax: 31 20 69114858.

Therapeutic endoscopy

The XIIIth European Workshop on Therapeutic Digestive Endoscopy will be held at the Erasme Hospital, ULB, Brussels, Belgium on 13-15 June, 1995. Further information from Mrs Françoise REY, Conference Services, Avenue de l'Observatoire 3, box 17

B-1180 Brussels, Belgium. Tel: 32 2 375 16 48; fax: 32 2 375 32 99.

Helicobacter pylori

The VIIIth International Workshop on Gastroduodenal pathology and *Helicobacter pylori* will be held at the Heriot Watt University Conference Centre in Edinburgh, Scotland, on 7-9 July 1995. Further information from VIIIth EHPG, Confrex, 145 Islingword Road, Brighton, BN2 2SH. Tel: 44 273 623 123; fax: 44 273 622 944.

Gastrointestinal motility

The XVth International Symposium on Gastrointestinal Motility will be held on 5-9 November, 1995 at Hotel Villa Pamphili, Rome, Italy. Further information from Dr Enrico Corazzari, Chairman, Cattedra di Gastroenterologia I, Clinica Medica 2, Policlinico Umberto I, 00161 Rome, Italy. Tel/fax: +39 6 446-9965.

Gastroenterology and digestive endoscopy

The 27th Argentine Congress of Gastroenterology, the 14th Congress of Digestive Endoscopy, and the 4th Meeting of Pediatric Gastroenterology and Nourishment, will be held in Buenos Aires, Argentina, from 5-10 November 1995. Further information from: Gastroenterology: Dr Fernando Magnanini, J E Urburu 1252-4 PD, (1114) Buenos Aires, Argentina. Tel and fax: 541 806 7871. Endoscopy: Dr Alejandro Ramirez, Ana Juan Congressos, Sarmiento 1562-4 PF, (1042) Buenos Aires, Argentina. Tel: 381 1777/384 5376; fax: 541 382 6703.

Gut

*Journal of the British Society of Gastroenterology which
is a registered charity*

VOLUME 35 · 1994

Editor: R N Allan

Technical Editor: Jackie Foulds

Review Editor: Ian Forgacs

Editorial Assistant: Michelle Dimler

EDITORIAL BOARD

M J P Arthur

T G Cooke

D Rampton

R G Newcombe

D C C Bartolo

C A Hart

P J Shorvon

(Statistical adviser)

I S Benjamin

C J Hawkey

D Swallow

Editor

P Bland

S G Hubscher

D G Thompson

British Medical Journal

J Calam

J Neuberger

B J R Whittle

D C A Candy

H O'Connor

R Chapman

P Quirke

INTERNATIONAL ADVISORY BOARD

B S Anand (USA)

D Y Graham (USA)

R Modigliani (France)

C Arvanitakis (Greece)

J Hansky (Australia)

T Muto (Japan)

G P van Berge Henegouwen
(Netherlands)

J Heathcote (Canada)

G Paumgartner (Germany)

G Bianchi-Porro (Italy)

J R Jass (New Zealand)

E W Pomare (New Zealand)

A L Blum (Switzerland)

S-J Jiang (China)

D Rachmilewitz (Israel)

M van Blankenstein
(Netherlands)

S J Konturek (Poland)

J Rask-Madsen (Denmark)

J P Delmont (France)

S K Lam (Hong Kong)

E Rene (France)

J Dent (Australia)

M M Levine (USA)

A Torsoli (Italy)

J-R Malagelada (Spain)

VOLUME 35 · CONTENTS

No 1 JANUARY 1994

Page	Leading articles
1	Travellers' diarrhoea <i>M J G Farthing</i>
5	Why measure C reactive protein? <i>M Z Mazlam, H J F Hodgson</i>
	Oesophageal reflux
8	Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients <i>Elbio Kuster, Emilio Ros, Victor Toledo-Pimentel, Amadeo Pujol, Josep M Bordas, Luis Grande, Cristóbal Pera</i>
	Peptic ulcer
15	One week's anti- <i>Helicobacter pylori</i> treatment for duodenal ulcer <i>R P H Logan, P A Gummett, J J Misiewicz, Q N Karim, M M Walker, J H Baron</i>
19	Evidence for the essential role of <i>Helicobacter pylori</i> in gastric ulcer disease <i>J Labenz, G Börsch</i>
23	Duodenal bacterial overgrowth during treatment in outpatients with omeprazole <i>Michael Fried, Hans Siegrist, Reno Frei, Florian Froehlich, Philippe Duroux, Joel Thorens, André Blum, Jacques Bille, Jean J Gonvers, Klaus Gyr</i>
	Small intestine
27	Effect of the quaternary ammonium compound tropium chloride on 24 hour jejunal motility in healthy subjects <i>T Schmidt, R Widmer, A Pfeiffer, H Kaess</i>
34	Lipid peroxidation and electrogenic ion transport in the jejunum of the vitamin E deficient rat <i>K J Lindley, M A Goss-Sampson, D P R Muller, P J Milla</i>
40	Effects of endotoxin and dexamethasone on group I and II phospholipase A ₂ in rat ileum and stomach <i>I Liija, J Dimberg, R Sjödahl, C Tagesson, C Gustafson-Svärd</i>
46	Immunohistochemical localisation of intercellular adhesion molecule-1 in follicle associated epithelium of Peyer's patches <i>Y Fujimura, T Kihara</i>
51	Phenotypic and genotypic variation in <i>Giardia lamblia</i> isolates during chronic infection <i>P D Butcher, A M Cevallos, S Carnaby, E M Alstead, E T Swarbrick, M J G Farthing</i>
	Coeliac disease
55	Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells <i>K Holm, E Savilahi, S Koskimies, V Lipsanen, M Mäki</i>
61	Serological screening suggests that adult coeliac disease is underdiagnosed in the UK and increases the incidence by up to 12% <i>D J Unsworth, D L Brown</i>
65	Coeliac disease in the elderly <i>G L Hankey, G K T Holmes</i>
	Inflammatory bowel disease
68	Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives <i>P Munkholm, E Langholz, D Hollander, K Thornberg, M Orholm, K D Katz, V Binder</i>
73	Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis <i>M A S Chapman, M F Grahn, M A Boyle, M Hutton, J Rogers, N S Williams</i>
77	Interrelations between interleukin-6, interleukin-1β, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease <i>M Z Mazlam, H J F Hodgson</i>
84	Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm <i>U Broomé, H Glaumann, G Hellers, B Nilsson, J Sörstad, R Hultcrantz</i>
90	Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT <i>H Nyhlin, M V Merrick, M A Eastwood</i>
94	Pathogenesis of gall stones in Crohn's disease: an alternative explanation <i>R Hutchinson, P N M Tyrrell, D Kumar, J A Dunn, J K W Li, R N Allan</i>
	Liver
98	Expression of mutant p53 protein in hepatocellular carcinoma <i>J D Collier, M Carpenter, A D Burt, M F Bassendine</i>
101	Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients <i>Humberto Reyes, Lorena Sandoval, Andres Wainstein, Jose Ribalta, Sergio Donoso, Gladys Smok, Helmar Rosenberg, Manuel Meneses</i>
	Gall stones
107	Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study <i>F E Murray, R F A Logan, P C Hannaford, C R Kay</i>
112	Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination <i>D K Agarwal, G Choudhuri, V A Saraswat, T S Negi, V K Kapoor, R Saxena</i>
117	Gall stone pulverisation strategy in patients treated with extracorporeal lithotripsy and follow up results of maintenance treatment with ursodeoxycholic acid <i>M Boscaini, M Piccinni-Leopardi, F Andreotti, A Montori</i>
	Biliary tract
122	Management of common bile duct stricture caused by chronic pancreatitis with metal mesh self expandable stents <i>J Deviere, M Cremer, M Baize, J Love, B Sugai, A Vandermeeren</i>
127	Endoscopic sphincteroplasty: a novel and safe alternative to papillotomy in the management of bile duct stones <i>P Mac Mathuna, P White, E Clarke, J Lennon, J Crowe</i>
	Case reports
130	Intramural haematoma of the oesophagus complicating sclerotherapy for varices <i>E Mosimann, B Brönnimann</i>
132	Multifocal osteonecrosis related to steroid treatment in a patient with ulcerative colitis <i>P V Madsen, G Andersen</i>
	Special report
135	Specialist training in gastroenterology in the European Community: the case for European Boards <i>European Board of Gastroenterology</i>
139	BSG President's report for 1992-93
140	Letters to the editor
142	Referees

No 2 FEBRUARY 1994

Page	Leading articles
145	Cholera and severe toxigenic diarrhoeas <i>D R Nalin</i>
150	Bone mineral density in coeliac disease <i>J R F Walters</i>

- Oesophagus**
- 152 Stimulation and characteristics of secondary oesophageal peristalsis in normal subjects *M N Schoeman, R H Holloway*
- 159 Strain induced augmentation of upper oesophageal sphincter pressure in children *J Willing, Y Furukawa, G P Davidson, J Dent*
- 165 Diminished oesophageal traction forces with swallowing in gastro-oesophageal reflux disease and in functional dysphagia *D Williams, D G Thompson, M Marples, L Heggie, T O'Hanrahan, J Bancewicz*
- Stomach**
- 172 Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride *R J Fraser, M Horowitz, A F Maddox, J Dent*
- 179 *Helicobacter pylori* stimulates antral mucosal reactive oxygen metabolite production in vivo *G R Davies, N J Simmonds, T R J Stevens, M T Sheaff, N Banatvala, I F Laurensen, D R Blake, D S Rampton*
- 186 Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals *M B Sidery, I A Macdonald, P E Blackshaw*
- 191 A database on dyspepsia *G P Crean, R J Holden, R P Knill-Jones, A D Beattie, W B James, F M Marjoribanks, D J Spiegelhalter*
- Small intestine**
- 203 Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome *D A Gorard, G W Libby, M J G Farthing*
- 211 Absorption of a hypotonic oral rehydration solution in a human model of cholera *J B Hunt, A V Thillainayagam, S Carnaby, P D Fairclough, M L Clark, M J G Farthing*
- 215 Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A₂ in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor *X Sun, M S Caplan, W Hsueh*
- Inflammatory bowel disease**
- 220 Surgical resections in parous patients with distal ileal and colonic Crohn's disease *C U Nwokolo, W C Tan, H A Andrews, R N Allan*
- 224 Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease *T Hibi, M Ohara, K Kobayashi, W R Brown, K Toda, H Takaishi, Y Hosoda, A Hayashi, Y Iwao, M Watanabe, S Aiso, Y Kawai, M Tsuchiya*
- 231 Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases *C Cellier, T Sahmoud, E Froguel, A Adenis, J Belaiche, J-F Bretagne, C Florent, M Bouvry, J-Y Mary, R Modigliani, and the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives*
- 236 Faecal diversion for Crohn's colitis: a model to study the role of the faecal stream in the inflammatory process *M C Winslet, A Allan, V Poxon, D Youngs, M R B Keighley*
- 243 Pouchitis – recurrence of the inflammatory bowel disease? *P Luukkonen, H Järvinen, M Tanskanen, A Kahri*
- Large intestine**
- 247 Effect of nicotine on rectal mucus and mucosal eicosanoids *F J Zijlstra, E D Srivastava, M Rhodes, A P M van Dijk, F Fogg, H J Samson, M Copeman, M A H Russell, C Feyerabend, G T Williams, R D Pullan, G A O Thomas, M Van Blankenstein, J H P Wilson, A Allen, J Rhodes*
- 252 Effects of biofeedback on obstructive defecation – reconditioning of the defecation reflex? *M Papachrysostomou, A N Smith*
- Liver**
- 257 Longterm outcome after injection sclerotherapy for oesophageal varices in children with extrahepatic portal hypertension *M D Stringer, E R Howard*
- 260 Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis *P Michieletti, I R Wanless, A Katz, P J Scheuer, S J Yeaman, M F Bassendine, J M Palmer, E J Heathcote*
- Pancreas**
- 266 Expression of glutathione S-transferases in normal and malignant pancreas: an immunohistochemical study *J D Collier, M K Bennett, A Hall, A R Cattan, R Lendrum, M F Bassendine*
- 270 Cholecystokinin type B receptor antagonist PD-136, 450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat *A Schmassmann, A Garner, B Flogerzi, M Y Hasan, M Santer, L Varga, F Halter*
- Case reports**
- 275 Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome *G E Feurle*
- 278 Crohn's disease and myasthenia gravis: a possible role for thymectomy *I A Finnie, R Shields, R Sutton, R Donnelly, A I Morris*
- 280 Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report *E M Yoshida, S R Erb, D N Ostrow, D R Ricci, C H Scudamore, G Fradet*
- 283 **BSG President's report**
- 284 **Letters to the editor** **Notes**
- Leading articles**
- 289 Parasitic infections of the small intestine *J Jernigan, R L Guerrant, R D Pearson*
- 294 Epithelial cell lineages in developing, restoring, and transforming liver: evidence for the existence of a 'differentiation window' *N Marceau*
- 297 Inflammatory mediators in the oesophagus *G P Morgan, J G Williams*
- Oesophagus**
- 299 Palliation of malignant dysphagia by ethanol induced tumour necrosis *C U Nwokolo, J J Payne-James, D B A Silk, J J Misiewicz, D E Loft*
- 304 Simultaneous two level oesophageal pH monitoring in healthy controls and patients with oesophagitis: comparison between two positions *P Singh, R H Taylor, D G Colin-Jones*
- Helicobacter pylori**
- 309 Prevalence of peptic ulcer in *Helicobacter pylori* positive blood donors *D Vaira, M Miglioli, P Mulè, J Holton, M Menegatti, M Vergura, G Biasco, R Conte, R P H Logan, L Barbara*
- 313 High prevalence of *Helicobacter pylori* infection in cohabiting children. Epidemiology of a cluster, with special emphasis on molecular typing *P Vincent, F Gottrand, P Pernes, M O Husson, M Lecomte-Houcke, D Turck, H Leclerc*
- 317 Effect of *Helicobacter pylori* and its eradication on gastric juice ascorbic acid *S Banerjee, C Hawksby, S Müller, S Dahill, A D Beattie, K E L McColl*

- 323 Eradication of *Helicobacter pylori* with clarithromycin and omeprazole R P H Logan, P A Gummatt, H D Schaufelberger, R R F H Greaves, G M Mendelson, M M Walker, P H Thomas, J H Baron, J J Misiewicz
- Gastric motility**
- 327 Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients L E A Troncon, R J M Bennett, N K Ahluwalia, D G Thompson
- 333 Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline B D Maes, M I Hiele, B J Geypens, P J Rutgeerts, Y F Ghoo, G Vantrappen
- Small intestine**
- 338 Polarised interleukin 8 secretion by HT 29/19A cells K M Lammers, J Jansen, P B Bijlsma, M Ceska, G N J Tytgat, C L Laboisse, S J H van Deventer
- 343 Cholesterol synthesis and high density lipoprotein uptake are regulated independently in rat small intestinal epithelium C Lutton, G Champarnaud
- Inflammatory bowel disease**
- 347 Lower gastrointestinal malignancy in Crohn's disease W R Connell, J P Sheffield, M A Kamm, J K Ritchie, P R Hawley, J E Lennard-Jones
- 353 Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis R D Pullan, G A O Thomas, M Rhodes, R G Newcombe, G T Williams, A Allen, J Rhodes
- 360 Frequency of glucocorticoid resistance and dependency in Crohn's disease P Munkholm, E Langholz, M Davidsen, V Binder
- 363 Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease G L Swift, E D Srivastava, R Stone, R D Pullan, R G Newcombe, J Rhodes, S Wilkinson, P Rhodes, G Roberts, B W Lawrie, K T Evans, P A Jenkins, G T Williams, G Strohmeyer, G Kreuzpaintner, G A O Thomas, B Calcraft, P S Davies, T J Morris, J Morris
- 369 Incidence of inflammatory bowel disease in north west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common E V Tsianos, C N Masalas, M Merkouropoulos, G N Dalekos, R F A Logan
- 373 Ileitis after colectomy for ulcerative colitis or carcinoma A Hallak, M Baratz, M Santo, Z Halpern, M Rabau, N Werbin, T Gilat
- Large intestine**
- 377 Desmoid tumours in familial adenomatous polyposis A K Gurbuz, R M Giardiello, G M Petersen, A J Krush, G J A Offerhaus, S V Booker, M C Kerr, S R Hamilton
- 382 Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area B Østenstad, T Lea, E Schlichting, M Harboe
- 388 Pelvic floor function in multiple sclerosis J S Jameson, J Rogers, Y W Chia, J J Misiewicz, M M Henry, M Swash
- 391 Fistulas in ano: endoanal ultrasonographic assessment assists decision making for surgery K I Deen, J G Williams, R Hutchinson, M R B Keighley, D Kumar
- Liver**
- 395 Focused liver ablation by cavitation in the rabbit: a potential new method of extracorporeal treatment F Prat, J-Y Chapelon, F Abou El Fadil, A Sibille, Y Theillière, T Ponchon, D Cathignol
- Pancreas**
- 401 Origin and development of exocrine pancreatic insufficiency in experimental renal failure M M Lerch, P Hoppe-Seyler, W Gerok
- Endoscopy**
- 408 Oxygen saturation during endoscopic retrograde cholangiopancreatography: a comparison of two protocols of oxygen administration J D Rigg, T C Wait, D E F Tweedle, D F Martin
- Biliary tree**
- 412 Non-adrenergic non-cholinergic inhibitory innervation shown by electrical field stimulation of isolated strips of human gall bladder muscle M L McKirdy, H C McKirdy, C D Johnson
- 417 Pulverisation of calcified and non-calcified gall bladder stones: extracorporeal shock wave lithotripsy used alone N Soehendra, V-C Nam, K F Binmoeller, H Koch, S Bohnacker, H W Schreiber
- Case reports**
- 423 Benign intracranial hypertension during prednisolone treatment for inflammatory bowel disease M Newton, B T Cooper
- 426 Drug induced lymphocytic colitis L Beaugerie, J Lubowski, N Brousse, J Cosnes, F-P Chatelet, J-P Gendre, Y Le Quintrec
- 429 **Letters to the editor Book reviews Notes**
- Leading articles**
- 433 Isolated hepatocytes: use in experimental and clinical hepatology Alastair J Strain
- 437 Strongyloidiasis: a conundrum for gastroenterologists D I Grove
- 441 Intestinal absorption of peptide drugs: advances in our understanding and clinical implications M Catnach, P D Fairclough, S M Hammond
- 445 Transjugular intrahepatic portosystemic stent shunts P C Hayes, D N Redhead, N D C Finlayson
- Oesophageal reflux**
- 447 Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease M Marrero, J S de Caestecker, J D Maxwell
- Duodenal ulcer**
- 451 Death from malignant disease after surgery for duodenal ulcer I M C Macintyre, F O'Brien
- 455 Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds E Verdu, F Viani, D Armstrong, R Fraser, H H Siegrist, B Pignatelli, J-P Idström, C Cederberg, A L Blum, M Fried
- Therapeutic endoscopy**
- 461 Endoscopic laser treatment of diffuse gastric antral vascular ectasia S Potamiano, C R Carter, J R Anderson
- 464 Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment C P Choudari, C Rajgopal, K R Palmer
- 467 Symptom relief and quality of life after stenting for malignant bile duct obstruction A B Ballinger, M McHugh, S M Catnach, E M Alstead, M L Clark
- Small intestine**
- 471 Localisation of neuroendocrine tumours of the upper gastrointestinal tract T Zimmer, K Ziegler, M Bäder, U Fett, B Hamm, E-O Riecken, B Wiedenmann
- 476 Intestinal antibody pattern of coeliac disease: association with γ/δ T cell receptor expression by intraepithelial lymphocytes, and other indices of potential coeliac disease E Arranz, J Bode, K Kingstone, A Ferguson

- 483 *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria *M F Bernet, D Brassart, J R Neeser, A L Servin*
- 490 Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor *F Mion, J-C Cuber, Y Minaire, J-A Chayvialle*
- 496 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake *D A Gorard, G W Libby, M J G Farthing*
- 501 Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide *R J Lieverse, J B M J Jansen, A A M Masclee, L C Rovati, C B H W Lamers*
- 506 Specific detection of *Mycobacterium paratuberculosis* DNA associated with granulomatous tissue in Crohn's disease *H M Fidler, W Thurrell, N McI Johnson, G A W Rook, J J McFadden*
- 511 Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease *K R Gardiner, A D Crockard, M I Halliday, B J Rowlands*
- 517 Abnormal leukotriene C₄ release by unaffected jejunal mucosa in patients with inactive Crohn's disease *F Casellas, F Guarner, M Antolin, R Rodriguez, A Salas, J-R Malagelada*
- 523 Relationship of small bowel motility to ileoanal reservoir function *S Groom, M A Kamm, R J Nicholls*
- Large intestine**
- 530 Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation *F J G M Kubben, A Peeters-Haesevoets, L G J B Engels, C G M I Baeten, B Schutte, J W Arends, R W Stockbrügger, G H Blijham*
- 536 Serotonergic mediation of postprandial colonic tonic and phasic responses in humans *M R von der Ohe, R B Hanson, M Camilleri*
- Liver**
- 542 Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact? *B P Rowan, A Smith, D Gleeson, L P Hunt, T W Warnes*
- Pancreatitis**
- 547 Dopamine in models of alcoholic acute pancreatitis *N D Karanjia, A L Widdison, F J Lutrin, H A Reber*
- 552 Progression of alcoholic acute to chronic pancreatitis *R W Ammann, B Muellhaupt*
- Case reports**
- 557 Intraluminal duodenal diverticulum causing recurrent pancreatitis: treatment by endoscopic incision *I A Finnie, P Ghosh, C Garvey, G J Poston, J M Rhodes*
- 560 Non-fatal portal pyaemia complicating Crohn's disease of the terminal ileum *H Al-Jahdali, C Pon, W G Thompson, F R Matzinger*
- 562 Ulcerative colitis in a husband and wife *G M Batty, W E Wilkins, J S Morris*
- 564 Primary biliary cirrhosis presenting with granulomatous skin lesions *D L Jardine, S T Chambers, D J Hart, B A Chapman*
- 567 Rim calcification in primary liver cell carcinoma mimicking hydatid disease *A W Mitchell, J N P Higgins, J Tate, R Dick*
- 569 Fulminant hepatic failure secondary to hydroxychloroquine *A J Makin, J Wendon, S Fitt, B C Portmann, Roger Williams*
- 571 **Letters to the editor** **Notes** **Book reviews**
- A574 **Pancreatic Society of Great Britain and Ireland**
- No 5 MAY 1994
- Leading articles**
- 577 Liver cell death: patterns and mechanisms *M R Alison, C E Sarraf*
- 582 Persisting diarrhoea and malabsorption *G C Cook*
- 587 Cancer surveillance in ulcerative colitis – a time for reappraisal *A T R Axon*
- Oesophagus**
- 590 Omeprazole *v* ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety *J Dent, N D Yeomans, M Mackinnon, W Reed, F M Narielvala, D J Hetzel, E Solcia, D J C Shearman*
- 599 Cytochrome P450 expression in oesophageal cancer *G I Murray, D Shaw, R J Weaver, J A McKay, S W B Ewen, W T Melvin, M D Burke*
- Stomach**
- 604 Expression of transforming growth factor alpha in experimental gastric carcinogenesis *J I Livingstone, M I Filipe, C Wastell*
- 608 Endoscopic injection therapy for bleeding peptic ulcer; a comparison of adrenaline alone with adrenaline plus ethanolamine oleate *C P Choudari, K R Palmer*
- 611 Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion *S M Kelly, J R Jenner, R J Dickinson, J O Hunter*
- 615 Gastrin and somatostatin in *Helicobacter pylori* infected antral mucosa *L Odum, H D Petersen, I B Andersen, B F Hansen, J F Rehfeld*
- 619 Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community *N J Talley, A R Zinsmeister, C D Schleck, L J Melton III*
- Small intestine**
- 625 Human small intestinal contractions and aboral traction forces during fasting and after feeding *N K Ahluwalia, D G Thompson, J Barlow, L Heggie*
- 631 Relation between chloride secretion and intracellular cyclic adenosine monophosphate in a cloned human intestinal cell line HT-29 cl 19A *S K Nath, X Huang, A L 'helgoualc'h, M Rautureau, A Bisalli, M Heyman, J F Desjeux*
- 637 Failure of tropisetron to inhibit jejunal water and electrolyte secretion induced by 5-hydroxytryptamine in healthy volunteers *L K Munck, O Eskerod, M B Hansen, K Bukhave, J Rask-Madsen*
- 641 Response of the human intestine to high volume infusion *C Steadman, P Kerlin*
- 646 Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract *S Parkkila, A-K Parkkila, T Juvonen, H Rajaniemi*
- Inflammatory bowel disease**
- 651 Crohn's disease and colorectal cancer *C D Gillen, H A Andrews, P Prior, R N Allan*
- 656 Timing of ileocolonic resection for symptomatic Crohn's disease – the patient's view *N A Scott, L E Hughes*
- 658 Pouchitis: result of microbial imbalance? *J G H Ruseler-van Embden, W R Schouten, L M C van Lieshout*
- 665 Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life *A Ferguson, D M Sedgwick, J Drummond*
- 669 Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes *J Rugtveit, P Brandtzaeg, T S Halstensen, O Fausa, H Scott*

- Large intestine**
- 675 Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E₂ S Pugh, G A O Thomas
- 679 Functional hyposplenism in alcoholic liver disease: a toxic effect of alcohol? A F Muller, P J Toghill
- 683 Measurement of androgen receptor expression in adult liver, fetal liver, and Hep-G2 cells by the polymerase chain reaction A P Stubbs, J L Engelman, J I H Walker, P Faik, G M Murphy, M L Wilkinson
- 687 Combined (short term plus long term) sclerotherapy v short term only sclerotherapy: a randomised prospective trial M Moretó, M Zaballa, E Ojembarrena, S Ibáñez, M-J Suárez, F Setien, E Delgado
- Biliary tree**
- 692 Percutaneous cholecystolithotomy: is gall stone recurrence inevitable? J J Donald, S Cheslyn-Curtis, A R Gillams, R C G Russell, W R Lees
- Progress report**
- 696 Genetics of inflammatory bowel disease J Satsangi, D P Jewell, W M C Rosenberg, J I Bell
- Case reports**
- 701 Healing of protein losing hypertrophic gastropathy by eradication of *Helicobacter pylori* – Is *Helicobacter pylori* a pathogenic factor in Ménétrier's disease? E Bayerdörffer, M M Ritter, R Hatz, W Brooks, G Ruckdeschel, M Stolte
- 705 Biliary obstruction resulting from *Strongyloides stercoralis* infection. Report of a case E Delarocque Astagneau, A Hadengue, C Degott, V Vilgrain, S Erlinger, J P Benhamou
- 707 Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction S Pearce, H Thomas, D Carr, A Tanner
- 709 Spontaneous bacterial peritonitis in cystic fibrosis C F Doershuk, R C Stern
- 712 Pancreatitis induced by nitrofurantoin J-L Christophe
- 714 **Letters to the editor** Notes
- A719 **British Association for the Study of the Liver**
- Leading articles**
- 723 The urea breath test for *Helicobacter pylori* J C Atherton, R C Spiller
- 726 *Salmonella typhi* and other salmonellas B K Mandal
- 729 Hepatocyte-matrix interactions J P Iredale, M J P Arthur
- Editorial**
- 732 Introduction to new section – Views and reviews
- Oesophagus**
- 733 Temporal relationships between episodes of non-cardiac chest pain and abnormal oesophageal function H G Th Lam, R Breumelhof, G P van Berge Henegouwen, A J P M Smout
- Peptic ulcer**
- 737 Effect of ranitidine on basal and bicarbonate enhanced intragastric PCO₂: a tonometric study J J Kolkman, A B J Groeneveld, S G M Meuwissen
- 742 Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection H M Malaty, D Y Graham
- 746 Bleeding peptic ulcer – risk factors for rebleeding and sequential changes in endoscopic findings Ping-I Hsu, Xi-Zhang Lin, Shih-Huang Chan, Ching-Yih Lin, Ting-Tsung Chang, Jeng-Shiann Shin, Lie-Yuan Hsu, Chi-Chieh Yang, Kuan-Wen Chen
- 750 Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements J C Delchier, F Roudot-Thoraval, L Stanescu, M C Deharvengt, L Elouaer Blanc
- 755 Effects of *Helicobacter pylori* on histamine and carbachol stimulated acid secretion by human parietal cells H Jablonowski, K J Hengels, N Kraemer, G Geis, W Opferkuch, G Strohmeyer
- Gastrointestinal cancer**
- 758 Goseki histological grading of gastric cancer is an important predictor of outcome I G Martin, M F Dixon, H Sue-Ling, A T R Axon, D Johnston
- 764 Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence R H Hardwick, N A Shepherd, M Moorghen, P V Newcomb, D Alderson
- Coeliac disease**
- 769 Lewis phenotype, secretor status, and coeliac disease W Dickey, J D C Wylie, J S A Collins, K G Porter, R G P Watson, J C McLoughlin
- 771 Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values G Corrao, G R Corazza, M L Andreani, P Torchio, R A Valentini, G Galatola, D Quaglino, G Gasbarrini, F di Orio
- 776 Endomysium antibodies in coeliac disease: an improved method B Ladinsker, E Rosspital, K Pittschieler
- 779 Effects of gluten enriched diet on the small intestinal mucosa of normal mice and mice with graft versus host reaction R Troncone, N Caputo, A Zibella, G Moliterno, L Maiuri, S Auricchio
- Inflammatory bowel disease**
- 783 Comparison of amino acid v peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome D Royall, K N Jeejeebhoy, J P Baker, J P Allard, F M Habal, S C Cunnane, G R Greenberg
- 788 Association between Meckel's diverticulum and Crohn's disease: a retrospective review H J N Andreyev, R A Owen, I Thompson, A Forbes
- Large intestine**
- 791 Serum free medium increases expression of markers of differentiation in human colonic crypt cells P Gibson, O Rosella, G Young
- 798 Discriminant value of psychological distress, symptom profiles, and segmental colonic dysfunction in outpatients with severe idiopathic constipation R L Grotz, J H Pemberton, N J Talley, D M Rath, A R Zinsmeister
- HIV**
- 803 Is there IgA of gut mucosal origin in the serum of HIV1 infected patients? A Quesnel, Ph Moja, F Lucht, J L Touraine, B Pozzetto, C Genin
- Liver**
- 809 Serious paracetamol poisoning and the results of liver transplantation D J Mutimer, R C S Ayres, J M Neuberger, M H Davies, J Holguin, J A C Buckels, A D Mayer, P McMaster, E Elias
- 815 Intrahepatic portal occlusion by microspheres: a new model of portal hypertension in the rat V Jaffe, B Alexander, R T Mathie
- Gall stones**
- 819 Relief of heterogeneous symptoms after successful gall bladder stone lithotripsy and complete stone disappearance U Stölzel, Ch Koszka, B Wölfer, U Kleine, W Pommerien, E O Riecken

	Pancreas
822	Inflammatory response in the early prediction of severity in human acute pancreatitis <i>J A Viedma, M Pérez-Mateo, J Agulló, J E Domínguez, F Carballo</i>
	Progress reports
828	Viruses and hepatocellular carcinoma <i>S Sherlock</i>
833	Chronic, non-visceral abdominal pain <i>D Sharpstone, D G Colin-Jones</i>
	Clinical trial
837	Effect of omeprazole and sucralfate on prepyloric gastric ulcer. A double blind comparative trial and one year follow up <i>H Toft Sørensen, H Højgaard Rasmussen, I Balslev, S Boesby, J Boné, A Kruse, S Nørby Rasmussen</i>
	Case reports
841	Gastric outlet obstruction as a presenting manifestation of systemic lupus erythematosus <i>E F M Posthuma, P Warmerdam, M P Chandie Shaw, F C Breedveld, J D Macfarlane, A van der Sluys Veer, C B H W Lamers</i>
844	Coeliac disease and autoimmune thyroid disease <i>C E Counsell, A Taha, W S J Ruddell</i>
847	Unusual pulmonary complication of ulcerative colitis with rapid response to corticosteroids: case report <i>G A L Hilling, D A F Robertson, A H Chalmers, H S Rigby</i>
849	Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E <i>R Sallie, J Chiyende, K C Tan, D Bradley, B Portmann, Roger Williams, A P Mowat, G Mieli-Vergani</i>
854	Adult rhabdomyosarcoma of the gall bladder: case report and review of published works <i>T M Al-Jaberi, M Al-Masri, A Tbukhi</i>
857	Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence <i>A F Engel, M A Kamm, I C Talbot</i>
	Views and reviews
860	Personal viewpoints
862	International gastroenterology
863	Letters to the editor Book reviews Notes Corrections

No 7 JULY 1994

	Leading articles
867	Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy <i>M J Weldon, J D Maxwell</i>
872	The shigella paradigm and colitis due to enterohaemorrhagic <i>Escherichia coli</i> <i>D W K Acheson, G T Keusch</i>
875	Isolation and culture of biliary epithelial cells <i>Ruth Joplin</i>
	Oesophagus
879	Tissue culture of epithelium derived from Barrett's oesophagus <i>K Washington, M R Gottfried, M J Telen</i>
884	Effects of intraluminal acidification on oesophageal motor activity <i>I Bontempo, L Piretta, E Corazziari, F Michetti, F Anzini, A Torsoli</i>
	Peptic ulcer
891	Predicting NSAID related ulcers – assessment of clinical and pathological risk factors and importance of differences in NSAID <i>A S Taha, S Dahill, R D Sturrock, F D Lee, R I Russell</i>
896	Antacid provides better restoration of glandular structures within the gastric ulcer scar than omeprazole <i>A Schmassmann, A Tarnawski, H A Gerber, B Flogerzi, M Sanner, L Varga, F Halter</i>
905	Polymerase chain reaction assay for the detection of <i>Helicobacter pylori</i> in gastric biopsy specimens: comparison with culture, rapid urease test, and histopathological tests <i>R Fabre, I Sobhani, P Laurent-Puig, N Hedef, N Yazigi, C Vissuzaine, I Rodde, F Potet, M Mignon, J P Etienne, M Braquet</i>
909	Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha <i>L Santucci, S Fiorucci, M Giansanti, P M Brunori, F M Di Matteo, A Morelli</i>
916	Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia <i>D David, H Mertz, L Fefer, B Sytnik, H Raean, N Niazi, A Kodner, E A Mayer</i>
	Small intestine
926	Effect of dietary nucleotides on small intestinal repair after diarrhoea. Histological and ultrastructural changes <i>J Bueno, M Torres, A Almendros, R Carmona, M C Nuñez, A Rios, A Gil</i>
934	Tumour necrosis factor α changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins <i>H M Kandil, H M Berschneider, R A Argenzio</i>
	Gastrointestinal cancer
941	An audit of the treatment of cancer of the oesophagus <i>P M Sagar, T Gauperaa, H Sue-Ling, M J McMahon, D Johnston</i>
946	Gastric cancer risk after vagotomy <i>G Lundegårdh, A Ekblom, J K McLaughlin, O Nyrén</i>
950	Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention <i>P M Choi, M P Zelig</i>
	Inflammatory bowel disease
955	Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients <i>L Manzano, M Alvarez-Mon, J A Vargas, J A Girón, L Abreu, A Fernández-Corugedo, L I Román, F Albarran, A Durántez</i>
961	Observer variation and discriminatory value of biopsy features in inflammatory bowel disease <i>A Theodossi, D J Spiegelhalter, J Jass, J Firth, M Dixon, M Leader, D A Levison, R Lindley, I Filipe, A Price, N A Shepherd, S Thomas, H Thompson</i>
	Large intestine
969	Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro <i>P Gibson, O Rosella, G Rosella, G Young</i>
976	Simplified method for the measurement of segmental colonic transit time <i>A Notghi, R Hutchinson, D Kumar, N B Smith, L K Harding</i>
	Liver
982	Extent of the acute phase response in fulminant hepatic failure <i>S Izumi, R D Hughes, R P Langley, J R B Pernambuco, Roger Williams</i>
987	Study of plasma and red cell phospholipid fatty acids in extrahepatic cholestatic jaundice <i>M W Scriven, D F Horrobin, M C A Puntis</i>
	Biliary tract
991	Imaging of the common bile duct in patients undergoing laparoscopic cholecystectomy <i>P J Hainsworth, M Rhodes, R H K Gompertz, C P Armstrong, T W J Lennard</i>
	Progress report
996	Current concepts in metastasis <i>A K Nigam, M Pignatelli, P B Boulos</i>

Case reports

- 1001 Interrelation of strongyloidiasis and tuberculosis *A D Dwarakanath, M Welton, C J Ellis, R N Allan*
 1004 Budd-Chiari syndrome in a young patient with anticardiolipin antibodies: need for prolonged anticoagulant treatment *R J Th Ouwendijk, J C Koster, J H P Wilson, J Stibbe, J S Lameris, W Visser, J P Benhamou*

Views and reviews

- 1007 Personal viewpoints
 1010 **Letters to the editor** **Book review** **Notes**

No 8 AUGUST 1994

Leading articles

- 1011 Combined percutaneous and endoscopic procedures for bile duct obstruction *D F Martin*
 1013 Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus *N V Naoumov, A L W F Eddleston*
 1018 Diagnosis of invasive amoebiasis – time to end the morphology era *J I Ravdin*

Editorial

- 1021 Gut index change

Oesophagus

- 1022 Classification and localisation of carcinoembryonic antigen (CEA) related antigen expression in normal oesophageal squamous mucosa and squamous carcinoma *D S A Sanders, C A Wilson, F J Bryant, J Hopkins, G D Johnson, D M Milne, M A Kerr*

Acid related disease

- 1026 Acupuncture inhibits vagal gastric acid secretion stimulated by sham feeding in healthy subjects *G Lux, J Hagel, P Bäcker, G Bäcker, R Vogl, H Ruppin, S Domschke, W Domschke*
 1030 Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs *N Hudson, S Everitt, C J Hawkey*

Helicobacter pylori

- 1033 Duodenal ulcer, *Helicobacter pylori*, and gastric secretion *K Chandrakumaran, D Vaira, M Hobsley*

Celiac disease

- 1037 Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation *M Kontakou, R P Sturgess, R T Przemioslo, G A Limb, J M Nelufer, P J Ciclitira*

Small intestine

- 1042 Morphological method for the diagnosis of human adult type hypolactasia *L Maiuri, M Rossi, V Raia, F Paparo, S Coletta, F Mazzeo, A Breglia, S Auricchio*
 1047 Role of bile in non-specific defence mechanisms of the gut *T Kalambaheti, G N Cooper, G D F Jackson*
 1053 Intestinal perfusion of dietary levels of aluminium: association with the mucosa *J J Powell, C C Ainley, R Evans, R P H Thompson*
 1058 Effects of diet on experimentally induced intestinal ulcers in rats: morphology and tissue leukotrienes *T Matsumoto, M Iida, F Kuroki, K Hizawa, H Koga, M Fujishima*

Motility

- 1064 Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders *K Haruma, J A Wiste, M Camilleri*

Inflammatory bowel disease

- 1070 The first 10 years' experience of restorative proctocolectomy for ulcerative colitis *P Setti-Carraro, J K Ritchie, K H Wilkinson, R J Nicholls, P R Hawley*
 1076 Surgery for ulcerative colitis in the era of the pouch: The St Mark's Hospital experience *D M Melville, J K Ritchie, R J Nicholls, P R Hawley*
 1081 Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis *S Schreiber, S Howaldt, A Raedler*

Large intestine

- 1086 Immunoelectron microscopic localisation of transforming growth factor alpha in rat colon *R Pérez-Tomás, X Culleré, M Asbert, D Díaz-Ruiz*
 1090 Role of intestinal microflora in chronic inflammation and ulceration of the rat colon *S Videla, J Vilaseca, F Guarner, A Salas, F Treserra, E Crespo, M Antolin, J-R Malagelada*
 1098 Methanogens outcomplete sulphate reducing bacteria for H₂ in the human colon *A Stocchi, J Furne, C Ellis, M D Levitt*
 1102 Enhancement of ethanol induced rectal mucosal hyper regeneration with age in F344 rats *U A Simanowski, P Suter, R M Russell, M Heller, R Waldherr, R Ward, T J Peters, D Smith, H K Seita*

Liver

- 1107 Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis *Y M Deugnier, A-F Rabot, D Guyader, R Moirand, B Turlin, E Boucher, P Lebert, P Brissot*
 1112 Safety of general anaesthesia and surgery in acute hepatic porphyria *S B Dover, L Plenderleith, M R Moore, K E L McColl*

Bile acids

- 1116 Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism *J-E Åkerlund, I Björkhem, B Angelin, L Liljeqvist, K Einarsson*

Gall bladder

- 1121 Prospective audit of the introduction of laparoscopic cholecystectomy in the west of Scotland *G M Fullarton, G Bell, and the west of Scotland laparoscopic cholecystectomy audit group*

Pancreatitis

- 1127 Bile induced acute oedematous pancreatitis in rats: non-parallel changes in pancreatic morphology and amylase release in vitro *T Arendt, U Broschewitz*
 1132 Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis *T Bozkurt, U Braun, S Leferink, G Gilly, G Lux*

Case reports

- 1137 Avulsion of short gastric arteries caused by vomiting *N Hayes, P D Waterworth, S M Griffin*
 1139 Bowel diversion should be used with caution in stenosing anal Crohn's disease *M E R Williamson, L E Hughes*
 1141 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment *A D Dwarakanath, J Nash, J M Rhodes*
 1145 Systemic arteriovenous malformations: a feature of advanced liver disease *R Alcolado, J Bowry, P J Winwood, C A Loehry*

	Views and reviews
1148	Personal viewpoint
1149	International gastroenterology
1150	Letters to the editor Book review Notes Correction

No 9 SEPTEMBER 1994

	Leading articles
1155	New salicylates as maintenance treatment in ulcerative colitis <i>Gunnar Järnerot</i>
1159	<i>Enterobius vermicularis</i> infection <i>G C Cook</i>
1163	Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms <i>C Trautwein, K Böker, M P Manns</i>
	Gastritis
1167	Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992 <i>P Sipponen, T Helske, P Järvinen, H Hyvärinen, K Seppälä, M Siurala</i>
1172	Histological assessment of the Sydney classification of endoscopic gastritis <i>S I Khakoo, A J Lobo, N A Shepherd, S P Wilkinson</i>
1176	Interaction of <i>Helicobacter pylori</i> and its fatty acids with parietal cells and gastric H ⁺ /K ⁺ -ATPase <i>W Beil, C Birkholz, S Wagner, K-F Sewing</i>
	Gastric mucosal injury
1181	A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats <i>D Rachmilewitz, F Karmeli, E Okon, A Samuni</i>
1189	Role of gastric blood flow, neutrophil infiltration, and mucosal cell proliferation in gastric adaptation to aspirin in the rat <i>S J Konturek, T Brzozowski, J Stachura, A Dembinski, J Majka</i>
1197	Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation <i>J W Konturek, A Dembinski, R Stoll, W Domschke, S J Konturek</i>
1205	Magnesium hydrogen breath test using end expiratory sampling to assess achlorhydria in pernicious anaemia patients <i>P Humbert, P López de Soria, F Fernández-Bañares, J Juncá, J Boix, R Planas, J C Quer, E Domenech, M A Gassull</i>
	Endoscopy
1209	Appropriate use of upper gastrointestinal endoscopy – a prospective audit <i>M A Quine, G D Bell, R F McCloy, H B Devlin, A Hopkins, and the Steering Group of the Upper Gastrointestinal Endoscopy Audit Committee</i>
	Coeliac disease
1215	Coeliac disease – associated disorders and survival <i>P Collin, T Reunala, E Pukkala, P Laippala, O Keyriläinen, A Pasternack</i>
1219	Localisation of vitamin D receptor in normal human duodenum and in patients with coeliac disease <i>K W Colston, A G Mackay, C Finlayson, J C Y Wu, J D Maxwell</i>
1226	Adenovirus 12 E1A gene detection by polymerase chain reaction in both the normal and coeliac duodenum <i>M Lawler, P Humphries, C O'Farrelly, H Hoey, O Sheils, M Jeffers, D S O'Briain, D Kelleher</i>
	Small intestine
1233	Phytase activity in the human and rat small intestine <i>T H Iqbal, K O Lewis, B T Cooper</i>
1237	Role of the enteric nervous system in the maintained hypersecretion induced by enterotoxin STa in the nutritionally deprived intestine <i>H C Nsegwu, R J Levin</i>
1244	Studies on the enteropathy associated with primary hypogammaglobulinaemia <i>K Teahon, A D Webster, A B Price, J Weston, I Bjarnason</i>
1250	Distribution of membrane bound guanylyl cyclases in human intestine <i>G Krause, A Bayerl, J-M Heim, S Singh, R Gerzer</i>
	Colorectal cancer
1258	Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours <i>M Yukawa, T Fujimori, S Maeda, M Tabuchi, K Nagasako</i>
1262	Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols <i>H F A Vasen, B G Taal, G Griffioen, F M Nagengast, A Cats, F H Menko, W Oskam, J H Kleibeuker, G J A Offerhaus, P Meera Khan</i>
1267	Comparison of gastrointestinal symptoms in colorectal carcinoma patients and community controls with respect to age <i>R Curless, J French, G V Williams, O F W James</i>
	Large intestine
1271	In vitro acetaldehyde formation by human colonic bacteria <i>K Jokelainen, R P Roine, H Väänänen, M Färkkilä, M Salaspuro</i>
1275	Diverting colostomy induces mucosal and muscular atrophy in rat distal colon <i>P Kissmeyer-Nielsen, H Christensen, S Laurberg</i>
	Inflammatory bowel disease
1282	Optimum dose of olsalazine for maintaining remission in ulcerative colitis <i>S P L Travis, C Tysk, H J de Silva, H Sandberg-Gertzén, D P Jewell, G Järnerot</i>
	Liver
1287	Thrombin – an effective treatment for gastric variceal haemorrhage <i>S G J Williams, R A Peters, D Westaby</i>
1290	Portal and systemic haemodynamic action of N-acetylcysteine in patients with stable cirrhosis <i>A L Jones, I H Bangash, I A D Bouchier, P C Hayes</i>
	Gall stones
1294	Cost effectiveness of adjuvant bile salt treatment in extracorporeal shock wave lithotripsy for the treatment of gall bladder stones <i>J P Nicholl, B Ross, P C Milner, J E Brazier, L Westlake, B Kohler, E Frost, B T Williams, A G Johnson</i>
1301	Symptoms and health status before and six weeks after open cholecystectomy: a European cohort study <i>N A Black, E Thompson, C F B Sanderson, and the ECHSS group</i>
	Acute pancreatitis
1306	Routes of spread of pathogens into the pancreas in a feline model of acute pancreatitis <i>A L Widdison, N D Karanjia, H A Reber</i>
1311	Trypsinogen activation peptides (TAP) concentrations in the peritoneal fluid of patients with acute pancreatitis and their relation to the presence of histologically confirmed pancreatic necrosis <i>D I Heath, C Wilson, A M Gudgeon, A Jehanli, A Shenkin, C W Imrie</i>
	Case reports
1316	Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium <i>M C Comes, C Gower-Rousseau, J F Colombel, J Belaïche, H J Van Kruiningen, M C Nuttens, A Cortot</i>

- 1319 Intraspincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction *P J Pasricha, E P Miskovsky, A N Kalloo*
 1322 Primary amyloidosis and severe intrahepatic cholestatic jaundice *R A Peters, G Koukoulis, A Gimson, B Portmann, D Westaby, R Williams*

Views and reviews

- 1326 International gastroenterology
 1329 **Letters to the editor** **Book reviews** **Note**

No 10 OCTOBER 1994

Leading articles

- 1331 Perisinusoidal lipocytes and fibrogenesis *A M Gressner*
 1334 Gastrointestinal manifestations of schistosomiasis *G Thomas Strickland*
 1338 Functional aspects of small bowel transplantation: past, present, and future *M A C Meijssen, E Heineman*

Special report

- 1342 Gastrointestinal endoscopy in general practice

Oesophagus

- 1343 Cell adhesion molecules in oesophageal epithelium *H Dobson, M Pignatelli, D Hopwood, C D'Arrigo*
 1348 Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus
M B E Menke-Pluymers, A H Mulder, W C J Hop, M van Blankenstein, H W Tilanus, The Rotterdam Oesophageal Tumour Study Group
 1352 24 Hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus *C S Neumann, B T Cooper*
 1356 β Adrenergic modulation of human upper intestinal propulsive forces *N K Ahluwalia, D G Thompson, J Barlow, L Heggie*
 1360 Forceful dilatation under endoscopic control in the treatment of achalasia: a randomised trial of pneumatic versus metallic dilator *F Mearin, J R Armengol, L Chicharro, M Papo, A Balboa, J R Malagelada*
 1363 Impaired oesophageal transit of capsule versus tablet formulations in the elderly *A C Perkins, C G Wilson, P E Blackshaw, R M Vincent, R J Dansereau, K D Juhlin, P J Bekker, R C Spiller*

Gastric cancer

- 1368 Dukes's classification: a valid prognostic indicator for gastric cancer *Y Adachi, M Mori, Y Maehara, K Sugimachi*
 1372 *Helicobacter pylori* and early gastric cancer *M E Craanen, P Blok, W Dekker, G N J Tytgat*

Helicobacter pylori

- 1375 Rebamipide, a novel antiulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidants *M Suzuki, S Miura, M Mori, A Kai, H Suzuki, D Fukumura, M Suematsu, M Tsuchiya*
 1379 Gastric T lymphocyte responses to *Helicobacter pylori* in patients with *H pylori* colonisation *X J Fan, A Chua, C N Shahi, J McDevitt, P W N Keeling, D Kelleher*
 1385 Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine *E El-Omar, I Penman, G Cruikshank, S Dover, S Banerjee, C Williams, K E L McColl*

Peptic ulcer

- 1389 Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study *Hwai-jeng Lin, Chin-Lin Perng, Fa-Yauh Lee, Chen-Hsen Lee, Shou-Dong Lee*
 1394 Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients *D Rachmilewitz, F Karmeli, R Eliakim, R Stalnikowicz, Z Ackerman, G Amir, J S Stamler*

Small intestine

- 1398 Raised pro-inflammatory cytokines interleukin 6 and tumour necrosis factor α in coeliac disease mucosa detected by immunohistochemistry *R T Przemioslo, M Kontakou, V Nobili, P J Ciclitira*
 1404 Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: need for standardisation *M Peeters, M Hiele, Y Ghos, V Huysmans, K Geboes, G Vantrappen, P Rutgeerts*
 1409 Gastrointestinal adaptation to enhanced small intestinal lipid exposure *N J Brown, R D E Rumsey, N W Read*
 1413 Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells *M El-Salhy, O Suhr, R Stenling, E Wilander, L Grimelius*

Inflammatory bowel disease

- 1419 Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis *W R Connell, I C Talbot, N Harpaz, N Britto, K H Wilkinson, M A Kamm, J E Lennard-Jones*
 1424 Ileal and colonic fatty acid profiles in patients with active Crohn's disease *S Bühner, E Nagel, J Körber, H Vogelsang, T Linn, R Pichlmayr*
 1429 Increased leukotriene B₄ release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis *D J Gertner, D S Rampton, M V Madden, I C Talbot, R J Nicholls, J E Lennard Jones*
 1433 Incidence of inflammatory bowel disease in northern France (1988-1990) *C Gower-Rousseau, J-L Salomez, J-L Dupas, R Marti, M-C Nuttens, A Votte, M Lemahieu, B Lemaire, J-F Colombel, A Cortot*
 1439 A budesonide prodrug accelerates treatment of colitis in rats *N Cui, D R Friend, R N Fedorak*

Large intestine

- 1447 Effect on lymph node status of triple levelling and immunohistochemistry with CAM 5.2 on node negative colorectal carcinomas *A G Nicholson, C G Marks, M G Cook*
 1449 Adhesion of human enterotoxigenic *Escherichia coli* to human mucus secreting HT-29 cell subpopulations in culture *S Kerneis, M F Bernet, M H Coconnier, A L Servin*
 1455 Evidence for the ambiguity of the term constipation: the role of irritable bowel syndrome *C S J Probert, P M Emmett, H A Cripps, K W Heaton*

Liver

- 1459 Respiratory function after injection sclerotherapy of oesophageal varices *T Samuels, M C Lovett, I T Campbell, C Makin, J Davies, S A Jenkins, J N Baxter*

Biliary tract

- 1464 Common bile duct stones are mainly brown and associated with duodenal diverticula *O Sandstad, T Osnes, V Skar, P Urdal, M Osnes*

Pancreas

- 1468 Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor α , and phospholipase C γ *M Korc, H Friess, Y Yamanaka, M S Kobrin, M Buchler, H G Beger*
 1474 Chronic ethanol consumption increases the fragility of rat pancreatic zymogen granules *P S Haber, J S Wilson, A V Apte, M A Korsten, R C Pirola*

1479 Natural course of operated pseudocysts in chronic pancreatitis *A Löhr-Happe, M Peiper, P G Lankisch*
Progress report
 1483 Enterocyte proliferation and intracellular bacteria in animals *S McOrist, C J Gebhart, G H K Lawson*
Hypothesis
 1487 Did malaria select for primary adult lactase deficiency? *B Anderson, C Vullo*
Case reports
 1490 Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR) *M G V M Russel, R N M Zeijen, R-J M Brummer, A P de Bruine, M J P G van Kroonenburgh, R W Stockbrügger*
 1493 Mesalazine induced interstitial nephritis *P J Thuluvath, M Ninkovic, J Calam, M Anderson*
 1497 Copper associated childhood cirrhosis *S P Horslen, M S Tanner, T D B Lyon, G S Fell, M F Lowry*
 1501 Pancreatic outflow obstruction as the critical event for human gall stone induced pancreatitis *M M Lerch, H Weidenbach, C A Hernandez, G Preclik, G Adler*
Views and reviews
 1504 Personal viewpoint
 1506 **Letter to the editor Book review Notes**

No 11 NOVEMBER 1994

Leading articles
 1507 Cancer in Crohn's disease: dispelling the myths *D B Sachar*
 1509 Cell biology of liver endothelial and Kupffer cells *B Smedsrød, P J De Bleser, F Braet, P Lovisetti, K Vanderkerken, E Wisse, A Geerts*
 1517 Echinococcus of the liver *D L Morris*
Oesophageal motility
 1519 Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring *R Timmer, R Breumelhof, J H S M Nadorp, A J P M Smout*
 1523 Secondary oesophageal peristalsis in patients with non-obstructive dysphagia *M N Schoeman, R H Holloway*
Oesophageal reflux
 1529 Prospective evaluation of 24 hour ambulatory pH metry in Belsey Mark IV antireflux surgery *J M L M Horbach, A A M Masclee, C B H W Lamers, H G Gooszen*
 1536 Primary peristalsis is the major acid clearance mechanism in reflux patients *A Anggiansah, G Taylor, N Bright, J Wang, W A Owen, T Rokkas, A R Jones, W J Owen*
Stomach
 1543 Intra-gastric nitric oxide production in humans: measurements in expelled air *J O N Lundberg, E Weitzberg, J M Lundberg, K Alving*
 1547 Evaluation of the trophic effect of longterm treatment with the histamine H₂ receptor antagonist loxidine on rat oxyntic mucosa by differential counting of dispersed cells *E Brenna, H G P Swarts, C H W Klaassen, J J H H M de Pont, H L Waldum*
 1551 Percutaneous endoscopic gastrostomy in a general hospital: prospective evaluation of indications, outcome, and randomised comparison of two tube designs *M Z Panos, H Reilly, A Moran, T Reilly, P J W Wallis, R Wears, I M Chesner*
Helicobacter pylori
 1557 Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect of diet on peptic ulceration *L Thompson, A Cockayne, R C Spiller*
 1562 High prevalence of *Helicobacter pylori* metronidazole resistance in migrants to east London; relation with previous nitroimidazole exposure and gastroduodenal disease *N Banatvala, G R Davies, Y Abdi, L Clements, D S Rampton, J M Hardie, R A Feldman*
 1567 Cytokine gene expression in *Helicobacter pylori* associated antral gastritis *S F Moss, S Legon, J Davies, J Calam*
 1571 Improved fold width and increased acid secretion after eradication of the organism in *Helicobacter pylori* associated enlarged fold gastritis *Y Yasunaga, Y Shinomura, S Kanayama, M Yabu, T Nakanishi, Y Miyazaki, Y Murayama, J J Bonilla-Palacios, Y Matsuzawa*
Small intestine
 1575 Characterisation of oxidative injury to an intestinal cell line (HT-29) by hydrogen peroxide *A J M Watson, J N Askew, G I Sandle*
 1582 Lymphoid and non-lymphoid cells in the epithelium and lamina propria of intestinal mucosa of pigs *H J Rothkötter, T Kirchoff, R Pabst*
Inflammatory bowel disease
 1590 Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis *C D Gillen, R S Walmsley, P Prior, H A Andrews, R N Allan*
 1593 Increased group II phospholipase A₂ in colonic mucosa of patients with Crohn's disease and ulcerative colitis *T Minami, H Tojo, Y Shinomura, Y Matsuzawa, M Okamoto*
 1599 Microalbuminuria in inflammatory bowel disease *N Mahmud, J Stinson, M A O'Connell, T J Mantle, P W N Keeling, J Feely, D G Weir, D Kelleher*
Large intestine
 1605 Nerve growth factor receptor immunostaining suggests an extrinsic origin for hypertrophic nerves in Hirschsprung's disease *H Kobayashi, D S O'Briain, P Puri*
 1608 Clinical significance of *Clostridium difficile* and its toxins in faeces of immunocompromised children *M J H M Wolfhagen, K Meijer, A C Fluit, R Torensma, R A Bruinsma, A Fleer, J Verhoef*
 1613 Effect of *Escherichia coli* enterotoxins on macromolecular absorption *M Verma, S Majumdar, N K Ganguly, B N S Walia*
 1617 Diagnostic yield and management benefit of laparoscopy: a prospective audit *G C Vander Velpen, S M Shimi, A Cuschieri*
Familial adenomatous polyposis
 1622 Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis *K P Nugent, R K S Phillips, S V Hodgson, S Cottrell, J Smith-Ravin, K Pack, W F Bodmer*
 1624 Rectal mucosal ornithine decarboxylase activity in familial adenomatous polyposis after ileorectal anastomosis *S E Patchett, E M Alstead, L Trzeciak, T Wocial, R K S Phillips, M J G Farthing*
Colorectal cancer
 1627 Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance *M Morrin, M Kelly, N Barrett, P Delaney*
 1632 Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth *W J Adams, J A Lawson, D L Morris*

- Liver**
- 1637 Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake *P Clot, M Tabone, S Aricò, E Albano*
- 1644 Lipid peroxidation in rats chronically fed ethanol *J P Teare, S M Greenfield, D Watson, N A Punchard, N Miller, C A Rice-Evans, R P H Thompson*
- 1648 Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis *J M Llovet, R Bartoli, R Planas, E Cabré, M Jimenez, A Urban, I Ojanguren, J Arnal, M A Gassull*
- Gall stones**
- 1653 Addition of dimethylsulphoxide to methyl-*tert*-butyl ether and ethyl propionate increases cholesterol dissolving capacity and cholesterol gall stone dissolution in vitro *J J G H M Bergman, A K Groen, K Huibregtse, G N J Tytgat*
- Pancreas**
- 1659 Specific interaction of pancreatic elastase and leucocytes to produce oxygen radicals and its implication in pancreatitis *N Tsuji, N Watanabe, T Okamoto, Y Niitsu*
- Case reports**
- 1665 Distal biliary stricture as a complication of sclerosant injection for bleeding duodenal ulcer *W Luman, N Hudson, C P Choudari, M A Eastwood, K R Palmer*
- 1668 Polypoid mucosal prolapse in a pelvic ileal reservoir *J M Blazeby, P Durdey, B F Warren*
- 1670 Cap polyposis occurring in the postoperative course of pelvic surgery *M Géhénot, J-F Colombel, W Wolschies, P Quandalle, P Gower, M Lecomte-Houcke, H Van Kruiningen, A Cortot*
- Views and reviews**
- 1673 Personal viewpoint
- 1675 **Letters to the editor Book reviews Notes**
- A1680 **British Stomach Cancer Group**
- No 12 DECEMBER 1994
- Leading articles**
- 1683 *Helicobacter pylori* in eastern European countries: what is the current status? *T Matysiak-Budnik, F Mégraud*
- 1687 Paediatric problems in tropical gastroenterology *J A Walker-Smith*
- Oesophagus**
- 1690 Nitrinergic and peptidergic innervation of the human oesophagus *C Singaram, A Sengupta, M A Sweet, D J Sugarbaker, R K Goyal*
- Stomach**
- 1697 Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa *M J Brito, G T Williams, H Thompson, M I Filipe*
- Small intestine**
- 1701 Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat *L Meleagros, M A Ghatel, S R Bloom*
- 1707 Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery: effect of zinc supplementation *A N Alam, S A Sarker, M A Wahed, M Khatun, M M Rahaman*
- Inflammatory bowel disease**
- 1712 Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody *A Dasgupta, A Mandal, K M Das*
- 1718 Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis *M G Thomas, K P Nugent, A Forbes, R C N Williamson*
- 1721 Longterm appraisal of the histological appearances of the ileal reservoir mucosa after restorative proctectomy for ulcerative colitis *P Setti Carraro, I C Talbot, R J Nicholls*
- 1728 Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection *G D'Haens, M Hiele, P Rutgeerts, K Geboes, J L Ceuppens*
- Large intestine**
- 1734 Colonic secretory effect in response to enteral feeding in humans *T E Bowling, A H Raimundo, G K Grimble, D B A Silk*
- 1742 Divergent effects of epidermal growth factor and calcipotriol on human rectal cell proliferation *M G Thomas, G R Brown, M R Alison, R C N Williamson*
- 1747 Digestibility and bulking effect of ispaghula husks in healthy humans *P Marteau, B Flourié, C Cherbut, J-L Corrèze, P Pellier, J Seylaz, J-C Rambaud*
- Liver**
- 1753 Resistance of erythrocytes to lipid peroxidation in alcoholic patients *N A Punchard, H Senturk, J P Teare, R P H Thompson*
- Biliary tree**
- 1757 Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid *S Ghosh, K R Palmer*
- Gall stones**
- 1760 Rapid cholesterol nucleation time and cholesterol gall stone formation after subtotal or total colectomy in humans *I Makino, K Chijiwa, H Higashijima, S Nakahara, M Kishinaka, S Kuroki, R Mibu*
- Progress report**
- 1765 Enteral nutrition and the small intestine *A P Jenkins, R P H Thompson*
- Views and reviews**
- 1770 Personal viewpoint
- 1772 **Letters to the editor Book reviews Notes**
- 1777 **Author index – Main headings, 1994**
- 1781 **Subject index – Main headings, 1994**
- 1796 **Author index – Supplements, 1994**
- 1800 **Subject index – Supplements, 1994**

AUTHOR INDEX - MAIN HEADINGS, 1994

Key: LA=Leading Article: C=Correspondence

- Abdi Y, 1562
 Abou El Fadil F, 395
 Abreu L, 955
 Acheson DWK, 872 (LA)
 Ackerman Z, 1394
 Adachi Y, 1368
 Adams WJ, 1632
 Adenis A, 231
 Adler G, 1501
 Agarwal DK, 112
 Agulló J, 822
 Ahluwalia NK, 327, 625, 1356
 Ainley CC, 1053
 Aiso S, 224
 Åkerlund J-E, 1116
 Al-Jaberi TM, 854
 Al-Jadhali H, 560
 Al-Mardini H, A719
 Al-Masri N, 854
 Alam AN, 1707
 Albano E, 1637
 Albarrañ F, 955
 Alcolado R, 1145
 Alderson D, 764
 Alexander B, 815
 Alexander-Williams J, 1673
 Alison MR, 577 (LA), 1742
 Allan A, 236
 Allan RN, 94, 220, 651, 1001, 1590
 Allard JP, 783
 Allen A, 247, 353
 Almendros A, 926
 Alstead EM, 51, 467, 1624
 Altwood A, A576
 Alvarez-Mon M, 955
 Alving K, 1543
 Amir G, 1394
 Ammann RW, 552
 Andersen G, 132
 Andersen IB, 615
 Anderson B, 1487
 Anderson JR, 461
 Anderson M, 1493
 Andreani ML, 771
 Andreotti F, 117
 Andrews HA, 220, 651, 1590
 Andreyev HJN, 788
 Angelin B, 1116
 Anggiansah A, 1536
 Anness V, 1676 (C)
 Antolin M, 517, 1090
 Anzini F, 884
 Apte MV, 1474
 Arends JW, 530
 Arendt T, 1127
 Argenzio RA, 934
 Aricó S, 1637
 Armengol JR, 1360
 Armstrong CP, 991
 Armstrong D, 455
 Arnal J, 1648
 Arranz E, 476
 Arthur MJ, 729 (LA)
 Arthur MJP, A721
 Asbert M, 1086
 Askew JN, 1575
 Asquith P, 1151 (C)
 Astagneau ED, 705
 Atherton JC, 723 (LA)
 Atkinson M, 861
 Auricchio S, 779, 1042
 Austin R, A1680
 Axon A, 284 (C)
 Axon ATR, 429 (C), 587 (LA), 758, 863 (C)
 Ayres RCS, 809
- Babb RR, 1151 (C)
 Bäcker G, 1026
 Bäcker P, 1026
 Bäder M, 471
 Baeten CGM1, 530
 Baillie J, 284 (C)
 Baize M, 122
 Baker JP, 783
 Balboa A, 1360
 Ballinger AB, 467
 Balslev I, 837
 Banatvala N, 179, 1562
 Bancewicz J, 165
 Banerjee S, 317, 1385
 Bangash IH, 1290
 Bannister S, A575
 Baratz M, 373
 Barbara L, 309
 Barbera R, 714 (C)
 Barlow J, 625, 1356
 Baron JH, 15, 323
 Barrett N, 1627
 Bartlett K, A719
 Bartoli R, 1648
 Basilisco G, 714 (C)
 Bassendine MF, 98, 260, 266, A720, A721, A722
 Bateson MC, 716 (C)
 Batty GM, 562
 Baxter JN, A575, 1459
 Bayerdörffer E, 701
 Bayerl A, 1250
 Beattie AD, 191, 317
 Beaugier L, 426
 Beger HG, 1468
 Bell W, 1176
 Bekker PJ, 1363
 Belaiche J, 231, 1316
- Bell G, 1121
 Bell GD, 1209
 Bell JI, 696
 Benhamou JP, 705, 1004
 Bennett MK, 266
 Bennett RJM, 327
 Bergman JGHM, 1653
 Bernet MF, 483, 1449
 Berry AR, 288 (C)
 Berschneider HM, 934
 Bhattacharya S, A721
 Bianchi PA, 714 (C)
 Biasco G, 309
 Bijlsma PB, 338
 Bille J, 23
 Binder V, 68, 360
 Binmoeller KF, 417
 Birkholz C, 1176
 Bisalli A, 631
 Bjarnason I, 1244
 Björkhem I, 1116
 Black NA, 1301
 Blackshaw PE, 186, 1363
 Blake DR, 179
 Blanc LE, 750
 Blazey JM, 1668
 Blijham GH, 530
 Blok P, 1372
 Bloom SR, 1701
 Blum A, 23
 Blum AL, 455
 Blumberg BS, 1770
 Bode J, 476
 Bodmer WF, 1622
 Boeig H, 717 (C)
 Boesby S, 837
 Bohnacker S, 417
 Boix J, 1205
 Böker K, 1163 (LA)
 Bomford A, A720
 Bone A, A575
 Boné J, 837
 Bonenkamp JJ, A1681
 Bonilla-Palacios JJ, 1571
 Bontempo I, 884
 Booker SV, 377
 Booth JC, A720
 Borch K, 140 (C)
 Bordas JM, 8
 Börsch G, 19
 Boscaini M, 117
 Bosma NB, 1151 (C)
 Boucher E, 1107
 Bouchier-Hayes D, A575
 Bouchier IAD, 1290
 Boulos PB, 996
 Bouvry M, 231
 Bowling TE, 1734
 Bowry J, 1145
 Boyle MA, 73
 Bozkurt T, 1132
 Bradley D, 849
 Braet F, 1509 (LA)
 Braganza JM, A574
 Bramhall SR, A576
 Brandtzaeg P, 669
 Braquet M, 905
 Brassart D, 483
 Braun U, 1132
 Brazier JE, 1294
 Breedveld FC, 841
 Breglia A, 1042
 Brenna E, 1547
 Bretagne J-F, 231
 Breumelhof R, 733, 1519
 Bright N, 1536
 Brito MJ, A1680, 1697
 Britto N, 1419
 Broe P, A575
 Brönnimann B, 130
 Brooks W, 701
 Broomé U, 84
 Broschewitz U, 1127
 Brotens C, 286 (C)
 Brousse N, 426
 Brown D, A721
 Brown DL, 61
 Brown GR, 1742
 Brown JL, A720
 Brown NJ, 1409
 Brown WR, 224
 Bruinsma RA, 1608
 Brullet E, 286 (C)
 Brummer R-JM, 1490
 Brunori PM, 909
 Bryant FJ, 1022
 Brzozowski T, 1189
 Buchler M, 1468
 Buckels JAC, 809
 Bueno J, 926
 Bühner S, 1424
 Bukhave K, 637
 Burke MD, 599
 Burke P, A575
 Burt AD, 98, A722
 Butcher PD, 51
- Cabré E, 1648
 Calam J, 1493, 1567
 Caleraft B, 363
 Calvet X, 286 (C)
 Cameron AJ, 864 (C)
 Camilleri M, 536, 1064
- Campbell G, A575
 Campbell IT, 1459
 Campo R, 286 (C)
 Caplan MS, 215
 Caputo N, 779
 Carballo F, 822
 Carmona R, 926
 Carnaby S, 51, 211
 Carpenter M, 98
 Carr D, 707
 Carter CR, 461
 Casellas F, 517
 Cathignol D, 395
 Catnach SM, 441 (LA), 467
 Cats A, 1262
 Cattan AR, 266
 Cawkwell L, 141 (C)
 Caygill CPJ, 1675 (C)
 Cederberg C, 455
 Celle G, 1151 (C)
 Cellier C, 231
 Ceska M, 338
 Ceuppens JL, 1728
 Cevallos AM, 51
 Chalmers AH, 847
 Chambers DL, 564
 Champarnaud G, 343
 Chan S-H, 746
 Chandie Shaw MP, 841
 Chandrakumaran K, 1033
 Chang T-T, 746
 Chapelon J-Y, 395
 Chapman BA, 564
 Chapman MAS, 73, 1152 (C)
 Chapman RWG, A719
 Chatelet F-P, 426
 Chaussade S, 141 (C), 287 (C)
 Chayvialle J-A, 490
 Cheeseman P, A719
 Chen D, A576
 Chen K-W, 746
 Cherbut C, 1747
 Cheslyn-Curtis S, 692
 Chesner IM, 1551
 Chia YW, 388
 Chicharro L, 1360
 Chijiwa K, 1760
 Chiyende J, 849
 Choi PM, 863 (C), 950
 Choudari CP, 464, 608, 1665
 Choudhuri G, 112
 Christensen H, 1275
 Christensen LA, 287 (C)
 Christophe J-L, 712
 Chu M, 140 (C)
 Chua A, 1379
 Cichitira PJ, 1037, 1398
 Clark ML, 211, 467
 Clarke E, 127
 Clements L, 1562
 Clot P, 1637
 Cockayne A, 1557
 Coconnier MH, 1449
 Coghill NF, 1153 (C)
 Coletta S, 1042
 Colin-Jones DG, 304, 833
 Collier JD, 98, 266, A721, A722
 Collin P, 1215
 Collins JSA, 769
 Colombel JF, 1316, 1433, 1670
 Colston KW, 1219
 Comes MC, 1316
 Connell WR, 347, 1419
 Conte R, 309
 Cook GC, 582 (LA), 1159 (LA)
 Cook MG, 1447
 Cooper BT, 423, 1233, 1352
 Cooper GN, 1047
 Copeman M, 247
 Corazza GR, 771
 Corazziari E, 884
 Corless DJ, A1681, A1682
 Corrao G, 771
 Corrèze J-L, 1747
 Cortot A, 1316, 1433, 1670
 Cosnes J, 426
 Cotton PB, 284 (C)
 Cottrell S, 1622
 Counsell CE, 844
 Cowan RE, 717 (C)
 Craanen ME, 1372
 Crean GP, 191
 Cremer M, 122
 Crespo E, 1090
 Cripps HA, 1455
 Crockard AD, 511
 Crowe J, 127, 1010 (C)
 Cruikshank G, 1385
 Cuber J-C, 490
 Cuccurullo F, 284 (C)
 Cui N, 1439
 Culleré X, 1086
 Cummins C, A576
 Cunnane SC, 783
 Curless R, 1267
 Cuschieri A, 1617
- Dahill S, 317, 891
 Dalekos GN, 369
 Dansereau RJ, 1363
 D'Arrigo C, 1343
 Das KM, 1712
 Dasgupta A, 1712
 David D, 916
- Davidson M, 360
 Davidson GP, 159
 Davies GR, 179, 1562
 Davies J, 1459, 1567
 Davies MH, 809
 Davies PS, 363
 Davison SM, A719
 De Bleser PJ, 1509 (LA)
 de Bruine AP, 1490
 de Castecker JS, 447
 de Maria N, 865 (C)
 de Pont JHHM, 1547
 de Silva HJ, 1282
 Deardon D, A574
 Deen KI, 391
 Degott C, 705
 Deharvengt MC, 750
 Dekker W, 1372
 Delaney P, 1627
 Delchier JC, 750
 Delgado E, 687
 Dembinski A, 1189, 1197
 Demizot Y, 141 (C), 287 (C)
 Dent J, 159, 172, 590
 Desjeux JF, 631
 Devigier YM, 1107
 Deviere J, 122
 Devlin HB, 1209
 Dewsnap MP, 285 (C)
 D'Haens G, 1728
 Dhawan A, A719
 Di Matteo FM, 909
 di Orio F, 771
 Diaz-Ruiz C, 1086
 Dick R, 567, A721
 Dickey W, 769
 Dickinson RJ, 611
 DiMaggio EP, 1772 (C)
 Dimani N, A1681
 Dimberg J, 40
 Dixon M, 961
 Dixon MF, 758
 Dobson H, 1343
 Doershuk CF, 709
 Dolan S, A575
 Domenech E, 1205
 Dominguez JE, 822
 Domschke S, 1026
 Domschke W, 1026, 1197
 Donald JJ, 692
 Donnelly R, 278
 Donoso S, 101
 Dover S, 1385
 Dover SB, 1112
 Drummond J, 665
 Dunn JA, 94
 Dupas J-L, 1433
 Duránte A, 955
 Durdey P, 1668
 Duroux P, 23
 Dusheiko GM, A721
 Dwarakanath AD, 1001, 1141
 Dyer NH, 429 (C)
- Eastwood MA, 90, 1665
 ECHSS group, 1301
 Ectors NL, 864 (C)
 Eddleston ALWF, 1013 (LA)
 Edwards FC, 1153 (C)
 Einarsson K, 1116
 Ekbohm, 946
 El-Omar E, 571 (C), 1385
 El-Salhy M, 1413
 El Sayed T, A1681
 Eliakim R, 141 (C), 1394
 Elias E, 809
 Ellis C, 1098
 Ellis CJ, 1001
 Ellul JPM, A719
 Emmett PM, 1455
 Engel AF, 857
 Engelman JL, 683
 Engels LGJB, 530
 Erb SR, 280
 Erlinger S, 705
 Eskerod O, 637
 Etienne JP, 905
 EUROGAST Study Group, 716 (C)
 European Board of Gastroenterology, 135
 Evans KT, 363
 Evans R, 1053
 Everitt S, 1030
 Ewen SWB, 599
- Fabre R, 905
 Faik P, 683
 Fairclough PD, 211, 441 (LA)
 Falke ThHM, 1676 (C)
 Fallingborg J, 287 (C)
 Fan XJ, 1379
 Farinati F, 865 (C)
 Färkkilä M, 1271
 Farthing MJG, 1 (LA), 51, 203, 211, 285 (C), 496, 1624
 Farzaneh F, A720
 Fausa O, 669
 Fedorak RN, 1439
 Feely J, 1599
 Fefer L, 916
 Feldman RA, 1562
 Fell GS, 1497
 Ferguson A, 476, 665
 Fernández-Bañares F, 1205

- Fernández-Corugedo A, 955
 Fernandez-Represa JA, 1773 (C)
 Fett U, 471
 Feurl GE, 275, 429 (C)
 Feyerabend C, 247
 Fidler HM, 506
 Fielding JWL, A1681
 Filipe J, 961
 Filipe MI, 604, A1680, 1697
 Fine D, A575
 Finlayson C, 1219
 Finlayson NDC, 445 (LA)
 Finnie IA, 278, 557, 1152 (C)
 Fiorucci S, 909
 Firth J, 961
 Fitt S, 569
 Flanagan BF, A575
 Fleer A, 1608
 Fleming KA, A719
 Fletcher J, 1150 (C)
 Flogerzi B, 270, 896
 Florent C, 231
 Flouric B, 1747
 Fluit AC, 1608
 Fogg F, 247
 Forbes A, 788, 1718
 Forgacs I, 732
 Forman D, 716 (C)
 Formela L, A574
 Formela LJ, A574, A575, A576
 Foster GR, A720
 Fradet G, 280
 Fraser R, 455
 Fraser RJ, 172
 Frei R, 23
 French J, 1267
 Fried M, 23, 455
 Friedman EH, 286 (C), 572 (C)
 Friend DR, 1439
 Friess H, 1468
 Froehlich F, 23
 Froguel E, 231
 Frost E, 1294
 Fujimori T, 1258
 Fujimura Y, 46
 Fujishima M, 1058
 Fukumura D, 1375
 Fullarton GM, 863 (C), 1121
 Furne J, 1098
 Furno A, 1676 (C)
 Furukawa Y, 159
- Galassini R, A720
 Galatola G, 771
 Gallagher G, A575
 Gallaway SW, A574
 Ganguly NK, 1613
 Gardner KR, 511
 Garner A, 270
 Garvey G, 557
 Gasbarrini G, 771
 Gassull MA, 1205, 1648
 Gauperaa T, 941
 Gebhart CJ, 1483
 Geboes K, 1404, 1728
 Geboes KJ, 864 (C)
 Geerts A, 1509 (LA)
 Géhenot M, 1670
 Geis G, 755
 Gendry J-P, 426
 Gemin C, 803
 Gentry J, A721
 Gerber HA, 896
 Gerok W, 401, 1772 (C)
 Gertner DJ, 1429
 Gerzer E, 1250
 Geyypens BJ, 333
 Ghatei MA, 1701
 Ghoo Y, 1404
 Ghoo YF, 333
 Ghosh P, 557
 Ghosh S, 1757
 Giansanti M, 909
 Giardiello FM, 377
 Gibson P, 791, 969
 Gil A, 926
 Gilat T, 373
 Gilbert JM, 572 (C)
 Giles TE, A575
 Gillams AR, 692
 Gillen CD, 651, 1590
 Gilly G, 1132
 Gilmore IT, A576
 Gimson A, 322
 Girón JA, 955
 Glummann H, 84
 Glezer G, A574
 Gleason D, 542
 Goggin P, A575
 Goldin RD, A720
 Gomborone JE, 285 (C)
 Gompertz RHK, 991
 Gonvers JJ, 23
 Gooszen HG, 1529
 Gorard DA, 203, 496
 Goss-Sampson MA, 34
 Gottfried MR, 879
 Gottrand F, 313
 Gower P, 1670
 Gower-Rousseau C, 1316, 1433
 Goyal RK, 1690
 Graham DY, 742
 Grahm MF, 73, 1152 (C)
 Grande L, 8
 Greaves RRFH, 323
 Greenberg GR, 783
 Greenfield SM, 1644
 Gressner AM, 1331 (LA)
 Griffin SM, 1137, A1681
 Griffioen G, 1262
 Grimble GK, 1734
- Grimmelius L, 1413
 Groen AK, 1653
 Groeneveld ABJ, 737
 Groom JS, 523
 Grotz RL, 798
 Grove DI, 437 (LA)
 Guarner F, 517, 1090
 Gudgeon AM, 1311
 Guerrant RL, 289 (LA)
 Gummett PA, 15, 323
 Gurbuz AK, 377
 Gustafson-Svrd C, 40
 Guyader D, 1107
 Gyr K, 23
- Habal FM, 783
 Haber PS, 1474
 Hadengue A, 705
 Hagel J, 1026
 Hainsworth PJ, 991, 1773 (C)
 Hall A, 266
 Hallak A, 373
 Halliday MI, 511, A575
 Halpern Z, 373
 Halstensen TS, 669
 Halter F, 270, 896
 Hamilton SR, 377
 Hamm B, 471
 Hammond SM, 441 (LA)
 Hankey GL, 65
 Hannaford PC, 107
 Hansen BF, 615
 Hansen MB, 637
 Hanson RB, 536
 Harboe M, 382
 Hardie JM, 1562
 Harding LK, 976
 Hardwick RJ, 764
 Harpaz N, 1419
 Harrison J, 717 (C)
 Harrison PM, A720, A721
 Hart DJ, 564
 Haruma K, 1064
 Harvey RF, 1150 (C)
 Hasan MY, 270
 Hatz R, 701
 Hawley CJ, 1030
 Hawksby C, 317
 Hawley PR, 347, 1070, 1076
 Hayashi A, 224
 Hayashi A, 1137, A1681
 Hayes PC, 445 (LA), 1290
 Healey CJ, A719
 Heath DJ, 1311
 Heathcote EJ, 260
 Heaton KW, 1455
 Hedef N, 905
 Heggie L, 165, 625, 1356
 Heim J-M, 1250
 Heineman E, 1338 (LA)
 Heller M, 1102
 Hellers G, 84
 Helske T, 1167
 Hengels KJ, 755
 Henry MM, 388
 Hermans J, A1681
 Hernandez CA, 1501
 Hershman MJ, A574, A576
 Herszenyi L, 865 (C)
 Hertzfel DJ, 590
 Heyman M, 631
 Hibit T, 224
 Hiele M, 1404, 1728
 Hiele MI, 333
 Higashijima H, 1760
 Higgins JNP, 567
 Hill MJ, 1675 (C)
 Hilling GAL, 847
 Hilson AJW, A721
 Hirohashi S, A1680
 Hittinger R, A574
 Hizawa K, 1058
 Hobbs KEF, A721
 Hobsley M, 139, 1007, 1033
 Hodgson HJF, 5 (LA), 77, 714 (C)
 Hodgson SV, 1622
 Hoey H, 1226
 Holden RJ, 191
 Holguin J, 809
 Hollander D, 68
 Holloway RH, 152, 1523
 Holm K, 55
 Holmes GKT, 65
 Holton J, 309
 Hop WCJ, 1348
 Hopkins A, 1209
 Hopkins J, 1022
 Hoppe-Seyler P, 401, 1772 (C)
 Hopwood D, 1343
 Horbach JMLM, 1529
 Horowitz M, 172
 Horrobin DF, 987
 Horslen SP, 1497
 Hosoda Y, 224
 Howaldt S, 1081
 Howard ER, 257
 Hsu L-Y, 746
 Hsu P-I, 746
 Hsueh W, 215
 Huang X, 631
 Hudson N, A720, 1030, 1665
 Hughes LE, 656, 1139
 Hughes RD, A720, 982
 Huijbregts K, 1653
 Hultcrantz R, 84
 Humbert P, 1205
 Humphries P, 1226
 Hunt JB, 211
 Hunt LP, 542
 Hunter JO, 571 (C), 611
 Husson MO, 313
- Hutchinson R, 94, 391, 976, 1676 (C)
 Hutton M, 73
 Huysmans V, 1404
 Hyvärinen H, 1167
- Ibañez A, 1648
 Ibañez S, 687
 Idström J-P, 455
 Iida M, 864 (C), 1058
 Imrie CW, A575, 1311
 Iqbal TH, 1233
 Iredale JP, 729 (LA)
 Irving WL, A719
 Iwao Y, 224
 Izumi S, A720, 982
- Jablonowski H, 755
 Jackson GDF, 1047
 Jaffe V, 815
 James OFW, A720, A721, 1267
 James WB, 191
 Jameson JS, 388
 Jankowski J, A1680
 Janowitz HD, 860
 Jansen J, 338
 Jansen JBMJ, 501
 Jardine DL, 564
 Järnerot G, 1155 (LA), 1282
 Järvinen H, 243
 Järvinen P, 1167
 Jass J, 961
 Jass JR, 1328
 Jeejeebhoy KN, 783
 Jeffers M, 1226
 Jehanli A, 1311
 Jenkins AP, 1765
 Jenkins PA, 363
 Jenkins SA, 1459
 Jenner JR, 611
 Jernigan J, 289 (LA)
 Jewell DP, 696, 714 (C), 1282
 Jiang S-J, 862
 Johnson AG, 1294
 Johnson CD, 140 (C), 412, A575, A576
 Johnson GD, 1022
 Johnson NMcI, 506
 Johnston D, 758, 941
 Jokelainen K, 1271
 Jolobe OMP, 140 (C), 1773 (C)
 Jones AG, A576
 Jones AL, 1290
 Jones AR, 1536
 Jones RH, 285 (C)
 Joplin R, A719, 875 (LA)
 Jewell PS, 284 (C)
 Juhlin KD, 1363
 Juncá J, 1205
 Juvonen T, 646
- Kaess H, 27
 Kahri A, 243
 Kai A, 1375
 Kakkar AK, A576
 Kalambaheti T, 1047
 Kalloo AN, 1319
 Kamm MA, 347, 523, 857, 1419
 Kanayama S, 1571
 Kandil HM, 934
 Kang JY, 863 (C)
 Kapoor VK, 112
 Karaniia ND, 547, 1306
 Karim QN, 15
 Karmeli F, 1181, 1394
 Katz A, 260
 Katz KD, 68
 Kawai Y, 224
 Kay CR, 107
 Keeling NJ, A1680
 Keeling PWN, 1379, 1599
 Keighley MRB, 236, 391
 Kelleher D, 1226, 1379, 1599
 Kelly C, A575
 Kelly DA, A719
 Kelly M, 1627
 Kelly P, A721
 Kelly SM, 611
 Kerlin P, 641
 Kerneis S, 1449
 Kerr MA, 1022
 Kerr MC, 377
 Keusch GT, 872 (LA)
 Keyriläinen O, 1215
 Khakoo SI, 1172
 Khatun M, 1707
 Kiff RS, 287 (C)
 Kihara T, 46
 Kim WH, 863 (C)
 Kingsnorth AN, A574, A575, A576
 Kingstone K, 476
 Kino J, 715 (C)
 Kirby GA, 571 (C)
 Kirchhoff T, 1582
 Kishinaka M, 1760
 Kissmeyer-Nielsen P, 1275
 Klaassen CHW, 1547
 Klar A, 1329 (C)
 Kleibeuker JH, 1262
 Kleine U, 819
 Knill-Jones RP, 191
 Knipschild P, 1506 (C)
 Kobayashi H, 1605
 Kobayashi K, 224
 Kobrin MS, 1468
 Koch H, 417
 Kodner A, 916
 Koga H, 1058
 Kohler B, 1294
 Kolkman JJ, 737, 1676 (C)
 Kontakou M, 1037, 1398
- Konturek JW, 1197
 Konturek SJ, 1189, 1197
 Körber J, 1424
 Korc M, 1468
 Korsten MA, 1474
 Koskimies S, 55
 Koster JC, 1004
 Koszka Ch, 819
 Koukoulis G, 1322
 Kraemer N, 755
 Krause G, 1250
 Kreuzpaintner G, 363
 Krige JEJ, 865 (C)
 Kruse A, 837
 Krush AJ, 377
 Kubben FJGM, 530
 Kumar D, 94, 391, 976
 Kumar U, A720
 Kuroki F, 1058
 Kuroki S, 1760
 Kuster E, 8
- Labenz J, 19
 Laboisie CL, 338
 Ladinser B, 776
 Laippala P, 1215
 Lam HGTh, 733
 Lameris JS, 1004
 Lamers CBHW, 501, 841, 1529
 Lammers KM, 338
 Langholz E, 68, 360
 Langley PG, 982, A720
 Lankisch PG, 1479
 Lapenna D, 284 (C)
 Lerner AJ, 714 (C)
 Laurberg S, 1275
 Laurensen IF, 179
 Laurent-Puig P, 905
 Lawler M, 1226
 Lawrie BW, 363
 Lawson GHK, 1483
 Lawson JA, 1632
 Le Quintrec Y, 426
 Lea T, 382
 Leader M, 961
 Lebert P, 1107
 Leclerc H, 313
 Lecomte-Houcke M, 313, 1670
 Lee C-H, 1389
 Lee F-Y, 1389
 Lee FD, 891
 Lee S-D, 1389
 Lees WR, 692
 Leferink S, 1132
 Leffers P, 1506 (C)
 Legon S, 1567
 Leicester RJ, 429 (C)
 Lemahieu M, 1433
 Lemaire B, 1433
 Lendrum R, 266
 Lennard-Jones JE, 347, 1419, 1429
 Lennard TWJ, 991, 1773 (C)
 Lennon J, 127, 1010 (C)
 Lennox G, 1677 (C)
 Lerrch MM, 401, 1501, 1772 (C)
 Levin RJ, 1237
 Levison DA, 961
 Levitt MD, 1098
 Lewis KO, 1233
 L'hegoualc'h A, 631
 Li JKW, 94
 Libby GW, 203, 285 (C), 496
 Lieveise RJ, 501
 Lijia I, 40
 Lillesqvist L, 1116
 Limb GA, 1037
 Lin C-Y, 746
 Lin H-J, 1389
 Lin X-Z, 746
 Lindley KJ, 34
 Linde R, 961
 Linhan J, A1680
 Linn T, 1424
 Lipsanen V, 55
 Livingston JI, 604, A1680, A1681, A1682
 Llovet JM, 1648
 Lobo AJ, 1150 (C), 1172
 López CA, 1145
 Loft DE, 299
 Logan RFA, 107, 369
 Logan RPH, 15, 309, 323
 Lühr-Happe A, 1479
 Long RG, 140 (C), 864 (C)
 López de Soria P, 1205
 Louw JA, 571 (C)
 Love J, 122
 Lovett MC, 1459
 Loviseti P, 1509 (LA)
 Lowry MF, 1497
 Luboinski J, 426
 Lucht F, 803
 Luman W, 1665
 Lundberg JM, 1543
 Lundberg JON, 1543
 Lundergardh G, 946
 Lutrin FJ, 547
 Lutton C, 343
 Luukkonen P, 243
 Lux G, 1026, 1132
 Lynch D, 863 (C)
 Lynch DAF, 429 (C)
 Lyon TDB, 1497
 Lysy J, 1329 (C)
- McAlindon ME, 1677 (C)
 McCloy RF, 1209
 McCluggage G, A575
 McColl KEL, 317, 571 (C), 863 (C), 1112, 1385
 McCulloch P, A1680

- McDevitt J, 1379
 McDicken IF, A575
 Macdonald IA, 186
 McFadden JJ, 506
 Macfarland JD, 841
 McGarvey MJ, A720
 McHugh M, 467
 McIntosh J, A574
 McIntyre AS, 140 (C)
 Macintyre IMC, 451, 1675 (C)
 McKay AG, 1219
 McKay C, A575
 McKay JA, 599
 Mackinnon M, 590
 McKirdy HC, 412
 McKirdy ML, 412
 McLoughlin JK, 946
 McLoughlin PJ, A575
 McLoughlin JC, 769
 McMabon MJ, 941
 McMaster P, 809
 MacMathuna P, 127, 1010 (C)
 McOrist S, 1483
 Madden MV, 865 (C), 1429
 Maddox AF, 172
 Madsen PV, 132
 Maeda S, 1258
 Maehara Y, 1368
 Maes BD, 333, 1599
 Mahmud N, 1599
 Maiuri L, 779, 1042
 Majka J, 1189
 Major GN, A722
 Majumdar S, 1613
 Mäki M, 55
 Makin AJ, 569
 Makin C, 1459
 Makino I, 1760
 Malagelada JR, 517, 1090, 1360
 Malaty HM, 742
 Mandal A, 1712
 Mandal BK, 726 (LA)
 Mann D, A574
 Manns MP, 1163 (LA)
 Mantle TJ, 1599
 Manzano L, 955
 Marafin C, 865 (C)
 Marceau N, 294 (LA)
 Marjoribanks FM, 191
 Marks CG, 1447
 Marks IN, 571 (C)
 Marples M, 165
 Marrero JM, 447
 Marteau P, 1747
 Marti R, 1433
 Martin DF, 408, 1011 (LA)
 Martin IG, 758
 Martin JF, A721
 Mary J-Y, 231
 Masalas CN, 369
 Masclee AAM, 501, 1529
 Maslam MZ, 714 (C)
 Mathie RT, 815
 Matsumoto T, 1058
 Matsuzawa Y, 1571, 1593
 Matysiak-Budnik T, 1683 (LA)
 Matzinger FR, 360
 Maxwell JD, 447, 867 (LA), 1219
 May GR, 1675 (C)
 Mayer AD, 809
 Mayer EA, 916
 Mayol J, 1773 (C)
 Mazlam MZ, 5 (LA), 77
 Mearin F, 1360
 Meddings JB, 1675 (C)
 Meera Khan P, 1262
 Mégraud F, 1683 (LA)
 Meijer K, 1608
 Meijssen MAC, 1338 (LA)
 Mela G, 1151 (C)
 Meleagros L, 1701
 Melton LJ, 619
 Melville DM, 1076
 Melvin WT, 599
 Mendelson GM, 323
 Menegatti M, 309
 Meneses M, 101
 Menke-Plumers MBE, 1348
 Menko FH, 1262
 Merkouropoulos M, 369
 Merrick MV, 90
 Mertz H, 916
 Meuwissen SGM, 737
 Meyrick Thomas J, A1681
 Mibu R, 1760
 Michetti F, 884
 Michiellini P, 260
 Michiellini G, 849
 Mieli-Vergani G, 309
 Miglioli M, 905
 Mignon M, 905
 Milla PJ, 34
 Miller N, 1644
 Miller S, 317
 Milne DM, 1022
 Milner PC, 1294
 Minaire Y, 490
 Minami T, 1593
 Mion F, 490
 Misiewicz JJ, 15, 299, 323, 388
 Miskovsky EP, 1319
 Mitchell AW, 567
 Mitchison H, A721
 Miura S, 1375
 Miyazaki Y, 1571
 Modigliani R, 231
 Moirand R, 1107
 Moja Ph, 803
 Molgora M, 714 (C)
 Molierno G, 779
 Moller H, 716 (C)
 Moncada S, A721
 Montori A, 117
 Moore MR, 1112
 Moorghen M, 764
 Moran A, 1551
 Morelli A, 909
 Moretó M, 687
 Morgan GP, 297 (LA)
 Mori M, 1368, 1375
 Morrin M, 1627
 Morris AI, 278
 Morris AJ, A721
 Morris DL, 1517 (LA), 1632
 Morris J, 363
 Morris JS, 562
 Morris TJ, 363
 Mosimann F, 130
 Moss SF, 1567
 Mowat AP, A719, 849
 Muellhaupt B, 552
 Mulder AH, 1348
 Mule P, 309
 Muller AF, 679
 Muller DPR, 34
 Munck LK, 637
 Munkholm P, 68, 360, 1675 (C)
 Murayama Y, 1571
 Murch SH, 715 (C)
 Murphy GM, 683, A719
 Murray FE, 107
 Murray GI, 599
 Mutimer DJ, 809
 Naccarato R, 865 (C)
 Nadorp JHSM, 1519
 Nagasako K, 1258
 Nagel E, 1424
 Nagengast FM, 1262
 Nakahara S, 1760
 Nakanishi T, 1571
 Nalin DR, 145 (LA)
 Nam V-C, 417
 Naoumov NV, 1013 (LA)
 Narielvala FM, 590
 Nash J, 1141, A1680
 Nath SK, 631
 Neeser JR, 483
 Negi TS, 112
 Nelufer JM, 1037
 Nemitz R, 717 (C)
 Neoptolemos JP, A576
 Neuberger JM, A719, 809
 Neumann CS, 1352
 Newcomb PV, 764
 Newcombe RG, 353, 363
 Newell D, 716 (C)
 Newton M, 423
 Niazi N, 916
 Nicholl JP, 1294
 Nicholls RJ, 523, 1070, 1076, 1429, 1721
 Nicholson AG, 1447
 Nigam AK, 996
 Niitsu Y, 1659
 Nilsson B, 84
 Ninkovic M, 1493
 Noach LA, 1151 (C)
 Nobili V, 1398
 Northover JMA, 141 (C)
 Notghi A, 976
 Novell JR, A721
 Nugent KP, 1622, 1718
 Nuñez MC, 926
 Nuttens MC, 1316, 1433
 Nwokolo CU, 220, 299
 Nyhlin H, 90
 Nyren O, 946
 Nzegwu HC, 1237
 O'Briain DS, 1226, 1605
 O'Brien F, 451
 Ochiai A, A1680
 O'Connell MA, 1599
 O'Donovan D, A575
 O'Dowd J, A1680
 Odum L, 615
 O'Farrelly C, 1226
 Offerhaus GJA, 377, 1262
 O'Hanrahan T, 165
 Ohara M, 224
 Ojanguren I, 1648
 Ojembarrena E, 687
 Okamoto H, A575
 Okamoto M, 1593
 Okamoto T, 1659
 Okazaki K, 715 (C)
 Okon E, 1181
 Oosting J, 1151 (C)
 Opferkuch W, 755
 Oppong K, A719
 Orholm M, 68
 Osborne M, A1680
 Oshitani N, 284 (C)
 Oskam W, 1262
 Osnes M, 1464
 Osnes T, 1464
 Ostenstad B, 382
 Ostrow DN, 280
 Ouwendijk RHTH, 1004
 Owen RA, 788
 Owen WA, 1536
 Owen WJ, 1536
 Ozmen MM, 140 (C)
 Pabst R, 1582
 Pack K, 1622
 Palmer JM, 260
 Palmer KR, 464, 608, 1665, 1757
 Panos MZ, 1151 (C), 1551
 Papachrysostomou M, 252
 Paparo F, 1042
 Papo M, 1360
 Parker MC, 1010 (C)
 Parkes HG, A719
 Parkkila A-K, 646
 Parkkila S, 646
 Pasricha PJ, 1319
 Pasternack A, 1215
 Patankar R, 140 (C)
 Patchett SE, 1624
 Payne-James JJ, 299
 Pearce S, 707
 Pearson RD, 289 (LA)
 Peeters-Haesevoets A, 530
 Peeters M, 1404
 Peiper M, 1479
 Pellier P, 1747
 Pemberton JH, 798
 Peña AS, 1676 (C)
 Penman I, 1385
 Pera C, 8
 Perez-Mateo M, 822
 Perez-Tomás R, 1086
 Perini L, 865 (C)
 Perkins AC, 1363
 Pernambuco IRB, A720, 982
 Pernes P, 313
 Perng C-L, 1389
 Peters RA, 1287, 1322
 Peters TJ, 1102
 Petersen GB, 377
 Petersen HD, 615
 Pfeiffer A, 27
 Phillips RKS, 1622, 1624
 Piccinni-Leopardi M, 117
 Pichlmayr R, 1424
 Pignatelli B, 455
 Pignatelli M, 996, 1343
 Piretta L, 884
 Pirola RC, 1474
 Pittschieler K, 776
 Planas R, 1205, 1648
 Plenderleith L, 1112
 Pommerien W, 819
 Pon C, 560
 Ponchon T, 395
 Porter KG, 769
 Portmann B, 849, 1322
 Portmann BC, 569
 Posthuma EFM, 841
 Poston GJ, 557
 Potamiano S, 461
 Potet F, 905
 Powell JJ, 1053
 Poxon V, 236
 Pozzetto B, 803
 Prat F, 395
 Preclik G, 1501
 Present DH, 1150 (C)
 Price A, 961
 Price AB, 1244
 Prior P, 651, 1590
 Probert CSJ, 1455
 Przemioslo RT, 1037, 1398
 Pugh S, 675
 Pujol A, 8
 Pukkala E, 1215
 Pullan RD, 247, 353, 363
 Punchard NA, 1644, 1753
 Puntis MCA, 987
 Puri P, 1605
 Quagliano D, 771
 Quandalle P, 1670
 Quensel A, 803
 Quer JC, 1205
 Quine MA, 1209
 Quirke P, 141 (C)
 Rabau M, 373
 Rabot A-F, 1107
 Rachmilewitz D, 141 (C), 1149, 1181, 1394
 Raedler A, 1081
 Raedsch R, 717 (C)
 Raehn H, 916
 Rahaman MM, 1707
 Raia V, 1042
 Raimes SA, A1681
 Raimundo AH, 1734
 Rajaniemi H, 646
 Rajgopal C, 464
 Rambaud J-C, 1747
 Rampton DS, 179, 1429, 1562
 Rask-Madsen J, 637, 1008
 Rasmussen HH, 837
 Rasmussen SN, 837
 Rath DM, 798
 Rautureau M, 631
 Rauws EAJ, 1151 (C)
 Ravdin JJ, 1018 (LA)
 Rayter Z, 429 (C)
 Read NW, 1409
 Reber HA, 547, 1306
 Record CO, A719
 Redhead DN, 445 (LA)
 Redmond H, A575
 Reed W, 599
 Rehfeld JF, 615, A576
 Reilly H, 1551
 Reilly T, 1551
 Reunala T, 1215
 Reyes H, 101
 Rhodes J, 247, 353, 363
 Rhodes JM, 557, 1141, 1152 (C)
 Rhodes M, 247, 353, 991, 1152 (C)
 Rhodes P, 363
 Ribalta J, 101
 Ricci DR, 280
 Rice-Evans CA, 1644
 Riecken EO, 471, 819
 Rigby HS, 847
 Rigg JD, 408
 Riordan AM, 571 (C)
 Rios A, 926
 Ritchie JK, 347, 1070, 1076
 Ritter MM, 701
 Roberts G, 363
 Robertson DAF, 847
 Robinson G, A1680
 Rodde I, 905
 Rodriguez R, 517
 Roe AM, 1329 (C)
 Rogers J, 73, 388
 Roine RP, 1271
 Rokkas T, 1536
 Rolf TM, 1151 (C)
 Román LI, 955
 Rook GAW, 506
 Ros E, 8
 Rose J, A720
 Rosella G, 969
 Rosella O, 791, 969
 Rosenberg H, 101
 Rosenberg W/MC, 696
 Ross B, 1294
 Ross JC, 1676 (C)
 Rossi M, 1042
 Rossipal E, 776
 Rothkötter HJ, 1582
 Rotterdam Oesophageal Tumour Study Group, 1348
 Roudot-Thoraval F, 750
 Rovati LC, 501
 Rowan BP, 342
 Rowlands BJ, 511, A575
 Royall D, 783
 Ruckdeschel G, 701
 Rucker JT, 571 (C)
 Ruddell WSJ, 844
 Rugtveit J, 669
 Rumsey RDE, 1409
 Ruppini H, 1026
 Ruseiler-van Embden JGH, 658
 Russel MGVM, 1490
 Russell MAH, 247
 Russell RCG, 692
 Russell RL, 891
 Russell RM, 1102
 Rutgeerts P, 1404, 1728
 Rutgeerts PJ, 333, 864 (C)
 Ryder SD, A720
 Sachar DB, 1507 (LA)
 Sagar PM, 941
 Sahnoud T, 231
 Saia A, 517, 1090
 Saiajuro M, 1271
 Sallie R, 849
 Salomez J-L, 1433
 Samson HJ, 247
 Samuels T, 1459
 Samuni A, 1181
 Sandberg-Gertzén H, 1282
 Sanders DSA, 1022
 Sanderson CFB, 1301
 Sandle GI, 1575
 Sandoval L, 101
 Sandstad O, 1464
 Sanidas E, A1680
 Sanner M, 270, 896
 Santo M, 373
 Santucci L, 909
 Saraswat VA, 112
 Sarker SA, 1707
 Sarraf CE, 577 (LA)
 Sarsfield P, A575
 Sasako M, A1680
 Satsangi J, 696, 714 (C)
 Savarino V, 1151 (C)
 Savilahti E, 55
 Saxena R, 112
 Sayer J, 864 (C)
 Schaeuberberger HD, 323
 Schauer PJ, 260
 Schlecht CD, 619
 Schlichting E, 382
 Schimmsmann A, 270, 896
 Schimidt T, 27
 Schoeman MN, 152, 1523
 Schofield D, A574
 Schofield PF, 717 (C)
 Schouven WR, 658
 Schreiber HW, 417
 Schreiber S, 1081
 Schutte B, 530
 Schwartz MP, 1151 (C)
 Sciarretta G, 1676 (C)
 Scott BB, 429 (C)
 Scott EM, 429 (C)
 Scott H, 669
 Scott N, 141 (C)
 Scott NA, 656
 Scriven MW, 987
 Scudamore CH, 280
 Scully MF, A576
 Sedgwick DM, 665
 Seitz HK, 1102
 Sengupta A, 1690
 Senturk H, 1753
 Seppälä K, 1167
 Sequeira S, A719
 Servin AL, 483, 1449
 Setien F, 687
 Setti Carraro P, 1070, 1721
 Sewing K-F, 1176
 Seylaz J, 1747
 Shahi CN, 1379
 Sharer NM, A574
 Sharpstone D, 833
 Shaw D, 599
 Sheaff MT, 179
 Shearman DJC, 590

- Sheffield JP, 347
 Sheils O, 1226
 Shenkin A, 1311
 Shepherd NA, 764, 961, 1172
 Sherlock S, 828
 Shidrawi RG, 1772 (C)
 Shields R, 278, A576
 Shimi SM, 1617
 Shin J-S, 746
 Shinomura Y, 1571, 1593
 Sibille A, 395
 Sidery MB, 186
 Siegrist H, 23
 Siegrist HH, 455
 Silk DBA, 299, 1734
 Simanowski UA, 1102
 Simmonds NJ, 179
 Singaram C, 1690
 Singh P, 304
 Singh S, 1250
 Sipponen P, 1167
 Siurala M, 1167
 Sjødahl R, 40
 Skar V, 1464
 Skidmore SJ, A719
 Smedsrod B, 1509 (LA)
 Smith A, 542
 Smith AN, 252
 Smith D, 1102
 Smith NB, 976
 Smith R, A721
 Smith-Ravin J, 1622
 Smok G, 101
 Smout AJPM, 733, 1519
 Sobhani I, 905
 Soehendra N, 417
 Solcia E, 590
 Songun I, A1681
 Sorensen HT, 837
 Sörstad J, 84
 Southern SN, A575
 Spiegelhalter DJ, 191, 961
 Spiller RC, 723 (LA), 1363, 1557
 Spiro H, 1504
 Srivastava ED, 247, 363
 Stachura J, 1189
 Stalnikowicz R, 1394
 Stamler JS, 1394
 Stanescu L, 750
 Steadman C, 641
 Steering Group of the Upper Gastrointestinal Endoscopy Audit Committee, 1209
 Stenling R, 1413
 Stern RC, 709
 Stevens AB, 717 (C)
 Stevens TRJ, 179
 Stibbe J, 1004
 Stinson J, 1599
 Stockbrügger RW, 530, 1490
 Stoll R, 1197
 Stolte M, 701
 Stölzel U, 819
 Stone R, 363
 Strain AJ, 433 (LA), A719
 Strickland GT, 1334 (LA)
 Stringer MD, 257
 Strocchi A, 1098
 Strohmeier G, 363, 755
 Stubbs AP, 683
 Sturgess RP, 1037
 Sturrock RD, 891
 Suárez M-J, 687
 Sue-Ling H, 758, 941
 Suematsu M, 1375
 Sugai B, 122
 Sugarbaker DJ, 1690
 Sugimachi K, 1368
 Suhr O, 1413
 Sun X, 215
 Suter P, 1102
 Sutherland LR, 1675 (C)
 Sutton R, 278, A576
 Suzuki H, 1375
 Suzuki M, 1375
 Swarbrick ET, 51
 Swarts HGP, 1547
 Swash M, 388
 Sweet MA, 1690
 Swift GL, 363
 Sykes RE, A1680
 Sytnik B, 916
 Taal BG, 1262
 Tabone M, 1637
 Tabuchi M, 1258
 Tada S, 864 (C)
 Tagesson C, 40
 Taha A, 844
 Taha AS, 891
 Takaishi H, 224
 Talbot IC, 715 (C), 857, 1419, 1429, 1721
 Talley NJ, 619, 798
 Tan KC, 849
 Tan WC, 220
 Tanner A, 707
 Tanner MS, 1497
 Tanskanen M, 243
 Tarnawski A, 896
 Tate J, 567
 Taylor BA, 287 (C)
 Taylor G, 1536
 Taylor RH, 304
 Tbukhi A, 854
 Teahon K, 571 (C), 1244
 Teare JP, 1644, 1753
 Tebbutt S, A576
 Telen MJ, 879
 Theillière Y, 395
 Theodossi A, 961
 Thijs C, 1506 (C)
 Thillainayagam AV, 211
 Thomas GAO, 247, 353, 363, 675
 Thomas HC, A720
 Thomas MG, 1718, 1742
 Thomas PJ, 323
 Thomas S, 961
 Thompson DG, 165, 327, 625, 1356
 Thompson E, 1301
 Thompson H, 961, 1697
 Thompson I, 788
 Thompson L, 1557
 Thompson RPH, 1053, 1644, 1753, 1765
 Thompson WG, 560
 Thorens J, 23
 Thornberg K, 68
 Thornes H, 707
 Thornton J, 284 (C)
 Thuluvath PJ, 1493
 Thurrell W, 506
 Thursz MR, A720
 Tilanus HW, 1348
 Timmer R, 1519
 Toda K, 224
 Toghiani PJ, 679, 1677 (C)
 Tojo H, 1593
 Toledo-Pimentel V, 8
 Torchio P, 771
 Torensma R, 1608
 Torres M, 926
 Torsoli A, 884
 Touraine JL, 803
 Trautwein C, 1163 (LA)
 Travis SPL, 1282
 Treserra F, 1090
 Trivedi P, A719
 Troncon LEA, 327
 Troncone R, 779
 Truelove SC, 1148
 Trzeciak L, 1624
 Tsianos EV, 369
 Tsuchiya M, 224, 1375
 Tsuji N, 1659
 Turck D, 313
 Turlin B, 1107
 Turnbull A, A720
 Tweedle DEF, 408
 Tyrrell PNM, 94
 Tysk C, 1282
 Tytgat GNJ, 338, 1151 (C), 1372, 1653
 Unsworth DJ, 61
 Urban A, 1648
 Urdal P, 1464
 Väänänen H, 1271
 Vaira D, 309, 1033
 Valentini RA, 771
 van Berge Henegouwen GP, 733, 1326
 Van Blankenstein M, 247, 1348
 van de Velde CJH, A1681
 van der Sluys Veer A, 841
 van Deventer SJH, 338
 van Dijk APM, 247
 van Kroonenburgh MJPG, 1490
 Van Kruijningen H, 1670
 Van Kruijningen HJ, 1316
 van Lieshout LMC, 658
 Vanderkerken K, 1509 (LA)
 Vandermeeren A, 122
 Vanoli M, 714 (C)
 Vantrappen G, 333, 1404, 1676 (C)
 Varga L, 270, 896
 Vargas JA, 955
 Vasen HFA, 1262
 Verdu E, 455
 Vergara M, 309
 Verhoef J, 1608
 Verma M, 1613
 Viani F, 455
 Videla S, 1090
 Viedma JA, 822
 Vigneri S, 1151 (C)
 Vilaseca J, 1090
 Vilgrain V, 705
 Vincent P, 313, 1153 (C)
 Vincent RM, 1363
 Visser W, 1004
 Vissuzaine C, 905
 Vogelsang H, 1424
 Vogl R, 1026
 von der Ohe MR, 536
 Votte A, i-433
 Vullo C, 1487
 Vyas SK, A721
 Wagner S, 1176
 Wahed MA, 1707
 Wainstein A, 101
 Waldherr R, 717 (C), 1102
 Waldum HL, 1547
 Walia BNS, 1613
 Walker JIH, 683
 Walker MM, 15, 323
 Walker-Smith JA, 1687 (LA)
 Wallace L, A719
 Wallis PJW, 1551
 Walmsley RS, 1590
 Walters JRF, 150 (LA)
 Wang J, 1536
 Wanless IR, 260
 Ward R, 1102
 Warmerdam P, 841
 Warnes TW, 542
 Warren BF, 1668
 Washington K, 879
 Wastell C, 604, A1682
 Watanabe M, 224
 Watanabe N, 1659
 Watanapa P, 140 (C)
 Waterworth PD, 1137
 Watson AJM, 1575
 Watson D, 1644
 Watson RGP, 769
 Watson SA, A1680
 Watson W, A575
 Watt TC, 408
 Wears R, 1551
 Weaver RJ, 599
 Webb P, 716 (C)
 Webster AD, 1244
 Weidenbach H, 1501
 Weir DG, 1599
 Weisgerber UM, 717 (C)
 Weitzberg E, 1543
 Welch NT, A1681
 Weldon MJ, 867 (LA)
 Welton M, 1001
 Wendon J, 569, A721
 Werbin N, 373
 Westaby D, 1287, 1322
 Westlake L, 1294
 Weston J, 1244
 White P, 127
 Whitelaw SC, 141 (C)
 Whittaker M, A574
 Widdison AL, 547, 1306
 Wilder R, 27
 Wiedenmann B, 471
 Wilander E, 1413
 Wilkins KE, 562
 Wilkinson KH, 1070, 1419
 Wilkinson ML, 683
 Wilkinson S, 363
 Wilkinson SP, 1172
 Williaros BT, 1294
 Williams C, 1385
 Williams D, 165
 Williams GT, 247, 353, 363, 1697
 Williams GV, 1267
 Williams JG, 297 (LA), 391
 Williams NS, 73
 Williams R, 569, A720, A721, 849, 982, 1322
 Williams SGJ, 1287
 Williamson MER, 1139
 Williamson RCN, 140 (C), A576, 1718, 1742
 Willing J, 159
 Wilson C, 1311
 Wilson CA, 1022
 Wilson CG, 1363
 Wilson JHP, 247, 1004
 Wilson JS, 1474
 Wilson MS, 717 (C)
 Winslet MC, 236, A1680
 Winwood PJ, 1145
 Wisse E, 1509 (LA)
 Wiste JA, 1064
 Wocial T, 1624
 Wötter B, 819
 Wolfhagen MjHM, 1608
 Wolschies E, 1670
 Wood MJ, 1151 (C)
 Wu JCY, 1219
 Wylie JDC, 769
 Yabu M, 1571
 Yamamoto Y, 715 (C)
 Yamanaka Y, 1468
 Yang C-C, 746
 Yasunaga Y, 1571
 Yazigi N, 905
 Yeaman SJ, 260
 Yeomans ND, 590
 Yokoyama Y, 715 (C)
 Yoshida EM, 280
 Young G, 791, 969
 Youngs D, 236
 Yukawa M, 1258
 Zaballa M, 687
 Zaman SN, A720
 Zeijen RNM, 1490
 Zelig MP, 950
 Zibella A, 779
 Ziegler K, 471
 Zijlstra FJ, 247
 Zimmer T, 471
 Zinsmeister AR, 619, 798

SUBJECT INDEX – MAIN HEADINGS, 1994

- Abdominal pain**, Chronic, non-visceral abdominal pain, 833
- Aboral traction forces**, Human small intestinal contractions and aboral traction forces during fasting and after feeding, 625
- Absorption**, Absorption of a hypotonic oral rehydration solution in a human model of cholera, 211
- Acetaldehyde**, In vitro acetaldehyde formation by human colonic bacteria, 1271
- Achalasia**
Antecedents of achalasia: *personal viewpoint*, 861
Forceful dilatation under endoscopic control in the treatment of achalasia: a randomised trial of pneumatic versus metallic dilator, 1361
- Achlorhydria**, Magnesium hydrogen breath test using end expiratory sampling to assess achlorhydria in pernicious anaemia patients, 1205
- Acidification**, Effects of intraluminal acidification on oesophageal motor activity, 884
- Acupuncture**, Acupuncture inhibits vagal gastric acid secretion stimulated by sham feeding in healthy subjects, 1026
- Acute fatty liver of pregnancy**, Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients, 101
- Acute phase reaction**, Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms: *leading article*, 1163
- Acute phase response**, Extent of the acute phase response in fulminant hepatic failure, 982
- Adenocarcinoma**, Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence, 764
- Adenomatous polyps and carcinomas**, Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E₂, 675
- Adenovirus 12 E1A gene**, Adenovirus 12 E1A gene detection by polymerase chain reaction in both the normal and coeliac duodenum, 1226
- Adherent mucus gel**, Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis, 353
- Adrenaline**, Endoscopic injection therapy for bleeding peptic ulcer; a comparison of adrenaline alone with adrenaline plus ethanolamine oleate, 608
- Alcohol**
Alcohol *v* epinephrine and polidocanol: *correspondence*, 286
In vitro acetaldehyde formation by human colonic bacteria, 1271
Lipid peroxidation in rats chronically fed ethanol, 1644
Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake, 1637
Resistance of erythrocytes to lipid peroxidation in alcoholic patients, 1753
Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups, 619
- Alcoholic acute and chronic pancreatitis**
Chronic ethanol consumption increases the fragility of rat pancreatic zymogen granules, 1474
Dopamine in models of alcoholic acute pancreatitis, 547
Progression of alcoholic acute to chronic pancreatitis, 552
- Alcoholic liver disease**, Functional hyposplenism in alcoholic liver disease, 679
- Aldehyde disinfectants**, Aldehyde disinfectants and health in endoscopy units: *correspondence*, 717
- Alimentary tract**, Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract, 646
- Aluminium**, Intestinal perfusion of dietary levels of aluminium: association with the mucosa, 1053
- Ambulatory pH metry**, Prospective evaluation of 24 hour ambulatory pH metry in Belsey Mark IV antireflux surgery, 1529
- Ambulatory pH and pressure monitoring**, Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring, 1519
- Amino acid**, Comparison of amino acid *v* peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome, 783
- Aminosalicic acid**, Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis, 1081
- 5-Aminosalicylic acid**
Mesalazine induced interstitial nephritis, 1493
New salicylates as maintenance treatment in ulcerative colitis: *leading article*, 1155
Oral transit of 5-aminosalicylic acid: *correspondence*, 287
- Amoebiasis**, Diagnosis of invasive amoebiasis – time to end the morphology era: *leading article*, 1018
- Amyloid**, Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells, 1413
- Amyloidosis**
Malabsorption and motor dysfunction in patients with small bowel amyloidosis: *correspondence*, 864
Primary amyloidosis and severe intrahepatic cholestatic jaundice, 1322
- Anaesthesia**, Safety of general anaesthesia and surgery in acute hepatic porphyria, 1112
- Anal sphincter**
Anal sphincter physiology: *correspondence*, 1329
Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence, 857
- Analgesics**, Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups, 619
- Androgen receptor expression**, Measurement of androgen receptor expression in adult liver, fetal liver, and Hep-G2 cells by the polymerase chain reaction, 683
- Aneuploidy**, Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus, 1348
- Anorectal carcinoma**, Lower gastrointestinal malignancy in Crohn's disease, 347
- Antacid**, Antacid provides better restoration of glandular structures within the gastric ulcer scar than omeprazole, 896
- Anti-goblet cell antibody**, Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease, 224
- Anti-tuberculous chemotherapy**, Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease, 363
- Antibiotics**, Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid, 1757
- Antibodies**, Intestinal antibody pattern of coeliac disease, 476
- Anticardiolipin antibodies**, Budd-Chiari syndrome in a young patient with anticardiolipin antibodies, 1004
- Anticoagulants**, Acute gastrointestinal haemorrhage in anticoagulated patients, 464
- Antimitochondrial antibody**, Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis, 260
- Antiulcerogenic stable radical**, A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats, 1181
- Antral gastritis**, Cytokine gene expression in *Helicobacter pylori* associated antral gastritis, 1567
- Antral mucosa**, Gastrin and somatostatin in *Helicobacter pylori* infected antral mucosa, 615
- Antral mucosal reactive oxygen metabolite**, *Helicobacter pylori* stimulates antral mucosal reactive oxygen metabolite production in vivo, 170
- Antropyloroduodenal motility**, Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride, 172
- Argyrophil cell hyperplasia**, Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome, 275
- Arteriovenous malformations**, Systemic arteriovenous malformations: a feature of advanced liver disease, 1145
- Ascorbic acid**, Effect of *Helicobacter pylori* and its eradication on gastric juice ascorbic acid, 317
- Aspirin**
Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation, 1197
Role of gastric blood flow, neutrophil infiltration, and mucosal cell proliferation in gastric adaptation to aspirin in the rat, 1189
- Atenolol**, Beta-adrenergic modulation of human upper intestinal propulsive forces, 1356
- Audit**
An audit of the treatment of cancer of the oesophagus, 941
Diagnostic yield and management benefit of laparoscopy: a prospective audit, 1617
Multicentre audit of surgical management of acute necrotising pancreatitis, A574
- Autoimmune cholangitis**, Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis, 260
- Autoimmune liver disease**, Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact?, 542
- Autoimmune thyroid disease**, Coeliac disease and autoimmune thyroid disease, 844

- Bacterial overgrowth**, Duodenal bacterial overgrowth during treatment in outpatients with omeprazole, 23
- Bacterial translocation**, Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis, 1648
- Barrett's oesophagus**
24 Hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus, 1352
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence, 764
Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus, 1348
Tissue culture of epithelium derived from Barrett's oesophagus, 879
- Belsey Mark IV antireflux surgery**, Prospective evaluation of 24 hour ambulatory pH metry in Belsey Mark IV antireflux surgery, 1529
- Benign intracranial hypertension**, Benign intracranial hypertension during prednisolone treatment for inflammatory bowel disease, 423: *correspondence*, 1677
- Beta-adrenergic modulation**, Beta-adrenergic modulation of human upper intestinal propulsive forces, 1356
- Beta-lactam antibiotics**, Intestinal absorption of peptide drugs: *leading article*, 441
- Biasing**, Selective affective biasing in recognition memory in the irritable bowel syndrome: *correspondence*, 285
- Bicarbonate**, Effect of ranitidine on basal and bicarbonate enhanced intragastric PCO₂: a tonometric study, 737
- Bile**
Bile induced acute oedematous pancreatitis in rats: non-parallel changes in pancreatic morphology and amylase release in vitro, 1127
Role of bile in non-specific defence mechanisms of the gut, 1047
- Bile acid**
Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism, 1116
Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT, 90
- Bile duct**
Bile duct injury after laparoscopic cholecystectomy: *correspondence*, 288
Combined percutaneous and endoscopic procedures for bile duct obstruction: *leading article*, 1011
Prospective audit of the introduction of laparoscopic cholecystectomy in the west of Scotland, 1121
Symptom relief and quality of life after stenting for malignant bile duct obstruction, 467
- Bile duct stones**, Endoscopic sphincteroplasty: a novel and safe alternative to papillotomy in the management of bile duct stones, 127: *correspondence*, 1010
- Bile salt**
Cost effectiveness of adjuvant bile salt treatment in extracorporeal shock wave lithotripsy for the treatment of gall bladder stones, 1294
Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination, 112
- Biliary cholesterol stability**, High resolution ¹H NMR to study biliary cholesterol stability, A719
- Biliary epithelial cells**, Isolation and culture of biliary epithelial cells: *leading article*, 875
- Biliary obstruction**
Biliary obstruction resulting from *Strongyloides stercoralis* infection, 705
Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction, 707
- Biliary stent occlusion**, Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid, 1757
- Biopsy**, Observer variation and discriminatory value of biopsy features in inflammatory bowel disease, 961
- Blood donors**, Prevalence of peptic ulcer in *Helicobacter pylori* positive blood donors, 309
- Bone mineral density**, Bone mineral density in coeliac disease: *leading article*, 150
- Book reviews**
Baillie J. Gastrointestinal endoscopy – basic principles and practice, 866
Bieck PR. Colonic drug absorption and metabolism, 432
Boucher IAD, Allan RN, Hodgson HJF, Keighley MRB, *editors*. Gastroenterology. Clinical science and practice, 1993, 1678
Brody T. Nutritional biochemistry, 1774
Cotton PB, Tytgat GNJ, Williams CB. Annual gastrointestinal endoscopy, 573
Craddock VM. Cancer of the esophagus: approaches to etiology, 430
Cuesta MA, Nagy A, *editors*. Minimally invasive surgery in gastrointestinal cancer, 1993, 1679
Go VLW, DiMagno EP, Gardner JD, Leventhal E, Reber HA, Scheele GA. The pancreas: biology, pathobiology and disease, 2nd edition, 431
Gracey M, Bouchier IAD. Ballière's clinical gastroenterology. Volume 7: 2 June 1993. Infectious diarrhoea, 573
Gracey M, Burke V, *editors*. Paediatric gastroenterology and hepatology, 1993, 1506
Grant DR, Wood RFM. Small bowel transplantation, 1994, 1677
Heatley RV, Green JH, Losowsky MS, *editors*. Consensus in clinical nutrition, 1775
Klatskin G, Conn HO. Histopathology of the liver – volume I and II, 1993, 1330
Kumar D, Alexander-Williams J, *editors*. Crohn's disease and ulcerative colitis surgical management, 1993, 1330
Kumar D, Wingate D, *editors*. An illustrated guide to gastrointestinal motility, second edition, 1993, 1677
Lemoine N, Neoptolemos J, Cooke T, *editors*. Cancer: a molecular approach, 1775
Margulis AR, Burhenne HJ, *editors*. Practical alimentary tract radiology, 431
Misiewicz JJ, Forbes A, Price AB, Shorvon PJ, Triger DR, Tytgat GNJ, *editors*. Atlas of clinical gastroenterology, 2nd ed., 1775
Misiewicz JJ, Pounder RE, Venables CW, *editors*. Diseases of the gut and pancreas, 2nd ed., 1154
Neuberger J, Lucey MR, *editors*. Liver transplantation: practice and management, 1994, 1329
Nicholls J, Bartolo D, Mortensen N, *editors*. Restorative proctocolectomy, 1993, 1329
Rustgi V, Van Thiel DH, *editors*. The liver in systemic disease, 432
Spiro HM. Clinical gastroenterology, 4th edition, 431
Tavoloni N, Berk PD, *editors*. Hepatic transport and bile secretion: physiology and pathophysiology, 430
Van Ness MM, Chobanian SM, *editors*. Manual of clinical problems in gastroenterology, 2nd ed, 1010
Walker-Smith JA, Macdonald TT, *editors*. Chronic inflammatory bowel disease in childhood, 1994, 1678
Wallace JL, *editor*. Handbook of immunopharmacology of the gastrointestinal system, 866
Walsh JH, Dockray GJ. Gut peptides: biochemistry and physiology, 1774
Wolfe MM, *editor*. Gastrointestinal pharmacotherapy, 573
Zuckerman AJ, Thomas HC. Viral hepatitis, scientific basis and clinical management, 1993, 1679
- Botulinum toxin**, Intraspincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction, 1319
- Bowel diversion**, Bowel diversion should be used with caution in stenosing anal Crohn's disease, 1139
- Bowel dysfunction**, Bowel dysfunction in young women: *correspondence*, 572
- British Society of Gastroenterology**, 1993-94, Monty Losowsky, 283
- British Society of Gastroenterology**, Presidential review of the year's activity 1992-93, 139
- Bromodeoxyuridine**
Correlation of PCNA with bromodeoxyuridine: *correspondence*, 717
Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation, 530
- Budd-Chiari syndrome**, Budd-Chiari syndrome in a young patient with anticardiolipin antibodies, 1004
- Budesonide (CIR)**, Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR), 1490
- Budesonide prodrug**, A budesonide prodrug accelerates treatment of colitis in rats, 1439
- Bulking effect**, Digestibility and bulking effect of ispaghula husks in healthy humans, 1747
- Butyrate**, Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis, 73
- c-erbB2**, Comparison of the molecular genetics of stomach cancers in Britain and Japan: c-erbB2 and p53, A1680
- C-reactive protein**
Interrelations between interleukin-6, interleukin-1 β , plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease, 77: *correspondence*, 714
Why measure C reactive protein: *leading article*, 5
- CA 19-9 concentrations**, Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction, 707
- Caco-2 cell line**, *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria, 483
- Calcipotriol**
Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis, 1718
Divergent effects of epidermal growth factor and calcipotriol on human rectal cell proliferation, 1742
- CAM 5.2**, Effect on lymph node status of triple levelling and immunohistochemistry with CAM 5.2 on node negative colorectal carcinomas, 1447

Cancer risk

- Cancer in Crohn's disease: dispelling the myths: *leading article*, 1507
- Cancer risk in patients treated surgically for duodenal ulcer: *correspondence*, 1675
- Cap polyposis**, Cap polyposis occurring in the postoperative course of pelvic surgery, 1670
- Capsule versus tablet formulations**, Impaired oesophageal transit of capsule versus tablet formulations in the elderly, 1363
- Carbachol**, Effects of *Helicobacter pylori* on histamine and carbachol stimulated acid secretion by human parietal cells, 755
- Carbohydrate 19.9 antigen**, Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis, 1107
- Carbohydrates**, Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals, 186
- Carbon labelled octanoic acid breath test**, Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline, 333: correction, 866
- Carbonic anhydrase isoenzymes**, Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract, 646
- Carcinoembryonic antigen**
- Cell adhesion molecules in oesophageal epithelium, 1343
 - Classification and localisation of carcinoembryonic antigen related antigen expression in normal oesophageal squamous mucosa and squamous carcinoma, 1022
- Carcinoid tumour**, Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome, 275
- Carcinoma**, Ileitis after colectomy for ulcerative colitis or carcinoma, 373
- Cavitation**, Focused liver ablation by cavitation in the rabbit: a potential new method of extracorporeal treatment, 395
- CD45RO molecule**, Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area, 382, correction, 866
- Cell adhesion molecules**, Cell adhesion molecules in oesophageal epithelium, 1343
- Chest pain**, Temporal relationships between episodes of non-cardiac chest pain and abnormal oesophageal function, 733
- Children**, High prevalence of *Helicobacter pylori* infection in cohabiting children. Epidemiology of a cluster, with special emphasis on molecular typing, 313
- China**, Gastroenterology in China, 862
- Chloride secretion**, Relation between chloride secretion and intracellular cyclic adenosine monophosphate in a cloned human intestinal cell line HT-29 cl 19A, 631
- Cholecystectomy**
- Bile duct injury after laparoscopic cholecystectomy: *correspondence*, 288
 - Symptoms and health status before and six weeks after open cholecystectomy: a European cohort study, 1301
- Cholecystokinin**
- Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide, 501
 - Plasma gastric and CCK response after pylorus preserving pancreaticoduodenectomy with Billroth II reconstruction and defunctioned Roux loop pancreaticojejunostomy, A576
- Cholecystokinin type B receptor antagonist**, Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat, 270
- Cholera**
- Absorption of a hypotonic oral rehydration solution in a human model of cholera, 211
 - Cholera and severe toxigenic diarrhoeas: *leading article*, 145
- Cholera toxin**, Relation between chloride secretion and intracellular cyclic adenosine monophosphate in a cloned human intestinal cell line HT-29 cl 19A, 631
- Cholesterol**
- Addition of dimethylsulphoxide to methyl-*tert*-butyl ether and ethyl propionate increases cholesterol dissolving capacity and cholesterol gall stone dissolution in vitro, 1653
 - Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism, 1116
 - Cholesterol synthesis and high density lipoprotein uptake are regulated independently in rat small intestinal epithelium, 343
 - High resolution ¹H NMR to study biliary cholesterol stability, A719
 - Rapid cholesterol nucleation time and cholesterol gall stone formation after subtotal or total colectomy in humans, 1760
- Cimetidine**, Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth, 1632

Cirrhosis

- Analysis of DNA repair in cirrhosis of different aetiologies, A722
- Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis, 1648
- Copper associated childhood cirrhosis, 1497
- Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake, 1637
- Portal and systemic haemodynamic action of *N*-acetylcysteine in patients with stable cirrhosis, 1290
- Cisapride**, Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride, 172
- Clarithromycin**, Eradication of *Helicobacter pylori* with clarithromycin and omeprazole, 323
- Clinical training**, Clinical training – back to the future: *personal viewpoint*, 1008
- Clostridium difficile***, Clinical significance of *Clostridium difficile* and its toxins in faeces of immunocompromised children, 1608
- Coeliac disease**
- Adenovirus 12 E1A gene detection by polymerase chain reaction in both the normal and coeliac duodenum, 1226
 - Bone mineral density in coeliac disease: *leading article*, 150
 - Coeliac disease – associated disorders and survival, 1215
 - Coeliac disease and autoimmune thyroid disease, 844
 - Coeliac disease in the elderly, 65
 - Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation, 1037
 - Endomysium antibodies in coeliac disease: an improved method, 776
 - Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells, 55
 - Intestinal antibody pattern of coeliac disease, 476
 - Lewis phenotype, secretor status, and coeliac disease, 769
 - Localisation of vitamin D receptor in normal human duodenum and in patients with coeliac disease, 1219
 - Raised pro-inflammatory cytokines, interleukin 6 and tumour necrosis factor α in coeliac disease mucosa detected by immunohistochemistry, 1398
 - Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values, 771
 - Serological screening suggests that adult coeliac disease is underdiagnosed in the UK and increases the incidence by up to 12%, 61
- Colectomy**
- Ileitis after colectomy for ulcerative colitis or carcinoma, 373
 - Rapid cholesterol nucleation time and cholesterol gall stone formation after subtotal or total colectomy in humans, 1760
- Colitis**
- A budesonide prodrug accelerates treatment of colitis in rats, 1439
 - Drug induced lymphocytic colitis, 426
 - Role of intestinal microflora in chronic inflammation and ulceration of the rat colon, 1090
 - Serum free medium increases expression of markers of differentiation in human colonic crypt cells, 791
 - The shigella paradigm and colitis due to enterohaemorrhagic *Escherichia coli*: *leading article*, 872
 - Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis, 353
- Colon, colonic**
- Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis, 73
 - Cancer in Crohn's disease: dispelling the myths: *leading article*, 1507
 - Cancer surveillance in ulcerative colitis – a time for reappraisal: *leading article*, 587
 - Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth, 1632
 - Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody, 1712
 - Colonic secretory effect in response to enteral feeding in humans, 1734
 - Colonoscopic surveillance in ulcerative colitis: *correspondence*, 429
 - Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: *correspondence*, 1152
 - Immunoelectron microscopic localisation of transforming growth factor alpha in rat colon, 1086
 - In vitro acetaldehyde formation by human colonic bacteria, 1271
 - Increased group II phospholipase A₂ in colonic mucosa of patients with Crohn's disease and ulcerative colitis, 1593
 - Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes, 669
 - Left sided colon cancer: *correspondence*, 286
 - Location of superoxide anion in the human colonic mucosa: *correspondence*, 284
 - Lower gastrointestinal malignancy in Crohn's disease, 347
 - Methanogens outcompete sulphate reducing bacteria for H₂ in the human colon, 1098
 - Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E₂, 675

- Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation, 530
- Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium *in vitro*, 969
- Serum free medium increases expression of markers of differentiation in human colonic crypt cells, 791
- Simplified method for the measurement of segmental colonic transit time, 976
- Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis, 353
- Colonoscopy**, Utility of surveillance colonoscopy in ulcerative colitis: *correspondence*, 863
- Colorectal adenoma**, Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours, 1258
- Colorectal cancer (carcinoma)**
- Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols, 1262
- Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis, 1419
- Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours, 1258
- Comparison of gastrointestinal symptoms in colorectal carcinoma patients and community controls with respect to age, 1267
- Crohn's disease and colorectal cancer, 651
- Effect on lymph node status of triple levelling and immunohistochemistry with CAM 5.2 on node negative colorectal carcinomas, 1447
- Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area, 382, correction, 866
- Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance, 1627
- Screening for hereditary bowel cancer in New Zealand, 1328
- Similarity of colorectal cancer in Crohn's disease and ulcerative colitis, 950
- The Nm23 gene and colorectal cancer: *correspondence*, 141
- Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis, 1590
- Common bile duct**
- Imaging of the common bile duct in patients undergoing laparoscopic cholecystectomy, 991: *correspondence*, 1773
- Management of common bile duct stricture caused by chronic pancreatitis with metal mesh self expandable stents, 122
- Common bile duct stones**, Common bile duct stones are mainly brown and associated with duodenal diverticula, 1464
- Complexity**, Complexity and the hepatitis viruses: *personal viewpoint*, 1770
- Computed tomography**, Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma: *correspondence*, 287
- Constipation**
- Discriminant value of psychological distress, symptom profiles, and segmental colonic dysfunction in outpatients with severe idiopathic constipation, 798
- Evidence for the ambiguity of the term constipation: the role of irritable bowel syndrome, 1455
- Copper**, Copper associated childhood cirrhosis, 1497
- Corrections**, 866, 1154
- Corticosteroids**
- 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment, 1141
- Unusual pulmonary complication of ulcerative colitis with a rapid response to corticosteroids, 847
- Crohn's colitis**, Faecal diversion for Crohn's colitis, 236
- Crohn's disease**
- Abnormal leukotriene C₄ release by unaffected jejunal mucosa in patients with inactive Crohn's disease, 517
- Association between Meckel's diverticulum and Crohn's disease: a retrospective review, 788
- Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT, 90
- Bowel diversion should be used with caution in stenosing anal Crohn's disease, 1139
- Cancer in Crohn's disease: dispelling the myths: *leading article*, 1507
- Comparison of amino acid *v* peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome, 783
- Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease, 363
- 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment, 1141
- Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease, 231
- Crohn's disease and colorectal cancer, 651
- Crohn's disease and myasthenia gravis: a possible role for thymectomy, 278
- Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection, 1728
- Food intolerance and Crohn's disease: *correspondence*, 571
- Frequency of glucocorticoid resistance and dependency in Crohn's disease, 360
- Ileal and colonic fatty acid profiles in patients with active Crohn's disease, 1424
- Incidence of inflammatory bowel disease in north west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common, 369
- Increased group II phospholipase A₂ in colonic mucosa of patients with Crohn's disease and ulcerative colitis, 1593
- Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives, 68: *correspondence*, 1675
- Lower gastrointestinal malignancy in Crohn's disease, 347
- Mycobacteria in the human intestine: *correspondence*, 715
- Non-fatal portal pyaemia complicating Crohn's disease of the terminal ileum, 560
- Pathogenesis of gall stones in Crohn's disease: an alternative explanation, 94: *correspondence*, 1676
- Platelet activating factor and Crohn's disease: *correspondence*, 141
- Similarity of colorectal cancer in Crohn's disease and ulcerative colitis, 950
- Specific detection of *Mycobacterium paratuberculosis* DNA associated with granulomatous tissue in Crohn's disease, 506
- Surgical resections in parous patients with distal ileal and colonic Crohn's disease, 220
- Timing of ileocolonic resection for symptomatic Crohn's disease – the patient's view, 656
- Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis, 1590
- Crohn's ileocolitis**, Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis, 1081
- Crypt cells**, Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells, 55
- Cyclic adenosine monophosphate**, Relation between chloride secretion and intracellular cyclic adenosine monophosphate in a cloned human intestinal cell line HT-29 cl 19A, 631
- Cystic fibrosis**, Spontaneous bacterial peritonitis in cystic fibrosis, 709
- Cytochrome P450**, Cytochrome P450 expression in oesophageal cancer, 599
- Cytokines**
- Cytokine gene expression in *Helicobacter pylori* associated antral gastritis, 1567
- Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms: *leading article*, 1163
- Raised pro-inflammatory cytokines, interleukin 6 and tumour necrosis factor α in coeliac disease mucosa detected by immunohistochemistry, 1398
- Systemic complications in acute pancreatitis are associated with increased monocyte cytokine release, A575
- Defecation reflex**, Effects of biofeedback on obstructive defecation – reconditioning of the defecation reflex?, 252
- Defence mechanisms**, Role of bile in non-specific defence mechanisms of the gut, 1047
- Desmoid tumours**, Desmoid tumours in familial adenomatous polyposis, 377
- Dexamethasone**, Effects of endotoxin and dexamethasone on group I and II phospholipase A₂ in rat ileum and stomach, 40
- Diarrhoea**
- Ambulatory small intestinal motility in diarrhoea predominant irritable bowel syndrome, 203
- Cholera and severe toxigenic diarrhoeas: *leading article*, 145
- Effect of dietary nucleotides on small intestinal repair after diarrhoea, 926
- Lipid peroxidation and electrogenic ion transport in the jejunum of the vitamin E deficient rat, 34
- Paediatric problems in tropical gastroenterology: *leading article*, 1687
- Persisting diarrhoea and malabsorption: *leading article*, 582
- Response of the human intestine to high volume infusion, 641
- Salmonella typhi* and other salmonellas: *leading article*, 726
- Travellers' diarrhoea: *leading article*, 1
- Diet**, Effects of diet on experimentally induced intestinal ulcers in rats: morphology and tissue leukotrienes, 1058
- Diet nucleotides**, Effect of dietary nucleotides on small intestinal repair after diarrhoea, 926
- Digestive surgery**
- Digestive surgery is a stillborn specialty in the United Kingdom: *personal viewpoint*, 1673
- Training for digestive surgery: *personal viewpoint*, 1007
- Dilators**, Forceful dilatation under endoscopic control in the treatment of achalasia: a randomised trial of pneumatic versus metallic dilator, 1361

- Dimethylsulphoxide**, Addition of dimethylsulphoxide to methyl-*tert*-butyl ether and ethyl propionate increases cholesterol dissolving capacity and cholesterol gall stone dissolution in vitro, 1653
- Disaccharidase deficiency**, Morphological method for the diagnosis of human adult type hypolactasia, 1042
- Distal colon**, Diverting colostomy induces mucosal and muscular atrophy in rat distal colon, 1275
- Distension**, The knee-elbow position relieves distension: *correspondence*, 1150
- Diverticulum**, Intraluminal duodenal diverticulum causing recurrent pancreatitis: treatment by endoscopic incision, 557
- Diverting colostomy**, Diverting colostomy induces mucosal and muscular atrophy in rat distal colon, 1275
- DNA repair**, Analysis of DNA repair in cirrhosis of different aetiologies, A722
- Dopamine**, Dopamine in models of alcoholic acute pancreatitis, 547
- Drugs**, Drug induced lymphocytic colitis, 426
- Dukes's classification**, Dukes's classification: a valid prognostic indicator for gastric cancer, 1368
- Duodenal bile**, Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination, 112
- Duodenal diverticula**, Common bile duct stones are mainly brown and associated with duodenal diverticula, 1464
- Duodenal endocrine cells**, Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells, 1413
- Duodenal juice**, Duodenal bacterial overgrowth during treatment in outpatients with omeprazole, 23
- Duodenal motor activity**, Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia, 916
- Duodenal ulcer**
Death from malignant disease after surgery for duodenal ulcer, 451: *correspondence*, 1675
Distal biliary stricture as a complication of sclerosant injection for bleeding duodenal ulcer, 1665
Duodenal ulcer, *Helicobacter pylori*, and gastric secretion, 1033
Duodenal ulcer pain – the role of acid and inflammation: *correspondence*, 863
Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients, 1394
Helicobacter pylori eradication, duodenal ulcer healing, and gastric secretory state: *correspondence*, 571
Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs, 1030
Maintenance of intragastric pH 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements, 750
One week's anti-*Helicobacter pylori* treatment for duodenal ulcer, 15
- Dyspepsia**
Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients, 327
Database on dyspepsia, 191
Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia, 916
Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups, 619
- Dysphagia**
Diminished oesophageal traction forces with swallowing in gastro-oesophageal reflux disease and in functional dysphagia, 165
Palliation of malignant dysphagia by ethanol induced tumour necrosis, 299
Secondary oesophageal peristalsis in patients with non-obstructive dysphagia, 1523
- Dysplasia**, Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus, 1348
- Dysplasia/carcinoma sequence**, Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence, 764
- E-cadherin**, Cell adhesion molecules in oesophageal epithelium, 1343
- Eastern Europe**, *Helicobacter pylori* in eastern European countries: what is the current status?: *leading article*, 1683
- Echinococcus**, Echinococcus of the liver: *leading article*, 1517
- Eggs**, *Salmonella typhi* and other salmonellas: *leading article*, 726
- Eicosanoids**
Effect of nicotine on rectal mucus and mucosal eicosanoids, 247
Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor, 490
- Elderly**
Coeliac disease in the elderly, 65
Comparison of gastrointestinal symptoms in colorectal carcinoma patients and community controls with respect to age, 1267
Impaired oesophageal transit of capsule versus tablet formulations in the elderly, 1363
- Electrogenic ion transport**, Lipid peroxidation and electrogenic ion transport in the jejunum of the vitamin E deficient rat, 34
- Elemental diets**, Comparison of amino acid v peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome, 783
- Endoanal ultrasonography**, Fistulas in ano: endoanal ultrasonographic assessment assists decision making for surgery, 391
- Endomysium antibodies**, Endomysium antibodies in coeliac disease: an improved method, 776
- Endoscopic gastritis**, Histological assessment of the Sydney classification of endoscopic gastritis, 1172
- Endoscopic injection therapy**, Endoscopic injection therapy for bleeding peptic ulcer; a comparison of adrenaline alone with adrenaline plus ethanolamine oleate, 608
- Endoscopic retrograde cholangiopancreatography**
Oxygen saturation during endoscopic retrograde cholangiopancreatography: a comparison of two protocols of oxygen administration, 408
Towards safer endoscopic retrograde cholangiopancreatography (ERCP): *correspondence*, 284
- Endoscopic retrograde cholangiopancreatography**, Combined percutaneous and endoscopic procedures for bile duct obstruction: *leading article*, 1011
- Endoscopic sphincteroplasty**, Endoscopic sphincteroplasty: a novel and safe alternative to papillotomy in the management of bile duct stones, 127: *correspondence*, 1010
- Endoscopy**
Acute gastrointestinal haemorrhage in anticoagulated patients, 464
Appropriate use of upper gastrointestinal endoscopy – a prospective audit, 1209
Bleeding peptic ulcer – risk factors for rebleeding and sequential changes in endoscopic findings, 746
Endoscopic laser treatment of diffuse gastric antral vascular ectasia, 461
Gastrointestinal endoscopy in general practice: *special report*, 1342
Training for digestive surgery: *personal viewpoint*, 1007
- Endoscopy units**, Aldehyde disinfectants and health in endoscopy units: *correspondence*, 717
- Endosonography**, Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma: *correspondence*, 287
- Endotoxin**, Effects of endotoxin and dexamethasone on group I and II phospholipase A₂ in rat ileum and stomach, 40
- Enlarged fold gastritis**, Improved fold width and increased acid secretion after eradication of the organism in *Helicobacter pylori* associated enlarged fold gastritis, 1571
- Entamoeba histolytica**, Diagnosis of invasive amoebiasis – time to end the morphology era: *leading article*, 1018
- Enteral feeding**, Colonic secretory effect in response to enteral feeding in humans, 1734
- Enteral nutrition**, Enteral nutrition and the small intestine, 1765
- Enteric nervous system**, Role of the enteric nervous system in the maintained hypersecretion induced by enterotoxin STa in the nutritionally deprived intestine, 1237
- Enteric protein loss**, Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery: effect of zinc supplementation, 1707
- Enterobius vermicularis** infection, *Enterobius vermicularis* infection: *leading article*, 1159
- Enterocytes**
Enterocyte proliferation and intracellular bacteria in animals, 1483
Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria, 483
- Enteroglucagon**, Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat, 1701
- Enterohaemorrhagic Escherichia coli**, The shigella paradigm and colitis due to enterohaemorrhagic *Escherichia coli*: *leading article*, 872
- Enteropathy**, Studies on the enteropathy associated with primary hypogammaglobulinaemia, 1244
- Enterotoxin STa**, Role of the enteric nervous system in the maintained hypersecretion induced by enterotoxin STa in the nutritionally deprived intestine, 1237
- Enzyme linked immunosorbent assay**, Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease, 224
- Eosinophilic enterocolitis**, Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR), 1490
- Epidermal growth factor**
Divergent effects of epidermal growth factor and calcipitriol on human rectal cell proliferation, 1742
Expression of growth factors in precursor lesions to gastric carcinoma, A1680
Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion, 611
- Epidermal growth factor receptor**, Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor α , and phospholipase C γ , 1468

- Epinephrine**, Alcohol *v* epinephrine and polidocanol: *correspondence*, 286
- Epithelial cells**, Epithelial cell lineages in developing, restoring, and transforming liver: evidence for the existence of a 'differentiation window': *leading article*, 294
- Epithelium**
Immunohistochemical localisation of intercellular adhesion molecule-1 in follicle associated epithelium of Peyer's patches, 46
Tissue culture of epithelium derived from Barrett's oesophagus, 879
- Erythrocytes**, Resistance of erythrocytes to lipid peroxidation in alcoholic patients, 1753
- Erythromycin**, Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline, 333: *correction*, 866
- Escherichia coli**
Adhesion of human enterotoxigenic *Escherichia coli* to human mucus secreting HT-29 cell subpopulations in culture, 1449
Routes of spread of pathogens into the pancreas in a feline model of acute pancreatitis, 1306
The shigella paradigm and colitis due to enterohaemorrhagic *Escherichia coli*: *leading article*, 872
- Escherichia coli** enterotoxins, Effect of *Escherichia coli* enterotoxins on macromolecular absorption, 1613
- Ethanol**
Chronic ethanol consumption increases the fragility of rat pancreatic zymogen granules, 1474
Enhancement of ethanol induced rectal mucosal hyper regeneration with age in F344 rats, 1102
In vitro acetaldehyde formation by human colonic bacteria, 1271
Lipid peroxidation in rats chronically fed ethanol, 1644
- Ethanol induced tumour necrosis**, Palliation of malignant dysphagia by ethanol induced tumour necrosis, 299
- Ethanolamine oleate**, Endoscopic injection therapy for bleeding peptic ulcer; a comparison of adrenaline alone with adrenaline plus ethanolamine oleate, 608
- Ethyl propionate**, Addition of dimethylsulphoxide to methyl-*tert*-butyl ether and ethyl propionate increases cholesterol dissolving capacity and cholesterol gall stone dissolution in vitro, 1653
- Exocrine functional impairment**, Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis, 1132
- Exocrine pancreatic insufficiency**, Origin and development of exocrine pancreatic insufficiency in experimental renal failure, 401: *correspondence*, 1772
- Expelled air measurements**, Intra-gastric nitric oxide production in humans: measurements in expelled air, 1543
- Extracorporeal lithotripsy**
Gall stone pulverisation strategy in patients treated with extracorporeal lithotripsy and follow up results of maintenance treatment with ursodeoxycholic acid, 117
Pulverisation of calcified and non-calcified gall bladder stones: extracorporeal shock wave lithotripsy used alone, 417
- Extracorporeal shock wave lithotripsy**, Cost effectiveness of adjuvant bile salt treatment in extracorporeal shock wave lithotripsy for the treatment of gall bladder stones, 1294
- Extracorporeal treatment**, Focused liver ablation by cavitation in the rabbit: a potential new method of extracorporeal treatment, 395
- Extrahepatic biliary atresia**, Serum hyaluronic acid in extrahepatic biliary atresia (EHBA) before portoenterostomy identifies patients who will require early liver transplantation, A719
- Faecal diversion**, Faecal diversion for Crohn's colitis, 236
- Faecal incontinence**, Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence, 857
- Familial adenomatous polyposis**
Desmoid tumours in familial adenomatous polyposis, 377
Increased leukotriene B₄ release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis, 1429
Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis: *correspondence*, 572
Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis, 1622
Rectal mucosal ornithine decarboxylase activity in familial adenomatous polyposis after ileorectal anastomosis, 1624
- Famotidine**
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease, 447
Maintenance of intragastric pH 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements, 750
- Fasting**, Human small intestinal contractions and aboral traction forces during fasting and after feeding, 625
- Fats**, Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals, 186
- Fatty acids**
Ileal and colonic fatty acid profiles in patients with active Crohn's disease, 1424
Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect of diet on peptic ulceration, 1557
Interaction of *Helicobacter pylori* and its fatty acids with parietal cells and gastric H⁺/K⁺-ATPase, 1176
- Fatty liver**, Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients, 101
- Fibrogenesis**, Perisinusoidal lipocytes and fibrinogenesis: *leading article*, 1331
- Fistulas in ano**, Fistulas in ano: endoanal ultrasonographic assessment assists decision making for surgery, 391
- Follicle associated epithelium**, Immunohistochemical localisation of intercellular adhesion molecule-1 in follicle associated epithelium of Peyer's patches, 46
- Food distribution, intra-gastric**, Abnormal intra-gastric distribution of food during gastric emptying in functional dyspepsia patients, 327
- Food intolerance**, Food intolerance and Crohn's disease: *correspondence*, 571
- Forceful dilatation**, Forceful dilatation under endoscopic control in the treatment of achalasia: a randomised trial of pneumatic versus metallic dilator, 1361
- Fucosylated retinol binding protein**, Fucosylated retinol binding protein in hepatocellular carcinoma: a new diagnostic test, A720
- Fulminant hepatic failure**
Extent of the acute phase response in fulminant hepatic failure, 982
Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E, 849
Fulminant hepatic failure secondary to hydroxychloroquine, 569
Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure, A720
L-mono-methyl-arginine in the treatment of hypotension resulting from fulminant hepatic failure, A721
- Gall bladder**
Adult rhabdomyosarcoma of the gall bladder, 854
Comparative studies of human intrahepatic biliary and gall bladder epithelial cells in vitro, A719
Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination, 112
Non-adrenergic non-cholinergic inhibitory innervation shown by electrical field stimulation of isolated strips of human gall bladder muscle, 412
- Gall bladder disease**
Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study, 107: *correspondence*, 1152, 1506
Prospective audit of the introduction of laparoscopic cholecystectomy in the west of Scotland, 1121
- Gall bladder stone lithotripsy**, Relief of heterogeneous symptoms after successful gall bladder stone lithotripsy and complete stone disappearance, 819
- Gall bladder stones**, Cost effectiveness of adjuvant bile salt treatment in extracorporeal shock wave lithotripsy for the treatment of gall bladder stones, 1294
- Gall stones**
Addition of dimethylsulphoxide to methyl-*tert*-butyl ether and ethyl propionate increases cholesterol dissolving capacity and cholesterol gall stone dissolution in vitro, 1653
Gall stone pulverisation strategy in patients treated with extracorporeal lithotripsy and follow up results of maintenance treatment with ursodeoxycholic acid, 117
Gall stones and gall bladder motility: *correspondence*, 140
Pancreatic outflow obstruction as the critical event for human gall stone induced pancreatitis, 1501
Pathogenesis of gall stones in Crohn's disease: an alternative explanation, 94: *correspondence*, 1676
Percutaneous cholecystolithotomy: is gall stone recurrence inevitable?, 692
Pulverisation of calcified and non-calcified gall bladder stones: extracorporeal shock wave lithotripsy used alone, 417
Rapid cholesterol nucleation time and cholesterol gall stone formation after subtotal or total colectomy in humans, 1760
- Gastric acid clearance**, Primary peristalsis is the major acid clearance mechanism in reflux patients, 1536
- Gastric acid secretion**
Acupuncture inhibits vagal gastric acid secretion stimulated by sham feeding in healthy subjects, 1026
Helicobacter pylori eradication, duodenal ulcer healing, and gastric secretory state: *correspondence*, 571
- Gastric antral vascular ectasia**, Endoscopic laser treatment of diffuse gastric antral vascular ectasia, 461

- Gastric biopsy**, Polymerase chain reaction assay for the detection of *Helicobacter pylori* in gastric biopsy specimens, 905
- Gastric blood flow**
Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation, 1197
Role of gastric blood flow, neutrophil infiltration, and mucosal cell proliferation in gastric adaptation to aspirin in the rat, 1189
- Gastric cancer (carcinoma)**
Can prescribing omeprazole delay the diagnosis of gastric malignancy? A1681
Comparison of computed tomography, endosonography, and intra-operative assessment in TN staging of gastric carcinoma: *correspondence*, 287
Comparison of the molecular genetics of stomach cancers in Britain and Japan: c-erbB2 and p53, A1680
'Curative' gastrectomy from gastric carcinoma – R1 versus R2, A1681
Dukes's classification: a valid prognostic indicator for gastric cancer, 1368
Expression of growth factors in precursor lesions to gastric carcinoma, A1680
Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa, 1697
Expression of transforming growth factor alpha in experimental gastric carcinogenesis, 604
Gastric cancer and *Helicobacter pylori* infection, A1682
Gastric cancer risk after vagotomy, 946
Goseki histological grading of gastric cancer is an important predictor of outcome, 758
Helicobacter pylori and early gastric cancer, 1372
Helicobacter pylori infection: *correspondence*, 716
Laparoscopic assessment of resectability in gastric cancer, A1680
- Gastric emptying**
Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients, 327
Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline, 333: correction, 866
Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride, 172
Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals, 186
- Gastric fundus**, Resection of the gastric fundus in rats: *correspondence*, 140
- Gastric juice**
Effect of *Helicobacter pylori* and its eradication on gastric juice ascorbic acid, 317
Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion, 611
- Gastric metaplasia**, Acid and gastric metaplasia in the duodenum: *correspondence*, 1151
- Gastric mucosa**
A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats, 1181
Gastrin receptor localisation in normal and neoplastic gastric mucosa, A1680
Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation, 1197
Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha, 909
Rebamipide, a novel antiulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidants, 1375
- Gastric outlet obstruction**, Gastric outlet obstruction as a presenting manifestation of systemic lupus erythematosus, 841
- Gastric secretion**, Duodenal ulcer, *Helicobacter pylori*, and gastric secretion, 1033
- Gastric T lymphocyte**, Gastric T lymphocyte responses to *Helicobacter pylori* in patients with *H. pylori* colonisation, 1379
- Gastric ulcer**
A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats, 1181
Effect of omeprazole and sucralfate on prepyloric gastric ulcer, 837
- Gastric ulcer disease**, Evidence for the essential role of *Helicobacter pylori* in gastric ulcer disease, 19
- Gastric ulcer scar**, Antacid provides better restoration of glandular structures within the gastric ulcer scar than omeprazole, 896
- Gastrin**, Gastrin and somatostatin in *Helicobacter pylori* infected antral mucosa, 615
- Gastrin receptor antagonists**, Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat, 270
- Gastrin receptor localisation**, Gastrin receptor localisation in normal and neoplastic gastric mucosa, A1680
- Gastritis**
Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992, 1167
Histological assessment of the Sydney classification of endoscopic gastritis, 1172
- Gastro-oesophageal junction carcinoma**, CT scanning and carcinoma of the gastro-oesophageal junction, A1681
- Gastro-oesophageal reflux**, Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring, 1519
- Gastro-oesophageal reflux disease**
Diminished oesophageal traction forces with swallowing in gastro-oesophageal reflux disease and in functional dysphagia, 165
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease, 447
Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients, 8
- Gastroduodenal lesions**, Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs, 1030
- Gastroenterological practice**, Gastroenterological practice in Israel, 1149
- Gastroenterology**
Gastroenterology in China, 862
Present position of gastroenterology in the Netherlands, 1326
Specialist training in gastroenterology in the European Community: the case for European Boards, 135
Training for digestive surgery: *personal viewpoint*, 1007
- Gastrointestinal endoscopy**, Gastrointestinal endoscopy in general practice: *special report*, 1342
- Gastrointestinal haemorrhage**, Acute gastrointestinal haemorrhage in anticoagulated patients, 464
- Gastrointestinal symptoms**, Comparison of gastrointestinal symptoms in colorectal carcinoma patients and community controls with respect to age, 1267
- Gastroparesis**, Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride, 172
- Genetics**, Genetics of inflammatory bowel disease, 696
- Giardia lamblia**, Phenotypic and genotypic variation in *Giardia lamblia* isolates during chronic infection, 51
- Glucocorticoid resistance**, Frequency of glucocorticoid resistance and dependency in Crohn's disease, 360
- Glutamate transport**, Synaptosomal glutamate transport in thioacetamide induced hepatic encephalopathy in rats, A719
- Glutathione S-transferases**, Expression of glutathione S-transferases in normal and malignant pancreas: an immunohistochemical study, 266
- Gluten enriched diet**, Effects of gluten enriched diet on the small intestinal mucosa of normal mice and mice with graft versus host reaction, 779
- Goseki histological grading**, Goseki histological grading of gastric cancer is an important predictor of outcome, 758
- Granulocyte scintigraphy**, Value of granulocyte scintigraphy in inflammatory bowel disease: *correspondence*, 1676
- Granulomatous skin lesions**, Primary biliary cirrhosis presenting with granulomatous skin lesions, 564
- Granulomatous tissue**, Specific detection of *Mycobacterium paratuberculosis* DNA associated with granulomatous tissue in Crohn's disease, 506
- Guanylyl cyclases**, Distribution of membrane bound guanylyl cyclases in human intestine, 1250
- H⁺/K⁺-ATPase**, Interaction of *Helicobacter pylori* and its fatty acids with parietal cells and gastric H⁺/K⁺-ATPase, 1176
- H₂**, Methanogens outcompete sulphate reducing bacteria for H₂ in the human colon, 1098
- ¹H NMR**, High resolution ¹H NMR to study biliary cholesterol stability, A719
- Haematoma**, Intramural haematoma of the oesophagus complicating sclerotherapy for varices, 130
- Haemochromatosis**, Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis, 1107
- Haemoperitoneum**, Avulsion of short gastric arteries caused by vomiting, 1137
- Haemorrhage**
Distal biliary stricture as a complication of sclerosant injection for bleeding duodenal ulcer, 1665
Thrombin – an effective treatment for gastric variceal haemorrhage, 1287
- Helicobacter pylori**
Acid and gastric metaplasia in the duodenum: *correspondence*, 1151
Cytokine gene expression in *Helicobacter pylori* associated antral gastritis, 1567
Duodenal ulcer, *Helicobacter pylori*, and gastric secretion, 1033
Effect of *Helicobacter pylori* and its eradication on gastric juice ascorbic acid, 317

- Effects of *Helicobacter pylori* on histamine and carbachol stimulated acid secretion by human parietal cells, 755
- Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients, 1394
- Eradication of *Helicobacter pylori* with clarithromycin and omeprazole, 323 7
- Evidence for the essential role of *Helicobacter pylori* in gastric ulcer disease, 19
- Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992, 1167
- Gastric cancer and *Helicobacter pylori* infection, A1682
- Gastric T lymphocyte responses to *Helicobacter pylori* in patients with *H. pylori* colonisation, 1379
- Gastrin and somatostatin in *Helicobacter pylori* infected antral mucosa, 615
- Healing of protein losing hypertrophic gastropathy by eradication of *Helicobacter pylori* – Is *Helicobacter pylori* a pathogenic factor in Ménétrier's disease?, 701
- Helicobacter pylori* and early gastric cancer, 1372
- Helicobacter pylori* in eastern European countries: what is the current status?: *leading article*, 1683
- Helicobacter pylori* eradication, duodenal ulcer healing, and gastric secretory state: *correspondence*, 571
- Helicobacter pylori* infection: *correspondence*, 716
- Helicobacter pylori* stimulates antral mucosal reactive oxygen metabolite production in vivo, 170
- High prevalence of *Helicobacter pylori* infection in cohabiting children. Epidemiology of a cluster, with special emphasis on molecular typing, 313
- High prevalence of *Helicobacter pylori* metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease, 1562
- Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection, 742
- Improved fold width and increased acid secretion after eradication of the organism in *Helicobacter pylori* associated enlarged fold gastritis, 1571
- Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect of diet on peptic ulceration, 1557
- Interaction of *Helicobacter pylori* and its fatty acids with parietal cells and gastric H⁺/K⁺-ATPase, 1176
- Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine, 1385
- One week's anti-*Helicobacter pylori* treatment for duodenal ulcer, 15
- Polymerase chain reaction assay for the detection of *Helicobacter pylori* in gastric biopsy specimens, 905
- Prevalence of peptic ulcer in *Helicobacter pylori* positive blood donors, 309
- Rebamipide, a novel antiulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidants, 1375
- Risk factors for *Helicobacter pylori*: *correspondence*, 1153
- The urea breath test for *Helicobacter pylori*: *leading article*, 723
- Hepatic encephalopathy, Synaptosomal glutamate transport in thioacetamide induced hepatic encephalopathy in rats, A719
- Hepatic porphyria, Safety of general anaesthesia and surgery in acute hepatic porphyria, 1112
- Hepatitis B, Expression of HBV polymerase in HBV related hepatocellular carcinoma, A720
- Hepatitis B virus, Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus: *leading article*, 1013
- Hepatitis C, Hepatitis C in children: role of serology in diagnosis, A719
- Hepatitis C genotypes, Hepatitis C genotypes and viral load, A721
- Hepatitis C infection, High prevalence of histological abnormality in asymptomatic hepatitis C infection with persistently normal liver enzymes, A719
- Hepatitis C virus, Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact?, 542
- Hepatitis C virus infection, Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha, A720
- Hepatitis E, Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E, 849
- Hepatitis viruses, Complexity and the hepatitis viruses: *personal viewpoint*, 1770
- Hepatocellular carcinoma
- Expression of HBV polymerase in HBV related hepatocellular carcinoma, A720
- Expression of mutant p53 protein in hepatocellular carcinoma, 98
- Fucosylated retinol binding protein in hepatocellular carcinoma: a new diagnostic test, A720
- Hepatocellular carcinoma in primary biliary cirrhosis, A721
- Measurement of androgen receptor expression in adult liver, fetal liver, and Hep-G2 cells by the polymerase chain reaction, 688
- Viruses and hepatocellular carcinoma, 828
- Hepatocyte growth factor**, Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure, A720
- Hepatocyte growth factor mRNA transcripts**, Differential effect of transforming growth factor beta on expression of 6.3 and 1.5 Kb hepatocyte growth factor mRNA transcripts in MRC-5 cells, A720
- Hepatocytes**
- Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms: *leading article*, 1163
- Hepatocyte-matrix interactions: *leading article*, 729
- Isolated hepatocytes: use in experimental and clinical hepatology: *leading article*, 433
- Hepatoma**
- Chemotherapy *v* symptomatic treatment for hepatoma: *correspondence*, 865
- Intra-arterial lipiodol targeted treatments for unresectable hepatoma, A721
- High carbohydrate meals**, Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals, 186
- High density lipoprotein**, Cholesterol synthesis and high density lipoprotein uptake are regulated independently in rat small intestinal epithelium, 343
- High fat meals**, Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals, 186
- Hirschsprung's disease**, Nerve growth factor receptor immunostaining suggests an extrinsic origin for hypertrophic nerves in Hirschsprung's disease, 1605
- Histamine**
- Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth, 1632
- Effects of *Helicobacter pylori* on histamine and carbachol stimulated acid secretion by human parietal cells, 755
- Histamine H₂ receptor antagonist**, Evaluation of the trophic effect of longterm treatment with the histamine H₂ receptor antagonist loxidine on rat oxyntic mucosa by differential counting of dispersed cells, 1547
- HIV1 infection**, Is there IgA of gut mucosal origin in the serum of HIV1 infected patients?, 803
- HLA**, Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells, 55
- HT-29 cell subpopulations**, Adhesion of human enterotoxigenic *Escherichia coli* to human mucus secreting HT-29 cell subpopulations in culture, 1449
- HT-29 cl 19A cell line**, Relation between chloride secretion and intracellular cyclic adenosine monophosphate in a cloned human intestinal cell line HT-29 cl 19A, 631
- HT-29 intestinal cell line**, Characterisation of oxidative injury to an intestinal cell line (HT-29) by hydrogen peroxide, 1575
- HT 29/19A cells**, Polarised interleukin 8 secretion by HT 29/19A cells, 338
- Human pancreas specific protein**, Human pancreas specific protein (HPASP): an early marker of severity in acute pancreatitis? A574
- Hyaluronic acid**, Serum hyaluronic acid in extrahepatic biliary atresia (EHBA) before portoenterostomy identifies patients who will require early liver transplantation, A719
- Hydatid disease**, Rim calcification in primary liver cell carcinoma mimicking hydatid disease, 567
- Hydrogen peroxide**, Characterisation of oxidative injury to an intestinal cell line (HT-29) by hydrogen peroxide, 1575
- Hydroxychloroquine**, Fulminant hepatic failure secondary to hydroxychloroquine, 569
- 5-Hydroxytryptamine**
- 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake, 496
- Failure of tropisetron to inhibit jejunal water and electrolyte secretion induced by 5-hydroxytryptamine in healthy volunteers, 637
- 5-Hydroxytryptamine**, Serotonergic mediation of postprandial colonic tonic and phasic responses in humans, 536
- Hypertension**
- Benign intracranial hypertension during prednisolone treatment for inflammatory bowel disease, 423: *correspondence*, 1677
- Longterm outcome after injection sclerotherapy for oesophageal varices in children with extrahepatic portal hypertension, 257
- Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension, 280
- Hypogammaglobulinaemia**, Studies on the enteropathy associated with primary hypogammaglobulinaemia, 1244
- Hypolactasia**, Morphological method for the diagnosis of human adult type hypolactasia, 1042
- Hyposplenism**, Functional hyposplenism in alcoholic liver disease, 679

- Ileal exclusion**, Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism, 1116
- Ileal metabolism**, Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: *correspondence*, 1152
- Ileal pouch mucosa**, Increased leukotriene B₂ release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis, 1429
- Ileal reservoir mucosa**, Longterm appraisal of the histological appearances of the ileal reservoir mucosa after restorative proctocolectomy for ulcerative colitis, 1721
- Ileitis**, Ileitis after colectomy for ulcerative colitis or carcinoma, 373
- Ileoanal pouch**, Polypoid mucosal prolapse in a pelvic ileal reservoir, 1668
- Ileoanal reservoir function**, Relationship of small bowel motility to ileoanal reservoir function, 523
- Ileocolonic resection**, Timing of ileocolonic resection for symptomatic Crohn's disease – the patient's view, 656
- Ileorectal anastomosis**, Rectal mucosal ornithine decarboxylase activity in familial adenomatous polyposis after ileorectal anastomosis, 1624
- Ileum**, Role of the enteric nervous system in the maintained hypersecretion induced by enterotoxin STa in the nutritionally deprived intestine, 1237
- Immune system**, Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms: *leading article*, 1163
- Immunocompromised children**, Clinical significance of *Clostridium difficile* and its toxins in faeces of immunocompromised children, 1608
- Immunoelectron microscopic localisation**, Immunoelectron microscopic localisation of transforming growth factor alpha in rat colon, 1086
- Immunoglobulin A**, Is there IgA of gut mucosal origin in the serum of HIV1 infected patients?, 803
- Immunoglobulin G1 antibody**, Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody, 1712
- Immunohistochemistry**, Expression of glutathione S-transferases in normal and malignant pancreas: an immunohistochemical study, 266
- Immunoprecipitation studies**, Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease, 224
- In situ hybridisation**, Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation, 1037
- Index**, Gut index change: *editorial*, 1021
- Indomethacin**
Effects of diet on experimentally induced intestinal ulcers in rats: morphology and tissue leukotrienes, 1058
Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha, 909
Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor, 490
- Infection**, Phenotypic and genotypic variation in *Giardia lamblia* isolates during chronic infection, 51
- Inflammatory bowel disease**
A modest proposal for future trials of medical treatment in inflammatory bowel disease: *personal viewpoint*, 860
Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease, 511
Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease, 224
Genetics of inflammatory bowel disease, 696
Incidence of inflammatory bowel disease in north west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common, 369
Incidence of inflammatory bowel disease in northern France (1988-1990), 1433
Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes, 669
Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium, 1316
Interrelations between interleukin-6, interleukin-1 β , plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease, 77: *correspondence*, 714
Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine, 1385
Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy? *leading article*, 867
Microalbuminuria in inflammatory bowel disease, 1599
Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life, 665
Observer variation and discriminatory value of biopsy features in inflammatory bowel disease, 961
- Pouchitis – recurrence of the inflammatory bowel disease?, 243
Role of intestinal microflora in chronic inflammation and ulceration of the rat colon, 1090
Tumour necrosis factor alpha in inflammatory bowel disease: *correspondence*, 715
Value of granulocyte scintigraphy in inflammatory bowel disease: *correspondence*, 1676
- Infusion**, Response of the human intestine to high volume infusion, 641
- Injection sclerotherapy**
Distal biliary stricture as a complication of sclerosant injection for bleeding duodenal ulcer, 1665
Longterm outcome after injection sclerotherapy for oesophageal varices in children with extrahepatic portal hypertension, 257
Respiratory function after injection sclerotherapy of oesophageal varices, 1459
- Integrins**, Cell adhesion molecules in oesophageal epithelium, 1343
- Intercellular adhesion molecule-1**, Immunohistochemical localisation of intercellular adhesion molecule-1 in follicle associated epithelium of Peyer's patches, 46
- Interferon gamma mRNA**, Detection of interferon gamma mRNA in the mucosa of patients with coeliac disease by in situ hybridisation, 1037
- Interleukin-1 β** , Interrelations between interleukin-6, interleukin-1 β , plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease, 77: *correspondence*, 714
- Interleukin-2**
Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients, 955
Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells, 55
- Interleukin-6**
Interrelations between interleukin-6, interleukin-1 β , plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease, 77: *correspondence*, 714
Raised pro-inflammatory cytokines, interleukin 6 and tumour necrosis factor α in coeliac disease mucosa detected by immunohistochemistry, 1398
- Interleukin-8**, Polarised interleukin 8 secretion by HT 29/19A cells, 338
- Interleukin receptors**, Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy? *leading article*, 867
- Interstitial nephritis**, Mesalazine induced interstitial nephritis, 1493
- Intestinal absorption**, Intestinal absorption of peptide drugs: *leading article*, 441
- Intestinal cells**, *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria, 483
- Intestinal ischaemia**, Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat, 1701
- Intestinal microflora**, Role of intestinal microflora in chronic inflammation and ulceration of the rat colon, 1090
- Intestinal mucosa**, Lymphoid and non-lymphoid cells in the epithelium and lamina propria of intestinal mucosa of pigs, 1582
- Intestinal permeability**
Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery: effect of zinc supplementation, 1707
Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives, 68: *correspondence*, 1675
- Intestinal ulcers**, Effects of diet on experimentally induced intestinal ulcers in rats: morphology and tissue leukotrienes, 1058
- Intracellular bacteria**, Enterocyte proliferation and intracellular bacteria in animals, 1483
- Intraduodenal fat**, Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist lorcigliumide, 501
- Intrahepatic biliary cells**, Comparative studies of human intrahepatic biliary and gall bladder epithelial cells in vitro, A719
- Intrahepatic cholestatic jaundice**, Primary amyloidosis and severe intrahepatic cholestatic jaundice, 1322
- Intraluminal acidification**, Effects of intraluminal acidification on oesophageal motor activity, 884
- Intraluminal duodenal diverticulum**, Intraluminal duodenal diverticulum causing recurrent pancreatitis: treatment by endoscopic incision, 557
- Intraoperative assessment**, Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma: *correspondence*, 287
- Ion transport**, Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins, 934
- Iron deficiency anaemia**, Iron deficiency anaemia: *correspondence*, 140, 864

Irritable bowel syndrome

- Ambulatory small intestinal motility in diarrhoea predominant irritable bowel syndrome, 203
- Evidence for the ambiguity of the term constipation: the role of irritable bowel syndrome, 1455
- Selective affective biasing in recognition memory in the irritable bowel syndrome: *correspondence*, 285

Ispaghula husks, Digestibility and bulking effect of ispaghula husks in healthy humans, 1747

Israel, Gastroenterological practice in Israel, 1149

Japan, Comparison of the molecular genetics of stomach cancers in Britain and Japan: c-erbB2 and p53, A1680

Japanese style gastric resection, Japanese style gastric resection – viable in the UK? A1681

Jaundice, Primary amyloidosis and severe intrahepatic cholestatic jaundice, 1322

Jejunal water and electrolyte secretion, Failure of tropisetron to inhibit jejunal water and electrolyte secretion induced by 5-hydroxytryptamine in healthy volunteers, 637

Jejunum

- Immunohistochemical changes in the jejunum in first degree relatives of patients with coeliac disease and the coeliac disease marker DQ genes. HLA class II antigen expression, interleukin-2 receptor positive cells and dividing crypt cells, 55
- Lipid peroxidation and electrogenic ion transport in the jejunum of the vitamin E deficient rat, 34
- Response of the human intestine to high volume infusion, 641
- Role of the enteric nervous system in the maintained hypersecretion induced by enterotoxin STa in the nutritionally deprived intestine, 1237

Ki-ras, Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance, 1627

Knee-elbow position, The knee-elbow position relieves distension: *correspondence*, 1150

Kupffer cells, Cell biology of liver endothelial cells and Kupffer cells: *leading article*, 1509

L-mono-methyl-arginine, L-mono-methyl-arginine in the treatment of hypotension resulting from fulminant hepatic failure, A721

Lactase deficiency, Did malaria select for primary adult lactase deficiency?, 1487

Lactobacillus acidophilus LA 1, *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria, 483

Laparoscopic cholecystectomy

- Imaging of the common bile duct in patients undergoing laparoscopic cholecystectomy, 991: *correspondence*, 1773
- Prospective audit of the introduction of laparoscopic cholecystectomy in the west of Scotland, 1121

Laparoscopic pancreatic cystogastrostomy, Laparoscopic pancreatic cystogastrostomy, A576

Laparoscopy

- Diagnostic yield and management benefit of laparoscopy: a prospective audit, 1617
- Laparoscopic assessment of resectability in gastric cancer, A1680

Lasers, Endoscopic laser treatment of diffuse gastric antral vascular ectasia, 461

Leucocytes, Specific interaction of pancreatic elastase and leucocytes to produce oxygen radicals and its implication in pancreatitis, 1659

Leukotriene B₂, Increased leukotriene B₂ release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis, 1429

Leukotriene C₄, Abnormal leukotriene C₄ release by unaffected jejunal mucosa in patients with inactive Crohn's disease, 517

Lewis phenotype, Lewis phenotype, secretor status, and coeliac disease, 769

Lipid peroxidation

- Lipid peroxidation and electrogenic ion transport in the jejunum of the vitamin E deficient rat, 34
- Lipid peroxidation in rats chronically fed ethanol, 1644
- Resistance of erythrocytes to lipid peroxidation in alcoholic patients, 1753

Lipids, Gastrointestinal adaptation to enhanced small intestinal lipid exposure, 1409

Lipiodol, Intra-arterial lipiodol targeted treatments for unresectable hepatoma, A721

Lipocytes

- Perisinusoidal lipocytes and fibrinogenesis: *leading article*, 1331
- Transin release by rat lipocytes in primary culture, A721

Lipoprotein, Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism, 1116

Lithostatin, Lithostatin expression in acute experimental and human chronic pancreatitis, A575

Lithotripsy, Relief of heterogeneous symptoms after successful gall bladder stone lithotripsy and complete stone disappearance, 819

Liver

Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients, 101

Cell biology of liver endothelial cells and Kupffer cells: *leading article*, 1509

Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction, 707

Echinococcus of the liver: *leading article*, 1517

Epithelial cell lineages in developing, restoring, and transforming liver: evidence for the existence of a 'differentiation window': *leading article*, 294

Focused liver ablation by cavitation in the rabbit: a potential new method of extracorporeal treatment, 395

High prevalence of histological abnormality in asymptomatic hepatitis C infection with persistently normal liver enzymes, A719

Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus: *leading article*, 1013

Liver cell death: patterns and mechanisms: *leading article*, 577

Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm, 84

Measurement of androgen receptor expression in adult liver, fetal liver, and Hep-G2 cells by the polymerase chain reaction, 688

Rim calcification in primary liver cell carcinoma mimicking hydatid disease, 567

Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis, 1107

Systemic arteriovenous malformations: a feature of advanced liver disease, 1145

Liver transplantation

Serious paracetamol poisoning and the results of liver transplantation, 809

Serum hyaluronic acid in extrahepatic biliary atresia (EHBA) before portoenterostomy identifies patients who will require early liver transplantation, A719

Lower gastrointestinal tract, Lower gastrointestinal malignancy in Crohn's disease, 347

Loxiglumide, Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide, 501

Loxidine, Evaluation of the trophic effect of longterm treatment with the histamine H₂ receptor antagonist loxidine on rat oxyntic mucosa by differential counting of dispersed cells, 1547

Lymph node, Effect on lymph node status of triple levelling and immunohistochemistry with CAM 5.2 on node negative colorectal carcinomas, 1447

Lymphocytes

Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area, 382, correction, 866

Intestinal antibody pattern of coeliac disease, 476

Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy? *leading article*, 867

Lymphocytes, mucosal, Lymphoid and non-lymphoid cells in the epithelium and lamina propria of intestinal mucosa of pigs, 1582

Lymphocytic colitis, Drug induced lymphocytic colitis, 426

Lynch syndrome, Screening for hereditary bowel cancer in New Zealand, 1328

Macromolecular absorption, Effect of *Escherichia coli* enterotoxins on macromolecular absorption, 1613

Macrophages

Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes, 669

Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy? *leading article*, 867

Magnesium hydrogen breath test, Magnesium hydrogen breath test using end expiratory sampling to assess achlorhydria in pernicious anaemia patients, 1205

Major histocompatibility complex, Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease, 511

Malabsorption, Persisting diarrhoea and malabsorption: *leading article*, 582

Malaria, Did malaria select for primary adult lactase deficiency?, 1487

Malignant disease, Death from malignant disease after surgery for duodenal ulcer, 451: *correspondence*, 1675

Meckel's diverticulum, Association between Meckel's diverticulum and Crohn's disease: a retrospective review, 788

- Medical audit**, Prospective audit of the introduction of laparoscopic cholecystectomy in the west of Scotland, 1121
- Ménétrier's disease**, Healing of protein losing hypertrophic gastropathy by eradication of *Helicobacter pylori* – Is *Helicobacter pylori* a pathogenic factor in Ménétrier's disease? 701
- Mesalazine**, Mesalazine induced interstitial nephritis, 1493
- Metastasis**, Current concepts in metastasis, 996
- Methanogens**, Methanogens outcompete sulphate reducing bacteria for H₂ in the human colon, 1098
- Methyl-tert-butyl ether**, Addition of dimethylsulphoxide to methyl-tert-butyl ether and ethyl propionate increases cholesterol dissolving capacity and cholesterol gall stone dissolution in vitro, 1653
- Metronidazole**
High prevalence of *Helicobacter pylori* metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease, 1562
Phenotypic and genotypic variation in *Giardia lamblia* isolates during chronic infection, 51
- Microalbuminuria**, Microalbuminuria in inflammatory bowel disease, 1599
- Microflora**, Role of intestinal microflora in chronic inflammation and ulceration of the rat colon, 1090
- Microspheres**, Intrahepatic portal occlusion by microspheres: a new model of portal hypertension in the rat, 815
- Monocytes**
Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease, 511
Systemic complications in acute pancreatitis are associated with increased monocyte cytokine release, A575
- Mucosa**
Abnormal leukotriene C₄ release by unaffected jejunal mucosa in patients with inactive Crohn's disease, 517
Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis, 73
- Mucosal cell proliferation**, Role of gastric blood flow, neutrophil infiltration, and mucosal cell proliferation in gastric adaptation to aspirin in the rat, 1189
- Mucus secreting HT-29 cell subpopulations**, Adhesion of human enterotoxigenic *Escherichia coli* to human mucus secreting HT-29 cell subpopulations in culture, 1449
- Multiple sclerosis**, Pelvic floor function in multiple sclerosis, 388
- Myasthenia gravis**, Crohn's disease and myasthenia gravis: a possible role for thymectomy, 278
- Mycobacteria**, Mycobacteria in the human intestine: *correspondence*, 715
- Mycobacterium paratuberculosis**, Specific detection of *Mycobacterium paratuberculosis* DNA associated with granulomatous tissue in Crohn's disease, 506
- N-acetylcysteine**, Portal and systemic haemodynamic action of N-acetylcysteine in patients with stable cirrhosis, 1290
- N-nitroso compounds**, Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds, 455
- NADPH diaphorase**, Nitriergic and peptidergic innervation of the human oesophagus, 1690
- National Health Service**, Clinical training – back to the future: *personal viewpoint*, 1008
- Nephritis**, Mesalazine induced interstitial nephritis, 1493
- Nerve growth factor receptor**, Nerve growth factor receptor immunostaining suggests an extrinsic origin for hypertrophic nerves in Hirschsprung's disease, 1605
- Netherlands**, Present position of gastroenterology in the Netherlands, 1326
- Neuroendocrine tumours**, Localisation of neuroendocrine tumours of the upper gastrointestinal tract, 471
- Neuropeptides**, Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat, 1701
- Neutrophil activation**, Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation, 1197
- Neutrophil infiltration**, Role of gastric blood flow, neutrophil infiltration, and mucosal cell proliferation in gastric adaptation to aspirin in the rat, 1189
- Nicotine**, Effect of nicotine on rectal mucus and mucosal eicosanoids, 247
- Nitrates**, Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds, 455
- Nitric oxide**
Intragastric nitric oxide production in humans: measurements in expelled air, 1543
Nitric oxide a novel therapy for pancreatitis induced lung injury, A575
Nitriergic and peptidergic innervation of the human oesophagus, 1690
- Nitric oxide synthase**, Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients, 1394
- Nitriergic innervation**, Nitriergic and peptidergic innervation of the human oesophagus, 1690
- Nitrites**, Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds, 455
- Nitrofurantoin**, Pancreatitis induced by nitrofurantoin, 712
- Nitroimidazole**, High prevalence of *Helicobacter pylori* metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease, 1562
- Nitroxide**, A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats, 1181
- Nm23 gene**, The Nm23 gene and colorectal cancer: *correspondence*, 141
- Non-adrenergic non-cholinergic inhibitory innervation**, Non-adrenergic non-cholinergic inhibitory innervation shown by electrical field stimulation of isolated strips of human gall bladder muscle, 412
- Non-steroidal anti-inflammatory drugs**
Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion, 611
Inflammatory mediators in the oesophagus: *leading article*, 297
Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs, 1030
Predicting NSAID related ulcers, 891
- Notes**, 288, 432, 718, 866, 1010, 1154, 1506, 1330, 1679, 1776
- Nucleotides**, Effect of dietary nucleotides on small intestinal repair after diarrhoea, 926
- Obstructive defecation**, Effects of biofeedback on obstructive defecation – reconditioning of the defecation reflex?, 252
- Octreotide**, Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders, 1064
- Oesophagitis**, Simultaneous two level oesophageal pH monitoring in healthy controls and patients with oesophagitis: comparison between two positions, 304
- Oesophagogastric carcinoma**, Palliation of malignant dysphagia by ethanol induced tumour necrosis, 299
- Oesophagus, oesophageal**
24 Hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus, 1352
An audit of the treatment of cancer of the oesophagus, 941
Cell adhesion molecules in oesophageal epithelium, 1343
Classification and localisation of carcinoembryonic antigen related antigen expression in normal oesophageal squamous mucosa and squamous carcinoma, 1022, 1022
Cytochrome P450 expression in oesophageal cancer, 599
Diminished oesophageal traction forces with swallowing in gastro-oesophageal reflux disease and in functional dysphagia, 165
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease, 447
Effects of intraluminal acidification on oesophageal motor activity, 884
Impaired oesophageal transit of capsule versus tablet formulations in the elderly, 1363
Inflammatory mediators in the oesophagus: *leading article*, 297
Intramural haematoma of the oesophagus complicating sclerotherapy for varices, 130
Longterm outcome after injection sclerotherapy for oesophageal varices in children with extrahepatic portal hypertension, 257
Nitriergic and peptidergic innervation of the human oesophagus, 1690
Oesophageal acid clearance: *correspondence*, 714
Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring, 1519
Primary peristalsis is the major acid clearance mechanism in reflux patients, 1536
Respiratory function after injection sclerotherapy of oesophageal varices, 1459
Secondary oesophageal peristalsis in patients with non-obstructive dysphagia, 1523
Simultaneous two level oesophageal pH monitoring in healthy controls and patients with oesophagitis: comparison between two positions, 304
Stimulation and characteristics of secondary oesophageal peristalsis in normal subjects, 152
Strain induced augmentation of upper oesophageal sphincter pressure in children, 159
Temporal relationships between episodes of non-cardiac chest pain and abnormal oesophageal function, 733
- Olsalazine**, Optimum dose of olsalazine for maintaining remission in ulcerative colitis, 1282
- Omeprazole**
Antacid provides better restoration of glandular structures within the gastric ulcer scar than omeprazole, 896

- Can prescribing omeprazole delay the diagnosis of gastric malignancy? **A1681**
- Duodenal bacterial overgrowth** during treatment in outpatients with omeprazole, **23**
- Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds, **455**
- Effect of omeprazole and sucralfate on prepyloric gastric ulcer, **837**
- Eradication of *Helicobacter pylori* with clarithromycin and omeprazole, **323**
- Omeprazole *v* ranitidine for prevention of relapse in reflux oesophagitis, **590**
- Ondansetron**, Serotonergic mediation of postprandial colonic tonic and phasic responses in humans, **536**
- Open cholecystectomy**, Symptoms and health status before and six weeks after open cholecystectomy: a European cohort study, **1301**
- Oral contraception**, Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study, **107: correspondence, 1152, 1506**
- Oral rehydration solution**, Absorption of a hypotonic oral rehydration solution in a human model of cholera, **211**
- Ornithine decarboxylase**, Rectal mucosal ornithine decarboxylase activity in familial adenomatous polyposis after ileorectal anastomosis, **1624**
- Oroileal transit**, Oroileal transit of 5-aminosalicylic acid: *correspondence*, **287**
- Osteonecrosis**, Multifocal osteonecrosis related to steroid treatment in a patient with ulcerative colitis, **132**
- Oxidative damage**, Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake, **1637**
- Oxygen**
- Helicobacter pylori* stimulates antral mucosal reactive oxygen metabolite production in vivo, **170**
- Oxygen saturation during endoscopic retrograde cholangiopancreatography: a comparison of two protocols of oxygen administration, **408**
- Oxygen radicals**, Specific interaction of pancreatic elastase and leucocytes to produce oxygen radicals and its implication in pancreatitis, **1659**
- Oxyntic mucosa**, Evaluation of the trophic effect of longterm treatment with the histamine H₂ receptor antagonist loxidine on rat oxyntic mucosa by differential counting of dispersed cells, **1547**
- p53**
- Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence, **764**
- Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours, **1258**
- Comparison of the molecular genetics of stomach cancers in Britain and Japan: c-erbB2 and p53, **A1680**
- Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa, **1697**
- p53 genes**, Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance, **1627**
- p53 mutation**, Different levels of p53 mutation in proximal and distal gastric cancers, **A1680**
- p53 protein**, Expression of mutant p53 protein in hepatocellular carcinoma, **98**
- Paediatric problems**, Paediatric problems in tropical gastroenterology: *leading article*, **1687**
- Pain**
- Chronic, non-visceral abdominal pain, **833**
- Duodenal ulcer pain – the role of acid and inflammation: *correspondence*, **863**
- Painful rib syndrome**, Painful rib syndrome: *correspondence*, **429**
- Pancreas**, Expression of glutathione S-transferases in normal and malignant pancreas: an immunohistochemical study, **266**
- Pancreatic cancer**
- Attitudes to palliative resection for pancreatic cancer, **A576**
- Incidence, treatment, and survival in 13 560 patients with pancreatic cancer: an epidemiological study in a UK region, **A576**
- Tissue factor is responsible for the procoagulant activity of human pancreatic carcinoma, **A576**
- Pancreatic elastase**, Specific interaction of pancreatic elastase and leucocytes to produce oxygen radicals and its implication in pancreatitis, **1659**
- Pancreatic Society of Great Britain and Ireland**, 18th annual meeting, London, November 1993, abstracts, **A574**
- Pancreatic zymogen granules**, Chronic ethanol consumption increases the fragility of rat pancreatic zymogen granules, **1474**
- Pancreatitis**
- Bile induced acute oedematous pancreatitis in rats: non-parallel changes in pancreatic morphology and amylase release in vitro, **1127**
- Biphasic tumour necrosis factor release in experimental acute pancreatitis, **A575**
- Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor α , and phospholipase C γ , **1468**
- Comparison of pancreatic morphology and exocrine functional impairment in patients with chronic pancreatitis, **1132**
- Demonstration of tumour necrosis factor in pancreatic acinar cells by in situ hybridisation in a model of acute pancreatitis, **A575**
- Dopamine in models of alcoholic acute pancreatitis, **547**
- E-selectin in acute pancreatitis, **A574**
- Inflammatory response in the early prediction of severity in human acute pancreatitis, **822**
- Intraluminal duodenal diverticulum causing recurrent pancreatitis: treatment by endoscopic incision, **557**
- Lithostatin expression in acute experimental and human chronic pancreatitis, **A575**
- Management of common bile duct stricture caused by chronic pancreatitis with metal mesh self expandable stents, **122**
- Multicentre audit of surgical management of acute necrotising pancreatitis, **A574**
- Natural course of operated pseudocysts in chronic pancreatitis, **1479**
- Pancreatic outflow obstruction as the critical event for human gall stone induced pancreatitis, **1501**
- Pancreatitis induced by nitrofurantoin, **712**
- Progression of alcoholic acute to chronic pancreatitis, **552**
- Role of platelet activating factor in a model of acute pancreatitis, **A574**
- Routes of spread of pathogens into the pancreas in a feline model of acute pancreatitis, **1306**
- Serial blood antioxidants in acute pancreatitis, **A574**
- Specific interaction of pancreatic elastase and leucocytes to produce oxygen radicals and its implication in pancreatitis, **1659**
- Systemic complications in acute pancreatitis are associated with increased monocyte cytokine release, **A575**
- Trypsinogen activation peptides (TAP) concentrations in the peritoneal fluid of patients with acute pancreatitis and their relation to the presence of histologically confirmed pancreatic necrosis, **1311**
- Paracetamol poisoning**, Serious paracetamol poisoning and the results of liver transplantation, **809**
- Paracrine mechanism**, Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins, **934**
- Parasitic infections**, Parasitic infections of the small intestine: *leading article*, **289**
- Parietal cells**, Effects of *Helicobacter pylori* on histamine and carbachol stimulated acid secretion by human parietal cells, **755**
- PCO₂**, Effect of ranitidine on basal and bicarbonate enhanced intragastric PCO₂: a tonometric study, **737**
- PD-136,450**, Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat, **270**
- Pelvic floor**, Pelvic floor function in multiple sclerosis, **388**
- Pelvic ileal reservoir**, Polypoid mucosal prolapse in a pelvic ileal reservoir, **1668**
- Pelvic surgery**, Cap polyposis occurring in the postoperative course of pelvic surgery, **1670**
- Pentoxifylline**, Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha, **909**
- Peptic ulcer**
- Bleeding peptic ulcer – risk factors for rebleeding and sequential changes in endoscopic findings, **746**
- Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels, **1389**
- Endoscopic injection therapy for bleeding peptic ulcer; a comparison of adrenaline alone with adrenaline plus ethanalamine oleate, **608**
- Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect of diet on peptic ulceration, **1557**
- Prevalence of peptic ulcer in *Helicobacter pylori* positive blood donors, **309**
- Why is peptic ulcer now a disease? *personal viewpoint*, **1504**
- Peptide**, Comparison of amino acid *v* peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome, **783**
- Peptidergic innervation**, Nitrinergic and peptidergic innervation of the human oesophagus, **1690**
- Percutaneous cholecystolithotomy**, Percutaneous cholecystolithotomy: is gall stone recurrence inevitable?, **692**
- Percutaneous endoscopic gastrostomy**, Percutaneous endoscopic gastrostomy in a general hospital: prospective evaluation of indications, outcome, and randomised comparison of two tube designs, **1551**
- Percutaneous transhepatic cholangiography**, Combined percutaneous and endoscopic procedures for bile duct obstruction: *leading article*, **1011**
- Peripheral blood monocytes**, Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes, **669**

- Perisinusoidal lipocytes**, Perisinusoidal lipocytes and fibrinogenesis: *leading article*, 1331
- Peristalsis**, Primary peristalsis is the major acid clearance mechanism in reflux patients, 1536
- Peritoneal fluid**, Trypsinogen activation peptides (TAP) concentrations in the peritoneal fluid of patients with acute pancreatitis and their relation to the presence of histologically confirmed pancreatic necrosis, 1311
- Peritonitis**
Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis, 1648
Spontaneous bacterial peritonitis in cystic fibrosis, 709
- Permeability tests**, Test conditions greatly influence permeation of water soluble molecules through the intestinal mucosa: need for standardisation, 1404
- Pernicious anaemia**, Magnesium hydrogen breath test using end expiratory sampling to assess achlorhydria in pernicious anaemia patients, 1205
- Personal viewpoint**, Hoist with my own petard!, 1148
- Peyer's patches**, Immunohistochemical localisation of intercellular adhesion molecule-1 in follicle associated epithelium of Peyer's patches, 46
- pH**, Maintenance of intragastric pH 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements, 750
- pH monitoring**, Simultaneous two level oesophageal pH monitoring in healthy controls and patients with oesophagitis: comparison between two positions, 304
- Phenotypic expression**, Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis, 1622
- Phospholipase A₂**
Effects of endotoxin and dexamethasone on group I and II phospholipase A₂ in rat ileum and stomach, 40
Increased group II phospholipase A₂ in colonic mucosa of patients with Crohn's disease and ulcerative colitis, 1593
Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A₂ in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor, 215
- Phospholipase C_γ**, Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C_γ, 1468
- Phospholipid fatty acids**, Study of plasma and red cell phospholipid fatty acids in extrahepatic cholestatic jaundice, 987
- Phytase**, Phytase activity in the human and rat small intestine, 1233
- Pinworm**, *Enterobius vermicularis* infection: *leading article*, 1159
- Plasminogen activation**, Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure, A720
- Plasminogen activator inhibitor-1**, Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro, 969
- Platelet activating factor**
Platelet activating factor and Crohn's disease: *correspondence*, 141
Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor, 490
The role of platelet activating factor in a model of acute pancreatitis, A574
Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A₂ in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor, 215
Tumour necrosis factor and platelet activating factor in stool during salmonellosis: *correspondence*, 287
- Polidocanol**, Alcohol *v* epinephrine and polidocanol: *correspondence*, 286
- Polymerase chain reaction**
Adenovirus 12 E1A gene detection by polymerase chain reaction in both the normal and coeliac duodenum, 1226
Measurement of androgen receptor expression in adult liver, fetal liver, and Hep-G2 cells by the polymerase chain reaction, 683
Polymerase chain reaction assay for the detection of *Helicobacter pylori* in gastric biopsy specimens, 905
- Polynuropathy**, Impact of familial amyloid associated polyneuropathy on duodenal endocrine cells, 1413
- Polypoid mucosal prolapse**, Polypoid mucosal prolapse in a pelvic ileal reservoir, 1668
- Polyps**, Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis: *correspondence*, 572
- Porphyria**, Safety of general anaesthesia and surgery in acute hepatic porphyria, 1112
- Portal hypertension**, Intrahepatic portal occlusion by microspheres: a new model of portal hypertension in the rat, 815
- Portal pyaemia**, Non-fatal portal pyaemia complicating Crohn's disease of the terminal ileum, 560
- Postenteritis enteropathy**, Paediatric problems in tropical gastroenterology: *leading article*, 1687
- Postprandial colonic tonic**, Serotonergic mediation of postprandial colonic tonic and phasic responses in humans, 536
- Pouchitis**
Pouchitis: result of microbial imbalance?, 658
Pouchitis – recurrence of the inflammatory bowel disease?, 243
- Precancerous adjacent mucosa**, Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa, 1697
- Prednisolone**, Benign intracranial hypertension during prednisolone treatment for inflammatory bowel disease, 423: *correspondence*, 1677
- Pregnancy**, Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients, 101
- Pressure profiles**, Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders, 1064
- Primary biliary cirrhosis**
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis, 260
Hepatocellular carcinoma in primary biliary cirrhosis, A721
Primary biliary cirrhosis presenting with granulomatous skin lesions, 564
Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension, 280
- Proctocolectomy**, Surgery for ulcerative colitis in the era of the pouch: The St Mark's Hospital experience, 1076
- Proliferating cell nuclear antigen**, Proliferating cell nuclear antigen (PCNA): a new marker to study human colonic cell proliferation, 530
- Proliferation cell nuclear antigen**, Correlation of PCNA with bromodeoxyuridine: *correspondence*, 717
- Propantheline**, Pharmacological modulation of gastric emptying rate of solids as measured by the carbon labelled octanoic acid breath test: influence of erythromycin and propantheline, 333: *correction*, 866
- Prostaglandins**
Inflammatory mediators in the oesophagus: *leading article*, 297
Tumour necrosis factor α changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins, 934
- Prostaglandin E₂**, Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E₂, 675
- Protein losing hypertrophic gastropathy**, Healing of protein losing hypertrophic gastropathy by eradication of *Helicobacter pylori* – Is *Helicobacter pylori* a pathogenic factor in Ménétrier's disease?, 701
- Pseudocysts**, Natural course of operated pseudocysts in chronic pancreatitis, 1479
- Pylorus preserving pancreatoduodenectomy**, Plasma gastric and CCK response after pylorus preserving pancreatoduodenectomy with Billroth II reconstruction and defunctioned Roux loop pancreaticojejunostomy, A576
- Quarternary ammonium compound**, Effect of the quarternary ammonium compound tropium chloride on 24 hour jejunal motility in healthy subjects, 27
- R1-R2 gastrectomy**, Short term morbidity and mortality in the Dutch R1-R2 trial, A1681
- R1 versus R2 gastrectomy**, 'Curative' gastrectomy from gastric carcinoma – R1 versus R2, A1681
- Ranitidine**
Effect of ranitidine on basal and bicarbonate enhanced intragastric PCO₂: a tonometric study, 737
Omeprazole *v* ranitidine for prevention of relapse in reflux oesophagitis, 590
- Ras**, Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours, 1258
- Rebamipide**, Rebamipide, a novel antiulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidants, 1375
- Rebleeding**, Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels, 1389
- Rectum, rectal**
Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis, 1718
Divergent effects of epidermal growth factor and calcipotriol on human rectal cell proliferation, 1742
Effect of nicotine on rectal mucus and mucosal eicosanoids, 247
Enhancement of ethanol induced rectal mucosal hyper regeneration with age in F344 rats, 1102
In vitro acetaldehyde formation by human colonic bacteria, 1271
Lower gastrointestinal malignancy in Crohn's disease, 347
Screening for hereditary bowel cancer in New Zealand, 1328
- Reflux oesophagitis**
Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring, 1519
Omeprazole *v* ranitidine for prevention of relapse in reflux oesophagitis, 590
- Renal failure**, Origin and development of exocrine pancreatic insufficiency in experimental renal failure, 401: *correspondence*, 1772
- Reperfusion**, Release of vasodilator, but not vasoconstrictor, neuro-peptides and of enteroglucagon by intestinal ischaemia/reperfusion in the rat, 1701

Restorative proctocolectomy

Longterm appraisal of the histological appearances of the ileal reservoir mucosa after restorative proctocolectomy for ulcerative colitis, 1721

Surgery for ulcerative colitis in the era of the pouch: The St Mark's Hospital experience, 1076

The first 10 years' experience of restorative proctocolectomy for ulcerative colitis, 1070

Review editor's note, 732

Rhabdomyosarcoma, Adult rhabdomyosarcoma of the gall bladder, 854

Rim calcification, Rim calcification in primary liver cell carcinoma mimicking hydatid disease, 567

Salicylates, New salicylates as maintenance treatment in ulcerative colitis: *leading article*, 1155

Salmonella typhi, *Salmonella typhi* and other salmonellas: *leading article*, 726

Salmonellosis, Tumour necrosis factor and platelet activating factor in stool during salmonellosis: *correspondence*, 287

Satiation, Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide, 501

Schistosomiasis, Gastrointestinal manifestations of schistosomiasis: *leading article*, 1334

Sclerosant injection, Distal biliary stricture as a complication of sclerosant injection for bleeding duodenal ulcer, 1665

Sclerotherapy

Combined (short term plus longterm) sclerotherapy *v* short term only sclerotherapy, 687

Intramural haematoma of the oesophagus complicating sclerotherapy for varices, 130

Longterm outcome after injection sclerotherapy for oesophageal varices in children with extrahepatic portal hypertension, 257

Respiratory function after injection sclerotherapy of oesophageal varices, 1459

Screening, Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values, 771

Secretor status, Lewis phenotype, secretor status, and coeliac disease, 769

SeHCAT, Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT, 90

Selectin E, E-selectin in acute pancreatitis, A574

Shigella, The shigella paradigm and colitis due to enterohaemorrhagic *Escherichia coli*: *leading article*, 872

Shigellosis, Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery: effect of zinc supplementation, 1707

Short gastric arteries, Avulsion of short gastric arteries caused by vomiting, 1137

Shunts, Transjugular intrahepatic portosystemic stent shunts: *leading article*, 445

Sleep, Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia, 916

Small intestine

Ambulatory small intestinal motility in diarrhoea predominant irritable bowel syndrome, 203

β adrenergic modulation of human upper intestinal propulsive forces, 1356

Cholesterol synthesis and high density lipoprotein uptake are regulated independently in rat small intestinal epithelium, 343

Effect of dietary nucleotides on small intestinal repair after diarrhoea, 926

Enteral nutrition and the small intestine, 1765

Functional aspects of small bowel transplantation: past, present, and future: *leading article*, 1338

Gastrointestinal adaptation to enhanced small intestinal lipid exposure, 1409

Human small intestinal contractions and aboral traction forces during fasting and after feeding, 625

5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake, 496

Parasitic infections of the small intestine: *leading article*, 289

Phytase activity in the human and rat small intestine, 1233

Relationship of small bowel motility to ileoanal reservoir function, 523

Response of the human intestine to high volume infusion, 641

Short term effects of indomethacin on rat small intestinal permeability. Role of eicosanoids and platelet activating factor, 490

Smoking

Cigarette smoking and parity as risk factors for the development of symptomatic gall bladder disease in women: results of the Royal College of General Practitioners' oral contraception study, 107: *correspondence*, 1152, 1506

Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups, 619

Socioeconomic status, Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection, 742

Somatostatin, Gastrin and somatostatin in *Helicobacter pylori* infected antral mucosa, 615

Sphincter of Oddi dysfunction, Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction, 1319

Sphincteroplasty, Endoscopic sphincteroplasty: a novel and safe alternative to papillotomy in the management of bile duct stones, 127: *correspondence*, 1010

Spontaneous bacterial peritonitis, Spontaneous bacterial peritonitis in cystic fibrosis, 709

Staff, Clinical training – back to the future: *personal viewpoint*, 1008

Stents

Management of common bile duct stricture caused by chronic pancreatitis with metal mesh self expandable stents, 122

Symptom relief and quality of life after stenting for malignant bile duct obstruction, 467

Transjugular intrahepatic portosystemic stent shunts: *leading article*, 445

Steroids, Multifocal osteonecrosis related to steroid treatment in a patient with ulcerative colitis, 132

Stomach to caecum transit time, Gastrointestinal adaptation to enhanced small intestinal lipid exposure, 1409

Stone, Relief of heterogeneous symptoms after successful gall bladder stone lithotripsy and complete stone disappearance, 819

Strongyloides stercoralis, Biliary obstruction resulting from *Strongyloides stercoralis* infection, 705

Strongyloidiasis

Interrelation of strongyloidiasis and tuberculosis, 1001

Strongyloidiasis: a conundrum for gastroenterologists: *leading article*, 437: *correspondence*, 1772

Sucralfate, Effect of omeprazole and sucralfate on prepyloric gastric ulcer, 837

Sulphasalazine

Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine, 1385

New salicylates as maintenance treatment in ulcerative colitis: *leading article*, 1155

Sulphate reducing bacteria, Methanogens outcompete sulphate reducing bacteria for H₂ in the human colon, 1098

Superior mesenteric artery blood flow, Superior mesenteric artery blood flow and gastric emptying in humans and the differential effects of high fat and high carbohydrate meals, 186

Superoxide anion, Location of superoxide anion in the human colonic mucosa: *correspondence*, 284

Surgery, Training for digestive surgery: *personal viewpoint*, 1007

Sydney classification, Histological assessment of the Sydney classification of endoscopic gastritis, 1172

Systemic lupus erythematosus, Gastric outlet obstruction as a presenting manifestation of systemic lupus erythematosus, 841

Systemic sclerosis

Oesophageal acid clearance: *correspondence*, 714

Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence, 857

T lymphocytes

Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients, 955

Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection, 1728

Gastric T lymphocyte responses to *Helicobacter pylori* in patients with *H. pylori* colonisation, 1379

Intestinal antibody pattern of coeliac disease, 476

Tablet versus capsule formulations, Impaired oesophageal transit of capsule versus tablet formulations in the elderly, 1363

Technetium-99m albumin scintigraphy, Eosinophilic enterocolitis diagnosed by means of technetium-99m albumin scintigraphy and treated with budesonide (CIR), 1490

Tempol, A novel antiulcerogenic stable radical prevents gastric mucosal lesions in rats, 1181

Thioacetamide, Synaptosomal glutamate transport in thioacetamide induced hepatic encephalopathy in rats, A719

Threadworm, *Enterobius vermicularis* infection: *leading article*, 1159

Thrombin, Thrombin – an effective treatment for gastric variceal haemorrhage, 1287

Thymectomy, Crohn's disease and myasthenia gravis: a possible role for thymectomy, 278

Thyroid disease, Coeliac disease and autoimmune thyroid disease, 844

Tissue culture, Tissue culture of epithelium derived from Barrett's oesophagus, 879

Tissue factor, Tissue factor is responsible for the procoagulant activity of human pancreatic carcinoma, A576

Toxic megacolon, The knee-elbow position relieves distension: *correspondence*, 1150

Toxigenic diarrhoea, Cholera and severe toxigenic diarrhoeas: *leading article*, 145

Training, Specialist training in gastroenterology in the European Community: the case for European Boards, 135

Transforming growth factor α

Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor α , and phospholipase C γ , 1468

Expression of growth factors in precursor lesions to gastric carcinoma, A1680

Expression of transforming growth factor α in experimental gastric carcinogenesis, 604

Immunoelectron microscopic localisation of transforming growth factor α in rat colon, 1086

Transforming growth factor β , Differential effect of transforming growth factor β on expression of 6.3 and 1.5 Kb hepatocyte growth factor mRNA transcripts in MRC-5 cells, A720

Transin release, Transin release by rat lipocytes in primary culture, A721

Transjugular intrahepatic portosystemic stent shunts

Transjugular intrahepatic portosystemic shunts (TIPSS): results at two years, A720

Transjugular intrahepatic portosystemic stent shunts: *leading article*, 445

Travellers' diarrhoea, Travellers' diarrhoea: *leading article*, 1

Trinitrobenzenesulphonic acid, Role of intestinal microflora in chronic inflammation and ulceration of the rat colon, 1090

Tropical gastroenterology, Paediatric problems in tropical gastroenterology: *leading article*, 1687

Tropisetron, Failure of tropisetron to inhibit jejunal water and electrolyte secretion induced by 5-hydroxytryptamine in healthy volunteers, 637

Tropium chloride, Effect of the quarternary ammonium compound tropium chloride on 24 hour jejunal motility in healthy subjects, 27

Trypsinogen activation peptides, Trypsinogen activation peptides (TAP) concentrations in the peritoneal fluid of patients with acute pancreatitis and their relation to the presence of histologically confirmed pancreatic necrosis, 1311

Tuberculosis

Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease, 363

Interrelation of strongyloidiasis and tuberculosis, 1001

Tumour infiltrating lymphocytes, Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area, 382, correction, 866

Tumour necrosis, Palliation of malignant dysphagia by ethanol induced tumour necrosis, 299

Tumour necrosis factor

Biphasic tumour necrosis factor release in experimental acute pancreatitis, A575

Demonstration of tumour necrosis factor in pancreatic acinar cells by in situ hybridisation in a model of acute pancreatitis, A575

Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A $_2$ in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor, 215

Tumour necrosis factor and platelet activating factor in stool during salmonellosis: *correspondence*, 287

Tumour necrosis factor α

Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha, 909

Raised pro-inflammatory cytokines, interleukin 6 and tumour necrosis factor α in coeliac disease mucosa detected by immunohistochemistry, 1398

Tumour necrosis factor α changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins, 934

Tumour necrosis factor α in inflammatory bowel disease: *correspondence*, 715

Typhoid fever, *Salmonella typhi* and other salmonellas: *leading article*, 726

Ulcerative colitis

Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis, 73

Cancer surveillance in ulcerative colitis – a time for reappraisal: *leading article*, 587

Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody, 1712

Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis, 1419

Colonoscopic surveillance in ulcerative colitis: *correspondence*, 429

'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment, 1141

Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients, 955

Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: *correspondence*, 1152

Ileitis after colectomy for ulcerative colitis or carcinoma, 373

Incidence of inflammatory bowel disease in north west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common, 369

Increased group II phospholipase A $_2$ in colonic mucosa of patients with Crohn's disease and ulcerative colitis, 1593

Increased leukotriene B $_2$ release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis, 1429

Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives, 68: *correspondence*, 1675

Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm, 84

Longterm appraisal of the histological appearances of the ileal reservoir mucosa after restorative proctocolectomy for ulcerative colitis, 1721

Multifocal osteonecrosis related to steroid treatment in a patient with ulcerative colitis, 132

New salicylates as maintenance treatment in ulcerative colitis: *leading article*, 1155

Optimum dose of olsalazine for maintaining remission in ulcerative colitis, 1282

Similarity of colorectal cancer in Crohn's disease and ulcerative colitis, 950

Surgery for ulcerative colitis in the era of the pouch: The St Mark's Hospital experience, 1076

The first 10 years' experience of restorative proctocolectomy for ulcerative colitis, 1070

Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis, 1590

Ulcerative colitis in a husband and wife, 562

Unusual pulmonary complication of ulcerative colitis with a rapid response to corticosteroids, 847

Utility of surveillance colonoscopy in ulcerative colitis: *correspondence*, 863

Ulcerative proctocolitis, Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis, 1718

United Kingdom, Digestive surgery is a stillborn specialty in the United Kingdom: *personal viewpoint*, 1673

Upper gastrointestinal endoscopy, Appropriate use of upper gastrointestinal endoscopy – a prospective audit, 1209

Upper gastrointestinal tract, Localisation of neuroendocrine tumours of the upper gastrointestinal tract, 471

Urea breath test, The urea breath test for *Helicobacter pylori*: *leading article*, 723

Urokinase, Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro, 969

Ursodeoxycholic acid

Gall stone pulverisation strategy in patients treated with extracorporeal lithotripsy and follow up results of maintenance treatment with ursodeoxycholic acid, 117

Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid, 1757

Vagotomy, Gastric cancer risk after vagotomy, 946

Variceal haemorrhage, Thrombin – an effective treatment for gastric variceal haemorrhage, 1287

Viruses, Viruses and hepatocellular carcinoma, 828

Vitamin D receptor, Localisation of vitamin D receptor in normal human duodenum and in patients with coeliac disease, 1219

Vitamin E deficiency, Lipid peroxidation and electrogenic ion transport in the jejunum of the vitamin E deficient rat, 34

Vomiting, Avulsion of short gastric arteries caused by vomiting, 1137

Watermelon stomach, Endoscopic laser treatment of diffuse gastric antral vascular ectasia, 461

Wilson's disease, Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E, 849

Zinc, Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery: effect of zinc supplementation, 1707

Zollinger-Ellison syndrome, Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome, 275

AUTHOR INDEX – SUPPLEMENTS, 1994

- Abercrombie JF, S5.31, S5.65
 Abrams K, S2.30
 Adam A, S5.14
 Adam DJ, S5.8
 Adams V, S2.46
 Adams W, S2.16
 Ahmed HA, S2.20, S5.17, S5.18
 Ahmed S, S2.46
 Ainley C, S2.34, S2.46, S5.18, S5.51, S5.61
 Al-Bloushi S, S2.11
 Alani S, S2.21, S5.11, S5.30
 Alderson D, S2.5, S2.22, S2.23, S5.8, S5.38
 Alexander B, S2.9, S5.9
 Allan RN, S2.42, S2.43, S5.29
 Allen A, S5.43
 Allen-Mersh TG, S2.30
 Allison MC, S5.35
 Alstead EM, S2.55, S5.40, S5.41, S5.51, S5.59, S5.76
 Altare F, S5.18
 Altendorf-Hofmann A, S5.67
 Amarrì S, S5.34
 Anand P, S2.28
 Anderson AP, S2.25
 Anderson JT, S2.45, S5.14, S5.78
 Anderson NH, S5.63
 Andre EA, S2.52, S5.70
 Andreu AL, S1.39
 Ang L, S5.5
 Angerson WJ, S5.21
 Anggiansah A, S2.7, S5.7, S5.13
 Anthony A, S2.38, S2.43, S2.50, S5.44
 Appel MJ, S2.14
 Appleton DR, S2.30
 Arcbós MA, S1.39
 Arcidiacono PG, S5.80
 Ardill JES, S2.4, S2.32, S2.35, S2.36
 Arends JW, S2.31
 Armstrong G, S2.37
 Armstrong I, S5.70
 Armstrong JG, S2.31
 Arnold MM, S2.8, S2.17
 Arthur G, S5.40
 Arthur MJP, S2.19, S5.1
 Ashraf W, S5.65
 Ashworth HM, S5.15
 Askew JN, S5.46
 Aspinall R, S2.54
 Aston NS, S5.25
 Auld C, S5.76
 Auricchio S, S5.45, S5.46
 Austin CA, S5.33
 Auwerda JJA, S2.61
 Axon ATR, S2.4, S2.19, S2.33, S2.34, S2.62, S5.3, S5.16, S5.38
 Ayliss U, S5.37
 Ayres R, S5.29
 Ayres RCS, S2.43, S5.2
 Aziz O, S2.21, S5.6, S5.11, S5.30
 Azzarone P, S5.18
- Badia JM, S5.46
 Baeten CGMI, S2.31
 Bahl A, S2.38
 Baier-Kustermann W, S5.46
 Baker A, S2.21
 Baker EH, S2.61
 Balaji V, S2.61
 Balan KK, S2.13, S5.67
 Balfour TW, S2.14
 Ballinger AB, S2.57, S5.51, S5.76
 Bancewicz J, S2.44, S5.6, S5.8, S5.27
 Banerjee AK, S2.14
 Banerjee S, S2.4, S2.35, S2.36
 Barbara L, S2.34, S2.44, S5.18
 Barbera R, S2.37
 Bardhan KD, S2.16, S2.17, S2.45, S5.12
 Barham CP, S2.5
 Baris G, S2.7
 Barlow J, S2.21, S2.44, S5.6, S5.11, S5.27, S5.30
 Barlow JD, S2.8, S5.32
 Barnes E, S5.51
 Baron JH, S5.3, S5.15, S5.49
 Barone TL, S2.59
 Barr H, S5.7
 Barrison IG, S5.59
 Barry K, S5.76
 Barry RE, S2.32
 Bartlett DW, S5.7
 Bartoli R, S5.22
 Bartolo DCC, S2.62, S5.64, S5.65
 Barton S, S5.75
 Bartram CI, S2.27, S2.62
 Bassi C, S2.20
 Basso L, S5.44, S5.65
 Basu S, S5.33
 Bateson MC, S2.20, S5.74, S5.75
 Battaglia G, S2.63, S5.16
 Bauer C, S5.46
 Baxter JN, S2.62
 Beales I, S2.54
 Beales ILP, S5.1, S5.45
 Bearcroft CP, S2.53, S5.54, S5.70
 Beath SV, S5.33
 Beattie AD, S2.35, S5.25
 Beattie S, S2.33
 Beccarello A, S5.69
 Beckley DE, S2.56
 Beesley A, S5.55
 Bell GD, S2.25, S5.2, S5.16
 Bellumat A, S2.36
 Ben Ari Z, S2.14, S5.45
- Benini L, S5.12, S5.13, S5.19, S5.48, S5.55
 Benjamin IS, S2.9, S5.9
 Bennett D, S5.63
 Bennett DH, S5.32, S5.33
 Bennett RJM, S2.43
 Benson MJ, S5.61
 Benson P, S5.75
 Beresford J, S2.16, S2.17
 Bessell E, S2.1
 Bethke Th, S2.63
 Bewick E, S5.51, S5.52
 Bhalla AK, S5.5
 Bhargava A, S5.69
 Bhatnagar V, S2.21
 Bianchi Porro G, S2.44
 Biasco G, S5.18
 Bibby M, S5.63
 Biemond I, S2.14
 Blake DR, S2.50, S5.29
 Blazeby JM, S5.8
 Blijham GH, S2.31
 Bloet F, S5.47
 Blower AL, S2.45
 Bodmer M, S2.50
 Boermeester MA, S1.28
 Boirivant M, S5.45, S5.46
 Bond A, S2.3
 Bonfils S, S5.72
 Boot H, S2.7, S2.39
 Boot-Handford RP, S2.61
 Booth IW, S1.69, S5.33
 Borman DG, S5.36
 Boriello SP, S5.38
 Borst P, S5.9
 Bortolato L, S5.69
 Boschini A, S2.34
 Bosman FT, S2.6
 Bostock K, S5.63
 Boswell AM, S5.80
 Bouault JM, S5.44
 Bouchier IAD, S2.10, S2.11, S5.23, S5.66, S5.68
 Boulougouris P, S5.63
 Boulton R, S5.69, S5.74
 Bowden A, S5.2, S5.16
 Bown SG, S2.39
 Bradby GVH, S5.79
 Brading AF, S5.31
 Bradley NJ, S5.43, S5.69
 Brandt de Oliveira R, S5.61
 Brentegani MT, S5.12, S5.19, S5.48, S5.55
 Bridger SA, S2.53
 Brierley C, S2.61
 Brierley C, S2.51
 Brighenti F, S5.19, S5.55
 Bright N, S2.7, S5.7, S5.13
 Brooks A, S2.45
 Brown G, S2.23, S2.40
 Brown J, S5.14
 Brown KD, S5.60
 Brown MG, S2.23
 Brown TH, S5.8
 Browne DJ, S2.9
 Brunetti G, S2.44
 Brunt PW, S2.16
 Brydon WG, S5.16
 Buchanan M, S2.49
 Büchler MW, S5.15
 Budhiraja S, S5.68
 Bugnoli M, S2.35
 Burchell B, S2.51
 Burgers JMV, S2.39
 Burnham WR, S2.47, S2.60, S5.75, S5.77
 Burroughs A, S2.14
 Burroughs AK, S2.12, S2.55, S3.23, S5.24, S5.25, S5.45, S5.77
 Butcher GP, S5.5
 Buxton-Thomas M, S2.32
 Bzeizi KI, S2.10, S5.70
- Cabrè E, S1.55
 Cahill RJ, S2.33
 Cairns S, S5.75
 Calam J, S2.4, S2.18, S5.1, S5.18, S5.45, S5.67
 Caliani S, S5.13
 Callanan M, S2.53
 Callander N, S2.23
 Calnan D, S5.69, S5.74
 Cambridge G, S2.42
 Cameron EWJ, S5.8
 Camilleri M, S5.56, S5.62
 Camm AJ, S2.64
 Campbell FC, S2.29, S2.46, S2.51
 Cann PA, S5.78
 Canva JY, S5.47, S5.72
 Caplin ME, S5.77
 Cardin R, S5.50
 Carè M, S5.22
 Carey C, S2.54
 Carlisle K, S5.5
 Carnaby S, S2.51, S5.37
 Carnochan F, S5.8
 Carpani de Kaski MS, S5.19
 Carpinelli L, S5.80
- Carpintero P, S5.17
 Carriè A-L, S1.13
 Carter DC, S5.8, S5.10, S5.21, S5.39, S5.45, S5.66, S5.73
 Cartmill M, S5.32
 Casiraghi C, S5.19
 Casiraghi MC, S5.55
 Castellani G, S5.12, S5.13, S5.19, S5.48, S5.55
 Castillo FD, S5.61
 Cavallini G, S5.12
 Cecchetti L, S5.4
 Cedrone C, S5.22
 Ceselli S, S5.69
 Cete M, S2.56
 Cevallos AM, S2.49, S5.40, S5.41
 Chadwick N, S5.41
 Chahal H, S2.42
 Chakravarty A, S5.68
 Chalmers AG, S2.15
 Chan M, S2.58
 Chandrakumar K, S2.18
 Chapman RW, S2.10, S2.20
 Charig JA, S2.61
 Charnley RM, S5.67
 Cherian P, S5.12
 Cherukuri AK, S2.41, S2.54
 Chin JKT, S2.12
 Choudari CP, S2.38, S5.26, S5.36
 Christie J, S2.24, S5.15
 Chua A, S2.35
 Ciclitira PJ, S2.29, S2.40, S2.54, S5.21
 Cipriano J, S5.58
 Clague M, S5.15
 Clamp S, S2.58
 Clancy T, S2.31
 Clark ML, S2.57, S5.76
 Clarke AMT, S2.4, S2.34
 Clarke E, S2.24
 Clements D, S5.35
 Codacci-Pisanelli M, S5.65
 Codling B, S2.24
 Cohen S, S2.41
 Cole AT, S2.49, S5.42, S5.47, S5.71
 Coletta S, S5.45, S5.46
 Collins JSA, S5.13
 Collins CE, S5.28
 Collins JSA, S2.22, S2.56, S5.7, S5.42
 Colombel JF, S5.44, S5.47, S5.72
 Conte R, S5.18
 Cook G, S5.70
 Cooper BT, S2.28, S5.20
 Cooper PJ, S5.41
 Coore J, S2.14
 Cope C, S2.5
 Corazza GR, S5.4, S5.22
 Corbishley CM, S2.33
 Corless DJ, S5.19, S5.26
 Cornelissen PL, S5.30
 Cortot A, S5.44, S5.47, S5.72
 Cosentino F, S5.80
 Cottrell S, S5.40, S5.63
 Coupland K, S2.52
 Courtney MG, S2.11
 Covacci A, S2.34, S2.35
 Coxward WA, S5.34
 Cox JGC, S5.79
 Cox MA, S2.28, S2.55, S5.20
 Crabtree JE, S2.34, S2.35
 Crean StJ, S5.76
 Crepaldi G, S5.69
 Critchley M, S2.13, S5.67
 Crovatto M, S5.69
 Crowe J, S2.11, S2.23, S2.24, S2.27
 Cruikshank A, S2.26
 Cuesta MA, S1.28, S2.28
 Cullen DJE, S2.37, S5.71
 Cunningham S, S5.35, S5.67
 Curry GW, S5.25
 Cuschieri A, S5.34
 Cynober L, S1.42
- da Silva RCMA, S2.12
 Dailianas A, S2.26
 Dal Bo' N, S2.18, S2.63, S5.16
 D'Amato G, S5.22
 Danesh BJ, S2.56
 Daniels S, S2.42
 Darbyshire PJ, S5.33
 D'Arrigo C, S2.31
 Dashwood MR, S2.50
 Davey N, S5.45
 Davidson B, S2.55, S5.45
 Davidson BR, S5.25, S5.69
 Davies DR, S2.31
 Davies J, S2.4
 Davies MH, S2.12
 Davies N, S2.13
 Davies SE, S2.29
 Dawes PJD, S5.15
 Dawkes R, S5.70
 Dawson B, S5.12
 Day P, S5.21
 de Beaux AC, S5.45
 de Belder A, S2.40
 De Bona M, S2.36
 De Boni M, S2.36
 De Ciocchis A, S5.21
 de Graaf EJR, S2.61
 de Groot GH, S2.7
 de Maria N, S5.72
 De Vincenzi M, S5.45, S5.46
 Debinski HS, S2.46, S2.54, S5.40, S5.63
 Debnam ES, S2.52, S5.21
- deDombal FT, S2.58
 Dehn TCB, S5.75
 Deitch EA, S1.23
 Del Bianco T, S2.18, S2.63, S5.16
 del Pozo A, S5.52
 Delicata R, S2.14
 Deligiannis E, S5.26
 Della Libera G, S5.50, S5.72
 Deprez P, S5.67
 Desai DC, S5.39
 Deschamps V, S5.72
 Desmond PV, S2.58
 Desremaux P, S5.47
 Devlin HB, S5.47
 Dewsnap PA, S2.47, S5.57
 Dhawan A, S2.21
 Dhillon A, S2.14, S5.45
 Dhillon AP, S2.38, S2.43, S5.41, S5.44
 Di Bella F, S5.44
 Di Giovambattista F, S5.21, S5.22, S5.45, S5.46
 di Giovine FS, S2.41
 Di Mario F, S5.16, S5.50
 Di Sario A, S5.4
 Dias JA, S2.52
 Dick R, S2.12
 Dickey W, S5.4
 Diffey BL, S5.75
 Difrancesco V, S5.12
 Dilawari JB, S5.68
 Dilkes M, S5.52
 Dillon J, S2.20
 Dillon JF, S2.10, S2.11, S5.68, S5.69
 DiMario F, S2.63
 Dingemans KP, S5.9
 Dix T, S5.7
 Dixon MF, S2.4, S2.33, S2.34
 Dobson H, S2.31
 Dodds SR, S2.27
 Doel C, S5.59
 Dogliani C, S2.36
 Donnellan I, S5.36
 Donnelly MT, S5.4, S5.6
 Donovan IA, S5.36
 Dooley J, S5.35
 Dorrain CA, S5.73
 Dotto P, S2.18, S2.63, S5.16
 Double J, S5.63
 Douds AC, S2.20
 Douglas S, S5.48
 Dowling F, S2.1
 Dowling RH, S2.57, S5.20
 Downie S, S5.22
 Drake IM, S2.19, S5.3
 Drug V, S2.44
 Drummond HE, S2.59, S5.77, S5.78
 Drummond O, S2.10
 Duff GW, S2.41
 Duffy MW, S2.1
 Duncan AJ, S5.8
 Dupas JL, S5.72
 Duthie GS, S5.64
- Eao J, S5.53
 Earlam S, S2.30
 Earle P, S5.41
 Easton D, S2.48, S5.30
 Eastwood MA, S5.16, S5.77
 Edwards RHT, S2.13
 Eggo MC, S2.2
 El-Omar E, S2.4, S2.32, S2.35, S2.36, S5.2
 Elder JB, S5.63
 Elferink RPJO, S5.9
 Elias E, S2.12
 Elliot S, S5.70
 Elliott LJ, S5.32
 Ellis HJ, S5.21
 Ellis PK, S2.56
 Ellul J, S5.14
 Elsyb B, S5.80
 Elton RA, S5.24
 Emmanuel AV, S5.59
 Engel AF, S2.16, S2.27
 Engels LGJB, S2.31
 Ensari A, S2.29
 Entwistle N, S5.47
 Epstein O, S2.52, S5.21, S5.76
 Evans A, S5.4
 Evans D, S2.46
 Evans DF, S2.8, S2.23, S2.40, S2.46, S5.6, S5.7, S5.12, S5.55, S5.61
 Evans DGR, S2.31
 Evans GS, S2.29, S2.51
 Evans JMM, S5.49
 Evans TJ, S5.34
 Eyre-Brook IA, S2.56
 Eyre D, S2.35
- Facer P, S2.37, S5.71
 Fairclough PD, S5.51, S5.54, S5.76
 Fais S, S5.46
 Falco F, S5.22
 Falconer JS, S5.73
 Falconer M, S3.20
 Fan XG, S2.35
 Fan XJ, S2.35
 Farinati F, S5.50, S5.72
 Farmery SM, S2.3, S2.34
 Farndon JR, S5.8
 Farouk R, S2.47, S5.48
 Farrant JM, S5.29, S5.51
 Farrell R, S2.54
 Farriol M, S1.39

- Farthing MJG, S2.29, S2.30, S2.47, S2.49, S2.51, S2.52, S2.53, S2.57, S3.5, S5.37, S5.40, S5.41, S5.54, S5.57, S5.59, S5.70, S5.71, S5.76
- Fawcett H, S5.52
- Fearon KCH, S5.10, S5.39, S5.45, S5.73
- Fell G, S2.26
- Felt-Bersma RJF, S2.28
- Fenn GC, S2.45
- Ferguson A, S1.10, S2.59, S5.16, S5.43, S5.77, S5.78
- Fernández-Bañares F, S1.55
- Ferrana M, S2.18, S2.63, S5.16
- Ferrari M, S5.12
- Ferwerda ChC, S1.28
- Festen HPM, S2.7
- Fidler H, S2.42
- Fielding JF, S2.11
- Filipowicz B, S5.71
- Finan PJ, S2.60
- Finch MD, S5.34
- Finlay IG, S2.62, S5.57, S5.64
- Finlayson NDC, S5.11, S5.24
- Finney KJ, S2.30
- Finnie IA, S5.50
- Fiorretta A, S5.13, S5.55
- Fleming KA, S2.10, S2.20
- Forbes A, S5.28
- Ford D, S2.48, S5.30
- Ford MJ, S5.56, S5.62
- Fordy C, S2.30
- Foreman D, S2.48
- Formela L, S5.35
- Forrest E, S2.20
- Forrest EH, S5.9, S5.23
- Forrest JAH, S2.56
- Foster J, S5.55
- Foulkes R, S2.50
- Frame D, S2.19
- Francis CY, S5.57
- Franks CM, S5.54
- Fraser I, S5.36
- Frayling I, S2.31
- Freeman A, S2.46
- Freeman JG, S2.24
- Friess H, S3.15
- Frizziero L, S2.44
- Fuchs D, S2.29
- Fukumoto M, S2.39
- Fukunaga Y, S2.44, S5.27
- Furlong P, S2.21
- Gaetini A, S5.44
- Gagliardi G, S2.2
- Gallivan S, S5.59
- Galloway D, S2.32
- Galloway SW, S5.35
- Galvin A, S2.49, S5.42, S5.47
- Gant P, S5.16
- Garcia-Arumi E, S1.39
- Garden OJ, S5.11, S5.25, S5.34, S5.66
- Gardner Q, S5.52
- Garioli V, S5.45, S5.46
- Garland CJ, S5.61
- Garlick N, S2.49
- Garlick NM, S5.42, S5.47
- Gasbarrini G, S5.4, S5.22
- Gassull MA, S1.55
- Gazzard B, S5.40
- Gazzard BG, S5.26
- Gearty J, S2.18
- Gearty JC, S2.28
- Gedling P, S2.20
- Geheot M, S5.72
- Gemmell CG, S2.35, S2.36, S5.37
- Geraedts AAM, S2.7
- Geraghty JG, S5.21
- Gerskowitch VP, S5.73
- Geypens B, S5.29
- Ghoos Y, S5.29
- Ghosh S, S2.59, S5.43, S5.77, S5.78
- Giaffer MH, S2.26
- Giannopoulou H, S5.3
- Gibbons D, S2.1
- Gibson GR, S2.3
- Gillen CD, S2.43
- Gilmore IT, S2.60, S5.50, S5.59
- Gilvarry J, S2.33
- Glass DM, S5.19
- Globe J, S2.15
- Glynn M, S5.51
- Goddard S, S2.19
- Godkin A, S2.40
- Goggin PM, S2.64
- Goggins M, S2.41
- Going TCH, S5.65
- Goldberg PA, S2.40
- Gomborone JE, S2.47, S5.57
- Gómez Cedenilla A, S5.17
- Gong F, S2.23, S2.38, S2.40, S5.52, S5.79, S5.80
- González-Huix F, S1.55
- Gooday R, S5.9
- Goodlad RA, S1.1
- Goodman MJ, S2.37
- Gorard DA, S2.47, S2.57, S5.59
- Gorey TF, S2.27
- Goudie BM, S5.58, S5.78
- Gough AL, S5.58
- Gould J, S5.25
- Gourlay R, S2.15
- Gowland P, S2.46
- Graham AK, S2.20
- Graham I, S2.51
- Grandinetti G, S2.44
- Grassi SA, S2.63
- Grasso GA, S5.16
- Gravalos RG, S5.17
- Gray M, S2.22
- Gray T, S5.38
- Greaves RRSB, S5.59
- Greco M, S5.21, S5.22, S5.45, S5.46
- Greenslade L, S2.12
- Greig JD, S5.21, S5.26, S5.34, S5.66
- Griffin EM, S5.58
- Griffin SM, S5.14
- Griffiths RD, S2.13
- Grimble GK, S1.1, S1.46
- Grime SJ, S2.13
- Groen BK, S5.9
- Grundman MJ, S5.4
- Gummett PA, S5.15, S5.49
- Gupta S, S5.61
- Guslandi M, S5.44
- Guthrie C, S5.66
- Guy SP, S2.31
- Guz A, S2.9
- Haak HR, S2.12
- Hadleigh J, S5.52
- Haglund U, S1.73
- Hale T, S5.70
- Hale TL, S5.71
- Hallett MB, S5.64, S5.72
- Halliday D, S2.63, S5.17
- Halligan S, S2.39, S2.62
- Hallissey M, S5.36
- Hamdy S, S5.11, S5.30
- Hamer-Hodges DW, S2.55
- Hamid BNA, S2.17
- Hamilton H, S2.33
- Hamilton M, S5.77
- Hamilton MI, S5.43
- Hammond S, S5.54
- Hanby AM, S5.53, S5.60
- Handy LM, S5.43
- Hansky J, S5.32
- Hanson PJV, S2.37
- Hanson RB, S5.56, S5.62
- Hardcastle J, S5.54, S5.55
- Hardcastle JD, S2.33, S5.32, S5.33, S5.48, S5.63, S5.64, S5.67
- Hardcastle PT, S5.54, S5.55
- Harding G, S2.21
- Harding LK, S2.18
- Harding M, S5.34
- Hardwick RH, S2.22
- Harris AG, S3.1
- Harris AW, S5.3, S5.15, S5.49
- Harris S, S2.18
- Harrison DJ, S2.11, S5.10, S5.24, S5.68
- Harrison G, S5.2, S5.16
- Hart AR, S2.59
- Hartley J, S5.78
- Harvey P, S2.46
- Hatfield ARW, S5.51
- Hawkey CJ, S2.37, S2.45, S2.49, S5.18, S5.42, S5.43, S5.47, S5.49, S5.50, S5.53, S5.70, S5.71
- Hawley PR, S2.16
- Hawtin P, S2.1
- Hawtin PR, S5.1
- Hay R, S2.51
- Hayes N, S5.14
- Hayes PC, S2.10, S2.11, S2.20, S5.9, S5.10, S5.11, S5.23, S5.24, S5.25, S5.40, S5.66, S5.68, S5.69, S5.70
- Hayllar K, S5.29
- Haynes W, S5.10
- Hayter B, S2.55
- Heading RC, S2.21, S2.27, S5.48, S5.56
- Healey CJ, S2.20
- Heaton KW, S5.5, S5.55
- Heaton ND, S2.21, S5.20
- Heely S, S5.12
- Hemingway DM, S5.57, S5.64
- Henderson K, S2.2
- Henderson M, S5.76
- Hengirmen S, S2.56
- Hennessy TPJ, S2.5, S2.6
- Hepburn NC, S5.40
- Hepworth C, S5.77
- Hepworth CC, S2.38, S5.75, S5.80
- Herszenji L, S5.50
- Hewin DF, S5.38
- Heyman D, S5.58
- Hicks S, S5.37
- Hiele M, S5.29
- Higham A, S2.44
- Higham S, S2.49
- Hill A, S2.45
- Hillier K, S5.61
- Hilson A, S2.55
- Hiscox S, S5.64
- Hobsley M, S2.18, S2.36, S5.49
- Hobson A, S2.21, S5.6
- Hodgson H, S5.69, S5.74
- Hodgson HJF, S2.49, S2.54, S5.19, S5.60
- Hodgson SV, S5.39, S5.40
- Hodgson SVH, S5.30
- Holden H, S2.49
- Holdsworth CD, S2.26, S2.41, S2.49
- Holdsworth PJ, S2.60, S5.31
- Holmes GKT, S5.4, S5.6
- Holtom K, S5.79
- Holton J, S2.34, S5.18
- Homer-Ward M, S5.6
- Hoper M, S5.63
- Hopwood D, S2.31, S2.45, S5.14
- Horsman R, S2.53
- Hosp M, S2.29
- Houdijk APJ, S1.28
- Houghton LA, S5.55, S5.58, S5.62
- Hovenden JL, S5.22
- Howard A, S5.60
- Howell WM, S2.53
- Howes LG, S2.32
- Huddy SPJ, S5.50
- Hudson M, S2.50
- Hudson N, S2.45, S5.16, S5.71
- Hughes SF, S2.44, S5.56
- Hull MA, S2.37, S5.49, S5.50, S5.71
- Hungin APS, S5.62
- Hunt RH, S2.8, S5.17
- Hunter JO, S2.25, S2.41, S5.61, S5.71
- Huntley S, S5.52
- Hurst H, S2.1
- Hussain A, S2.27
- Hussain A, S5.74, S5.79
- Hussain I, S5.40
- Hussaini SH, S2.37, S2.57
- Hussain I, S5.66
- Hyde S, S5.38
- Hykin J, S2.46
- Ibbotson JP, S2.42
- Ifitkhar SI, S5.32
- Ifitkhar SY, S2.24
- Ilyas M, S2.32
- Innes JA, S2.9
- Interisano A, S5.44
- Iqbal TH, S2.28, S5.20
- Iredale JP, S2.19
- Irving MH, S5.32
- Isaacs P, S2.26
- Jabbar M, S5.50
- Jackson D, S5.73
- Jackson NA, S5.62
- Jackson P, S2.4, S2.34
- Jacyna MR, S2.63, S5.17
- Jagelman D, S2.41
- Jain R, S2.14
- Jalan R, S2.10, S5.9, S5.11, S5.23, S5.24, S5.25
- Jamieson C, S2.47
- Jamieson CP, S2.60, S5.77
- Janin A, S5.47
- Jankowski J, S2.1, S2.2, S2.6
- Jankowski JA, S1.1
- Jarvie DR, S5.11
- Jaskiewicz K, S2.17, S2.25, S2.63
- Jazrawi RP, S2.20, S2.33, S5.10, S5.11
- Jenkins D, S2.1, S5.18, S5.43, S5.49, S5.59
- Jenkins P, S2.57
- Jenkins SA, S2.13, S5.67
- Jewell DP, S2.42, S5.28, S5.29, S5.30, S5.37, S5.42
- Jiang WG, S5.64, S5.72
- Jinlai L, S2.13
- John TG, S5.11, S5.25, S5.34
- Johnson AG, S2.15, S2.22
- Johnson CD, S2.56
- Johnston BT, S2.22, S5.7, S5.13
- Johnston D, S2.60, S5.14, S5.31, S5.73
- Johnston DA, S2.58, S5.42, S5.78
- Johnston S, S2.58
- Jonas SK, S5.19
- Jones A, S2.20, S5.40
- Jones AL, S2.10, S5.10, S5.11
- Jones AR, S2.7, S5.7, S5.13
- Jones AT, S2.13, S5.67
- Jones DB, S2.12, S2.53, S5.52
- Jones MD, S5.60
- Jones P, S5.2
- Jones PH, S5.16
- Jones R, S5.66
- Jones RH, S5.62
- Jones T, S2.55
- Jordinson M, S5.67
- Jorizzo R, S5.4
- Joseph AEA, S5.10
- Justin TA, S2.5, S5.48, S5.63, S5.64
- Kadirkamanathan SS, S2.8, S2.23, S2.38, S2.40, S5.6, S5.12, S5.80
- Kaizaki S, S2.6
- Kamm MA, S2.16, S2.27, S2.43, S2.46, S2.54, S2.60, S5.32, S5.77
- Kane KF, S2.2, S5.39
- Kane SP, S2.40
- Kapur K, S5.35
- Kar P, S5.68
- Kashiwagi H, S5.39
- Katelaris PH, S2.30, S5.41, S5.52
- Katsogridakis J, S5.3
- Kattaa H, S5.75
- Kay CL, S5.8
- Kay E, S2.31
- Keane CT, S2.3
- Keating J, S5.26
- Kee F, S2.22, S5.7, S5.13
- Keeling PWN, S2.35, S2.41, S2.54
- Keighley MRB, S2.42, S5.27, S5.28
- Kelleher D, S2.41
- Kelly DA, S5.33
- Kelly P, S2.27, S2.29, S5.37
- Kelly SM, S2.3, S5.3
- Kennedy C, S2.57
- Kennedy TM, S5.62
- Kerr PM, S5.61
- Kershaw J, S5.13
- Kesse-Elia M, S5.3
- Kettlewell MGW, S5.29
- Keymling M, S1.77
- Khalusi S, S5.18
- Khan A, S5.59
- Khan K, S2.43
- Khan MI, S2.41, S2.54
- Kho DE, S2.55
- Khulusi S, S2.3, S2.63, S5.2, S5.17
- Kidd M, S2.25
- King D, S2.16
- Kingsnorth AN, S2.22, S5.35
- Kingston RD, S2.42
- Kirby GA, S2.25
- Kirkland S, S2.2
- Kitching A, S2.27
- Kite P, S5.5
- Kmiot W, S2.41
- Knill-Jones R, S5.2
- Knutton S, S5.37
- Ko R, S5.20
- Kolios G, S5.47
- Kontakou M, S2.40, S2.54
- Koorrevaar M, S2.28
- Korman MG, S5.32
- Korsgen S, S5.27
- Koskinas J, S2.19
- Kossa K, S2.49
- Kotler DP, S5.37
- Kouroumalis EA, S5.72
- Koutsomanis D, S2.43
- Kovacs TOG, S5.18
- Krishnadath KK, S2.6
- Kroes ACM, S2.12
- Krukowski ZH, S2.16
- Krubben FJGM, S2.31
- Kudsk KA, S1.52
- Kulhali V, S2.46, S5.61
- Kumar R, S2.1
- Kurzawinski T, S2.55
- Kynaston H, S2.13
- Kyriacou E, S2.11
- Kyriakides CA, S5.34
- Lacey S, S5.19
- Laine A, S5.45
- Laing S, S2.42
- Lam CM, S5.34
- Lamers CBHW, S2.12, S2.14
- Land DV, S2.9
- Lane A, S2.14
- Lang MW, S5.32, S5.33
- Langman MJS, S2.2, S5.39
- Larvin M, S2.15
- Lastovica AJ, S2.17
- Laszlo F, S2.52
- Laterza O, S5.52
- Lauter JG, S5.6, S5.80
- Leader M, S2.31
- Leandro G, S2.18
- Lechler R, S5.45
- Lee A, S2.10, S5.68
- Lee AU, S5.52
- Lee FI, S2.42
- Lee JC, S5.30
- Lee JCW, S2.42, S2.48, S2.49
- Lee P, S5.10
- Lees WR, S5.51
- Legon S, S2.4, S2.18, S2.54, S5.60
- Leigh-Smith S, S2.30
- Lehmer E, S2.53
- Lennard-Jones JE, S2.42, S2.43, S2.48, S2.49, S5.30
- Lennon JR, S2.27
- Lesage X, S5.44
- Letizia C, S5.21
- Leung ST, S2.53
- Levi AJ, S2.63
- Levi J, S2.4
- Levi S, S2.54
- Levin RJ, S2.61
- Levy J, S2.3, S2.63, S2.64, S5.2
- Lewin J, S5.41
- Lewis CE, S2.10
- Lewis F, S2.35
- Lewis KO, S2.28, S5.20
- Lewis SJ, S5.48
- Lewis WG, S2.60, S5.31
- Li X, S5.9
- Liapakis G, S5.72
- Libby GW, S2.47, S5.57
- Lim AG, S2.20, S2.42, S5.10, S5.11
- Lindley IJD, S2.34
- Lipscomb GR, S2.37
- Lirussi F, S5.69
- Little J, S2.1
- Lloyd DR, S5.33
- Lloyd R, S5.2
- Lo Cascio V, S5.12
- Lobley R, S2.29
- Lof J, S5.65
- Loft D, S5.36
- Loft DE, S5.59
- Logan EGM, S2.47
- Logan RFA, S2.1, S2.30, S2.47, S5.47
- Logan RPH, S2.48, S5.15
- Loizou S, S5.1
- Lombard MG, S5.50
- Lombardi M, S5.18
- Long RG, S2.52, S5.6
- Longfellow M, S5.38
- Lopez Hellin J, S1.39
- Lopez M, S5.78
- Lord MG, S2.25, S2.28, S5.31, S5.57
- Lorenzotti A, S5.65
- Lott M, S2.22
- Loudon MA, S2.46
- Low JA, S2.17, S2.63
- Love AHG, S2.22, S5.7, S5.13
- Lubowski D, S2.16
- Lucas GA, S2.47
- Lucas F, S2.41
- Lucke W, S2.17
- Lundin KEA, S2.29
- Luo N, S2.29
- Lynch DAF, S2.4, S2.33, S2.34
- Ma QY, S2.60, S5.63
- Mac Mathuna P, S2.11, S2.23, S2.24, S2.27
- McAlindon ME, S5.70
- McAnena O, S2.8
- McArdle AH, S1.60
- McCaigue M, S5.63
- McCall JL, S2.15
- McCarthy P, S2.1

- McCull KEL, S2.4, S2.32, S2.35, S2.36, S5.2, S5.73
 McCullough JB, S2.45
 McCollum R, S5.78
 McConkey CC, S5.27
 McCormick C, S2.33
 McCormick J, S5.76
 McCormick PA, S2.12
 McCulloch J, S5.14
 McCulloch P, S2.17
 McDevitt DG, S5.49
 MacDonald A, S2.62
 MacDonald TM, S5.49, S5.58
 McDougall NI, S2.22, S5.7, S5.13
 McFadden JJ, S2.42
 McFarland RJ, S2.22, S5.7, S5.13
 Macfarlane B, S5.76
 MacFarlane IG, S2.19
 MacFarlane X, S5.5
 MacGilchrist AJ, S5.10
 McGilchrist MM, S5.49
 McGoogan E, S5.66
 McGowan I, S5.30, S5.37, S5.42
 McGregor C, S5.32
 McGregor I, S2.10
 McGregor JR, S2.32
 McHugh M, S5.76
 McClrath EM, S2.56
 McClroy BS, S5.6
 Macintyre IMC, S2.55
 McIntyre N, S2.12, S5.24, S5.77
 MacKay CK, S5.35
 Mackay EH, S5.1
 McKenna F, S2.8, S2.17
 McKenzie H, S5.42
 McKenzie JF, S2.9, S5.36, S5.73
 McKenzie PE, S5.58
 Mackie CR, S2.17, S5.6
 McKinley A, S5.66
 McLaughlan J, S5.18, S5.43
 Maclean AD, S2.55
 McLoughlin JC, S5.4
 McMahon AD, S5.49
 McMahon MJ, S2.15, S5.5, S5.23, S5.38
 McMaster D, S5.4
 McMillan SA, S5.4
 McNeil IRR, S5.25
 McNulty C, S5.15
 MacSween RNM, S2.19
 Magee GD, S2.60, S5.63
 Mahida YR, S5.38
 Mahmud N, S2.41
 Mahoney A, S2.1
 Maingay JP, S5.10, S5.39, S5.73
 Maiuri L, S5.22, S5.45, S5.46
 Makh S, S5.38
 Malamou H, S5.3
 Maloney M, S2.54
 Malu AP, S5.23
 Maly FE, S5.46
 Mandanda B, S2.29
 Mangham CM, S5.32, S5.33
 Mangnall YF, S2.22
 Mani V, S2.42
 Mann SG, S2.45, S5.58
 Mannur K, S2.8
 Manousos ON, S5.72
 Mansfield JC, S2.41, S2.49, S2.59
 Mansfield P, S2.46
 Mapstone NP, S2.4, S2.33, S2.34
 Marafin C, S5.50, S5.72
 Marchbank T, S5.53
 Marcus CD, S5.24, S5.25
 Margulies M, S2.58
 Marks IN, S2.17, S2.63
 Marley R, S2.54
 Marrero JM, S2.21, S2.33
 Marsh MN, S2.29
 Marshall D, S5.25
 Marshall DG, S2.3
 Marshall REK, S2.14
 Martin DF, S5.34, S5.57
 Martin IG, S5.73
 Martin J, S2.40
 Martin PA, S2.13
 Martins EBG, S2.10, S2.20
 Masaki T, S2.39
 Mascee AAM, S2.12
 Masiero M, S2.18
 Mason R, S5.14
 Mason RC, S2.9
 Mathew A, S5.63
 Mathew CG, S2.48, S5.30
 Mathialagan R, S5.1
 Mathieu D, S5.44
 Mattana C, S5.44
 Matthewson K, S5.15
 Mauad TH, S5.9
 Maxwell JD, S2.20, S2.21, S2.42, S5.2, S5.5, S5.10, S5.11
 May J, S5.14
 May RE, S5.35, S5.67
 Mayberry JF, S2.59, S5.1, S5.15, S5.60, S5.73
 Meadows N, S5.33
 Medbak SH, S2.57
 Mee AS, S5.51
 Melkian V, S2.18
 Melling P, S5.14
 Mellor NM, S5.60
 Mendall M, S2.33
 Mendall MA, S2.3, S2.4, S2.63, S2.64, S5.2, S5.17, S5.18
 Mengatti M, S2.34, S2.44, S5.18
 Merriman R, S2.23, S2.27
 Mesquita MA, S2.43, S5.27
 Metcalf J, S5.66
 Meuwissen SGM, S2.28
 Meyer S, S1.28
 Michaeli D, S2.33
 Michell NP, S2.2, S5.39
 Middleton S, S2.60, S5.75
 Middleton SJ, S2.25, S5.61, S5.71
 Miglioli M, S2.34, S2.44, S5.18
 Miles WFA, S5.26
 Milla P, S5.33
 Milla PJ, S2.46, S5.39
 Millar AD, S2.50, S5.29
 Millar Jones D, S5.1
 Miller AS, S5.31
 Mills A, S2.5
 Mills PR, S2.19
 Mills T, S2.23
 Mills TN, S2.40, S5.52
 Milne R, S2.48
 Miloszewski KJA, S5.23
 Misiewicz JJ, S2.48, S5.3, S5.15, S5.49
 Mitchell CL, S5.55
 Mitchell I, S5.26
 Moayyedi P, S2.62, S5.16
 Mohamed AH, S2.8, S5.17
 Mokhashi M, S2.9, S2.26, S5.36
 Molari A, S5.50
 Molineaux N, S2.3, S2.4, S2.63, S2.64, S5.2
 Molloy RG, S5.65
 Monga AK, S2.21
 Montrone F, S2.44
 Moorghen M, S2.30
 Moqbel R, S2.14
 Morandi E, S5.80
 Morant S, S2.45
 Morden A, S5.50
 Morgan S, S2.29
 Moriarty K, S2.29
 Morrell K, S5.49
 Morris AI, S2.60
 Morris AJ, S2.26, S5.36
 Morris PE, S2.15, S2.16, S2.32
 Morris J, S5.55
 Morris PA, S5.25
 Morris T, S5.64
 Morris TM, S2.33
 Morrison L, S2.4
 Mortensen N, S5.62
 Mortensen NJMcC, S5.31
 Mortensen NM, S5.29
 Moss SF, S2.4, S2.18
 Mostafa AB, S2.18
 Mothersill C, S2.6
 Motson RW, S2.55
 Motta R, S5.80
 Mourad FH, S2.52, S5.54, S5.70, S5.71, S5.76
 Moussa ME, S2.39
 Mowat A, S2.35
 Mowat AP, S2.21
 Muiesan P, S5.20
 Mulcahy H, S2.1, S2.27, S2.31
 Mulder AH, S2.6
 Mulder HD, S2.28
 Mulé P, S2.34, S5.18
 Mulla R, S5.19
 Müller A, S5.51
 Muller AF, S2.1, S5.4
 Muller F, S5.70
 Mulligan E, S2.27
 Mullins D, S2.17
 Munakata T, S2.13
 Munro A, S2.16
 Murday V, S5.39
 Murfitt J, S5.52, S5.79
 Murphy C, S2.55
 Murphy G, S2.19
 Murphy GM, S2.57, S5.20
 Murray A, S2.53
 Murray FE, S2.45, S5.14, S5.34, S5.49, S5.58, S5.71, S5.78
 Murray WR, S5.35, S5.57
 Mussaddeq Y, S2.42
 Muto T, S2.6
 Myskow MW, S2.22
 Naccarato R, S2.36, S5.50, S5.72
 Naeem A, S2.49
 Nagawa H, S2.6
 Nair P, S5.1, S5.15, S5.73
 Nakamura K, S5.42
 Nakshabendi IM, S2.53, S5.22, S5.37
 Naom IS, S2.48, S5.30
 Naoumov N, S2.19, S5.38
 Narang A, S5.68
 Nash J, S2.22
 Nassim M, S5.47
 Nathavitharana KA, S5.33
 Nazim M, S2.60
 Neal KR, S2.30
 Neale G, S5.3
 Neale K, S5.39
 Neilson JMM, S2.11
 Nelufu JM, S5.21
 Neoptolemos JP, S5.36
 New H, S2.54
 Newsholme EA, S1.13
 Newton JM, S5.55
 Newton M, S2.60, S5.75, S5.77
 Ngu MC, S2.12, S5.52
 Ngwenya B, S2.29, S5.37
 Nicholls RJ, S2.27, S2.40
 Nicholson DA, S5.8
 Nicholson J, S2.51
 Nightingale JMD, S5.73
 Nikiteas N, S5.28
 Nitri D, S5.72
 Nixon SJ, S2.55, S5.26
 Noel GE, S2.25
 Noguera J, S2.41
 Noonan N, S2.54
 Norris TL, S5.6
 Northfield TC, S2.3, S2.4, S2.20, S2.33, S2.42, S2.63, S2.64, S5.2, S5.10, S5.11, S5.17, S5.18, S5.47
 Norton B, S5.6
 Norwood W, S5.63
 Notenboom RGE, S5.9
 Notghi A, S2.18
 Nott DM, S2.13
 Nwokolo C, S5.36
 Nwokolo CU, S2.18, S5.59
 Nyam DC, S2.62
 Nygard G, S2.38, S2.43
 Nzegwu H, S2.61
 O'Byrne K, S2.54
 O'Carroll R, S5.9
 Odera G, S5.18
 O'Donnell LJD, S2.52
 O'Donoghue DP, S2.1, S2.27, S2.31
 O'Dwyer PJ, S2.32
 O'Farrell BJ, S2.11
 Offerhaus GJA, S5.9
 Ogdin JM, S2.53
 Ogutu E, S2.52
 O'Keefe SJD, S2.25, S2.53, S5.48
 Olivieri M, S5.12
 O'Mahony S, S5.38
 O'Morain CA, S2.3, S2.33
 O'Riordan DK, S2.52, S5.21
 O'Rourke K, S5.40
 O'Rourke D, S2.60
 O'Shea C, S5.78
 O'Toole PA, S5.50
 Otto WR, S5.53
 Owen RJ, S5.1
 Owen W, S5.7
 Owen WA, S2.7, S5.7, S5.13
 Owen WJ, S2.7, S5.7, S5.13
 Owyang C, S3.11
 Ozmen MM, S2.56
 Pack K, S5.40
 Pajares JM, S5.17, S5.52
 Palmer KR, S2.28, S2.48, S5.16, S5.26, S5.36, S5.56, S5.77
 Panagou EB, S2.12
 Panos MZ, S5.58
 Papadopoulou A, S5.33
 Parfrey NA, S2.1
 Parikh A, S2.15
 Parikh D, S2.15
 Park R, S2.26
 Park RHR, S2.9, S2.35
 Parker AJ, S2.61
 Parker DR, S5.5
 Parrott D, S5.42
 Parsons K, S2.13
 Parsons ME, S5.46
 Passaro U, S5.65
 Passoni GR, S5.80
 Patchett SE, S5.40, S5.41
 Patel HRH, S2.51
 Patel P, S2.3, S2.63, S2.64, S5.2, S5.17, S5.18
 Paton JY, S5.34
 Patterson J, S2.42
 Pazianas M, S5.5
 Pearce MY, S2.45
 Pearson JP, S5.43
 Peck N, S2.23
 Pederzoli P, S3.20
 Pedler SJ, S5.74
 Peeters M, S5.29
 Penman I, S2.36
 Penman ID, S2.4, S2.32
 Pennington C, S5.22
 Pennington CR, S2.58, S5.42, S5.78
 Penny JI, S2.29, S2.51
 Penith J, S2.33
 Pera G, S5.44
 Pereira SP, S2.37, S2.57, S5.20
 Pérez Miranda M, S5.17, S5.52
 Perini L, S5.72
 Perrett D, S2.53, S5.54
 Perry S, S2.34
 Pescatori M, S5.44
 Peters AM, S5.19
 Phillips AD, S5.37, S5.74
 Phillips G, S5.22
 Phillips RKS, S5.39, S5.40, S5.63
 Phull PS, S2.63, S5.17
 Piasecki C, S2.50
 Picarelli A, S5.21, S5.22, S5.45, S5.46
 Pignatelli M, S2.1, S2.2, S5.60
 Pilot MA, S2.28, S2.44, S5.56
 Pilotto A, S5.16
 Pitcher MC, S2.3
 Pitcher MCL, S5.3
 Playford RJ, S5.53, S5.67
 Plebani M, S2.18, S5.16, S5.50
 Plebris J, S5.68
 Plebris JN, S5.66
 Plusa SM, S2.53, S2.61
 Polak JM, S2.37, S5.71
 Pollard AJ, S5.33
 Polli D, S5.44
 Poole S, S2.2, S2.6
 Porter KG, S5.4
 Portmann B, S2.21, S5.38
 Poschet JF, S5.54
 Poulosom R, S5.53, S5.60
 Pounder R, S2.43
 Pounder RE, S2.38, S2.40, S2.50, S5.28, S5.41, S5.43, S5.44
 Powell KU, S5.2, S5.16
 Powell-Tuck J, S5.52
 Poxon V, S5.2
 Prabhakar MC, S2.11
 Prach AT, S2.56
 Pranteria C, S5.44
 Prescott LF, S5.11
 Price AB, S5.17
 Primrose JN, S2.53
 Proudfoot AT, S5.11
 Pryde A, S2.21, S2.47, S5.48, S5.56
 Prytherch D, S2.61
 Przemioslo RT, S2.29, S2.40, S2.54, S5.21
 Pugh S, S5.1
 Puntis MCA, S5.64, S5.72
 Purkiss SF, S2.55
 Pusey C, S5.45
 Pyrah EM, S2.34
 Quandale P, S5.44
 Quigley EMM, S5.65
 Quirke P, S2.4, S2.33, S2.34, S5.38
 Radford-Smith G, S5.28, S5.30, S5.42
 Raethien I, S2.28
 Rajan E, S2.11
 Raju GS, S2.16, S2.17
 Ralston P, S5.76
 Ramake JK, S2.32, S5.38
 Ramazzotti A, S5.21, S5.22
 Rameh B, S5.50
 Ramirez J, S5.62
 Rampton DS, S2.50, S5.28, S5.29
 Rankin BJ, S5.43
 Rappoli R, S2.34, S2.35
 Raptis SA, S5.3
 Rashid N, S5.40
 Rate AJ, S5.6, S5.8, S5.27
 Rathbone B, S5.73
 Rathbone BJ, S5.1, S5.15
 Ray RA, S5.41
 Read AE, S2.32
 Read NW, S2.37
 Record CO, S5.15, S5.43, S5.66
 Redhead D, S5.23, S5.66
 Redhead DN, S2.10, S5.9, S5.11, S5.24, S5.25
 Reed MWR, S2.15
 Rees CD, S5.30
 Rees WDW, S2.8, S2.17, S2.37
 Reid I, S2.6
 Reid IM, S2.5
 Reilly TG, S5.2, S5.58
 Reka S, S5.37
 Rela M, S2.21, S5.20
 Rennie MJ, S5.22
 Rentsch R, S2.54
 Revier D, S2.41
 Reynolds AP, S5.33
 Reynolds N, S5.42
 Reynolds PD, S2.41, S5.61, S5.71
 Rhodus ST, S2.41
 Rhodes JM, S2.60, S5.50
 Ribeiro B, S5.26
 Ricci C, S5.18
 Richards J, S2.58
 Rigaud A, S5.72
 Riley S, S5.13
 Ringers J, S2.12
 Rizzi PM, S2.19, S5.38
 Roach EJ, S2.12
 Roberts D, S5.7
 Roberts NB, S5.67
 Robertson DAF, S5.5, S5.47
 Robins A, S2.49, S5.18, S5.42, S5.43, S5.47
 Robinson G, S2.33, S5.64
 Robinson MHE, S5.63
 Robinson PJ, S2.15
 Robinson RJ, S2.59, S5.60
 Rockall TA, S5.47
 Rodriguez Cortés J, S5.52
 Rodriguez Gómez S, S5.52
 Rogers J, S5.26, S5.31, S5.57, S5.65
 Rolando N, S5.20, S5.41
 Rolles K, S2.14, S2.55, S5.25, S5.45
 Romani R, S2.32
 Rooney N, S2.32
 Rose JDR, S2.51
 Ross JA, S5.10, S5.39, S5.45, S5.73
 Ross PE, S2.45, S5.14
 Ross SJ, S2.16
 Ross WB, S2.15
 Rowthell JC, S2.21, S5.11
 Round C, S5.14
 Rowbottom A, S5.40
 Rowlands BJ, S2.60, S5.63
 Roy AJ, S2.43
 Royston C, S2.16, S2.17
 Rucker JT, S2.25
 Ruggie M, S2.63, S5.16, S5.50
 Rumley A, S2.26
 Russell RI, S2.26, S2.35, S2.36, S2.45, S2.53, S5.22, S5.37
 Rutgeerts P, S5.29
 Ryan E, S2.11, S2.27
 Ryder SD, S2.19, S2.63, S5.38
 Sagar PM, S5.31
 Saidi M, S5.5
 Salam I, S2.30
 Salandin S, S2.18, S2.63, S5.16
 Samways J, S2.9
 Sanderson JD, S2.47, S2.58
 Sandie GI, S2.61
 Sandoval L, S5.41
 Sanfey HA, S5.25
 Santalucia F, S2.44
 Santander C, S5.17
 Santini G, S5.69
 Sargentoni IR, S2.39
 Sargentoni J, S5.24, S5.25
 Satsangi J, S5.30
 Saunders BP, S2.25, S2.39, S5.80
 Saunders JH, S2.55
 Sawade TC, S5.74
 Sawda Y, S5.20
 Sawyerr AM, S5.77
 Sayer JM, S2.52

- Scavo D, S5.21
 Schaaqe-Koning CCE, S2.7
 Scheele J, S5.67
 Schepbach W, S1.35
 Schinkel AH, S5.9
 Schofield J, S2.54
 Schorah C, S2.19
 Schorah CS, S5.3
 Schouten WR, S2.61
 Schürer-Maly C-C, S5.46
 Schutte B, S2.31
 Schwartz S, S1.39
 SCOTIA Study Group, S2.16
 Scott BB, S2.24, S5.43, S5.59
 Scott-Coombes DM, S5.46, S5.66
 Scott HM, S2.30
 Scott M, S2.23, S2.44
 Scott NA, S5.32
 Scott-Russell AM, S5.41
 Scott SM, S5.56
 Scunes D, S5.1, S5.45
 Sebastian M, S5.35
 Selden C, S5.60, S5.69, S5.74
 Selves L, S5.25
 Sembenini C, S5.12, S5.13, S5.19, S5.48, S5.55
 Service Y, S5.34
 Seth R, S5.18, S5.43
 Seto Y, S2.6
 Seymour CB, S2.6
 Shaffer JL, S2.61
 Shah H, S2.15
 Shah N, S2.15
 Sharp PA, S2.52, S5.21
 Sharpstone D, S5.40
 Shattock AG, S2.11
 Shaw R, S5.37
 Shaw-Smith C, S5.60
 Sheahan K, S2.1
 Shephard N, S5.7
 Sheridan M, S2.6
 Shidrawi RG, S5.21
 Shields R, S2.13, S2.15
 Shmakov AN, S5.74
 Shmueli E, S5.15
 Shorthouse M, S5.61, S5.71
 Shousha S, S5.19
 Silk DBA, S1.V
 Sim R, S5.41, S5.44
 Simi M, S5.44
 Simmonds P, S2.19
 Simpson KJ, S2.10, S5.9, S5.10, S5.24, S5.68
 Singh K, S5.11, S5.30, S5.60, S5.76
 Singh SD, S2.7, S5.7, S5.13
 Skelly M, S2.27
 Skinner AC, S2.60
 Skordilis P, S5.72
 Slack RCB, S2.30
 Sladen GE, S2.37
 Sloan J, S5.42
 Small PK, S2.46
 Smilgin Humphries M, S5.62
 Smit JJM, S5.9
 Smith AD, S2.51
 Smith BC, S2.58
 Smith BGN, S5.7
 Smith CML, S5.4
 Smith G, S2.48
 Smith JA, S2.52
 Smith L, S5.13
 Smith M, S5.12, S5.75, S5.77
 Smith P, S2.1
 Smith S, S2.1
 Smithson JE, S5.28
 Smyth CJ, S2.3
 Smythe A, S2.22
 Sobala GM, S2.4
 Sollid LM, S2.29
 Somers R, S2.39
 Sorghi M, S5.44
 Sorghi M, S5.44
 Spence E, S2.19
 Spencer GM, S2.39
 Spiers E, S5.14
 Spigelman A, S5.40
 Spigelman AD, S5.39, S5.63
 Spiller RC, S1.5
 Spychal RT, S2.23
 Srai SK, S5.43
 Srai SKS, S2.52, S5.21
 Srb F, S5.65
 Sreeram N, S5.33
 Srivastava E, S5.15
 Srivastava ED, S2.59, S5.43
 Stack WA, S5.53
 Stanley AJ, S5.69
 Stanton SL, S2.21
 Stebbing J, S5.62
 Stebbing JF, S5.31
 Steele RJC, S2.5, S5.48, S5.63
 Steger AC, S2.14
 Stephens JC, S5.1
 Stephens S, S2.50
 Stern AI, S5.32
 Stewart KJ, S2.62
 Stockbrugger RW, S2.31
 Stoddard CJ, S2.15
 Stone M, S5.60
 Strachan D, S2.4, S2.64
 Stratford J, S5.75
 Stratford JM, S5.51
 Sturgess RP, S2.54
 Sturrock RD, S2.45
 Sue-Ling H, S5.14, S5.73
 Sultan AH, S2.27
 Sutton R, S2.13, S5.50, S5.67
 Swain CP, S2.23, S2.38, S2.40, S5.6, S5.51, S5.52, S5.79, S5.80
 Swain P, S5.52
 Swannell AJ, S2.45
 Sykes R, S5.64
 Sytnik B, S5.18
 Taal BG, S2.7, S2.39
 Tabakopoulos D, S5.51
 Taha AS, S2.45
 Tait I, S2.51
 Tait IS, S2.29, S2.51
 Talbot I, S2.54
 Talbot IC, S5.39
 Tallis RC, S5.11
 Tan CC, S2.24
 Tan KC, S2.21, S5.20
 Tang C, S2.14
 Tanner AR, S2.59
 Tanner MS, S5.25
 Tarlow JK, S2.41
 Tarozzi C, S5.4
 Tarisani P, S5.21
 Taylor B, S2.13
 Taylor CJ, S5.55
 Taylor G, S2.7, S5.7, S5.13
 Taylor-Robinson SD, S5.24, S5.25
 Taylor TM, S5.59, S5.76
 Teijgeman R, S2.6
 Tempstra OT, S2.12
 Terzi MC, S2.56
 Testolin G, S5.19, S5.55
 Tham TCK, S2.56, S2.58, S5.42
 Tharakan J, S5.74
 Thermos K, S5.72
 Theron I, S2.63
 Thomas GAO, S5.1
 Thomas J, S2.62
 Thomas PA, S2.55
 Thompson AM, S5.8
 Thompson DG, S2.8, S2.21, S2.43, S2.44, S5.6, S5.11, S5.27, S5.30, S5.32
 Thompson JN, S5.46, S5.66
 Thompson MR, S2.27, S2.61
 Thompson NP, S2.40, S5.28, S5.77
 Thorpe SM, S2.39
 Thrasivoulou C, S5.43
 Tighe MJ, S5.5, S5.23
 Tigler-Wybrandt NA, S2.53
 Tilanus HW, S2.6
 Tish K, S5.15
 Tirobelli A, S5.44
 Tobias JS, S2.39
 Toghiani PJ, S2.1, S5.4
 Toker N, S2.18
 Tominaga O, S2.6
 Tompkins DS, S2.34, S5.16
 Tonelli F, S5.44
 Torsoli A, S5.21, S5.22, S5.45, S5.64
 Tougas G, S2.8
 Travis SPL, S5.29, S5.30
 Trimble KC, S2.47, S5.48
 Trotter G, S2.9
 Trowell JE, S5.2, S5.16
 Trudgill N, S5.13
 Trye P, S2.45
 Tunio M, S2.36, S5.49
 Turnbull G, S5.11
 Turnbull GK, S5.30
 Turvill JL, S5.54, S5.71
 Tweedle DEF, S5.34
 Tyrrell M, S2.9, S5.14
 Unsworth D, S2.29
 Unsworth DJ, S5.3
 Vaira D, S2.18, S2.34, S2.44, S5.18
 Valori R, S2.24, S5.15
 van Blankenstein M, S2.6
 van Dekken H, S2.6
 van den Bergh Weerman MA, S5.9
 van der Akker O, S5.27
 van Heerde P, S2.39
 van Hoek B, S2.12
 van Krieken JHJM, S2.12
 van Krieken-Hogenberk LG, S2.12
 Van Leeuwen PAM, S1.28
 van Nieuwkerk CMJ, S5.9
 van Rensburg CJ, S2.63
 van Schelven WD, S2.12
 Van Someren N, S5.51, S5.79
 Vantini I, S5.12, S5.13, S5.19, S5.48, S5.55
 Vautier G, S5.43, S5.59
 Veitch A, S5.76
 Verkruijsen RP, S5.9
 Vianello F, S2.18, S2.63, S5.16
 Vickers J, S2.23, S5.8
 Vigneri S, S5.16
 Vipond M, S2.23
 Vipond MN, S5.38
 Vyas SK, S5.1
 Wachter H, S2.29
 Wade J, S5.20, S5.41
 Watula J, S2.14
 Waghorn A, S5.46
 Wakefield AJ, S2.38, S2.40, S2.43, S2.50, S5.28, S5.41, S5.43, S5.44
 Walker MM, S5.3
 Walker MW, S5.49
 Walker-Smith JA, S5.37, S5.74
 Walker WS, S5.8
 Waller JM, S5.3, S5.49
 Wallis RM, S5.61
 Walls A, S5.76
 Walmsley RS, S2.43, S5.29
 Walsh CJ, S2.55
 Walsh JH, S5.18
 Walsh TN, S2.5, S2.6
 Walt RP, S5.2, S5.58
 Walters JRF, S2.54, S5.60
 Wang J, S2.7, S5.7, S5.13
 Ward J, S2.15
 Ward P, S2.50
 Wardle TD, S2.48
 Waring A, S2.19
 Warland D, S5.3
 Warner G, S2.28
 Warnes TW, S2.31
 Warren BF, S2.22, S2.50
 Warren SJ, S2.25, S2.28, S5.31, S5.57
 Wass JAH, S2.57
 Wastell C, S5.19, S5.26
 Watkins PE, S2.50
 Watkinson A, S5.14
 Watson A, S2.5, S2.23
 Watson AJ, S2.30
 Watson AJM, S5.46
 Watson DJ, S2.15, S2.22
 Watson RGP, S2.22, S2.56, S2.58, S5.4, S5.7, S5.13
 Watson SA, S2.33, S5.64
 Watson W, S2.35
 Watts A, S2.61
 Wayman J, S5.14
 Weaver JB, S2.12
 Weaver LT, S5.34
 Webb DJ, S5.10
 Webster N, S2.53
 Weir DG, S2.41
 Welbourn CRB, S2.56
 Weldon MJ, S2.42
 Wesdorp RIC, S1.28
 West K, S5.1
 Westaby D, S2.9
 Westwick J, S5.47
 Wexner S, S2.41
 Whatley G, S5.59
 Whawell SA, S5.46, S5.66
 White G, S5.49
 White J, S5.30
 White K, S2.19
 White KLM, S5.3
 White P, S2.24
 Whitfield PF, S5.49
 Whittle BJR, S2.52
 Whorwell PJ, S5.55, S5.57, S5.58, S5.62
 Wicks ACB, S2.59, S5.1, S5.15, S5.73, S5.78
 Widdison AL, S5.35, S5.67
 Wigmore SJ, S5.10, S5.39, S5.73
 Wilkinson J, S5.17
 Wilkinson ML, S2.37, S2.58
 Williams AJK, S2.26, S5.56
 Williams CB, S2.25, S2.39
 Williams GR, S2.2, S5.39
 Williams JG, S5.36
 Williams MD, S5.33
 Williams MH, S5.8
 Williams NS, S2.25, S2.28, S2.44, S5.26, S5.31, S5.56, S5.57, S5.65
 Williams R, S2.19, S2.21, S2.32, S5.20, S5.38, S5.41
 Williams SGJ, S2.9
 Williamson MER, S2.60, S5.31
 Wilson P, S2.8
 Wilson G, S5.26
 Wilson GW, S5.65
 Wilson JA, S2.21
 Wilson PD, S5.26
 Wilson RG, S2.55
 Windle HJ, S2.3
 Wingate DL, S2.8, S5.12, S5.61
 Winter TA, S2.17, S2.53
 Wirz A, S2.36, S5.2
 Wiste JA, S5.56, S5.62
 Wong C, S5.23
 Wong S, S2.40, S2.60
 Woutersen RA, S2.14
 Wright DH, S2.53
 Wright J, S2.46, S5.48
 Wright JG, S5.33
 Wright N, S2.2
 Wright NA, S1.1, S2.1, S5.53, S5.60
 Wright TA, S2.22
 Wyatt AP, S2.14
 Wyke RJ, S5.50
 Xia HX, S2.3
 Xiang Z, S2.34
 Yap P, S2.19
 Yapp T, S5.1
 Yasaki E, S2.23
 Yates J, S2.13
 Yeomans ND, S5.70
 Yiannakou Y, S2.13
 Young GO, S2.25, S5.48
 Young S, S5.73
 Zandvliet DW, S5.53, S5.60
 Zhang QB, S2.35, S2.36, S5.37
 Zimmerman M, S5.42
 Zoli G, S5.22
 Zuccali V, S5.12
 Zuin M, S2.20

SUBJECT INDEX – SUPPLEMENTS, 1994

- Abdominal closure**, Advanced diffuse peritonitis managed by planned multiple laparotomies utilising zippers/velcro analogue for temporary abdominal closure, **S2.15**
- Abscesses**, Abscesses after liver transplantation: a 10- year study, **S5.41**
- Absorption**, Intestinal absorptive function, **S1.5**
- Achalasia**
Causes of pathological oesophageal acidification after pneumatic LOS dilatation in achalasia, **S5.12**
Pneumatic dilatation for achalasia, **S2.8**
- Acid clearance**, Motor activity of the oesophagus probably only has a minimal effect on acid clearance, **S5.7**
- Acromegaly**, Meal-stimulated gallbladder emptying in acromegaly. The effect of octreotide treatment, **S2.57**
- Acute phase response**, Titres of serum IL-8 correlate with the presence of an acute phase response in patients with pancreatic cancer, **S5.73**
- Adenosine blockade**, The effects of adenosine blockade upon the portal circulation in patients with cirrhosis, **S5.23**
- Adenosine triphosphate**, ATP dilates the hepatic artery via P₁-purinoceptors, **S2.9**
- Adhesion molecules**, Expression of adhesion molecules and endothelial phenotypic markers in human orthotopic liver transplantation, **S5.69**
- Adrenaline**, Bleeding peptic ulcer: injection of adrenaline or tissue adhesive (histoacryl), **S5.36**
- Adrenoceptors**, Adrenoceptors and the colocolonic inhibitory relax, **S2.44**
- AIDS**, The role of laparoscopy in AIDS, **S5.26**
- Alcoholic liver disease**, Recognition of hepatitis C complicating alcoholic liver disease, **S2.11**
- Alpha-one-antitrypsin**, Faecal tumour necrosis factor-alpha and faecal alpha-one-antitrypsin in HIV infection, **S5.40**
- Ambulatory pH monitoring**, Continuous ambulatory pH monitoring in pigs, **S5.48**
- 5-Aminolaevulinic acid**, Eradication of high grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with oral 5-aminolaevulinic acid and 630nm light, **S5.7**
- Aminosalicylic acid**, Aminosalicylic acid derivatives bind nitric oxide, **S5.71**
- Amoxicillin**, The effect of pantoprazole, as monotherapy and in combination with amoxicillin, on gastric *H. pylori* status, in duodenal ulcer subjects, **S2.63**
- Amoxicillin**
A successful one week antibiotic regime for *Helicobacter pylori* eradication, **S5.16**
Helicobacter pylori eradication therapy. A comparison between either omeprazole or ranitidine in combination with amoxicillin plus metronidazole, **S5.16**
- Ampullectomy**, Endoscopic ampullectomy – a new approach to difficult cannulation, **S2.54**
- Anal endosonography**
Anal endosonography after failed anterior sphincter repair for obstetric trauma is imperative, **S2.27**
Effect of anal sphincter repair on anal endosonography, **S2.28**
- Anal fissures**, Island advancement flaps in the treatment of anal fissures, **S2.62**
- Anal sphincter**
Do rectal myenteric nitric oxide synthase neurones innervate internal anal sphincter? Retrograde neuronal tracing in a guinea pig model, **S5.31**
Representation of the anal sphincter on the human cerebral cortex, **S5.30**
- Angiotensin converting enzyme**, Angiotensin converting enzyme activity in stools of healthy subjects and patients with coeliac disease, **S5.21**
- Animal models**
An animal model of *Helicobacter pylori* infection, **S5.19**
Survival of *Helicobacter pylori* in animal models, **S5.19**
- Anorectal reconstruction**, Sensory effects of total anorectal reconstruction, **S5.31**
- Antigliadin antibody(ies)**
Large scale population survey of antibodies to gliadin, reticulins and endomysium, **S5.4**
Low or negative antigliadin antibody may also indicate disease, **S5.4**
- Antineutrophil antibodies**, Antineutrophil antibodies in familial inflammatory bowel disease: specificity for ulcerative colitis but not Crohn's disease in genetically related individuals, **S2.42**
- Antineutrophil cytoplasmic antibodies**, Specificity and significance of ANCA in inflammatory bowel disease, **S2.49**
- Antioxidant nutrient therapy**, An open trial of antioxidant nutrient therapy in active ulcerative colitis, **S5.29**
- Antituberculous chemotherapy**, The need for audit: preventable deaths due to hepatotoxicity of antituberculous chemotherapy, **S5.77**
- APC germline**, Germline APC mutation at codon 1061 is associated with severe duodenal polyposis but not high colonic polyp counts in familial adenomatous polyposis, **S5.40**
- Appendicectomy**, Appendicectomy, tonsillectomy and inflammatory bowel disease, **S5.28**
- Appendicitis**, Clinical diagnostic performance, scoring systems and computer aided diagnosis in suspected acute appendicitis, **S2.58**
- Arginine**, Can arginine and ornithine support gut functions? **S1.42**
- Ascitis of unknown origin**, Diagnostic value of laparoscopy in peritoneal diseases presenting as ascitis of unknown origin, **S5.52**
- Ascorbic acid**, Ascorbic acid concentrations in plasma, gastric juice and gastrointestinal mucosa. Effects of gastritis and oral supplementation, **S2.19**
- Aspirin**, Aspirin and non-steroidal anti-inflammatory drug (NSAID) use and symptomatic colorectal cancer, **S2.1**
- Aspirin-induced gastroduodenal mucosal injury**, The effect of allopurinol, salazopyrin and vitamin C on aspirin-induced gastroduodenal mucosal injury in humans, **S5.70**
- Aspirin-induced intragastric bleeding**, Specific prevention of aspirin induced intragastric bleeding with sucralfate, **S5.71**
- Audit**
A prospective audit of new inpatient referrals for upper gastrointestinal endoscopy to the gastroenterology firm of a district general hospital, **S5.77**
An audit of gastroenterology out-patient referrals: improving efficiency and shortening waiting lists, **S2.47**
An audit of the outcome of patients undergoing 24hr pH oesophageal tests, **S5.75**
An audit of plasma vitamin B12 and folic acid monitoring in out-patients with Crohn's disease, **S5.77**
Audit of an interactive open access endoscopy service, **S5.75**
Audit of *H. pylori* eradication by C14 urea breath tests, **S5.75**
Audit of the investigation and outcome of iron-deficiency anaemia in one health district, **S2.47**
Colorectal cancer surgery: is there a role for the nonspecialist? **S5.76**
Helicobacter pylori serology – audit of local assay and evaluation in screening dyspepsia under 45 years, **S5.74**
Is 'censorship' for open access gastroscopy justified? **S5.76**
Oesophageal cancer in Yorkshire: a regional audit, **S5.14**
Palliation of oesophageal carcinoma with expandable metal prostheses is a cost-effective procedure, **S5.8**
Shortcomings of computer versus note based audit of upper GIT bleeds, **S5.76**
The need for audit: preventable deaths due to hepatotoxicity of anti-tuberculous chemotherapy, **S5.77**
- Autoimmune chronic active hepatitis**
Hepatocellular carcinoma in autoimmune chronic active hepatitis: the role of hepatitis C infection, **S2.19**
Soluble adhesion molecules and cytokines in autoimmune chronic active hepatitis, **S2.10**
- Azaserine**, Expression of peptide receptors both in normal rat pancreas and in rat pancreatic premalignant lesions induced by azaserine, **S2.14**
- Azygos blood flow**, The effect of N^ω-monomethyl-L-arginine on portal pressure gradient and azygos blood flow amongst patients with cirrhosis, **S2.20**
- Azythromycin**, Azithromycin in a triple therapy for eradicating *Helicobacter pylori*, **S2.63**
- Bacterial translocation**, Bacterial translocation: the influence of dietary variables, **S1.23**
- Balloon distension**, Motility change and perception to balloon distension in the jejunal loop of postgastrectomy patients, **S2.44**
- Balloon expulsion**, Imaging of rectal balloon expulsion compared with evacuation proctography, **S2.62**
- Barium enema**, Is a barium enema of use in the diagnosis of cancer in patients with rectal bleeding? **S2.27**
- Barrett's oesophagus**
Aneuploidy, loss of the Y-chromosome and p53 overexpression as potential markers for malignant progression in Barrett's esophagus, **S2.6**
Eradication of high grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with oral 5-aminolaevulinic acid and 630nm light, **S5.7**
Helicobacter infection is associated with oesophagitis in patients with Barrett's oesophagus, **S2.5**

- High grade dysplasia in Barrett's oesophagus – how should it be managed? **S2.22**
- Malignant cytology in Barrett's oesophagus: an indication for oesophagectomy? **S2.22**
- BB-882**, A double blind placebo controlled study of BB-882 (a potent PAF antagonist) in human acute pancreatitis, **S5.35**
- Bile**, The use of a sodium ion selective electrode to detect bile in the oesophagus, **S2.22**
- Bile duct obstruction**, A prospective randomised trial of 10 and 11.5 FG endoprostheses in malignant bile duct obstruction, **S5.50**
- Bile duct stones**
Endoscopic balloon sphincteroplasty for bile duct stones: efficacy and follow-up in the first 90 patients, **S2.24**
Laser lithotripsy of large stones in the bile duct with a stone recognition system, **S5.51**
- Biliary carcinoma**, Identification of Kirsten-ras mutations in bile of patients with pancreatic and biliary carcinomas, **S5.38**
- Biliary cytology**, Diagnostic biliary cytology for strictures managed by percutaneous transhepatic biliary drainage, **S5.66**
- Biofeedback**, Controlled randomized trial of biofeedback versus muscle training alone for intractable constipation, **S2.43**
- Bladder function**, Altered bladder function and oesophageal pain threshold in irritable bowel syndrome, **S2.21**
- Bleeding peptic ulcer**
Failures of endoscopic therapy for bleeding peptic ulcer; an analysis of risk factors, **S2.38**
Increasing age does not influence outcome in patients treated endoscopically for major peptic ulcer haemorrhage, **S2.38**
- Bleeding, rectal**, Is a barium enema of use in the diagnosis of cancer in patients with rectal bleeding? **S2.27**
- Bleeding ulcer**, Bleeding ulcer patients: a study on hormone profile, **S2.18**
- BMK-13**, Monoclonal antibodies against major basic protein (BMK-13) and eosinophil cationic protein (EG2) for quantifying eosinophils in human hepatic allograft rejection, **S2.14**
- Bone loss**, Prevalence, degree and pathophysiology of bone loss in adult coeliac disease, **S5.4**
- Bone marrow transplantation**, Diarrhoea, protein losing enteropathy and trace element deficiency in children following bone marrow transplantation, **S5.33**
- Bone mineral density**
Effect of a gluten free diet on bone density in coeliac disease, **S5.5**
Fractional calcium absorption and bone mineral density in coeliac disease, **S5.5**
- Bowel preparation**, A mannitol/Picolax mixture or two-dose polyethylene glycol lavage solution as bowel preparation for colonoscopy? **S2.39**
- Brachytherapy**, Laser recanalisation followed by brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia, **S2.39**
- Buscopan**, Changes in blood pressure and duodenal atony during ERCP. Studies of the influence of buscopan and glucagon, **S5.50**
- C14 urea breath test**, Audit of *H. pylori* eradication by C14 urea breath tests, **S5.75**
- c-erbB-2 gene expression**, C-erbB-2 gene expression in non-metastatic colorectal cancer, **S2.31**
- c-erbB3**, Altered gene expression of c-erbB3 during oesophageal tumorigenesis, applications for surveillance, **S2.1**
- CagA protein**
Detection of CagA positive *Helicobacter pylori*: a comparison of polymerase chain reaction and immunoblotting protocols, **S2.34**
Helicobacter pylori induced gastric epithelial interleukin-8 secretion is associated with the CagA positive phenotype, **S2.34**
Serum CagA IgG antibodies in *Helicobacter pylori* positive healthy volunteers and patients with dyspeptic disease, **S2.35**
- Calcium**
Fractional calcium absorption and bone mineral density in coeliac disease, **S5.5**
The influence of one year calcium supplementation on colorectal epithelial cell proliferation in colorectal adenoma patients, **S2.31**
- Calmodulin antagonist**, Effect of the calmodulin antagonist zaldaride maleate on cholera toxin induced small intestinal secretion, **S5.71**
- Campylobacter infection**, Omeprazole treatment, a potent risk factor for *Campylobacter* gastroenteritis, **S2.30**
- Cancer**, Is enteral nutrition a primary therapy in cancer patients? **S1.65**
- Capsaicin**, Tussive effect of capsaicin in symptomatic gastroesophageal refluxers without cough, **S5.12**
- Carbon**, Glucose and urea: sources of carbon for *H. pylori*? **S5.17**
- Carcinoid tumours**, Imaging of secondary carcinoid tumours of the liver: comparison of I^{123} -metaiodobenzylguanidine and IN^{111} -labelled octreotide scans, **S2.32**
- Catheter**, The presence of a catheter through lower oesophageal sphincter does not promote gastro-oesophageal reflux, **S2.7**
- Catheter-related sepsis**, An endoluminal brush to detect the infected central venous catheter in situ in patients receiving intravenous nutrition, **S5.5**
- Celiac intestine**, Recruitment of mucosal mononuclear cells in the subepithelial and interepithelial compartments after in vitro exposure to gliadin peptides of the treated celiac intestine: evidence for a local immune response to gliadin, **S5.46**
- Cerebral evoked potentials**, Cerebral evoked potentials. Are they useful in assessing oesophageal motility disorders, **S5.6**
- Chest pain**, Cause of chest pain after sumatriptan: is it oesophageal? **S5.55**
- Children**
Acquisition of *H. pylori* infection in British children: community factors or family circumstances? **S2.64**
Diarrhoea, protein losing enteropathy and trace element deficiency in children following bone marrow transplantation, **S5.33**
Does *Helicobacter pylori* infection affect growth in children? **S2.64**
Pulmonary embolism in children – another hazard of parenteral feeding, **S5.33**
- Cholecystectomy**, Increased rate of cholecystectomy in Scotland following introduction of laparoscopic cholecystectomy, **S5.34**
- Cholecystokinin**, D-Fenfluramine administration is not associated with an increase in plasma cholecystokinin, **S2.57**
- Cholera toxin**
Cholera toxin stimulates 5-hydroxytryptamine release into human jejunum, **S5.54**
Differential effect of 5HT₂ receptor antagonism on cholera toxin and *E. coli* heat labile toxin-induced secretion, **S2.52**
Effect of the calmodulin antagonist zaldaride maleate on cholera toxin induced small intestinal secretion, **S5.71**
- Cholestasis**, Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid, **S2.12**
- Chronic fatigue syndrome**, Prevalence of irritable bowel syndrome in chronic fatigue, **S2.47**
- Cimetidine**, Cimetidine prevents postoperative suppression of immune function following colorectal cancer surgery, **S2.16**
- Ciprofloxacin**, A prospective, randomised, placebo-controlled trial of single dose ciprofloxacin for the treatment of travellers' diarrhoea, **S2.30**
- Cirrhosis**
Gastric acid secretion and serum gastrin concentration in cirrhotic patients with *Helicobacter pylori* infection, **S5.67**
Survival analysis of cirrhotic patients by autonomic function testing over three years, **S5.68**
The effect of N^ω-monomethyl-L-arginine on portal pressure gradient and azygos blood flow amongst patients with cirrhosis, **S2.20**
The effects of adenosine blockade upon the portal circulation in patients with cirrhosis, **S5.23**
The haemodynamic effects of 8 ornithin vasopressin in portal hypertension and cirrhosis, **S2.13**
The mechanism of the autonomic neuropathy of cirrhosis, **S2.11**
- Clarithromycin**
Clarithromycin for the cure of *Helicobacter pylori* infection, **S5.16**
Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating *Helicobacter pylori*, **S5.16**
Eradication of *Helicobacter pylori* with lansoprazole and clarithromycin, **S5.15**
- Clostridium difficile**, Cellular responses of intestinal epithelial cells to toxin A of *C. difficile*, **S5.38**
- Clustering**, Intrafamilial clustering of *Helicobacter pylori* strains and correlation of virulence with disease activity, **S5.1**
- cMG1/ERF-1**, cMG1/ERF-1, a novel EGF-inducible early response gene, is a putative marker of proliferation and differentiation, **S5.60**
- Coagulopathies**, Inherited coagulopathies protect against inflammatory bowel disease, **S5.28**
- Coeliac disease**
Angiotensin converting enzyme activity in stools of healthy subjects and patients with coeliac disease, **S5.21**
Coeliac disease and intestinal lymphoma, **S2.32**
Cytokine mRNA expression in coeliac disease after gliadin challenge, **S2.54**
Effect of a gluten free diet on bone density in coeliac disease, **S5.5**
Fractional calcium absorption and bone mineral density in coeliac disease, **S5.5**
HLA-class II phenotypes in coeliac disease and enteropathy-associated T-cell lymphoma, **S2.53**
IgA anti-endomysial antibody is superior to the ^{51}Cr -EDTA: ^{14}C -mannitol intestinal permeability test in the diagnosis of coeliac disease, **S5.3**
In vitro coeliac toxicity of gluten peptides assessed by organ culture, **S5.21**
Increased blood levels of 5-hydroxytryptamine in coeliac disease, **S5.22**
Large scale population survey of antibodies to gliadin, reticulin and endomysium, **S5.4**
Low or negative anti-gliadin antibody may also indicate disease, **S5.4**
Measurement of duodenal mucosal protein synthesis in patients with coeliac disease, **S5.22**
Neurological complications of coeliac disease, **S5.4**
Prevalence, degree and pathophysiology of bone loss in adult coeliac disease, **S5.4**

- Celiac intestine**, Time-course of the immunological activation in treated celiac intestine after in vitro exposure to gliadin, **S5.45**
- Colecotomy**, Sub-total colectomy or segmental resection for malignant left-sided colonic obstruction, **S2.16**
- Colitis**
A really useful simple colitis activity index, **S5.29**
Prospective comparison of restorative proctocolectomy for indeterminate colitis versus ulcerative colitis, **S2.41**
- Collagenase**, TIMP-1 activity in lipocytes conditioned media predominates over collagenase even after TNF alpha stimulation, **S2.19**
- Colocolonic inhibitory reflex**, Adrenoceptors and the colocolonic inhibitory reflex, **S2.44**
- Colon, colonic**
Are there differences in colonic anatomy between men and women? **S2.39**
Basal electrogenic ion transport is inhibited by L-NAME in muscle-stripped but not intact rat colon *in vitro*, **S2.61**
Colonic pouches – motility may explain evacuatory difficulty, **S5.56**
Human colonic motility is unaffected by short chain fatty acids *in vivo*, **S2.25**
Hyperventilation increases colonic tone: is hypocapnia the key player? **S5.62**
Insulin-like growth factor binding protein production in normal and neoplastic colonic epithelium, **S2.2**
Luminal contents and human colonic motility, **S5.57**
Motor complex propagation across colonic anastomoses, **S5.56**
Na⁺ channel-specific mRNA is not sufficient for Na⁺ channel expression in rat colonic epithelium, **S2.61**
Proliferative activity in DMG-treated mouse colonic mucosa is enhanced by sulindac, **S2.30**
Regional colonic responses to standard stimuli, **S5.56**
Structurally weaker adherent colonic mucus gel barrier in ulcerative colitis, **S5.43**
- Colon cancer**
Cost effectiveness of colonoscopic screening of colon cancer families, **S2.26**
Dietary factors related to the low incidence of colon cancer in Africans, **S2.25**
Expression of EGFR and tumour rates in mouse adenocarcinoma of the colon, **S5.63**
Gastrin inhibits the growth of two gastrin receptor positive rat colon cancers, **S2.33**
Helicobacter pylori and colonic neoplasms, **S5.63**
IL-4 and IL-10 inhibit monocyte stimulated growth and motility on human colon cancer cells, **S5.72**
Insulin-like growth factor binding protein production in normal and neoplastic colonic epithelium, **S2.2**
New gastrin receptor antagonists, possible treatment for colon cancer, **S2.32**
Sub-total colectomy or segmental resection for malignant left-sided colonic obstruction, **S2.16**
- Colon J-pouch anal anastomosis**, Ambulatory manometry after colon J-pouch anal anastomosis: pouch motility may explain imperfections of continence, **S5.62**
- Colonic epithelial cells**
Colonic epithelial cell neutral endopeptidase is an important inactivator of f-met-leu-phe, **S5.42**
Hypoxia induces IL-8 production in colonic and hepatic epithelial cell lines, **S5.46**
Interleukin-13 enhances IL-1 α but not TNF- α -induced chemokine expression in human colonic epithelial cells, **S5.47**
Protection of colonic epithelial cells against oxidant damage by poly-ADP-ribose polymerase inhibitors, **S5.46**
- Colonocytes**, Anti-colonocyte and anti-tropomyosin serum antibodies in patients with ulcerative colitis, **S2.49**
- Colonoscopy**
A mannitol/Picolax mixture or two-dose polyethylene glycol lavage solution as bowel preparation for colonoscopy? **S2.39**
Cost effectiveness of colonoscopic screening of colon cancer families, **S2.26**
Could compliance with colonoscopic surveillance of ulcerative colitis be improved by patient education? **S2.59**
Early clinical experience with a real-time, 3-dimensional, electromagnetic imaging system to aid colonoscopy, **S2.25**
- Colorectal cancer**
Altered E-cadherin expression in colorectal tumorigenesis, *in-vivo* and *in-vitro* comparisons, **S2.2**
An employee targeted approach to bowel cancer prevention, **S5.32**
Aspirin and non-steroidal anti-inflammatory drug (NSAID) use and symptomatic colorectal cancer, **S2.1**
C-erbB-2 gene expression in non-metastatic colorectal cancer, **S2.31**
Cimetidine prevents postoperative suppression of immune function following colorectal cancer surgery, **S2.16**
Colorectal cancer surgery: is there a role for the nonspecialist? **S5.76**
Continuous hepatic artery floxuridine infusion prolongs overall and normal quality survival in colorectal liver metastasis patients, **S2.30**
Endoscopic laser palliation for colorectal cancer, **S2.24**
Estimated cost and resource implications of potential strategies for colorectal cancer screening in Scotland, **S2.26**
Fasting and meal-stimulated gastrin levels pre- and post-operatively in colorectal tumour patients, **S2.32**
Functional vitamin D₃ receptors are present in human colorectal neoplasms, **S5.39**
Haemoccult screening improves stage-specific survival from colorectal cancer, **S5.33**
In-vivo and *in-vitro* gene expression in colorectal tumorigenesis, **S2.2**
Increasing compliance with colorectal cancer screening: the development of effective health education, **S2.59**
Influence of one year calcium supplementation on colorectal epithelial cell proliferation in colorectal adenoma patients, **S2.31**
Interval cancers in a colorectal cancer screening programme, **S5.32**
L-arginine modulates T-lymphocyte function and inhibits adenocarcinoma growth in a rodent model of colorectal cancer, **S5.63**
Predicting survival in obstructing colorectal cancers, **S2.27**
Prognostic significance of retinoblastoma gene product expression in colorectal cancer, **S2.27**
Urokinase-type plasminogen activator (uPA) as a prognostic indicator in colorectal cancer, **S2.1**
Value of a negative flexible sigmoidoscopy as an indicator of low risk of colorectal cancer, **S5.32**
Vitamin D₃ and retinoid X receptor mRNAs are expressed in human colorectal mucosa and neoplasms, **S2.2**
- Colorectal carcinogenesis**, Gastrin receptor expression in chemically induced colorectal carcinogenesis, **S5.64**
- Common bile duct stones**
A direct comparison of laparoscopic ultrasound and laparoscopic cholangiography for detection of common bile duct stones, **S5.34**
Detection of common bile duct stones by intravenous cholangiography using meglumine iotroxate (Biliscopin) compared to endoscopic retrograde cholangiography, **S2.56**
Presentation and clinical and laboratory features of patients with common bile duct stones, **S2.56**
- Community**, Gastrointestinal and respiratory symptoms in the community, **S5.62**
- Constipation**
Controlled randomized trial of biofeedback versus muscle training alone for intractable constipation, **S2.43**
Does delayed gastric emptying recover after colectomy for idiopathic slow transit constipation? **S5.64**
Effect of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation, **S5.65**
Five year follow up of colectomy and ileorectal anastomosis for slow transit constipation with or without anismus, **S5.64**
Human rectocolonic inhibitory reflex – normal and constipated patients, **S2.28**
Idiopathic slow transit constipation – is there also an abnormality of gall bladder and gastric function? **S5.57**
Selective autonomic deficits in slow transit constipation, **S2.28**
- Contractions**, Abnormal contractile patterns identified in small bowel pathology, **S5.61**
- Copper**, Hepatic copper status in neonatal rats and effects of retrorsine, **S5.25**
- Coronary heart disease**, Relation of *Helicobacter pylori* infection and coronary heart disease, **S2.64**
- Cost effectiveness**
Cost effectiveness of colonoscopic screening of colon cancer families, **S2.26**
Estimated cost and resource implications of potential strategies for colorectal cancer screening in Scotland, **S2.26**
- Cripto-1**, A role for Cripto-1 (CR-1) in Barrett's tumorigenesis, **S2.6**
- Crohn's disease**
An audit of plasma vitamin B12 and folic acid monitoring in out-patients with Crohn's disease, **S5.77**
An open trial of anti-platelet therapy in active Crohn's disease using picotamide, a thromboxane antagonist, **S5.28**
Detection by polymerase chain reaction of *Mycobacterium paratuberculosis*-specific DNA in Crohn's disease tissues, **S2.42**
Enteral nutrition as primary therapy in Crohn's disease, **S1.55**
Familial Crohn's disease: no evidence for genetic linkage to the major histocompatibility complex, **S2.48**
Hyperbaric oxygenation in severe perineal Crohn's disease, **S5.44**
Increased L/M permeability index in a fraction of healthy relatives of Crohn's patients: a subclinical marker, **S5.29**
Intestinal permeability, **S1.18**
Long chain triglycerides adversely affect dietary treatment of active Crohn's disease, **S2.25**
Management of perianal Crohn's disease in 225 patients. Results of a multicentric study, **S5.44**
Monocyte numbers and activation in Crohn's disease: superoxide, lysozyme and cytokine production and the effect of elemental diet treatment, **S2.49**
Nutritional supplement with elemental diet as a steroid replacement in patients with steroid-dependent Crohn's disease, **S2.26**

- Positive benefit of selenium supplementation in Crohn's disease, **S2.26**
- Serum concentrations of interleukin-1 receptor antagonist are a marker of Crohn's disease activity, **S2.41**
- Soluble ICAM-1 in Crohn's disease: relationships with disease activity, inflammation and immune activation, **S2.42**
- Vapreotide (Octastatine, RC 160) in the treatment of acute Crohn's disease, **S5.72**
- Cryotherapy**, Cryotherapy with liver resection for the treatment of liver tumours, **S2.15**
- Cryptosporidium** sp., Polymerase chain reaction detection of *Cryptosporidium* sp. in human small intestine, **S5.37**
- Cystic fibrosis**
- Adverse hepato-pulmonary interaction in cystic fibrosis – a mechanism for increased mortality? **S2.9**
- Monitoring pancreatic enzyme supplements in children with cystic fibrosis using a mixed triglyceride breath test, **S5.34**
- Cytokines**
- Cytokine mRNA expression in coeliac disease after gliadin challenge, **S2.54**
- Cytokine profile in auto-immune liver diseases using the reverse haemolytic plaque assay, **S2.10**
- Hepatic expression of proinflammatory cytokines in needle liver biopsies detected using hot-start reverse transcriptase PCR, **S5.10**
- Immunoregulatory cytokine production by lamina propria mononuclear cells from patients with inflammatory bowel disease and controls, **S5.42**
- Monocyte numbers and activation in Crohn's disease: superoxide, lysozyme and cytokine production and the effect of elemental diet treatment, **S2.49**
- Soluble adhesion molecules and cytokines in autoimmune chronic active hepatitis, **S2.10**
- The peritoneal cytokine profile in acute peritonitis, **S5.46**
- Cytoskeletal modifying agents**, Effects of cytoskeletal modifying agents on cancer cell motility, **S5.64**
- Dark-blood (coffee grounds) haematemesis**, Does dark-blood (coffee grounds) haematemesis predict a good prognosis in upper gastrointestinal haemorrhage? **S5.59**
- Delorme's procedure**, Restoration of rectal function by the Delorme's procedure for rectal prolapse, **S2.61**
- Dental erosion**, The relationship between gastro-oesophageal reflux and palatal dental erosion, **S5.7**
- Dexamethasone**, Dexamethasone inhibits ulceration and promotes healing of experimental indomethacin-induced jejunal ulceration, **S5.44**
- Diarrhoea**
- An audit of rectal biopsy in the investigation of diarrhoea, **S5.60**
- Determinants of villus shortening in Zambian patients with HIV related diarrhoea, **S2.29**
- Diarrhoea, protein losing enteropathy and trace element deficiency in children following bone marrow transplantation, **S5.33**
- Intestinal proliferative response in intractable diarrhoea, **S5.74**
- Octreotide in the treatment of refractory diarrhoea and intestinal fistulae, **S3.5**
- Patients with diarrhoea-predominant irritable bowel syndrome have increased post-prandial plasma 5-hydroxytryptamine, **S2.53**
- Prospective, randomised, placebo-controlled trial of single dose ciprofloxacin for the treatment of travellers' diarrhoea, **S2.30**
- Dietary factors**, Dietary factors related to the low incidence of colon cancer in Africans, **S2.25**
- Dietary variables**, Bacterial translocation: the influence of dietary variables, **S1.23**
- Distension**, Motor and sensory responses of human small bowel to distension: the effect of rate, duration and length, **S2.44**
- Drugs**
- Efficacy of a new one week triple therapy regime in eradicating *Helicobacter pylori*, **S2.62**
- Prescription of ulcer healing drugs in medical inpatients: do patients know why they are taking them and are the prescriptions appropriate? **S2.58**
- Drugs, gastric retention**, Therapeutic implications of prolonged gastric retention of non-disintegrating oral dosage forms, **S5.55**
- Duodenal mucosal protein synthesis**, Measurement of duodenal mucosal protein synthesis in patients with coeliac disease, **S5.22**
- Duodenal mucosa**, Histological changes in duodenal mucosa produced by soluble mediators from gliadin sensitive T-cells, **S2.29**
- Duodenal ulcer (duodenal ulcer disease)**
- Chronic duodenal ulcer disease: a community based study of the economic and symptomatic benefits of *Helicobacter pylori* eradication, **S2.63**
- Duodenal ulcer relapse following successful *Helicobacter pylori* eradication, **S5.17**
- Effect of pantoprazole, as monotherapy and in combination with amoxicillin, on gastric *H. pylori* status, in duodenal ulcer subjects, **S2.63**
- Gastric juice epidermal growth factor in *Helicobacter pylori* associated gastritis and duodenal ulcer disease, **S2.33**
- H. pylori* eradication in the African setting: re-infection and duodenal ulcer recurrence, **S2.17**
- H. pylori* and impaired inhibitory control of gastric acid secretion in DU patients, **S2.4**
- H. pylori* lowers duodenal but not corpus somatostatin RNA, in DU patients, **S2.18**
- Helicobacter pylori* eradication vs maintenance therapy for the prevention of recurrent bleeding from duodenal ulcer, **S5.17**
- Interleukin-8 and tumour necrosis factor-alpha RNA in antral mucosa of duodenal ulcer patients, **S2.4**
- Omeprazole in maintenance therapy for duodenal ulcer: effect on gastrin and pepsinogen A and C basal serum levels, **S2.36**
- Secretion of epidermal growth factor by the stomach in response to histamine: a difference between duodenal ulcer and other subjects, **S2.36**
- Serum CagA IgG antibodies in *Helicobacter pylori* positive healthy volunteers and patients with dyspeptic disease, **S2.35**
- The predictive value of *Helicobacter pylori* negativity for duodenal ulcer recurrence, **S5.17**
- Duodenogastric reflux**, Effect of *Helicobacter pylori* eradication on duodenogastric reflux, **S5.3**
- Dyspepsia**
- A prospective trial of screening dyspepsia using *H. pylori* serology, **S5.2**
- Clinical value of *Helicobacter pylori* specific salivary IgG in dyspeptic patients, **S2.63**
- Effect of a selective 5HT3 antagonist ondansetron on symptoms in functional dyspepsia, **S2.37**
- Gastric emptying and intragastric distribution of low and high fat meals in functional dyspepsia patients, **S2.43**
- H. pylori* does not increase the incidence of dyspepsia associated with NSAID gastropathy, **S2.17**
- Helicobacter pylori* serology – audit of local assay and evaluation in screening dyspepsia under 45 years, **S5.74**
- NSAID dyspepsia: role of *H. pylori*, prostaglandins and enteric neurones, **S5.71**
- Peptic ulcer, dyspepsia and *Helicobacter pylori*: BSG members perspective and practice, **S2.48**
- Public education about dyspepsia and gastric cancer, **S2.17**
- Studies of gastric emptying and histology before and after the eradication of *Helicobacter pylori*, **S2.18**
- The Glasgow dyspepsia severity score – a new tool for measuring the clinical and personal impact of dyspepsia, **S5.2**
- "The sentient gut": enhanced visceral sensation in the oesophagus and rectum in functional dyspepsia, **S5.48**
- Dysphagia**
- A randomised comparison of percutaneous endoscopic gastrostomy feeding and nasogastric tube feeding following acute dysphagic stroke, **S5.6**
- Dysphagia and delay in treatment for oesophageal carcinoma, **S2.5**
- Mapping the cortical centres for swallowing in man: evidence for hemispheric dominance, **S5.11**
- The combination of laser treatment and intraluminal radiotherapy for malignant dysphagia, **S5.15**
- Electrically stimulated neoanal sphincter**, Detection of neoanal filling by bioelectrical impedance: an in vivo feasibility study, **S5.65**
- Electrogastrography**, Electrogastrography in chronic pseudo-obstruction, **S2.46**
- Electrogenic ion transport**, Basal electrogenic ion transport is inhibited by L-NAME in muscle-stripped but not intact rat colon *in vitro*, **S2.61**
- Electromagnetic imaging system**, Early clinical experience with a real-time, 3-dimensional, electromagnetic imaging system to aid colonoscopy, **S2.25**
- Elemental diet**
- Nutritional supplement with elemental diet as a steroid replacement in patients with steroid-dependent Crohn's disease, **S2.26**
- Protection from radiation injury by elemental diet: does added glutamine change the effect? **S1.60**
- ELISA**, Who gets false-negative *H. pylori* ELISA results? **S5.1**
- Endoluminal brush culture**, An endoluminal brush to detect the infected central venous catheter in situ in patients receiving intravenous nutrition, **S5.5**
- Endoluminal ultrasound**, Endoluminal ultrasound: accuracy and limitations in lymph node evaluation for oesophageal carcinoma, **S5.8**
- Endomysial antibodies**, Nuclear expression of anti endomysial antibodies, **S5.22**
- Endomysial antibodies**, Large scale population survey of antibodies to gliadin, reticulin and endomysium, **S5.4**
- Endoprostheses**, A prospective randomised trial of 10 and 11.5 FG endoprostheses in malignant bile duct obstruction, **S5.50**
- Endorobot**, An endorobot for gastrointestinal endoscopy, **S5.52**

- Endorphins**, Bleeding ulcer patients: a study on hormone profile, **S2.18**
- Endoscopes**, The use of ultra-thin endoscopes in gastroenterology, **S5.79**
- Endoscopic balloon sphincteroplasty**, Endoscopic balloon sphincteroplasty for bile duct stones: efficacy and follow-up in the first 90 patients, **S2.24**
- Endoscopic retrograde cholangiography**, Detection of common bile duct stones by intravenous cholangiography using meglumine iotroxate (Biliscopin) compared to endoscopic retrograde cholangiography, **S2.56**
- Endoscopic retrograde cholangiopancreatography**
Can a 2 hour post ERCP serum amylase estimation predict post ERCP acute pancreatitis? **S5.35**
Changes in blood pressure and duodenal atony during ERCP. Studies of the influence of buscopan and glucagon, **S5.50**
Day case transfer of in-patients for diagnostic and therapeutic ERCP: efficacy and safety, **S5.34**
Interval ERCP for gall stone pancreatitis prior to laparoscopic cholecystectomy, **S2.55**
Review of 1733 ERCP examinations performed in a single centre over five years, **S2.60**
Sublingual GTN spray improves success at ERCP cannulation, **S5.36**
The use of high frequency ultrasound miniprobe in routine ERCP, **S5.51**
- Endoscopic sphincterotomy**
Endoscopic sphincterotomy as sole definitive treatment for gallstone pancreatitis, **S2.56**
Endoscopic sphincterotomy in young patients, **S5.51**
Sphincterotomy for an empty duct? **S5.51**
- Endoscopic ultrasound**, Early experience of the use of endoscopic ultrasound in an upper G.I. surgical unit, **S2.5**
- Endoscopy**
Comparison of endoscopic mechanical and injection methods of hemostasis on mesenteric vessels, **S2.38**
Cutting threads at flexible endoscopy, **S5.80**
Endoscopic ampullectomy – a new approach to difficult cannulation, **S2.54**
Endoscopy in the Trent Region 1992, **S2.24**
Failures of endoscopic therapy for bleeding peptic ulcer; an analysis of risk factors, **S2.38**
Helicobacter pylori status, endoscopic findings and serology in HIV-1 seropositive patients, **S2.34**
Non-anxious patients prefer throat spray alone rather than IV sedation for upper endoscopy, **S2.37**
Observer variation in the assessment of stigmata of recent haemorrhage: a multicentre study by 13 skilled endoscopists, **S5.80**
Open access endoscopy: how is a developing service viewed by general practitioners? **S2.60**
Risk of post-operative death is high after failed endoscopic therapy for bleeding ulcer, **S5.26**
Sewing at flexible endoscopy in human gastrointestinal tract, **S2.40**
- Endothelial phenotypic markers**, Expression of adhesion molecules and endothelial phenotypic markers in human orthotopic liver transplantation, **S5.69**
- Endothelin**, [¹²⁵I] Endothelin-1 binding in normal human intestine and inflammatory bowel disease, **S2.50**
- Energy content**, Haemodynamic and neuroendocrine responses to feeding: relationship to energy content of a meal, **S5.5**
- Enteral nutrition**
Bacterial translocation: the influence of dietary variables, **S1.23**
Can arginine and ornithine support gut functions? **S1.42**
Clinical significance of translocation, **S1.28**
Dietary nucleotides and gut mucosal defence, **S1.46**
Effect of medium chain triglycerides (MCT) on jejunal mucosa mass and protein synthesis, **S1.39**
Effects of short chain fatty acids on gut morphology and function, **S1.35**
Enteral nutrition as primary therapy in Crohn's disease, **S1.55**
Enteral nutrition as primary therapy in short bowel syndrome, **S1.69**
Gut ischaemia, **S1.73**
Gut mucosal nutritional support – enteral nutrition as primary therapy after multiple system trauma, **S1.52**
Immunological functions of the gut in relation to nutritional state and mode of delivery of nutrients, **S1.10**
Intestinal absorptive function, **S1.5**
Intestinal permeability, **S1.18**
Introduction to Proceedings on Gut Mucosal Nutrition Support – Enteral nutrition as primary therapy? **S1.V**
Is enteral nutrition a primary therapy in cancer patients? **S1.65**
Maintenance of normal intestinal mucosa: function, structure, and adaptation, **S1.1**
Protection from radiation injury by elemental diet: does added glutamine change the effect? **S1.60**
Quantitative aspects of glucose and glutamine metabolism by intestinal cells, **S1.13**
Technical aspects of enteral nutrition, **S1.77**
- Enteric nervous system**, Doubts about nitric oxide as a neurotransmitter in the enteric nervous system, **S5.61**
- Enteropathy**, Dynamic studies of acute indomethacin induced enteropathy: rapid and sustained microvascular stasis, **S2.50**
- Eosinophil cationic protein**, Monoclonal antibodies against major basic protein (BMK-13) and eosinophil cationic protein (EG2) for quantifying eosinophils in human hepatic allograft rejection, **S2.14**
- Eosinophil infiltration**, Non-steroidal anti-inflammatory drug ingestion in humans is associated with increased eosinophil infiltration of duodenal mucosa, **S2.45**
- Eosinophilic gastroenteritis**, Interleukin-3, IL-5 and granulocyte-macrophage colony stimulating factor synthesis in the intestinal mucosa of patients with eosinophilic gastroenteritis, **S5.47**
- Epidermal growth factor**
Gastric juice epidermal growth factor in *Helicobacter pylori* associated gastritis and duodenal ulcer disease, **S2.33**
Secretion of epidermal growth factor by the stomach in response to histamine: a difference between duodenal ulcer and other subjects, **S2.36**
- Epidermal growth factor receptor**, Expression of EGFR and tumour rates in mouse adenocarcinoma of the colon, **S5.63**
- Epithelial cell proliferation**
Cell proliferation in the gastric corpus in *Helicobacter pylori* associated gastritis and the post-surgical stomach, **S2.34**
Eradication of *Helicobacter pylori* reduces gastric epithelial cell proliferation, **S2.33**
The influence of one year calcium supplementation on colorectal epithelial cell proliferation in colorectal adenoma patients, **S2.31**
- Epithelium**
Adenoviral mediated gene transfer to postnatal intestinal epithelium: gene expression *in vitro* and *in vivo*, **S2.51**
Does topography influence epithelial differentiation and digestive function in postnatal intestine? **S2.51**
Na⁺ channel-specific mRNA is not sufficient for Na⁺ channel expression in rat colonic epithelium, **S2.61**
- Escherichia coli**, Differential effect of 5HT₁ receptor antagonism on cholera toxin and *E. coli* heat labile toxin-induced secretion, **S2.52**
- Escherichia coli** infection, Enterocolitiform *Escherichia coli* infection *in vivo*, **S5.37**
- Ethnic differences**, Study into ethnic differences in Leicester of *Helicobacter pylori* in peptic ulcer disease, **S5.15**
- Evacuation proctography**, Imaging of rectal balloon expulsion compared with evacuation proctography, **S2.62**
- Expandable metal prostheses**, Palliation of oesophageal carcinoma with expandable metal prostheses is a cost-effective procedure, **S5.8**
- f-met-leu-phe**, Colonic epithelial cell neutral endopeptidase is an important inactivator of f-met-leu-phe, **S5.42**
- Faecal incontinence**
Biofeedback training for faecal incontinence: functional implications of vector volume analysis, **S5.32**
Faecal incontinence after severe traumatic sphincter rupture, **S2.16**
- Familial adenomatous polyposis**
Allelic heterogeneity in familial adenomatous polyposis: a family with mild phenotype and a mutation near the 5' end of the APC gene, **S2.31**
Audit of function, satisfaction and irritable bowel syndrome following restorative proctocolectomy for ulcerative colitis and familial adenomatous polyposis, **S5.27**
Germline APC mutation at codon 1061 is associated with severe duodenal polyposis but not high colonic polyp counts in familial adenomatous polyposis, **S5.40**
GST Mu1 polymorphism in familial adenomatous polyposis, **S5.63**
p53 overexpression is closely correlated with grade of duodenal neoplasm in familial adenomatous polyposis, **S5.39**
- Famotidine**, Prevention of NSAID-related gastric and duodenal ulcers by famotidine, **S2.45**
- Fasting**
Fasting may prevent indomethacin-induced jejunal ulceration in the rat by reducing enterohepatic cycling of drug, **S2.38**
Fasting and meal-stimulated gastrin levels pre- and post-operatively in colorectal tumour patients, **S2.32**
- Fatty acids**, Omega-3 and omega-6 fatty acids upregulate IL-6-stimulated hepatocyte acute phase protein production *in vitro*, **S5.10**
- Fenfluramine**, *D*-Fenfluramine administration is not associated with an increase in plasma cholecystokinin, **S2.57**
- Fetal mortality**, Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid, **S2.12**
- Fibresigmoidoscope**, Examining the unprepared bowel with the 60cm fibresigmoidoscope – our flexible friend in outpatients, **S5.35**
- Fibrinogen**, Fibrinogen concentration in oesophageal cancer, **S5.14**
- Fibroblast growth factor**
Localization of basic fibroblast growth factor in gastric ulcers, **S5.49**
Low basic fibroblast growth factor levels in intact mucosa of gastric ulcer patients: evidence for a constitutional deficiency, **S5.50**

- Fistula-in-ano**, Mucosal advancement flap in the treatment of fistula-in-ano, S5.65
- FK506 conversion therapy**, Experience with FK506 conversion therapy for liver allograft rejection in children, S2.21
- Floxuridine**, Continuous hepatic artery floxuridine infusion prolongs overall and normal quality survival in colorectal liver metastasis patients, S2.30
- Free radicals**, Determinants for gastric intestinal metaplasia: the role of free radicals, S5.50
- Gallbladder**
Meal-stimulated gallbladder emptying in acromegaly. The effect of octreotide treatment, S2.57
Polypoid lesions of gallbladder, S2.56
- Gallbladder acidification**, Gallbladder acidification and bile pH: differences between male and female in the bovine gallbladder model, S5.66
- Gallbladder bile**, The fibrinolytic activity of normal and calculous gall bladder bile, S5.66
- Gallbladder stones**
Gallbladder stone (GBS) recurrence after medical dissolution: do GBS recur true to type? S2.57
The role of intestinal transit in the pathogenesis of octreotide-induced gallbladder stones, S2.57
- Gallstone pancreatitis**
Endoscopic sphincterotomy as sole definitive treatment for gallstone pancreatitis, S2.56
Interval ERCP for gall stone pancreatitis prior to laparoscopic cholecystectomy, S2.55
- Gastrectomy**, Motility change and perception to balloon distension in the jejunal loop of postgastrectomy patients, S2.44
- Gastric acid secretion**
Gastric acid secretion and serum gastrin concentration in cirrhotic patients with *Helicobacter pylori* infection, S5.67
Marked rebound acid hypersecretion following treatment with ranitidine, S2.36
Sucralfate suppresses *H. pylori* infection and reduces gastric acid secretion by 50% in DU patients, S2.35
- Gastric cancer**
Effect of *Helicobacter pylori* eradication on precancerous lesions of the stomach, S2.33
Gastric cancer presenting with uncomplicated dyspepsia is rare and not worth screening for below the age of 55, S2.24
Helicobacter pylori infection alone does not predispose to gastric cancer, S5.73
Public education about dyspepsia and gastric cancer, S2.17
Significant delays in the diagnosis of gastric cancer: a cause for concern? S5.3
- Gastric emptying**
Do alterations in the rate of gastric emptying contribute to the pathogenesis of portal hypertensive gastropathy? S2.13
Does delayed gastric emptying recover after colectomy for idiopathic slow transit constipation? S5.64
Gastric emptying, motility and flow measured by echo planar magnetic resonance imaging, S2.46
Gastric emptying and intragastric distribution of low and high fat meals in functional dyspepsia patients, S2.43
Gastric emptying of a solid meal is accelerated by the removal of fibre naturally present in food, S5.55
Gastric emptying of solid meal in patients with gastro-oesophageal reflux, S5.13
Omeprazole markedly delays gastric emptying, S5.48
Studies of gastric emptying and histology before and after the eradication of *Helicobacter pylori*, S2.18
Therapeutic implications of prolonged gastric retention of non-disintegrating oral dosage forms, S5.55
- Gastric juice**, Swallowed saliva in gastric juice, S5.49
- Gastric lymphoma**, Primary gastric lymphoma in Nottinghamshire 1973-1992, S2.1
- Gastric metaplasia**, Determinants for gastric intestinal metaplasia: the role of free radicals, S5.50
- Gastric metaplasia of the duodenal bulb**, The relationship between gastric acid output and gastric metaplasia of the duodenal bulb, S5.49
- Gastric mucosa**, Gastric mucosal damage and adaptation occurs with enteric coated NSAIDs in man, S2.37
- Gastric mucosal changes**, 8 year quantitative follow-up of gastric mucosal changes related to *Helicobacter pylori* infection, S5.42
- Gastric retention**, Therapeutic implications of prolonged gastric retention of non-disintegrating oral dosage forms, S5.55
- Gastric secretion**, Effect of *Helicobacter pylori* on maximal gastric secretion stimulated with histamine, S2.18
- Gastric ulcer**
Bleeding gastric ulcer in the H2RA era, S2.17
Long term outcome of medical management of gastric ulcer, S2.16
Low basic fibroblast growth factor levels in intact mucosa of gastric ulcer patients: evidence for a constitutional deficiency, S5.50
- Gastrin**
Fasting and meal-stimulated gastrin levels pre- and post-operatively in colorectal tumour patients, S2.32
Gastrimmune inhibits the growth of two gastrin receptor positive rat colon cancers, S2.33
Histology, IGG, IGA, IGM to *Helicobacter pylori*, serum pepsinogen I and gastrin in asymptomatic blood donors, S5.18
New gastrin receptor antagonists, possible treatment for colon cancer, S2.32
Omeprazole in maintenance therapy for duodenal ulcer: effect on gastrin and pepsinogen A and C basal serum levels, S2.36
- Gastrin receptor expression**, Gastrin receptor expression in chemically induced colorectal carcinogenesis, S5.64
- Gastrin receptors**, Development of an assay to detect gastrin receptors in gastrointestinal tumours, S5.73
- Gastritis**
Cell proliferation in the gastric corpus in *Helicobacter pylori* associated gastritis and the post-surgical stomach, S2.34
Cell proliferation in *Helicobacter pylori* associated gastritis and the long term effect of eradication therapy, S2.4
Gastric juice epidermal growth factor in *Helicobacter pylori* associated gastritis and duodenal ulcer disease, S2.33
- Gastro-oesophageal reflux**
Gastric emptying of solid meal in patients with gastro-oesophageal reflux, S5.13
Gastroplasty at flexible endoscopy for gastro-oesophageal reflux disease, S2.23
Investigation of gastro-oesophageal reflux and acid secretion in patients unresponsive to therapeutic doses of omeprazole, S5.12
Is defective acid clearance important in severe gastro-oesophageal reflux disease? S2.5
Presence of a catheter through lower oesophageal sphincter does not promote gastro-oesophageal reflux, S2.7
Symptoms are questionable indicators of the severity of gastro-oesophageal reflux post fundoplication, S2.7
The relationship between gastro-oesophageal reflux and palatal dental erosion, S5.7
Tussive effect of capsaicin in symptomatic gastroesophageal refluxers without cough, S5.12
Understanding the patho-physiology of gastro-oesophageal reflux using a new dynamic model, S5.6
- Gastro-pancreatic secretion**, The effect of malnutrition, and intensive nutritional support on total body protein synthesis and gastro-pancreatic secretion, S2.53
- Gastrointestinal symptoms**, Gastrointestinal and respiratory symptoms in the community, S5.62
- Gastrointestinal tract**, Sewing at flexible endoscopy in human gastrointestinal tract, S2.40
- Gastrointestinal tumours**, Development of an assay to detect gastrin receptors in gastrointestinal tumours, S5.73
- General practitioner run endoscopy**
Endoscopy in general practice: one year's experience, S5.79
Is there a place for a GP run community based endoscopy unit, S5.78
Open access endoscopy: satisfying general practitioners and reassuring patients, but increasing hospital workload, S5.78
Open access endoscopy: how is a developing service viewed by general practitioners? S2.60
Why does a GP refer to clinic if open access gastroscopy is available? S5.78
- Genetic predisposition**, Genetic predisposition to ulcerative colitis: a detailed study of the HLA region by linkage analysis, S5.30
- Giardia lamblia**
DNA fingerprinting of *Giardia lamblia* with human minisatellites 33.6 and 33.15, S2.51
Stimulation of gut ornithine decarboxylase activity by *Giardia lamblia* in vivo, S5.40
The role of the cytoskeleton in *Giardia*-stimulated ornithine decarboxylase activity, S5.41
- Gliadin**
Large scale population survey of antibodies to gliadin, reticulin and endomysium, S5.4
Recruitment of mucosal mononuclear cells in the subepithelial and interepithelial compartments after in vitro exposure to gliadin peptides of the treated celiac intestine: evidence for a local immune response to gliadin, S5.46
Time-course of the immunological activation in treated celiac intestine after in vitro exposure to gliadin, S5.45
- Gliadin challenge**, Cytokine mRNA expression in coeliac disease after gliadin challenge, S2.54
- Gliadin sensitive T-cells**, Histological changes in duodenal mucosa produced by soluble mediators from gliadin sensitive T-cells, S2.29
- Glucagon**, Changes in blood pressure and duodenal atony during ERCP. Studies of the influence of buscopan and glucagon, S5.50
- Glucose**
Effect of glucose polymer chain lengths in oral rehydration solutions: studies in secreting rat intestine, S5.70
Quantitative aspects of glucose and glutamine metabolism by intestinal cells, S1.13

Glutamine

- Protection from radiation injury by elemental diet: does added glutamine change the effect? **S1.60**
- Quantitative aspects of glucose and glutamine metabolism by intestinal cells, **S1.13**
- Gluten challenge**, A comparative, prospective study of rectal gluten challenge in the diagnosis of gluten-sensitivity, **S2.29**
- Gluten free diet**, Effect of a gluten free diet on bone density in coeliac disease, **S5.5**
- Gluten peptides**, *In vitro* coeliac toxicity of gluten peptides assessed by organ culture, **S5.21**
- Glyceril trinitrate**, Sublingual GTN spray improves success at ERCP cannulation, **S5.36**
- Granulocyte-macrophage CSF**, Interleukin-3, IL-5 and granulocyte-macrophage colony stimulating factor synthesis in the intestinal mucosa of patients with eosinophilic gastroenteritis, **S5.47**
- GST Mu1 genetic polymorphism**, GST Mu1 polymorphism in familial adenomatous polyposis, **S5.63**
- Gut ischaemia**, Gut ischaemia, **S1.73**
- Gut mucosal defence**, Dietary nucleotides and gut mucosal defence, **S1.46**
- Gut mucosal nutritional support**
- Gut mucosal nutritional support – enteral nutrition as primary therapy after multiple system trauma, **S1.52**
- Proceedings of the Abbott Ross Research Conference, Vevey, Switzerland, June 1992, **S1.1-80**

H₂-antagonists, Repeat prescribing of H₂-antagonists in general practice – prevalence and underlying diagnosis, **S5.58**

H₂-receptor antagonists, Low-dose H₂-receptor antagonists as single post-prandial doses: a placebo-controlled comparative study of overnight pH, **S5.58**

Haematological malignancies, Significant transfusional iron overload during treatment of haematological malignancies, **S5.25**

Haemoccult screening, Haemoccult screening improves stage-specific survival from colorectal cancer, **S5.33**

Haemochromatosis, HLA-G polymorphism in hereditary haemochromatosis, **S2.11**

Haemostasis, Comparison of endoscopic mechanical and injection methods of hemostasis on mesenteric vessels, **S2.38**

Heater probe therapy, Push enteroscopy and heater probe therapy for small bowel bleeding, **S5.36**

Height, Association of *H. pylori* with diminished adult height, **S2.4**

Helicobacter pylori

8 year quantitative follow-up of gastric mucosal changes related to *Helicobacter pylori* infection, **S5.42**

A new rapid whole blood test for *Helicobacter pylori* antibodies could reduce diagnostic oesophago-gastro-duodenoscopy (OGD) in patients with dyspepsia, **S5.1**

A prospective trial of screening dyspepsia using *H. pylori* serology, **S5.2**

A simple 3 minute latex agglutination test for rapid *H. pylori* serodiagnosis, **S5.1**

A successful one week antibiotic regime for *Helicobacter pylori* eradication, **S5.16**

Acquisition of *H. pylori* infection in British children: community factors or family circumstances? **S2.64**

An animal model of *Helicobacter pylori* infection, **S5.19**

Association of *H. pylori* with diminished adult height, **S2.4**

Audit of *H. pylori* eradication by C14 urea breath tests, **S5.75**

Azithromycin in a triple therapy for eradicating *Helicobacter pylori*, **S2.63**

Cell proliferation in the gastric corpus in *Helicobacter pylori* associated gastritis and the post-surgical stomach, **S2.34**

Cell proliferation in *Helicobacter pylori* associated gastritis and the long term effect of eradication therapy, **S2.4**

Chronic duodenal ulcer disease: a community based study of the economic and symptomatic benefits of *Helicobacter pylori* eradication, **S2.63**

Clarithromycin for the cure of *Helicobacter pylori* infection, **S5.16**

Clinical value of *Helicobacter pylori* specific salivary IgG in dyspeptic patients, **S2.63**

Comparison of serum and salivary immunoassays for *Helicobacter pylori*, **S5.15**

Detection of CagA positive *Helicobacter pylori*: a comparison of polymerase chain reaction and immunoblotting protocols, **S2.34**

Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating *Helicobacter pylori*, **S5.16**

Does *Helicobacter pylori* infection affect growth in children? **S2.64**

Duodenal ulcer relapse following successful *Helicobacter pylori* eradication, **S5.17**

Early serological assessment of *Helicobacter pylori* eradication, **S2.3**

Effect of *Helicobacter pylori* eradication on duodenogastric reflux, **S5.3**

Effect of *Helicobacter pylori* eradication on precancerous lesions of the stomach, **S2.33**

Effect of *Helicobacter pylori* on maximal gastric secretion stimulated with histamine, **S2.18**

Effect of pantoprazole, as monotherapy and in combination with amoxicillin, on gastric *H. pylori* status, in duodenal ulcer subjects, **S2.63**

Efficacy of a new one week triple therapy regime in eradicating *Helicobacter pylori*, **S2.62**

Eradication of *Helicobacter pylori* with lansoprazole and clarithromycin, **S5.15**

Eradication of *Helicobacter pylori* reduces gastric epithelial cell proliferation, **S2.33**

Gastric acid secretion and serum gastrin concentration in cirrhotic patients with *Helicobacter pylori* infection, **S5.67**

Gastric juice epidermal growth factor in *Helicobacter pylori* associated gastritis and duodenal ulcer disease, **S2.33**

Glucose and urea: sources of carbon for *H. pylori*? **S5.17**

H. pylori does not increase the incidence of dyspepsia associated with NSAID gastropathy, **S2.17**

H. pylori eradication in the African setting: re-infection and duodenal ulcer recurrence, **S2.17**

H. pylori and impaired inhibitory control of gastric acid secretion in DU patients, **S2.4**

H. pylori impairs acid-inhibition of peptone-stimulated acid secretion, **S5.18**

H. pylori lowers duodenal but not corpus somatostatin RNA, in DU patients, **S2.18**

Helicobacter infection is associated with oesophagitis in patients with Barrett's oesophagus, **S2.5**

Helicobacter pylori and colonic neoplasms, **S5.63**

Helicobacter pylori eradication therapy. A comparison between either omeprazole or ranitidine in combination with amoxicillin plus metronidazole, **S5.16**

Helicobacter pylori eradication vs maintenance therapy for the prevention of recurrent bleeding from duodenal ulcer, **S5.17**

Helicobacter pylori growth is inhibited by uptake and incorporation of linoleic acid, **S5.18**

Helicobacter pylori induced gastric epithelial interleukin-8 secretion is associated with the CagA positive phenotype, **S2.34**

Helicobacter pylori infection alone does not predispose to gastric cancer, **S5.73**

Helicobacter pylori serology – audit of local assay and evaluation in screening dyspepsia under 45 years, **S5.74**

Helicobacter pylori status, endoscopic findings and serology in HIV-1 seropositive patients, **S2.34**

Histology, IGG, IGA, IGM to *Helicobacter pylori*, serum pepsinogen I and gastrin in asymptomatic blood donors, **S5.18**

HLA class II type and *H. pylori*-induced gastric atrophy, **S5.45**

Increased interleukin-8 mRNA in gastric epithelial cells of patients with *Helicobacter pylori* infection: detection using a novel quantitative chemiluminescent assay for PCR products, **S5.18**

Increased local production of IL-8 and TNF in patients with *H. pylori* infection, **S2.35**

Inhibition of *Helicobacter pylori* cytotoxin by omeprazole, **S5.37**

Intrafamilial clustering of *Helicobacter pylori* strains and correlation of virulence with disease activity, **S5.1**

Isolation of *Helicobacter pylori* in faeces from patients in the UK, confirmation of culture, **S2.3**

NSAID dyspepsia: role of *H. pylori*, prostaglandins and enteric neurones, **S5.71**

Omeprazole can inhibit cell vacuolation in Vero cells induced by culture supernatants of *Helicobacter pylori*, **S2.35**

Peptic ulcer, dyspepsia and *Helicobacter pylori*: BSG members perspective and practice, **S2.48**

Persistent excretion of *Helicobacter pylori* in faeces after gastric eradication, **S2.3**

Reactive oxygen species damage in *H. pylori* gastritis, **S5.3**

Reinfection or recrudescence of *Helicobacter pylori* infection, **S2.3**

Relation of *Helicobacter pylori* infection and coronary heart disease, **S2.64**

Relative role of cytotoxin and urease of *Helicobacter pylori* in cell vacuolation of cultured Vero cells, **S2.36**

Studies of gastric emptying and histology before and after the eradication of *Helicobacter pylori*, **S2.18**

Study into ethnic differences in Leicester of *Helicobacter pylori* in peptic ulcer disease, **S5.15**

Sucralfate suppresses *H. pylori* infection and reduces gastric acid secretion by 50% in DU patients, **S2.35**

Survival of *Helicobacter pylori* in animal models, **S5.19**

The effect of *Helicobacter pylori* eradication on the well-being of patients with peptic ulcer, **S5.2**

The predictive value of *Helicobacter pylori* negativity for duodenal ulcer recurrence, **S5.17**

The prevalence of parietal cells in the duodenum and their relationship to *Helicobacter pylori* infection, **S5.3**

Treatment of *Helicobacter pylori* infection – relationship between initial eradication rate and the observed 're-infection' rate six months post treatment, **S5.2**

Who gets false-negative *H. pylori* ELISA results? **S5.1**

Hepatic ³¹P MRS, Hepatic ³¹P MRS in chronic graft rejection, **S5.25**

Hepatic artery

ATP dilates the hepatic artery via P₁-purinoceptors, **S2.9**

Continuous hepatic artery floxuridine infusion prolongs overall and normal quality survival in colorectal liver metastasis patients, **S2.30**

Hepatic carcinoma, Imaging of secondary carcinoid tumours of the liver: comparison of I¹²⁵-metaiodobenzylguanidine and IN¹¹¹-labelled octreotide scans, **S2.32**

Hepatic encephalopathy, Proton MRS in chronic hepatic encephalopathy, **S5.24**

Hepatic epithelial cell lines, Hypoxia induces IL-8 production in colonic and hepatic epithelial cell lines, **S5.46**

Hepatic failure, Autonomic dysfunction in fulminant hepatic failure, **S5.68**

Hepatitis

Hepatocellular carcinoma in auto-immune chronic active hepatitis: the role of hepatitis C infection, **S2.19**

Soluble adhesion molecules and cytokines in autoimmune chronic active hepatitis, **S2.10**

Hepatitis A, Salivary immunoglobulins as diagnostic markers of previous hepatitis A infection, **S2.11**

Hepatitis B

Do health service guidelines for hepatitis B vaccination work? **S5.76**

Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B, **S2.12**

Hepatitis C

Chronic hepatitis C and ursodeoxycholic acid treatment. Are HCV genotypes important? **S5.69**

Hepatitis C virus infection in acute liver diseases from a North Indian hospital, **S5.68**

Recognition of hepatitis C complicating alcoholic liver disease, **S2.11**

Serotypic variation and clinical characteristics of chronic hepatitis C detected at blood donor screening, **S2.19**

Serum and tissue vascular adhesion molecules in hepatitis C, **S5.68**

The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland, **S5.40**

Hepato-pulmonary interaction, Adverse hepato-pulmonary interaction in cystic fibrosis – a mechanism for increased mortality? **S2.9**

Hepatocarcinogenesis, Mice with homozygous disruption of the MDR2 P-glycoprotein gene; an animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis, **S5.9**

Hepatocellular carcinoma

Hepatocellular carcinoma in auto-immune chronic active hepatitis: the role of hepatitis C infection, **S2.19**

Survival and side effects after transcatheter arterial chemoembolization in hepatocellular carcinoma, **S5.72**

Treatment of hepatocellular carcinoma with somatostatin, **S5.72**

Hepatocellular cholangiocarcinoma, p53 mutation in mixed hepatocellular cholangiocarcinoma, **S5.38**

Hepatocyte growth factor gene, Transfection of the HGF gene into an immortal liver epithelial cell line markedly slows growth, **S5.60**

Hepatocyte proliferation, Is the storage of retinoids in the liver important to hepatocyte proliferation, **S5.74**

Hepatocyte regeneration, IL-1 is a major contributor to the control of hepatocyte regeneration after partial hepatectomy, **S5.74**

Hepatorenal reflex, Reduction in renal blood flow with acute increase in the portal pressure gradient. Evidence for the existence of hepatorenal reflex in man? **S5.9**

Hepatotoxicity, The need for audit: preventable deaths due to hepatotoxicity of anti-tuberculous chemotherapy, **S5.77**

HIDA scanning, HIDA scanning for detecting early biliary complications of orthotopic liver transplantation, **S2.55**

Hindgut dysmotility, The pathophysiology of hindgut dysmotility – a failure to generate high pressure waves, **S2.62**

Histamine, Secretion of epidermal growth factor by the stomach in response to histamine: a difference between duodenal ulcer and other subjects, **S2.36**

Histoacryl, Bleeding peptic ulcer: injection of adrenaline or tissue adhesive (histoacryl), **S5.36**

HIV, *Helicobacter pylori* status, endoscopic findings and serology in HIV-1 seropositive patients, **S2.34**

HIV infection, Faecal tumour necrosis factor-alpha and faecal alpha-one-antitrypsin in HIV infection, **S5.40**

HIV-1 RNA, Identification of HIV-1 RNA in intestinal tissue, **S5.37**

HLA

HLA-class II phenotypes in coeliac disease and enteropathy-associated T-cell lymphoma, **S2.53**

HLA class II type and *H. pylori*-induced gastric atrophy, **S5.45**

HLA-G polymorphism in hereditary haemochromatosis, **S2.11**

Home parenteral nutrition, An ongoing audit of home parenteral nutrition: monitoring the effects of change on the incidence of complications, **S2.58**

5-Hydroxytryptamine

Cholera toxin stimulates 5-hydroxytryptamine release into human jejunum, **S5.54**

Differential effect of 5HT₂ receptor antagonism on cholera toxin and *E. coli* heat labile toxin-induced secretion, **S2.52**

Effect of a selective 5HT₂ antagonist ondansetron on symptoms in functional dyspepsia, **S2.37**

Increased blood levels of 5-hydroxytryptamine in coeliac disease, **S5.22**

Patients with diarrhoea-predominant irritable bowel syndrome have increased post-prandial plasma 5-hydroxytryptamine, **S2.53**

Tissue 5-hydroxytryptamine content in rat small intestine in absorptive and secretory states, **S5.54**

Hyoscine-n-butyl bromide, Intravenous hyoscine-n-butyl bromide and inhaled nitrous oxide/oxygen mixture improve the quality of flexible sigmoidoscopy, **S5.80**

Hyperbaric oxygenation, Hyperbaric oxygenation in severe perineal Crohn's disease, **S5.44**

Hypermanganaemia, Paediatric TPN and hypermanganaemia, **S5.33**

Hyperventilation, Hyperventilation increases colonic tone: is hypocapnia the key player? **S5.62**

Hypnotherapy, Hypnotherapy: effect on quality of life and economic consequences of irritable bowel syndrome, **S5.58**

Ileoanal pouch

Factors associated with functional outcome in ileoanal pouch construction for ulcerative colitis, **S5.27**

How long does a pouch live – causes of pouch failure and life expectancy of the ileoanal pouch, **S5.27**

Imaging, Imaging of secondary carcinoid tumours of the liver: comparison of I¹²⁵-metaiodobenzylguanidine and IN¹¹¹-labelled octreotide scans, **S2.32**

Immunoglobulins, Histology, IGG, IGA, IGM to *Helicobacter pylori*, serum pepsinogen I and gastrin in asymptomatic blood donors, **S5.18**

Immunogold electron microscopy, Confirmation of persistent measles virus infection of intestinal tissue by immunogold electron microscopy, **S5.41**

Immunology, gut, Immunological functions of the gut in relation to nutritional state and mode of delivery of nutrients, **S1.10**

¹¹¹In chloride-transferring scanning, ¹¹¹In chloride-transferrin scanning for detection and quantification of protein losing enteropathy, **S5.19**

Indomethacin

Dexamethasone inhibits ulceration and promotes healing of experimental indomethacin-induced jejunal ulceration, **S5.44**

Dynamic studies of acute indomethacin induced enteropathy: rapid and sustained microvascular stasis, **S2.50**

Fasting may prevent indomethacin-induced jejunal ulceration in the rat by reducing enterohepatic cycling of drug, **S2.38**

Morphological and biochemical changes in the rat intestine in response to chronic indomethacin, **S2.43**

Inflammatory bowel disease

[¹²⁵I] Endothelin-1 binding in normal human intestine and inflammatory bowel disease, **S2.50**

Anti-neutrophil antibodies in familial inflammatory bowel disease: specificity for ulcerative colitis but not Crohn's disease in genetically related individuals, **S2.42**

Appendectomy, tonsillectomy and inflammatory bowel disease, **S5.28**

Audit of education and work record of Scottish children with inflammatory bowel disease, **S2.59**

Childhood risk factors for inflammatory bowel disease, including measles infections, **S2.40**

Immunoregulatory cytokine production by lamina propria mononuclear cells from patients with inflammatory bowel disease and controls, **S5.42**

Inherited coagulopathies protect against inflammatory bowel disease, **S5.28**

Monitoring of growth and development variables in children with inflammatory bowel disease, **S5.77**

Morbidity and treatment in Scottish children with IBD – a comparison of two cohorts from '68-'83 and '84-'88, **S5.78**

Outpatient review for inflammatory bowel disease: a valuable exercise? **S2.48**

Quantification of interleukin-8 mRNA using reverse transcription-PCR technique in inflammatory bowel disease and in irritable bowel syndrome, **S5.43**

Reduced expression of neutrophil neutral endopeptidase in inflammatory bowel disease, **S2.49**

Specificity and significance of ANCA in inflammatory bowel disease, **S2.49**

Stimulus to neutrophil migration into the gut lumen in IBD, **S5.43**

Survey of information received by patients about inflammatory bowel disease, **S2.59**

Urinary nitrite dipstick: a reliable disease activity marker in inflammatory bowel disease, **S2.41**

Inflammatory mediator production, Interleukin 10 inhibits inflammatory mediator production in ulcerative colitis, **S2.48**

- Insulin-like growth factor**, Insulin-like growth factor binding protein production in normal and neoplastic colonic epithelium, S2.2
- Integrins**, Integrins and migration of oesophageal keratinocytes, S2.31
- Intensive sclerotherapy**, Intensive sclerotherapy does not prevent recurrence of oesophageal varices, S5.23
- Intercellular adhesion molecule-1**
Clinical significance of soluble intercellular adhesion molecule-1 in chronic liver disease, S2.20
Soluble ICAM-1 in Crohn's disease: relationships with disease activity, inflammation and immune activation, S2.42
- Interferon-gamma**
Cytokine profile in auto-immune liver diseases using the reverse haemolytic plaque assay, S2.10
Expression of interferon-gamma, tumour necrosis factor-alpha and interleukins-6 and -2 in pouchitis mucosa, S2.40
- Interleukin-1**
IL-1 is a major contributor to the control of hepatocyte regeneration after partial hepatectomy, S5.74
Serum concentrations of interleukin-1 receptor antagonist are a marker of Crohn's disease activity, S2.41
- Interleukin-2**
Cytokine profile in auto-immune liver diseases using the reverse haemolytic plaque assay, S2.10
Expression of interferon-gamma, tumour necrosis factor-alpha and interleukins-6 and -2 in pouchitis mucosa, S2.40
- Interleukin-3**, Interleukin-3, IL-5 and granulocyte-macrophage colony stimulating factor synthesis in the intestinal mucosa of patients with eosinophilic gastroenteritis, S5.47
- Interleukin-4**, IL-4 and IL-10 inhibit monocyte stimulated growth and motility on human colon cancer cells, S5.72
- Interleukin-4 mRNA**, Upregulation of interleukin 4 mRNA in inflamed intestinal mucosa. Is this increase real or apparent? S5.30
- Interleukin-6**
Expression of interferon-gamma, tumour necrosis factor-alpha and interleukins-6 and -2 in pouchitis mucosa, S2.40
IL-8 and IL-6 are produced constitutively by human pancreatic cancer cell lines, S5.39
Supplemental taurine reduces plasma IL-6 concentrations but enhances pulmonary neutrophil sequestration in rodent intraperitoneal sepsis, S2.60
- Interleukin-8**
Down-regulation of interleukin-8 production from peripheral blood mononuclear cells from patients with acute pancreatitis by IL-4 and IL-10, S5.45
Helicobacter pylori induced gastric epithelial interleukin-8 secretion is associated with the CagA positive phenotype, S2.34
Hypoxia induces IL-8 production in colonic and hepatic epithelial cell lines, S5.46
IL-8 and IL-6 are produced constitutively by human pancreatic cancer cell lines, S5.39
Increased local production of IL-8 and TNF in patients with *H. pylori* infection, S2.35
Interleukin-8 and tumour necrosis factor-alpha RNA in antral mucosa of duodenal ulcer patients, S2.4
Titres of serum IL-8 correlate with the presence of an acute phase response in patients with pancreatic cancer, S5.73
- Interleukin-8 mRNA**
Increased interleukin-8 mRNA in gastric epithelial cells of patients with *Helicobacter pylori* infection: detection using a novel quantitative chemiluminescent assay for PCR products, S5.18
Quantification of interleukin-8 mRNA using reverse transcription-PCR technique in inflammatory bowel disease and in irritable bowel syndrome, S5.43
- Interleukin-10**, Interleukin 10 inhibits inflammatory mediator production in ulcerative colitis, S2.48
- Interleukin-13**, Interleukin-13 enhances IL-1 α but not TNF- α -induced chemokine expression in human colonic epithelial cells, S5.47
- Intestinal absorptive function**, Intestinal absorptive function, S1.5
- Intestinal cells**, Quantitative aspects of glucose and glutamine metabolism by intestinal cells, S1.13
- Intestinal epithelial cells**, Cellular responses of intestinal epithelial cells to toxin A of *C. difficile*, S5.38
- Intestinal fistulae**, Octreotide in the treatment of refractory diarrhoea and intestinal fistulae, S3.5
- Intestinal mucosa**, Maintenance of normal intestinal mucosa: function, structure, and adaptation, S1.1
- Intestinal proliferative response**, Intestinal proliferative response in intractable diarrhoea, S5.74
- Intraluminal irradiation**, High-dose rate intraluminal irradiation for esophageal cancer in clinical practice, S2.7
- Intrathoracic stomach**, Gastric fundal tone and perception of the intrathoracic stomach after radical oesophagectomy, S5.27
- Intravenous nutrition**, An endoluminal brush to detect the infected central venous catheter in situ in patients receiving intravenous nutrition, S5.5
- Inulin**, Inulin is a better probe than lactulose for the measurement of oro-caecal transit time, S5.19
- Iron-deficiency anaemia**, Audit of the investigation and outcome of iron-deficiency anaemia in one health district, S2.47
- Iron overload**, Significant transfusional iron overload during treatment of haematological malignancies, S5.25
- Iron transfer**
Enhanced intestinal iron transfer in 2-3 day streptozotocin-diabetic rats, S5.21
Increased iron transfer in overnight fasted rats, S2.52
- Irritable bowel syndrome**
Altered bladder function and oesophageal pain threshold in irritable bowel syndrome, S2.21
Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome, S5.57
Effect of acute stress on ano-rectal physiology in patients with irritable bowel syndrome, S5.62
Enhanced sensitivity at both ends of the gut in patients with irritable bowel syndrome, S2.47
Fed state motor abnormalities in irritable bowel syndrome, S2.46
Hypnotherapy: effect on quality of life and economic consequences of irritable bowel syndrome, S5.58
Natural history of bowel symptom reports in consulters and non-consulters with irritable bowel syndrome, S5.57
Patients with diarrhoea-predominant irritable bowel syndrome have increased post-prandial plasma 5-hydroxytryptamine, S2.53
Prevalence of irritable bowel syndrome in chronic fatigue, S2.47
Quantification of interleukin-8 mRNA using reverse transcription-PCR technique in inflammatory bowel disease and in irritable bowel syndrome, S5.43
- Ischaemia**, Gut ischaemia, S1.73
- Island advancement flaps**, Island advancement flaps in the treatment of anal fissures, S2.62
- Jejunal loop**, Motility change and perception to balloon distension in the jejunal loop of postgastrectomy patients, S2.44
- Jejunal mucosa**, Effect of medium chain triglycerides (MCT) on jejunal mucosa mass and protein synthesis, S1.39
- Jejunal ulceration**, Fasting may prevent indomethacin-induced jejunal ulceration in the rat by reducing enterohepatic cycling of drug, S2.38
- Kato-3 gastric carcinoma cell line**, Induction of anchorage dependence by the trefoil peptide PSP upon Kato-3 gastric carcinoma cell line, S5.53
- Keratinocytes**, Integrins and migration of oesophageal keratinocytes, S2.31
- Kirsten-ras mutations**, Identification of Kirsten-ras mutations in bile of patients with pancreatic and biliary carcinomas, S5.38
- L-arginine**, L-arginine modulates T-lymphocyte function and inhibits adenocarcinoma growth in a rodent model of colorectal cancer, S5.63
- L-NAME**
A vasopressin V₁-receptor antagonist protects against acute intestinal vascular damage induced by nitric oxide synthase inhibition in the endotoxaemic rat, S2.52
Basal electrogenic ion transport is inhibited by L-NAME in muscle-stripped but not intact rat colon *in vitro*, S2.61
- Lansoprazole**
Eradication of *Helicobacter pylori* with lansoprazole and clarithromycin, S5.15
Lansoprazole is superior to ranitidine 300mg bd in prevention of relapse of reflux oesophagitis, S5.58
- Laparoscopic cholecystectomy**
Increased rate of cholecystectomy in Scotland following introduction of laparoscopic cholecystectomy, S5.34
Instrument safety during laparoscopic cholecystectomy, S5.26
Interval ERCP for gall stone pancreatitis prior to laparoscopic cholecystectomy, S2.55
Laparoscopic cholecystectomy can be performed with acceptable morbidity and mortality, S2.55
- Laparoscopic choledochoscopy**, Laparoscopic choledochoscopy during cholecystectomy, S2.55
- Laparoscopic fundoplication**
A prospective, objective evaluation of laparoscopic fundoplication, S2.8
Prospective randomised trial of laparoscopic versus open Nissen fundoplication, S2.15
- Laparoscopic resection rectopexy**, A retrospective evaluation of the results of laparoscopic resection rectopexy compared to trans-abdominal sutured resection rectopexy, S5.65
- Laparoscopic splenectomy**, Technique of laparoscopic splenectomy using a powered vascular linear stapler, S5.26

- Laparoscopic ultrasound**, A direct comparison of laparoscopic ultrasound and laparoscopic cholangiography for detection of common bile duct stones, **S5.34**
- Laparoscopy**
 Diagnostic value of laparoscopy in peritoneal diseases presenting as ascitis of unknown origin, **S5.52**
 The role of laparoscopy in AIDS, **S5.26**
- Large bowel cancer**, Lessons from aggressive colonoscopic follow up of large bowel cancer, **S5.36**
- Laser endoscopy**, Endoscopic laser palliation for colorectal cancer, **S2.24**
- Laser lithotripsy**, Laser lithotripsy of large stones in the bile duct with a stone recognition system, **S5.51**
- Lasers**
 Laser recanalisation followed by brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia, **S2.39**
 The combination of laser treatment and intraluminal radiotherapy for malignant dysphagia, **S5.15**
 The incidence and management of laser associated oesophageal perforation, **S2.9**
- Lateral internal sphincterotomy**, Why do anal fissures heal after lateral internal sphincterotomy? **S2.61**
- Latex agglutination test**, A simple 3 minute latex agglutination test for rapid *H. pylori* serodiagnosis, **S5.1**
- Leukotriene B₄**, Inactivation of rectal LTB₄ in vivo and by Caco2 cells in vitro, **S5.47**
- Linoleic acid**, *Helicobacter pylori* growth is inhibited by uptake and incorporation of linoleic acid, **S5.18**
- Lipocytes**, TIMP-1 activity in lipocytes conditioned media predominates over collagenase even after TNF alpha stimulation, **S2.19**
- Liver allograft rejection**, Eosinophil response to OKT₃ therapy in human liver allograft rejection, **S5.45**
- Liver biopsy**
 Day case liver biopsy in Victoria using ultrasound and 'Biopty' gun: safe, quick and cost-effective, **S2.58**
 Percutaneous liver biopsy – the influence of clotting status and ultrasound guidance on complication rate, **S2.12**
 Ultrasound guided or undirected liver biopsy? **S5.59**
- Liver disease**
 Clinical significance of soluble intercellular adhesion molecule-1 in chronic liver disease, **S2.20**
 Measurement of neutrophil elastase in patients with chronic liver disease, **S5.69**
- Liver metastases**, Continuous hepatic artery floxuridine infusion prolongs overall and normal quality survival in colorectal liver metastasis patients, **S2.30**
- Liver resection**, Cryotherapy with liver resection for the treatment of liver tumours, **S2.15**
- Liver transplant rejection**, Hepatic ³¹P MRS in chronic graft rejection, **S5.25**
- Liver transplantation**
 Abscesses after liver transplantation: a 10- year study, **S5.41**
 Expression of adhesion molecules and endothelial phenotypic markers in human orthotopic liver transplantation, **S5.69**
 HIDA scanning for detecting early biliary complications of orthotopic liver transplantation, **S2.55**
 Monoclonal antibodies against major basic protein (BMK-13) and eosinophil cationic protein (EG2) for quantifying eosinophils in human hepatic allograft rejection, **S2.14**
 Role of neutrophil activation in reperfusion injury following liver transplant, **S2.10**
 Role of reactive oxygen intermediates in the pathogenesis of primary graft dysfunction following liver transplantation, **S5.70**
 Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B, **S2.12**
- Liver tumours**, Cryotherapy with liver resection for the treatment of liver tumours, **S2.15**
- Local anaesthetic throat spray**, Local anaesthetic throat spray in the over 60's allows increased throughput on an endoscopic gastrointestinal unit, **S5.75**
- Long chain triglycerides**, Long chain triglycerides adversely affect dietary treatment of active Crohn's disease, **S2.25**
- Low anterior resection**, Recovery of physiology and function in the first year after low anterior resection of the rectum for carcinoma: does it occur? **S2.60**
- Lower oesophageal sphincter pressure**, A comparison of three-dimensional and conventional manometric methods in assessing changes in lower oesophageal sphincter pressure during fasting, **S5.6**
- Lymph node**, Endoluminal ultrasound: accuracy and limitations in lymph node evaluation for oesophageal carcinoma, **S5.8**
- Lymphocytes**, Activated lymphocytes in the liver of patients with primary sclerosing cholangitis, **S2.20**
- Lymphomas**, Coeliac disease and intestinal lymphoma, **S2.32**
- Lysozymes**, Monocyte numbers and activation in Crohn's disease: superoxide, lysozyme and cytokine production and the effect of elemental diet treatment, **S2.49**
- Magnetic resonance imaging**
 Dynamic, contrast enhanced magnetic resonance imaging: the imaging modality of choice for severe acute pancreatitis? **S2.15**
 Gastric emptying, motility and flow measured by echo planar magnetic resonance imaging, **S2.46**
- Major histocompatibility complex**, Familial Crohn's disease: no evidence for genetic linkage to the major histocompatibility complex, **S2.48**
- Mannitol/Picolax**, A mannitol/Picolax mixture or two-dose polyethylene glycol lavage solution as bowel preparation for colonoscopy? **S2.39**
- MDR2 P-glycoprotein gene**, Mice with homozygous disruption of the MDR2 P-glycoprotein gene; an animal model for studies of non-suppurative inflammatory cholangitis and hepatocarcinogenesis, **S5.9**
- Measles virus**
 Confirmation of persistent measles virus infection of intestinal tissue by immunogold electron microscopy, **S5.41**
 Novel molecular approaches in gastroenterology: direct *in situ* reverse transcription/PCR for detection of measles virus, **S5.41**
- Medical audit**, An ongoing audit of home parenteral nutrition: monitoring the effects of change on the incidence of complications, **S2.58**
- Medium chain triglycerides**, Effect of medium chain triglycerides (MCT) on jejunal mucosa mass and protein synthesis, **S1.39**
- Meglumine iotroxate**, Detection of common bile duct stones by intravenous cholangiography using meglumine iotroxate (Bilis-copin) compared to endoscopic retrograde cholangiography, **S2.56**
- Mesalazine**, A randomised trial comparing the efficacy and safety of 5-ASA and prednisolone foam enemas in the treatment of acute distal ulcerative colitis, **S2.42**
- Mesenteric vessels**, Comparison of endoscopic mechanical and injection methods of hemostasis on mesenteric vessels, **S2.38**
- Metronidazole**
 A successful one week antibiotic regime for *Helicobacter pylori* eradication, **S5.16**
Helicobacter pylori eradication therapy. A comparison between either omeprazole or ranitidine in combination with amoxicillin plus metronidazole, **S5.16**
- Microsphere injection**, Regulation of portal venous pressure by intrahepatic shunts after microsphere injection in the rat, **S5.9**
- Microspheres**, Oesophageal cell endocytosis of fluorescent microspheres. A comparison of normal and inflamed oesophagus, **S5.14**
- Microvascular injury**, Dynamic studies of acute indomethacin induced enteropathy: rapid and sustained microvascular stasis, **S2.50**
- Monoclonal antibodies**, Monoclonal antibodies against major basic protein (BMK-13) and eosinophil cationic protein (EG2) for quantifying eosinophils in human hepatic allograft rejection, **S2.14**
- Monocytes**, Monocyte numbers and activation in Crohn's disease: superoxide, lysozyme and cytokine production and the effect of elemental diet treatment, **S2.49**
- Monomethyl-L-arginine**, The effect of N^ω-monomethyl-L-arginine on portal pressure gradient and azygos blood flow amongst patients with cirrhosis, **S2.20**
- Motility**
 Fed state motor abnormalities in irritable bowel syndrome, **S2.46**
 Gastric emptying, motility and flow measured by echo planar magnetic resonance imaging, **S2.46**
 Octreotide in gastrointestinal motility disorders, **S3.11**
- Motor responses**, Motor and sensory responses of human small bowel to distension: the effect of rate, duration and length, **S2.44**
- Mucosa**
 Mucosal erosions in chronic NSAID users. Predisposition to ulceration and relationship to *Helicobacter pylori*, **S2.45**
 Non-steroidal anti-inflammatory drug ingestion in humans is associated with increased eosinophil infiltration of duodenal mucosa, **S2.45**
 Upregulation of interleukin 4 mRNA in inflamed intestinal mucosa. Is this increase real or apparent? **S5.30**
- Mucosa associated lymphoid tissue**, The endoscopic spectrum of primary non-Hodgkin's lymphoma of the stomach: the impact of the MALT (mucosa associated lymphoid tissue) classification, **S2.39**
- Mucosal advancement flap technique**, Mucosal advancement flap in the treatment of fistula-in-ano, **S5.65**
- Multiple system trauma**, Gut mucosal nutritional support – enteral nutrition as primary therapy after multiple system trauma, **S1.52**
- Muscarinic receptors**, Pharmacological characterisation of muscarinic receptors which mediate contractility of human colon, **S5.61**
- Mycobacterium paratuberculosis**, Detection by polymerase chain reaction of *Mycobacterium paratuberculosis*-specific DNA in Crohn's disease tissues, **S2.42**
- N-acetylcysteine**
 N-acetylcysteine – a mixed blessing? **S5.69**
 N-acetylcysteine is a potent peripheral vasodilator, **S5.10**
 Pharmacokinetics of N-acetylcysteine are altered in chronic liver disease, **S5.11**

- Naproxen**, Does adaptation to naproxen occur in humans? S5.70
- Nasogastric tube feeding**, A randomised comparison of percutaneous endoscopic gastrostomy feeding and nasogastric tube feeding following acute dysphagic stroke, S5.6
- Neorectal filling**, Detection of neorectal filling by bioelectrical impedance: an in vivo feasibility study, S5.65
- Neurological complications**, Neurological complications of coeliac disease, S5.4
- Neutrophil elastase**, Measurement of neutrophil elastase in patients with chronic liver disease, S5.69
- Neutrophil migration**, Stimulus to neutrophil migration into the gut lumen in IBD, S5.43
- Neutrophil neutral endopeptidase**, Reduced expression of neutrophil neutral endopeptidase in inflammatory bowel disease, S2.49
- Neutrophils**, Role of neutrophil activation in reperfusion injury following liver transplant, S2.10
- Nissen fundoplication**, Prospective randomised trial of laparoscopic versus open Nissen fundoplication, S2.15
- Nitric oxide**
A vasopressin V₁-receptor antagonist protects against acute intestinal vascular damage induced by nitric oxide synthase inhibition in the endotoxaemic rat, S2.52
Aminosalicylic acid derivatives bind nitric oxide, S5.71
Doubts about nitric oxide as a neurotransmitter in the enteric nervous system, S5.61
Metabolites of nitric oxide in severe acute ulcerative colitis, S5.30
Tissue expression of inducible nitric oxide synthase in ulcerative colitis, S2.40
- Nitric oxide synthase**, Do rectal myenteric nitric oxide synthase neurones innervate internal anal sphincter? Retrograde neuronal tracing in a guinea pig model, S5.31
- Nitrous oxide/oxygen mixture**, Intravenous hyoscine-n-butyl bromide and inhaled nitrous oxide/oxygen mixture improve the quality of flexible sigmoidoscopy, S5.80
- Non-disintegrating drugs**, Therapeutic implications of prolonged gastric retention of non-disintegrating oral dosage forms, S5.55
- Non-Hodgkin's lymphoma**, The endoscopic spectrum of primary non-Hodgkin's lymphoma of the stomach: the impact of the MALT (mucosa associated lymphoid tissue) classification, S2.39
- Non-steroidal anti-inflammatory drugs**
Aspirin and non-steroidal anti-inflammatory drug (NSAID) use and symptomatic colorectal cancer, S2.1
Emergency admissions and deaths from upper gastrointestinal crises in relation to NSAID use, S2.45
Gastric mucosal damage and adaptation occurs with enteric coated NSAIDs in man, S2.37
H. pylori does not increase the incidence of dyspepsia associated with NSAID gastropathy, S2.17
Intestinal permeability, S1.18
Mucosal erosions in chronic NSAID users. Predisposition to ulceration and relationship to *Helicobacter pylori*, S2.45
Non-steroidal anti-inflammatory drug ingestion in humans is associated with increased eosinophil infiltration of duodenal mucosa, S2.45
NSAID dyspepsia: role of *H. pylori*, prostaglandins and enteric neurones, S5.71
Oesophagitis is common in patients with rheumatic diseases and is increased by NSAIDs, S2.8
Prevention of NSAID-related gastric and duodenal ulcers by famotidine, S2.45
Prevention of NSAIDs-induced gastroduodenal lesions in arthritic patients by sucralfate gel, S2.44
Substance P containing enteric neurones and prostaglandin E₂ in non-steroidal anti-inflammatory drug ulceration, S2.37
Topical NSAIDs and upper gastrointestinal bleeding and perforation, S5.49
- Nonsuppurative inflammatory cholangitis**, Mice with homozygous disruption of the MDR2 P-glycoprotein gene; an animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis, S5.9
- Nucleotides**, Dietary nucleotides and gut mucosal defence, S1.46
- Nutrition**, The effect of malnutrition, and intensive nutritional support on total body protein synthesis and gastro-pancreatic secretion, S2.53
- Octreotide**
Effects of octreotide on hepatic energy metabolism in portal hypertension, S2.13
Meal-stimulated gallbladder emptying in acromegaly. The effect of octreotide treatment, S2.57
Octreotide in gastrointestinal motility disorders, S3.11
Octreotide in the treatment of refractory diarrhoea and intestinal fistulae, S3.5
Octreotide in variceal bleeding, S3.23
Role of intestinal transit in the pathogenesis of octreotide-induced gallbladder stones, S2.57
- Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis, S3.15
- Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery, S3.20
- Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects, S3.1
- Oesophageal cancer (carcinoma)**
Aggressive surgery for oesophageal carcinoma – is it worth it? S5.8
Altered gene expression of c-erbB3 during oesophageal tumorigenesis, applications for surveillance, S2.1
Dysphagia and delay in treatment for oesophageal carcinoma, S2.5
Endoluminal ultrasound: accuracy and limitations in lymph node evaluation for oesophageal carcinoma, S5.8
Endoscopic palliation of oesophageal cancer: experience with a novel expandable (microvase) metal prosthesis, S2.23
Expression of plasminogen activators and their inhibitors in oesophageal carcinoma, S5.38
Fibrinogen concentration in oesophageal cancer, S5.14
High-dose rate intraluminal irradiation for oesophageal cancer in clinical practice, S2.7
Laser recanalisation followed by brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia, S2.39
Macroscopic shape and node involvement in the superficial type of oesophageal cancer, S2.6
Oesophageal cancer in Yorkshire: a regional audit, S5.14
Palliation of oesophageal carcinoma with expandable metal prostheses is a cost-effective procedure, S5.8
Predictive assay for response of oesophageal carcinoma to chemoradiotherapy, S2.6
Quality of life in patients with oesophageal cancer, S5.8
Role for Cripto-1 (CR-1) in Barrett's tumorigenesis, S2.6
The use of endoluminal ultrasonography in staging oesophageal carcinoma, S2.23
- Oesophageal cell endocytosis**, Oesophageal cell endocytosis of fluorescent microspheres. A comparison of normal and inflamed oesophagus, S5.14
- Oesophageal distension**, Reproducibility of perception to oesophageal distension, S2.8
- Oesophageal ischaemia**, Oesophageal ischaemia in unexplained chest pain, S2.9
- Oesophageal metal stents**
Difficulties with placement of oesophageal metal stents and development and testing of new delivery methods and covered stents, S5.79
The treatment of iatrogenic oesophageal perforation with covered expanding metal stents, S5.14
- Oesophageal motility disorders**, Cerebral evoked potentials. Are they useful in assessing oesophageal motility disorders, S5.6
- Oesophageal motor activity**, Motor activity of the oesophagus probably only has a minimal effect on acid clearance, S5.7
- Oesophageal motor function**, The assessment of transit efficiency of a swallowed bolus as a measure of oesophageal motor function, S5.12
- Oesophageal perforation**
The incidence and management of laser associated oesophageal perforation, S2.9
The treatment of iatrogenic oesophageal perforation with covered expanding metal stents, S5.14
- Oesophageal pressure recording**, Comparison of manual and automated analysis of oesophageal body contractility with on-line and compressed data, S5.13
- Oesophageal tests**, An audit of the outcome of patients undergoing 24hr pH oesophageal tests, S5.75
- Oesophageal varices**, Intensive sclerotherapy does not prevent recurrence of oesophageal varices, S5.23
- Oesophagectomy**
Gastric fundal tone and perception of the intrathoracic stomach after radical oesophagectomy, S5.27
Malignant cytology in Barrett's oesophagus: an indication for oesophagectomy? S2.22
- Oesophagitis**
Helicobacter infection is associated with oesophagitis in patients with Barrett's oesophagus, S2.5
Oesophagitis is common in patients with rheumatic diseases and is increased by NSAIDs, S2.8
The effect of healing of oesophagitis on patient quality of life, S5.13
- Oesophagus**
Altered bladder function and oesophageal pain threshold in irritable bowel syndrome, S2.21
Sensory and motor representation of the human oesophagus on the cerebral cortex, S2.21
The use of a sodium ion selective electrode to detect bile in the oesophagus, S2.22
- OKT, therapy**, Eosinophil response to OKT, therapy in human liver allograft rejection, S5.45
- Omeprazole**
A successful one week antibiotic regime for *Helicobacter pylori* eradication, S5.16

- Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating *Helicobacter pylori*, S5.16
- Helicobacter pylori* eradication therapy. A comparison between either omeprazole or ranitidine in combination with amoxicillin plus metronidazole, S5.16
- Inhibition of *Helicobacter pylori* cytotoxin by omeprazole, S5.37
- Investigation of gastro-oesophageal reflux and acid secretion in patients unresponsive to therapeutic doses of omeprazole, S5.12
- Omeprazole can inhibit cell vacuolation in Vero cells induced by culture supernatants of *Helicobacter pylori*, S2.35
- Omeprazole in maintenance therapy for duodenal ulcer: effect on gastrin and pepsinogen A and C basal serum levels, S2.36
- Omeprazole markedly delays gastric emptying, S5.48
- Omeprazole treatment, a potent risk factor for *Campylobacter* gastroenteritis, S2.30
- Omeprazole versus ranitidine in the treatment of symptomatic mild reflux oesophagitis, S2.7
- Relationship of change in bowel habit to bacterial overgrowth in patients treated with omeprazole, S5.48
- Ondansetron**, Effect of a selective 5HT₂ antagonist ondansetron on symptoms in functional dyspepsia, S2.37
- Open access endoscopy**
- Audit of an interactive open access endoscopy service, S5.75
- Endoscopy in general practice: one year's experience, S5.79
- Is there a place for a GP run community based endoscopy unit, S5.78
- Open access endoscopy: satisfying general practitioners and reassuring patients, but increasing hospital workload, S5.78
- Open access gastroscopy**
- Is 'censorship' for open access gastroscopy justified? S5.76
- Open access gastroscopy and the influence of prior treatment, S5.59
- Why does a GP refer to clinic if open access gastroscopy is available? S5.78
- Open-access oesophageal manometry service**, First three years of an open-access oesophageal manometry service, S5.59
- Oral rehydration solutions**, Effect of glucose polymer chain lengths in oral rehydration solutions: studies in secreting rat intestine, S5.70
- 8 Ornithin vasopressin**, The haemodynamic effects of 8 ornithin vasopressin in portal hypertension and cirrhosis, S2.13
- Ornithine**, Can arginine and ornithine support gut functions? S1.42
- Ornithine decarboxylase**
- Stimulation of gut ornithine decarboxylase activity by *Giardia lamblia* *in vivo*, S5.40
- The role of the cytoskeleton in *Giardia*-stimulated ornithine decarboxylase activity, S5.41
- Oro-caecal transit time**, Inulin is a better probe than lactulose for the measurement of oro-caecal transit time, S5.19
- Out-patient referrals**, An audit of gastroenterology out-patient referrals: improving efficiency and shortening waiting lists, S2.47
- Oxygen**, Iron chelation in ulcerative colitis: a new antioxidant approach, S2.50
- Oxygen therapy**, Oxygen therapy improves ultrasonic imaging of the pancreas, S2.14
- p53**
- Aneuploidy, loss of the Y-chromosome and p53 overexpression as potential markers for malignant progression in Barrett's esophagus, S2.6
- p53 mutation in mixed hepatocellular cholangiocarcinoma, S5.38
- p53 overexpression is closely correlated with grade of duodenal neoplasia in familial adenomatous polyposis, S5.39
- Pancreas**
- Expression of peptide receptors both in normal rat pancreas and in rat pancreatic premalignant lesions induced by azaserine, S2.14
- Oxygen therapy improves ultrasonic imaging of the pancreas, S2.14
- Pancreatic cancer (carcinoma)**
- Carcinoma of the pancreas: the value of portal lymph node resection, S5.67
- Identification of Kirsten-ras mutations in bile of patients with pancreatic and biliary carcinomas, S5.38
- IL-8 and IL-6 are produced constitutively by human pancreatic cancer cell lines, S5.39
- Titres of serum IL-8 correlate with the presence of an acute phase response in patients with pancreatic cancer, S5.73
- Pancreatic enzyme supplements**, Monitoring pancreatic enzyme supplements in children with cystic fibrosis using a mixed triglyceride breath test, S5.34
- Pancreatic secretory trypsin inhibitor**, Distribution of human pancreatic secretory trypsin inhibitor using *in situ* hybridisation and immunological staining techniques, S5.53
- Pancreatic surgery**, Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery, S3.20
- Pancreatitis**
- A double blind placebo controlled study of BB-882 (a potent PAF antagonist) in human acute pancreatitis, S5.35
- Can a 2 hour post ERCP serum amylase estimation predict post ERCP acute pancreatitis? S5.35
- Changes in circulating T lymphocyte subsets early in acute pancreatitis, S5.67
- Down-regulation of interleukin-8 production from peripheral blood mononuclear cells from patients with acute pancreatitis by IL-4 and IL-10, S5.45
- Dynamic, contrast enhanced magnetic resonance imaging: the imaging modality of choice for severe acute pancreatitis? S2.15
- Early changes in circulating polymorphonuclear neutrophil function in acute pancreatitis, S5.35
- Is plasma osmolality raised in severe acute pancreatitis? S2.14
- Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis, S3.15
- Pantoprazole**, The effect of pantoprazole, as monotherapy and in combination with amoxicillin, on gastric *H. pylori* status, in duodenal ulcer subjects, S2.63
- Parenteral nutrition**
- A study of the growth of bacteria and fungi in parenteral nutrition solutions in the presence of taurolin, S5.22
- Dedicated peripheral feeding lines for parenteral nutrition – 100 cases, S2.53
- Pulmonary embolism in children – another hazard of parenteral feeding, S5.33
- Parietal cells**, The prevalence of parietal cells in the duodenum and their relationship to *Helicobacter pylori* infection, S5.3
- Penicillin**, Penicillin transport in small intestinal brush-border membrane vesicles, S5.54
- Peppermint oil**, Peppermint oil reduces Na⁺ dependent glucose absorption in rat small intestine, S5.55
- Pepsinogen**, Omeprazole in maintenance therapy for duodenal ulcer: effect on gastrin and pepsinogen A and C basal serum levels, S2.36
- Pepsinogen I**, Histology, IGG, IGA, IGM to *Helicobacter pylori*, serum pepsinogen I and gastrin in asymptomatic blood donors, S5.18
- Peptic ulcer**
- Bleeding peptic ulcer: injection of adrenaline or tissue adhesive (histoacryl), S5.36
- Peptic ulcer, dyspepsia and *Helicobacter pylori*: BSG members perspective and practice, S2.48
- Risk of post-operative death is high after failed endoscopic therapy for bleeding ulcer, S5.26
- The effect of *Helicobacter pylori* eradication on the well-being of patients with peptic ulcer, S5.2
- Peptic ulcer disease**, Study into ethnic differences in Leicester of *Helicobacter pylori* in peptic ulcer disease, S5.15
- Peptone-stimulated acid secretion**, *H. pylori* impairs acid-inhibition of peptone-stimulated acid secretion, S5.18
- Percutaneous endoscopic gastrostomy**
- A comparison of the value and safety of percutaneous endoscopic gastrostomy in malignant and benign disease, S5.52
- A randomised comparison of percutaneous endoscopic gastrostomy feeding and nasogastric tube feeding following acute dysphagic stroke, S5.6
- Incidence of unsuspected upper gastrointestinal diseases in patients with stroke receiving percutaneous endoscopic gastrostomies, S5.79
- Short and long term outcome after percutaneous endoscopic gastrostomy placement, S5.52
- Percutaneous transhepatic biliary drainage**, Diagnostic biliary cytology for strictures managed by percutaneous transhepatic biliary drainage, S5.66
- Peripheral intravenous nutrition**, The reduction of local complications from peripheral intravenous nutrition, S5.23
- Peritonitis**
- Advanced diffuse peritonitis managed by planned multiple laparotomies utilising zippers/velcro analogue for temporary abdominal closure, S2.15
- The peritoneal cytokine profile in acute peritonitis, S5.46
- Permeability**, Intestinal permeability, S1.18
- Permeability index**, Increased L/M permeability index in a fraction of healthy relatives of Crohn's patients: a subclinical marker, S5.29
- Permeability tests**, IgA anti-endomysial antibody is superior to the ⁵¹Cr-EDTA:¹⁴C-mannitol intestinal permeability test in the diagnosis of coeliac disease, S5.3
- pH tests**, An audit of the outcome of patients undergoing 24hr pH oesophageal tests, S5.75
- Pharyngo-oesophageal motility**, Normal pharyngo-oesophageal motility at rest, during eating and sleep, S2.21
- Photodynamic therapy**, Eradication of high grade dysplasia in columnar lined (Barrett's) oesophagus by photodynamic therapy with oral 5-aminolaevulinic acid and 630nm light, S5.7
- "Physiological" anti-reflux procedure**, Laparoscopic "physiological" anti-reflux procedure: preliminary results of a prospective symptomatic and objective study, S2.23
- Picotamide**, An open trial of anti-platelet therapy in active Crohn's disease using picotamide, a thromboxane antagonist, S5.28

- Pituitary adenylate cyclase activating peptide**, VIP and PACAP stimulated adenylate cyclase activity is not inhibited by the VIP antagonist [D-p-CI Phe⁶,Leu²⁷] VIP in human duodenum, **S2.52**
- Plasma osmolarity**, Is plasma osmolarity raised in severe acute pancreatitis? **S2.14**
- Plasminogen activator**
Expression of plasminogen activators and their inhibitors in oesophageal carcinoma, **S5.38**
Urokinase-type plasminogen activator (uPA) as a prognostic indicator in colorectal cancer, **S2.1**
- Platelets**, An open trial of anti-platelet therapy in active Crohn's disease using picotamide, a thromboxane antagonist, **S5.28**
- Pneumatic dilatation**, Pneumatic dilatation for achalasia, **S2.8**
- Pneumatic LOS dilatation**, Causes of pathological oesophageal acidification after pneumatic LOS dilatation in achalasia, **S5.12**
- Poly-ADP-ribose polymerase inhibitors**, Protection of colonic epithelial cells against oxidant damage by poly-ADP-ribose polymerase inhibitors, **S5.46**
- Polyamines**
Fasting and post-prandial polyamine concentrations in the human small bowel, **S5.20**
Origins of intestinal luminal polyamines in man, **S5.20**
- Polyethylene glycol**, Problems with polyethylene glycol as a marker of small intestinal permeability, **S5.20**
- Polymerase chain reaction**
Detection by polymerase chain reaction of *Mycobacterium paratuberculosis*-specific DNA in Crohn's disease tissues, **S2.42**
Polymerase chain reaction detection of *Cryptosporidium* sp. in human small intestine, **S5.37**
- Polymorphonuclear neutrophils**, Early changes in circulating polymorphonuclear neutrophil function in acute pancreatitis, **S5.35**
- Polypoid lesions**, Polypoid lesions of gallbladder, **S2.56**
- Polyposis**
A survey of phenotypic abnormalities in juvenile polyposis, **S5.39**
Germline APC mutation at codon 1061 is associated with severe duodenal polyposis but not high colonic polyp counts in familial adenomatous polyposis, **S5.40**
- Porphyria cutanea tarda**, The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland, **S5.40**
- Portal hypertension**
Do alterations in the rate of gastric emptying contribute to the pathogenesis of portal hypertensive gastropathy? **S2.13**
Intestinal blood flow distribution in portal hypertension, **S5.21**
Reduction in renal blood flow with acute increase in the portal pressure gradient. Evidence for the existence of hepatorenal reflex in man? **S5.9**
The effects of octreotide on hepatic energy metabolism in portal hypertension, **S2.13**
The haemodynamic effects of 8 ornithin vasopressin in portal hypertension and cirrhosis, **S2.13**
- Portal lymph node resection**, Carcinoma of the pancreas: the value of portal lymph node resection, **S5.67**
- Post cholecystectomy pain**, Two years experience of sphincter of Oddi manometry as a clinical service in the evaluation of post cholecystectomy pain, **S5.56**
- Postgastroectomy**, Motility change and perception to balloon distension in the jejunal loop of postgastroectomy patients, **S2.44**
- Pouchitis**, Expression of interferon-gamma, tumour necrosis factor-alpha and interleukins-6 and -2 in pouchitis mucosa, **S2.40**
- Prednisolone**, A randomised trial comparing the efficacy and safety of 5-ASA and prednisolone foam enemas in the treatment of acute distal ulcerative colitis, **S2.42**
- Pressure waves**, The pathophysiology of hindgut dysmotility – a failure to generate high pressure waves, **S2.62**
- Primary biliary cirrhosis**
Effect of ursodeoxycholic acid therapy on survival in primary biliary cirrhosis, **S2.20**
Ultrasound – a non-invasive method of assessing disease severity in primary biliary cirrhosis, **S5.10**
Ursodeoxycholic acid improves hepatic excretion in primary biliary cirrhosis, **S5.11**
- Primary sclerosing cholangitis**, Activated lymphocytes in the liver of patients with primary sclerosing cholangitis, **S2.20**
- Proctosigmoiditis**, Progression of ulcerative proctosigmoiditis to more proximal regions of the colon, **S2.43**
- Prostaglandin E₂**, Substance P containing enteric neurones and prostaglandin E₂ in non-steroidal anti-inflammatory drug ulceration, **S2.37**
- Protein losing enteropathy**
¹¹¹In chloride-transferrin scanning for detection and quantification of protein losing enteropathy, **S5.19**
Diarrhoea, protein losing enteropathy and trace element deficiency in children following bone marrow transplantation, **S5.33**
- Proton MRS**, Proton MRS in chronic hepatic encephalopathy, **S5.24**
- Pseudo-obstruction**
Clinicopathological characteristics of adults with sporadic chronic intestinal pseudo-obstruction, **S2.54**
Electrogastrography in chronic pseudo-obstruction, **S2.46**
- Psyllium therapy**, Effect of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation, **S5.65**
- Pulmonary embolism**, Pulmonary embolism in children – another hazard of parenteral feeding, **S5.33**
- Purinoceptors**, ATP dilates the hepatic artery via P₁-purinoceptors, **S2.9**
- Push enteroscopy**, Push enteroscopy and heater probe therapy for small bowel bleeding, **S5.36**
- Quality of life**
Quality of life in patients with oesophageal cancer, **S5.8**
The effect of healing of oesophagitis on patient quality of life, **S5.13**
- Radiation injury**, Protection from radiation injury by elemental diet: does added glutamine change the effect? **S1.60**
- Ranitidine**
Helicobacter pylori eradication therapy. A comparison between either omeprazole or ranitidine in combination with amoxicillin plus metronidazole, **S5.16**
Marked rebound acid hypersecretion following treatment with ranitidine, **S2.36**
Omeprazole versus ranitidine in the treatment of symptomatic mild reflux oesophagitis, **S2.7**
- Rapid whole blood test**, A new rapid whole blood test for *Helicobacter pylori* antibodies could reduce diagnostic oesophagogastrroduodenoscopy (OGD) in patients with dyspepsia, **S5.1**
- Re-infection**, Treatment of *Helicobacter pylori* infection – relationship between initial eradication rate and the observed 're-infection' rate six months post treatment, **S5.2**
- Reactive oxygen intermediates**, Role of reactive oxygen intermediates in the pathogenesis of primary graft dysfunction following liver transplantation, **S5.70**
- Reactive oxygen metabolites**, The effect of allopurinol, salazopyrin and vitamin C on aspirin-induced gastroduodenal mucosal injury in humans, **S5.70**
- Reactive oxygen species**, Reactive oxygen species damage in *H. pylori* gastritis, **S5.3**
- Rebleeding**, Risk of post-operative death is high after failed endoscopic therapy for bleeding ulcer, **S5.26**
- Rectocolonic inhibitory reflex**
Neural mediation of the human rectocolonic inhibitory reflex, **S5.31**
The human rectocolonic inhibitory reflex – normal and constipated patients, **S2.28**
- Rectum, rectal**
An audit of rectal biopsy in the investigation of diarrhoea, **S5.60**
Imaging of rectal balloon expulsion compared with evacuation proctography, **S2.62**
Is a barium enema of use in the diagnosis of cancer in patients with rectal bleeding? **S2.27**
Recovery of physiology and function in the first year after low anterior resection of the rectum for carcinoma: does it occur? **S2.60**
Restoration of rectal function by the Delorme's procedure for rectal prolapse, **S2.61**
The incidence and causes of rectal bleeding in the community, **S5.66**
- Reflux oesophagitis**
Causes of pathological oesophageal acidification after pneumatic LOS dilatation in achalasia, **S5.12**
Lansoprazole is superior to ranitidine 300mg bd in prevention of relapse of reflux oesophagitis, **S5.58**
Omeprazole versus ranitidine in the treatment of symptomatic mild reflux oesophagitis, **S2.7**
The natural history of reflux oesophagitis: a 10 year follow-up, **S2.22**
The natural history of reflux oesophagitis and its effect on quality of life: a 10 year follow-up, **S5.7**
- Reperfusion**, Role of neutrophil activation in reperfusion injury following liver transplant, **S2.10**
- Respiratory symptoms**, Gastrointestinal and respiratory symptoms in the community, **S5.62**
- Restorative proctocolectomy**
Audit of function, satisfaction and irritable bowel syndrome following restorative proctocolectomy for ulcerative colitis and familial adenomatous polyposis, **S5.27**
Preservation of complete anal sphincteric proprioception in the course of restorative proctocolectomy for ulcerative colitis, **S5.31**
Prospective comparison of restorative proctocolectomy for indeterminate colitis versus ulcerative colitis, **S2.41**
- Reticulin antibodies**, Large scale population survey of antibodies to gliadin, reticulin and endomysium, **S5.4**
- Retinoblastoma**, Prognostic significance of retinoblastoma gene product expression in colorectal cancer, **S2.27**

- Retinoid X receptor**, Vitamin D, and retinoid X receptor mRNAs are expressed in human colorectal mucosa and neoplasms, **S2.2**
- Retinoids**, Is the storage of retinoids in the liver important to hepatocyte proliferation, **S5.74**
- Retrorsine**, Hepatic copper status in neonatal rats and effects of retrorsine, **S5.25**
- Reverse transcription/PCR**, Novel molecular approaches in gastroenterology: direct *in situ* reverse transcription/PCR for detection of measles virus, **S5.41**
- Saccharomyces cerevisiae**, Diagnostic implications of raised antibody titres to *Saccharomyces cerevisiae* in gastrointestinal disease, **S5.42**
- Saliva**
Comparison of serum and salivary immunoassays for *Helicobacter pylori*, **S5.15**
Swallowed saliva in gastric juice, **S5.49**
The impact of smoking cessation on salivary bicarbonate and epidermal growth factor, **S5.13**
- Salivary IgG**, Clinical value of *Helicobacter pylori* specific salivary IgG in dyspeptic patients, **S2.63**
- Salivary immunoglobulins**, Salivary immunoglobulins as diagnostic markers of globulins hepatitis A infection, **S2.11**
- Scleroderma**, Octreotide in gastrointestinal motility disorders, **S3.11**
- Sedation**, Non-anxious patients prefer throat spray alone rather than IV sedation for upper endoscopy, **S2.37**
- Selenium**, Positive benefit of selenium supplementation in Crohn's disease, **S2.26**
- Sensory responses**, Motor and sensory responses of human small bowel to distension: the effect of rate, duration and length, **S2.44**
- Short bowel syndrome**, Enteral nutrition as primary therapy in short bowel syndrome, **S1.69**
- Short chain fatty acids**
Effects of short chain fatty acids on gut morphology and function, **S1.35**
Human colonic motility is unaffected by short chain fatty acids *in vivo*, **S2.25**
- Sigmoidoscopy**
Intravenous hyoscine-n-butyl bromide and inhaled nitrous oxide/oxygen mixture improve the quality of flexible sigmoidoscopy, **S5.80**
Value of a negative flexible sigmoidoscopy as an indicator of low risk of colorectal cancer, **S5.32**
- Small bowel (intestine)**
A vasopressin V_1 -receptor antagonist protects against acute intestinal vascular damage induced by nitric oxide synthase inhibition in the endotoxaemic rat, **S2.52**
Abnormal contractile patterns identified in small bowel pathology, **S5.61**
Adenoviral mediated gene transfer to postnatal intestinal epithelium: gene expression *in vitro* and *in vivo*, **S2.51**
Does neomucosa induced by stem cell transplantation have adequate mucosal function? **S2.29**
Does topography influence epithelial differentiation and digestive function in postnatal intestine? **S2.51**
Fasting and post-prandial polyamine concentrations in the human small bowel, **S5.20**
Motor and sensory responses of human small bowel to distension: the effect of rate, duration and length, **S2.44**
Polymerase chain reaction detection of *Cryptosporidium* sp. in human small intestine, **S5.37**
Push enteroscopy and heater probe therapy for small bowel bleeding, **S5.36**
Simultaneous measurement of fluid transport and transintestinal PD *in vivo* using an on-line technique, **S5.54**
Small bowel flora in potential small bowel transplant donors, **S5.20**
Small intestinal permeability, morphology and brush border enzyme activities in immigrants resident in a British inner city, **S2.28**
- Smoking cessation**, The impact of smoking cessation on salivary bicarbonate and epidermal growth factor, **S5.13**
- Sodium**, Na^+ channel-specific mRNA is not sufficient for Na^+ channel expression in rat colonic epithelium, **S2.61**
- Sodium ion selective electrode**, The use of a sodium ion selective electrode to detect bile in the oesophagus, **S2.22**
- Sodium nitroprusside**, Sodium nitroprusside, a nitric oxide donating compound, stimulates human colonic ion transport *in vitro*, **S5.53**
- Somatostatin**
Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis, **S3.15**
Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery, **S3.20**
Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects, **S3.1**
Treatment of hepatocellular carcinoma with somatostatin, **S5.72**
- Soybean lectin**, Soybean lectin is the main pancreatic stimulant in raw soya flour, **S5.67**
- Sphincter of Oddi manometry**
Does sphincter of Oddi manometry predict efficacy of sphincterotomy? **S2.46**
Sphincter of Oddi manometry. Is tachyoddia a duodenal pacemaker dysfunction? **S5.61**
Two years experience of sphincter of Oddi manometry as a clinical service in the evaluation of post cholecystectomy pain, **S5.56**
- Sphincter repair**
A 5 year audit of sphincter repair (1988-93), **S5.28**
Anal endosonography after failed anterior sphincter repair for obstetric trauma is imperative. **S2.27**
Effect of anal sphincter repair on anal endosonography, **S2.28**
- Sphincter rupture**, Faecal incontinence after severe traumatic sphincter rupture, **S2.16**
- Sphincterotomy**, Does sphincter of Oddi manometry predict efficacy of sphincterotomy? **S2.46**
- Stem cell transplantation**, Does neomucosa induced by stem cell transplantation have adequate mucosal function? **S2.29**
- Stents**, Difficulties with placement of oesophageal metal stents and development and testing of new delivery methods and covered stents, **S5.79**
- Steroids**, Nutritional supplement with elemental diet as a steroid replacement in patients with steroid-dependent Crohn's disease, **S2.26**
- Stigmata of recent haemorrhage**, Observer variation in the assessment of stigmata of recent haemorrhage: a multicentre study by 13 skilled endoscopists, **S5.80**
- Streptozotocin-diabetic rats**, Enhanced intestinal iron transfer in 2-3 day streptozotocin-diabetic rats, **S5.21**
- Stress**, Effect of acute stress on ano-rectal physiology in patients with irritable bowel syndrome, **S5.62**
- Stroke**, A randomised comparison of percutaneous endoscopic gastrostomy feeding and nasogastric tube feeding following acute dysphagic stroke, **S5.6**
- Substance P**, Substance P containing enteric neurones and prostaglandin E_2 in non-steroidal anti-inflammatory drug ulceration, **S2.37**
- Sucralfate**, Specific prevention of aspirin induced intragastric bleeding with sucralfate, **S5.71**
- Sucralfate gel**, Prevention of NSAIDs-induced gastroduodenal lesions in arthritic patients by sucralfate gel, **S2.44**
- Sulindac**, Proliferative activity in DMG-treated mouse colonic mucosa is enhanced by sulindac, **S2.30**
- Sumatriptan**, Cause of chest pain after sumatriptan: is it oesophageal? **S5.55**
- Superoxide**, Monocyte numbers and activation in Crohn's disease: superoxide, lysozyme and cytokine production and the effect of elemental diet treatment, **S2.49**
- Superoxide anion**, The source of superoxide anion in ulcerative colitis is not xanthine oxidase, **S2.41**
- Swallowing**
Mapping the cortical centres for swallowing in man: evidence for hemispheric dominance, **S5.11**
The assessment of transit efficiency of a swallowed bolus as a measure of oesophageal motor function, **S5.12**
- T-cell lymphoma**, HLA-class II phenotypes in coeliac disease and enteropathy-associated T-cell lymphoma, **S2.53**
- T lymphocyte subsets**, Changes in circulating T lymphocyte subsets early in acute pancreatitis, **S5.67**
- Tachyoddia**, Sphincter of Oddi manometry. Is tachyoddia a duodenal pacemaker dysfunction? **S5.61**
- Taurine**, Supplemental taurine reduces plasma IL-6 concentrations but enhances pulmonary neutrophil sequestration in rodent intra-peritoneal sepsis, **S2.60**
- Taurolin**, A study of the growth of bacteria and fungi in parenteral nutrition solutions in the presence of taurolin, **S5.22**
- Tinidazole**, Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating *Helicobacter pylori*, **S5.16**
- TIPS**, Emergency TIPS as salvage treatment for uncontrolled variceal bleeding, **S2.12**
- Tissue adhesive**, Bleeding peptic ulcer: injection of adrenaline or tissue adhesive (histoacryl), **S5.36**
- Tissue inhibitor of metalloproteinase-1**, TIMP-1 activity in lipocytes conditioned media predominates over collagenase even after TNF alpha stimulation, **S2.19**
- Tonsillectomy**, Appendicectomy, tonsillectomy and inflammatory bowel disease, **S5.28**
- Topoisomerase type II**, Expression sites of isoforms (α and β) of type II topoisomerase in human foetal tissues, **S5.53**
- Total body protein**, The effect of malnutrition, and intensive nutritional support on total body protein synthesis and gastro-pancreatic secretion, **S2.53**
- Total parenteral nutrition**, Paediatric TPN and hypermanganasaemia, **S5.33**
- Trace element deficiency**, Diarrhoea, protein losing enteropathy and trace element deficiency in children following bone marrow transplantation, **S5.33**

- Transcatheter arterial chemoembolization**, Survival and side effects after transcatheter arterial chemoembolization in hepatocellular carcinoma, **S5.72**
- Transcription factor HNF-4**, Intestinal distribution of the transcription factor HNF-4, **S5.60**
- Transintestinal PD**, Simultaneous measurement of fluid transport and transintestinal PD *in vivo* using an on-line technique, **S5.54**
- Transit efficiency**, The assessment of transit efficiency of a swallowed bolus as a measure of oesophageal motor function, **S5.12**
- Transjugular intrahepatic portosystemic stent-shunt**
A comparative study of TIPSS and oesophageal transection in the management of uncontrolled variceal haemorrhage, **S5.11**
A prospective evaluation of haematological alterations following TIPSS, **S5.24**
Analysis of prognostic variables in the prediction of variceal rebleeding, stent failure, encephalopathy and early mortality following TIPSS, **S5.24**
Cerebral and liver function following TIPSS: a prospective study, **S5.9**
Direct measurement of portal vein flow in patients with transjugular intrahepatic portosystemic stent shunts – a new model for therapeutic studies? **S5.23**
TIPSS, Palmaz or Wall stents? **S2.10**
TIPSS occlusion and the role of biliary venous fistula, **S5.24**
Transjugular intrahepatic portosystemic stent-shunt insertion as a prelude to orthotopic liver transplantation in patients with severe portal hypertension, **S5.25**
- Translocation**
Bacterial translocation: the influence of dietary variables, **S1.23**
Clinical significance of translocation, **S1.28**
- Travellers' diarrhoea**, A prospective, randomised, placebo-controlled trial of single dose ciprofloxacin for the treatment of travellers' diarrhoea, **S2.30**
- Trefoil peptide PSP**, Induction of anchorage dependence by the trefoil peptide PSP upon Kato-3 gastric carcinoma cell line, **S5.53**
- Trent region**, Endoscopy in the Trent Region 1992, **S2.24**
- Triglyceride breath test**, Monitoring pancreatic enzyme supplements in children with cystic fibrosis using a mixed triglyceride breath test, **S5.34**
- Triple therapy**
Azithromycin in a triple therapy for eradicating *Helicobacter pylori*, **S2.63**
Efficacy of a new one week triple therapy regime in eradicating *Helicobacter pylori*, **S2.62**
- Tropheryma Whipple II**, PCR amplification of tropheryma Whipple II 16S RNA gene in treated and untreated Whipple's disease, **S2.54**
- Tropomyosin**
Anti-colonocyte and anti-tropomyosin serum antibodies in patients with ulcerative colitis, **S2.49**
Evidence that tropomyosin is not the major antigenic target of the Das antibody 7E12H12 in ulcerative colitis, **S5.43**
- Tumour necrosis factor**
Cytokine profile in auto-immune liver diseases using the reverse haemolytic plaque assay, **S2.10**
Increased local production of IL-8 and TNF in patients with *H. pylori* infection, **S2.35**
- Tumour necrosis factor-alpha**
Anti TNF alpha treatment of a model of human ulcerative colitis, **S2.50**
Expression of interferon-gamma, tumour necrosis factor-alpha and interleukins-6 and -2 in pouchitis mucosa, **S2.40**
Faecal tumour necrosis factor-alpha and faecal alpha-one-antitrypsin in HIV infection, **S5.40**
Interleukin-8 and tumour necrosis factor-alpha RNA in antral mucosa of duodenal ulcer patients, **S2.4**
TIMP-1 activity in lipocytes conditioned media predominates over collagenase even after TNF alpha stimulation, **S2.19**
- Ulcer healing drugs**, Prescription of ulcer healing drugs in medical inpatients: do patients know why they are taking them and are the prescriptions appropriate? **S2.58**
- Ulcerative colitis**
A really useful simple colitis activity index, **S5.29**
An open trial of antioxidant nutrient therapy in active ulcerative colitis, **S5.29**
Anti-colonocyte and anti-tropomyosin serum antibodies in patients with ulcerative colitis, **S2.49**
Anti TNF alpha treatment of a model of human ulcerative colitis, **S2.50**
Assessment of microcirculation in ulcerative colitis, **S5.44**
Audit of function, satisfaction and irritable bowel syndrome following restorative proctocolectomy for ulcerative colitis and familial adenomatous polyposis, **S5.27**
Could compliance with colonoscopic surveillance of ulcerative colitis be improved by patient education? **S2.59**
Evidence that tropomyosin is not the major antigenic target of the Das antibody 7E12H12 in ulcerative colitis, **S5.43**
- Factors associated with functional outcome in ileoanal pouch construction for ulcerative colitis, **S5.27**
- Genetic predisposition to ulcerative colitis: a detailed study of the HLA region by linkage analysis, **S5.30**
- Inactivation of rectal LTB₄ *in vivo* and by Caco₂ cells *in vitro*, **S5.47**
- Interleukin 10 inhibits inflammatory mediator production in ulcerative colitis, **S2.48**
- Iron chelation in ulcerative colitis: a new antioxidant approach, **S2.50**
- Metabolites of nitric oxide in severe acute ulcerative colitis, **S5.30**
- Predicting outcome in severe ulcerative colitis, **S5.29**
- Preservation of complete anal sphincter proprioception in the course of restorative proctocolectomy for ulcerative colitis, **S5.31**
- Prospective comparison of restorative proctocolectomy for indeterminate colitis versus ulcerative colitis, **S2.41**
- Randomised trial comparing the efficacy and safety of 5-ASA and prednisolone foam enemas in the treatment of acute distal ulcerative colitis, **S2.42**
- Structurally weaker adherent colonic mucus gel barrier in ulcerative colitis, **S5.43**
- The source of superoxide anion in ulcerative colitis is not xanthine oxidase, **S2.41**
- Tissue expression of inducible nitric oxide synthase in ulcerative colitis, **S2.40**
- Ultrasound miniprobes**, The use of high frequency ultrasound miniprobes in routine ERCP, **S5.51**
- Upper gastrointestinal bleeding (haemorrhage)**
Does dark-blood (coffee grounds) haematemesis predict a good prognosis in upper gastrointestinal haemorrhage? **S5.59**
Incidence and mortality of acute upper gastrointestinal bleeding in the U.K., **S5.47**
Topical NSAIDs and upper gastrointestinal bleeding and perforation, **S5.49**
- Upper gastrointestinal cancer**, Early experience of the use of endoscopic ultrasound in an upper G.I. surgical unit, **S2.5**
- Upper gastrointestinal diseases**, Incidence of unsuspected upper gastrointestinal diseases in patients with stroke receiving percutaneous endoscopic gastrostomies, **S5.79**
- Upper gastrointestinal endoscopy**
A prospective audit of new inpatient referrals for upper gastrointestinal endoscopy to the gastroenterology firm of a district general hospital, **S5.77**
Local anaesthetic throat spray in the over 60's allows increased throughput on an endoscopic gastrointestinal unit, **S5.75**
- Upper gastrointestinal tract**
Emergency admissions and deaths from upper gastrointestinal crises in relation to NSAID use, **S2.45**
Shortcomings of computer versus note based audit of upper GIT bleeds, **S5.76**
- Urinary nitrite dipstick**, Urinary nitrite dipstick: a reliable disease activity marker in inflammatory bowel disease, **S2.41**
- Ursodeoxycholic acid**
Effect of ursodeoxycholic acid therapy on survival in primary biliary cirrhosis, **S2.20**
Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid, **S2.12**
Ursodeoxycholic acid improves hepatic excretion in primary biliary cirrhosis, **S5.11**
- Vapreotide**, Vapreotide (Octastatine, RC 160) in the treatment of acute Crohn's disease, **S5.72**
- Variceal bleeding**
Emergency TIPS as salvage treatment for uncontrolled variceal bleeding, **S2.12**
Octreotide in variceal bleeding, **S3.23**
- Vasoactive intestinal peptide**, VIP and PACAP stimulated adenylate cyclase activity is not inhibited by the VIP antagonist [D-p-CI Phe⁶,Leu¹⁷] VIP in human duodenum, **S2.52**
- Vasopressin**
A vasopressin V₁-receptor antagonist protects against acute intestinal vascular damage induced by nitric oxide synthase inhibition in the endotoxaemic rat, **S2.52**
The haemodynamic effects of 8 ornithin vasopressin in portal hypertension and cirrhosis, **S2.13**
Vasopressin and organic nitrates, effects of portal haemodynamics, **S2.13**
- Vero cells**
Omeprazole can inhibit cell vacuolation in Vero cells induced by culture supernatants of *Helicobacter pylori*, **S2.35**
Relative role of cytotoxin and urease of *Helicobacter pylori* in cell vacuolation of cultured Vero cells, **S2.36**
- Villous atrophy**, Scallops, grooves and subtotal villous atrophy, **S2.51**
- Villus**, Determinants of villus shortening in Zambian patients with HIV related diarrhoea, **S2.29**
- Visceral sensation**, "The sentient gut": enhanced visceral sensation in the oesophagus and rectum in functional dyspepsia, **S5.48**

Vitamin D₃, Vitamin D₃ and retinoid X receptor mRNAs are expressed in human colorectal mucosa and neoplasms, **S2.2**

Vitamin D, receptors, Functional vitamin D₃ receptors are present in human colorectal neoplasms, **S5.39**

Whipple's disease, PCR amplification of tropheryma Whipple II 16S RNA gene in treated and untreated Whipple's disease, **S2.54**

Xanthine oxidase, The source of superoxide anion in ulcerative colitis is not xanthine oxidase, **S2.41**

Zaldaride maleate, Effect of the calmodulin antagonist zaldaride maleate on cholera toxin induced small intestinal secretion, **S5.71**

Gut

*Journal of the British Society of Gastroenterology
which is a registered charity*

Gut publishes original papers, short rapid communications, leading articles, and reviews concerned with all aspects of the scientific basis of diseases of the alimentary tract, liver, and pancreas. Case reports will only be accepted if of exceptional merit. Letters related to articles published in *Gut* or with topics of general professional interest are welcomed. Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.

COMMUNICATIONS Two copies of the manuscript and figures should be addressed to the Editor, *Gut*, BMA House, Tavistock Square, London WC1H 9JR, UK. Manuscripts should follow the Vancouver conventions (see *BMJ* 1979; i: 532-5. *Gut* 1979; 20: 651-2). They should be in double spaced typewriting on one side of the paper only. The title page should include the name of the author with initials or distinguishing first name only, and the name and address of the hospital or laboratory where the work was performed. The paper must include a precise summary of the work of less than 200 words. Use of abbreviation is discouraged. Short rapid communications should not be more than 10 double spaced A4 pages including references, tables, and figures. These papers will be subject to peer review in the normal way. The interval from acceptance to publication will be much shorter. A covering letter should include a request for the paper to be considered in this category with valid reasons for that request. A separate covering letter signed by all authors must state that the data have not been published elsewhere in whole or in part and that all authors agree to publication in *Gut*. Previous publication in abstract form must be disclosed in a footnote. Papers must not be published elsewhere without prior permission of the Editorial Committee. If requested, authors shall produce the data upon which the manuscript is based for examination by the editor.

ACKNOWLEDGEMENT OF MANUSCRIPTS Manuscripts will only be acknowledged if an addressed postcard is enclosed.

ILLUSTRATIONS *Photographs* Unmounted photographs on glossy paper should be provided. Illustrations should not be inserted in the text but marked on the back with the figure numbers, title of paper and name of author. All photographs, graphs, diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet.

ETHICS Ethical aspects will be considered in the assessment of papers (see the Medical Research Council's publications on the ethics of human experimentation, and the World Medical Association's code of ethics, known as the Declaration of Helsinki (see *BMJ* 1964; ii: 177)).

SI UNITS All measurements except blood pressure are expressed in SI units. In tables and illustrations values are given in SI units. For general guidance on the International System of Units and some useful conversion

factors, see *The SI for Health Professions* (WHO, 1977). **NB: Such conversion is the responsibility of the author.**

REFERENCES These follow the Vancouver system - that is, references numbered consecutively in the text and listed numerically with journal titles abbreviated in the style of *Index Medicus, Standard journal article*. List up to six authors, then add *et al.*

CORRECTIONS other than printers' errors may be charged to the author.

REPRINTS Reprints will be available on payment of the necessary costs; the number of reprints required should be sent to the Publishing Manager on the form provided with the proof.

NOTICE TO ADVERTISERS All applications for advertisement space and rates should be addressed to the Advertisement Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR.

NOTICE TO SUBSCRIBERS *Gut* is published monthly. The annual subscription rates are £191.00 (USA \$309.00). Reduced subscriptions of £79.00 available to trainees for one year (direct only). Orders should be sent to the Subscription Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, can be sent to: *British Medical Journal*, Box 560B, Kennebunkport, Maine 04046. All enquiries, however, must be addressed to the Publisher in London.) Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and the expiry date of the card. All overseas copies of the journal are sent by accelerated surface post. If required, full air mail rates and enquiries for single copies already published should be addressed to the Publisher in London.

COPYRIGHT © 1994 *Gut*. This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Apart from any relaxations permitted under national copyright laws, no part of the publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the copyright owners. Permission is not, however, required to copy abstracts of papers or articles on condition that a full reference to the source is shown. Multiple copying of the contents of the publication without permission is always illegal.

Second class postage paid, Rahway NJ. Postmaster: send address changes to: *Gut*, c/o Mercury Airfreight International Ltd Inc, 2323 Randolph Avenue, Avenel, NJ 07001, USA. ISSN 0017-5749.

Published by British Medical Association, Tavistock Square, London WC1H 9JR.
Typeset by Bedford Typesetters Ltd
Printed by Stott Brothers Ltd, Halifax